Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
(Mark One)
☐
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES
EXCHANGE ACT OF 1934
or
☒
☐
☐
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the fiscal year ended December 31, 2020
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from to .
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
or
Date of event requiring this shell company report . . . . . . . . . . . . . . . . . . .
Commission file number: 001-38639
For the transition period from to
111, Inc.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s name into English)
Cayman Islands
(Jurisdiction of incorporation or organization)
3-5/F, No.295 ZuChongZhiRoad,
Pudong New Area
Shanghai, 201203
The People’s Republic of China
(Address of principal executive offices)
Junling Liu, Chief Executive Officer
Telephone: +86 21 2053-6666
Email: junling @111.com.cn
Pudong New Area
Shanghai, 201203
The People’s Republic of China
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class
American depositary shares (one American depositary share
representing two Class A ordinary shares, par value US$0.00005
per share)
Class A ordinary shares, par value US$0.00005 per share”
Trading Symbol
YI
Name of each exchange on which registered
The Nasdaq Stock Market LLC
(The Nasdaq Global Market)
The Nasdaq Stock Market LLC
(The Nasdaq Global Market)
*
Not for trading, but only in connection with the listing on the Nasdaq Global Market of American depositary shares.
Table of Contents
Securities registered or to be registered pursuant to Section 12(g) of the Act:
Not Applicable
(Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
Not Applicable
(Title of class)
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual
report.
As of December 31, 2020, there were 165,353,402 ordinary shares outstanding, par value US$0.00005 per share, being the sum of
93,353,402 Class A ordinary shares and 72,000,000 Class B ordinary shares.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☐ No ⌧
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
Yes ☐ No ⌧
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes ⌧ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File Required to be submitted pursuant to Rule 405 of
Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files).
Yes ⌧ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,or a non-accelerated filer or an emerging growth company.
See definition of “large accelerated filer” “accelerated filer” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ☐
Accelerated Filer ⌧
Non-accelerated Filer ☐
Emerging growth
company ☐
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards* provided pursuant to Section 13(a) of
the Exchange Act. ☐
* The term “new or revised financial accounting standard: refers to any update issued by the Financial Accounting Board to its Accounting Standards
Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. ☒
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP ☒
International Financial Reporting Standards as
issued by the International Accounting
Standards Board ☐
Other ☐
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to
follow.
☐ Item 17 ☐ Item 18
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.
Yes ☐ No ⌧
Yes ☐ No ☐
Table of Contents
TABLE OF CONTENTS
PAGE
INTRODUCTION
FORWARD-LOOKING INFORMATION
PART I
Item 1.
Item 2.
Item 3.
Item 4.
Item 4A.
Item 5.
Item 6.
Item 7.
Item 8.
Item 9.
Item 10.
Item 11.
Item 12.
Identity of Directors, Senior Management and Advisers
Offer Statistics and Expected Timetable
Key Information
Information on the Company
Unresolved Staff Comments
Operating and Financial Review and Prospects
Directors, Senior Management and Employees
Major Shareholders and Related Party Transactions
Financial Information
The Offer and Listing
Additional Information
Quantitative and Qualitative Disclosures about Market Risk
Description of Securities Other Than Equity Securities
PART II
Defaults, Dividend Arrearages and Delinquencies
Material Modifications to the Rights of Security Holders and Use of Proceeds
Controls and Procedures
Audit Committee Financial Expert
Item 13.
Item 14.
Item 15.
Item 16A.
Item 16B. Code of Ethics
Item 16C.
Item 16D.
Item 16E.
Item 16F. Change in Registrant's Certifying Accountant
Corporate Governance
Item 16G.
Item 16H. Mine Safety Disclosure
Principal Accountant Fees and Services
Exemptions from the Listing Standards for Audit Committees
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
PART III
Item 17.
Item 18.
Item 19.
Financial Statements
Financial Statements
Exhibits
i
1
3
4
4
4
4
50
83
83
100
110
112
113
113
130
131
133
133
133
133
134
134
134
135
135
135
135
136
137
137
137
137
Table of Contents
INTRODUCTION
Unless otherwise indicated or the context otherwise requires, all information in this annual report reflects the following:
● “1 Clinic” refers to our internet hospital;
● “1 Pharmacy", previously known as "1 Drug Mall”, refers to our online wholesale pharmacy;
● "1 Medicine Marketplace", previously known as “1 Drugstore” refers to our online retail pharmacy;
● “ADSs” refer to American depositary shares, each of which represents two Class A ordinary shares;
● “China” or the “PRC” refers to the People’s Republic of China, excluding, for the purposes of this annual report only,
Hong Kong, Macau and Taiwan;
● "DTP" refers to direct to patient;
● “GMV” refers to the total value of all orders shipped for products sold under our direct sales model, net of returns, plus the
total value of all orders shipped for products sold on our marketplace by our marketplace sellers, inclusive of returns,
during the specified period;
● “marketplace sellers” refer to third-party merchants on our 1 Medicine Marketplace and 1 Pharmacy, which include
distributors and resellers that sell products through our online retail pharmacy or online wholesale pharmacy under our
marketplace model;
● “medical professionals” refer to doctors, pharmacists and medical assistants;
● “New Retail” refers to the seamless integration of our online retail pharmacy and offline pharmacy network by leveraging
our smart supply chain and cloud-based solutions to improve the efficiency throughout the value chain;
● “pharmaceutical companies” refer to manufacturers of pharmaceutical and other health and wellness products;
● “pharmacies” refer to independent pharmacies, pharmacy chains and in-house pharmacies within clinics and private
hospitals;
● “RMB” or “Renminbi” refers to the legal currency of China;
● “shares” or “ordinary shares” refers to our ordinary shares comprising Class A and Class B ordinary shares, par value
US$0.00005 per share;
● “SKU” refers to stock keeping unit;
● “smart supply chain” refers to a supply chain built upon a technology infrastructure that is designed to analyze massive
amounts of data to facilitate the customization, productivity and efficiency needed in the New Retail era. Our smart supply
chain consists of multiple components, including our fulfillment infrastructure, cloud-based inventory management and our
supply chain management;
● “suppliers” refer to distributors and pharmaceutical companies from whom we source our products for our direct
sales model;
● “U.S. GAAP” refers to generally accepted accounting principles in the United States;
● “US$,” “U.S. dollars,” “$,” or “dollars” refers to the legal currency of the United States; and
● “we,” “us,” “our company,” “our,” or “111” refers to 111, Inc., its subsidiaries, and, in the context of describing our
operations and consolidated financial information, our variable interest entities in China.
1
Table of Contents
Our reporting currency is the Renminbi because our business is mainly conducted in China and all of our revenues are
denominated in Renminbi. However, periodic reports made to shareholders will include current period amounts translated into U.S.
dollars using the then-current exchange rates, for the convenience of the readers. The conversion of RMB into U.S. dollars in this annual
report is based on the exchange rate set forth in the H.10 statistical release of the Federal Reserve Board. Unless otherwise noted, all
translations from RMB to U.S. dollars and from U.S. dollars to RMB in this annual report were made at a rate of RMB6.5250 to
US$1.00, the exchange rate on December 31, 2020 set forth in the H.10 statistical release of the Federal Reserve Board. We make no
representation that any RMB or U.S. dollar amounts could have been, or could be, converted into U.S. dollars or RMB, as the case may
be, at any particular rate, or at all.
2
Table of Contents
FORWARD-LOOKING INFORMATION
This annual report on Form 20-F contains forward-looking statements that involve risks and uncertainties. All statements other
than statements of current or historical facts are forward-looking statements. These statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those
expressed or implied by the forward-looking statements.
You can identify these forward-looking statements by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. We have based these forward-looking statements largely
on our current expectations and projections about future events and financial trends that we believe may affect our financial condition,
results of operations, business strategy and financial needs. These forward-looking statements include, but are not limited to:
● our goals and strategies;
● our future business development, financial condition and results of operations;
● expected changes in our revenues, costs or expenditures;
● our expectations regarding demand for and market acceptance of our services;
● competition in our industry; and
● government policies and regulations relating to our industry.
We would like to caution you not to place undue reliance on these forward-looking statements and you should read these
statements in conjunction with the risk factors disclosed in “Item 3D. Key Information—Risk Factors.” Those risks are not exhaustive.
We operate in a rapidly evolving environment. New risks emerge from time to time and it is impossible for our management to predict all
risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ from those contained in any forward-looking statement. We do not undertake any obligation to update or
revise the forward-looking statements except as required under applicable law.
3
Table of Contents
PART I
Item 1. Identity of Directors, Senior Management and Advisers
Not applicable.
Item 2. Offer Statistics and Expected Timetable
Not applicable.
Item 3. Key Information
A. Selected Financial Data
Not applicable.
B. Capitalization and Indebtedness
Not applicable.
C. Reasons for the Offer and Use of Proceeds
Not applicable.
D. Risk Factors
Below please find a summary of the principal risks we face, organized under relevant headings.
Risks Related to Our Business and Industry
● We are subject to extensive and evolving regulatory requirements, non-compliance with which, or changes in which,
may materially and adversely affect our business and prospects.
● Our business, financial condition and results of operations may be materially and adversely affected if we are unable
to compete effectively in the PRC general health and wellness market, and we may fail to sufficiently and promptly
respond to rapid changes in government regulations, treatment of diseases and customer preferences.
● We may not be able to manage the growth of our business and our expansion plans and operations or implement our
business strategies on schedule or within our budget, or at all.
● We have incurred operating losses in the past, and may not be able to achieve or maintain profitability in the future.
● Our pharmaceutical retail and wholesale businesses are subject to a variety of risks, which may have a material and
adverse effect on our business, financial condition and results of operations.
● Our business generates and processes a large amount of data, and the improper use or disclosure of such data could
harm our reputation and have a material adverse effect on our business and prospects.
● Our failure to properly manage various participants in our ecosystem may materially and adversely affect our
business.
4
Table of Contents
● Any lack of requisite approvals, licenses or permits applicable to our business, or any non-compliance with relevant
laws and regulations, may have a material and adverse effect on our business, financial condition, results of
operations and prospects.
● We may become subject to product liability and medical liability claims, which could cause us to incur significant
expenses and be liable for significant damages if not covered by insurance.
● If we are unable to implement our strategy to expand our PRC operations by completing an initial public offering and
listing on the STAR Market, our ability to strengthen our market position and operations in the PRC could be
materially impaired. Even if we complete the STAR Market listing, we may not achieve the results contemplated by our
business strategy and our strategy for growth in the PRC may not result in increase in the trading price of our ADSs.
Risks Related to Our Corporate Structure
● If the PRC government deems that the contractual arrangements in relation to our variable interest entities and their
subsidiaries do not comply with PRC regulatory restrictions on foreign investment in the relevant industries, or if these
regulations or the interpretation of existing regulations change in the future, we could be subject to severe penalties or
be forced to relinquish our interests in those operations.
● We rely on contractual arrangements with our variable interest entities and their shareholders, for a significant
portion of our business operations, which may not be as effective as direct ownership in providing operational control.
● Any failure by our variable interest entities or their respective shareholders to perform their obligations under our
contractual arrangements with them would have a material adverse effect on our business.
● The shareholders of our variable interest entities may have potential conflicts of interest with us, which may materially
and adversely affect our business and financial condition.
● Contractual arrangements in relation to our variable interest entities, may be subject to scrutiny by the PRC tax
authorities and they may determine that we, or our variable interest entities and their subsidiaries, owe additional
taxes, which could negatively affect our financial condition and the value of your investment.
Risks Related to Doing Business in China
● Changes in China’s economic, political or social conditions or government policies could have a material adverse
effect on our business and results of operations.
● Uncertainties in the interpretation and enforcement of PRC laws and regulations could limit the legal protections
available to us.
● We may be adversely affected by the complexity, uncertainties and changes in PRC regulation of pharmaceutical and
healthcare industry and internet-related businesses, and any lack of requisite approvals, licenses or permits applicable
to our business may have a material adverse effect on our business and results of operations.
● We rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing
requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could
have a material adverse effect on our ability to conduct our business.
● The recent enactment of the Holding Foreign Companies Accountable Act, the SEC's ongoing rulemaking with respect
to such law, and other legislative developments in the United States may result in delisting of the ADSs.
5
Table of Contents
Risks Related to American Depositary Shares
● The trading price for the ADSs may be volatile.
● Techniques employed by short sellers may drive down the trading price of the ADSs.
● Our dual-class share structure with different voting rights will limit your ability to influence corporate matters and
could discourage others from pursuing any change of control transactions that holders of our Class A ordinary shares
and ADSs may view as beneficial.
● The dual-class structure of our ordinary shares may adversely affect the trading market for our ADSs.
Risks Related to Our Business and Industry
We are subject to extensive and evolving regulatory requirements, non-compliance with which, or changes in which, may
materially and adversely affect our business and prospects.
Due to the complex nature of our business, we are subject to legal and regulatory requirements of multiple industries in the
PRC. These industries primarily include internet, healthcare, internet healthcare and pharmaceutical retail and wholesale industries.
Various regulatory authorities of the PRC government are empowered to promulgate and implement regulations governing
broad aspects of the internet and healthcare industries. In respect of the healthcare industry, in particular, any violation of the relevant
laws, rules and regulations may result in harsh penalties and, under certain circumstances, lead to criminal prosecution.
Meanwhile, the regulations of both the internet industry and its internet healthcare sector are relatively new and evolving, and
their interpretation and enforcement involve significant uncertainty. As a result, under certain circumstances, it may be difficult to
determine what actions or omissions would be deemed in violation of applicable laws and regulations. These uncertainties entail risks
that may materially and adversely affect our business prospects. Due to the uncertainty and complexity of the regulatory environment, we
cannot assure you that future laws and regulations would not render our operations non-compliant or that we would always be in full
compliance with applicable laws and regulations. Compliance with future laws and regulations may require us to change our business
models and practices at an undeterminable and possibly significant financial cost. These additional monetary expenditures may increase
future overhead, which may, in turn, have a material adverse effect on our business, financial condition and results of operations.
Furthermore, the introduction of new services and products may require us to comply with additional, yet undetermined, laws
and regulations. Compliance may require obtaining appropriate permits, licenses or certificates as well as expending additional resources
to monitor developments in the relevant regulatory environment. The failure to adequately comply with these future laws and regulations
may delay, or possibly prevent, some of our products or services from being offered to users, which may have a material adverse effect
on our business, financial condition and results of operations.
6
Table of Contents
The pharmaceutical retail and wholesale industry in China is subject to extensive government regulation and supervision as well
as monitoring by various government authorities. Certain other laws, rules and regulations may affect the pricing, demand and
distribution of pharmaceutical products, such as those relating to procurement, prescription and dispensing of drugs by hospitals and
other medical institutions, retail pharmacy, government funding for private healthcare and medical services, and the inclusion of products
in the drugs catalogs for national basic medical insurance, on-the-job injury insurance and maternity insurance promulgated by the
Ministry of Human Resources and Social Security of the People’s Republic of China, or the MOHRSS. In addition, the pharmaceutical
manufacturing, pharmaceutical distribution, pharmaceutical retail, healthcare services and medical device industries in China are each
subject to extensive and changing government regulations and supervision. Any unfavorable regulatory changes in these industries may
also increase our compliance burden and materially and adversely affect our business, profitability and prospects.
Our business, financial condition and results of operations may be materially and adversely affected if we are unable to compete
effectively in the PRC general health and wellness market, and we may fail to sufficiently and promptly respond to rapid changes
in government regulations, treatment of diseases and customer preferences.
The PRC general health and wellness market is highly competitive. Our key competitors include pharmaceutical retail
companies including traditional offline pharmacies, and online platforms, as well as B2B platforms and traditional pharmaceutical
distributors, and companies that offer internet healthcare services. These companies may have substantially greater financial, technical,
research and development, marketing, distribution, retail and other resources than we do. They may also have longer operating histories,
a larger customer base or broader and deeper market coverage. Furthermore, when we expand into other markets, we will face
competition from new competitors, domestic or foreign, who may also enter markets where we currently operate.
In addition, many operators in the healthcare industry have consolidated in recent years to create larger healthcare enterprises
with greater bargaining power, which has resulted in greater pricing pressures. If this consolidation trend continues, it could give the
resulting enterprises even greater bargaining power, which may lead to further competitive pressure. New partnerships and strategic
alliances in the healthcare industry also can alter market dynamics and adversely impact our businesses and competitive positioning.
The technologies that we and our competitors employ are evolving rapidly, and new developments frequently result in price
competition, product obsolescence and altered market landscape. Any significant increase in competition may have a material adverse
effect on our revenue and profitability as well as on our business and prospects. We cannot assure you that we will be able to continually
distinguish our products and services from our competitors’, preserve and improve our relationships with various participants in the
healthcare value chain, or increase or even maintain our existing market share. We may lose market share, and our financial condition
and results of operations may deteriorate significantly if we fail to compete effectively.
We may not be able to manage the growth of our business and our expansion plans and operations or implement our business
strategies on schedule or within our budget, or at all.
Our business has become increasingly complex in terms of both the type and scale of our operations. Any expansion may
increase the complexity of our operations and place a significant strain on our managerial, technological, operational, financial and
human resources. We recently launched our online wholesale business and various value-added services, including online consultation
services, cloud prescription services and data services. Our current and planned personnel, systems, procedures and controls may not be
adequate to support our future operations. We cannot assure you that we will be able to effectively manage our growth or to implement
all these systems, procedures and control measures successfully. If we are not able to manage our growth effectively, our business and
prospects may be materially and adversely affected.
We are also continually executing a number of growth initiatives, strategies and operating plans designed to enhance our
business, including launching various new services utilizing the latest big data and AI technologies. The anticipated benefits from these
efforts are based on assumptions that may prove to be inaccurate. Moreover, we may not be able to successfully complete these growth
initiatives, strategies and operating plans and realize all of the benefits that we expect to achieve or it may be more costly to do so than
we anticipate. If, for any reason, the benefits we realize are less than our estimates or the implementation of these growth initiatives,
strategies and operating plans adversely affect our operations or cost more or take longer to effectuate than we expect, or if our
assumptions prove inaccurate, our business, financial condition and results of operations may be materially and adversely affected.
In addition, we may seek and pursue opportunities via joint ventures or strategic partnerships for expansion from time to time,
and we may face similar risks and uncertainties as listed above. Failure to properly address these risks and uncertainties may
7
Table of Contents
materially and adversely affect our ability to carry out acquisitions and other expansion plans, integrate and consolidate newly acquired
or newly formed businesses, and realize all or any of the anticipated benefits of such expansion, which may have a material adverse
effect on our business, financial condition, results of operations and prospects.
We have incurred operating losses in the past, and may not be able to achieve or maintain profitability in the future.
We began our operations in 2012 and we experienced net loss in the amount of RMB382.0 million, RMB501.8 million and
RMB467.1 million (US$71.6 million) in 2018, 2019 and 2020, respectively. We expect our operating costs and expenses to increase in
the future in absolute terms as we expand our operations. We may also incur additional legal, accounting, and other expenses as a public
company. If our revenue does not grow at a greater rate than our expenses, we will not be able to achieve and maintain profitability. We
may incur significant losses in the future for various reasons, many of which may be beyond our control. Additionally, we may encounter
unforeseen expenses, operating delays, or other unknown factors that may result in losses in the future. If our cost of sales and expenses
continuously exceed our revenue, our business may be materially and adversely affected and we may not be able to achieve or maintain
profitability.
Our pharmaceutical retail and wholesale businesses are subject to a variety of risks, which may have a material and adverse
effect on our business, financial condition and results of operations.
We are subject to certain risks in our pharmaceutical retail and wholesale businesses, including:
● inability to successfully execute effective advertising, marketing and promotional programs necessary to maintain and
increase awareness of our brands, products and services;
● failure to implement effective pricing and other strategies in response to market competition;
● inability to respond to changes in demand and preferences of pharmacy customers and consumers in a timely manner;
● inability to stock an adequate supply of pharmaceutical and other health and wellness products that meet the demand of our
pharmacy customers and consumers;
● overall consumer spending on healthcare in China;
● inability to obtain and maintain regulatory or governmental permits, approvals and clearances, or to pass PRC government
inspections or audits; and
● the risk of, and resulting liability from, any contamination, injury or other harm caused by any use, misuse or misdiagnosis
involving products distributed by us.
The occurrence of any such risks in our pharmaceutical retail and wholesale businesses may damage our overall business and
reputation, and may have a material and adverse effect on our financial condition and results of operations.
Our business generates and processes a large amount of data, and the improper use or disclosure of such data could harm our
reputation and have a material adverse effect on our business and prospects.
We generate and process a large amount of personal, transaction, demographic and behavioral data including medical records
and other personal information. We face risks inherent in handling large volumes of data and in securing and protecting such data. In
particular, we face a number of data-related challenges related to our business operations, including:
● protecting the data in and hosted on our system, including against attacks on our system by external parties or fraudulent
behavior by our employees;
● addressing concerns related to privacy and sharing, safety, security and other factors; and
8
Table of Contents
● complying with applicable laws, rules and regulations relating to the collection, use, disclosure or security of personal
information, including any requests from regulatory and government authorities relating to such data.
Regulatory requirements regarding the protection of such data are constantly evolving and can be subject to significant change,
making the extent of our responsibility in that regard uncertain. Under certain regulations, rules and measures promulgated by the
Ministry of Industry and Information Technology of the People’s Republic of China, or the MIIT, since 2011, any collection and use of a
user’s personal information by an internet services provider must be subject to the consent of the user, abide by the principles of legality,
rationality and necessity, and be within the specified purposes, methods and scopes. The internet services provider must keep all
information collected strictly confidential and is prohibited from divulging, tampering with or destroying any such information, or selling
or providing such information to other parties. In particular, the Cyber Security Law of the People’s Republic of China, or the Cyber
Security Law, which took effect on June 1, 2017, is formulated to maintain network security, safeguard the cyberspace sovereignty,
national security and public interests, protect the lawful rights and interests of citizens, legal persons and other organizations, and further
enhance personal information protection, such as through requirements on the collection, use, processing, storage and disclosure of
personal information. Furthermore, in August 2018, the Standing Committee of China's National People's Congress, or the SCNPC
promulgated the E-Commerce Law of the People’s Republic of China, or the E-Commerce Law, to regulate the e-commerce activities
conducted within the territory of the PRC, which further strengthens the protection of consumers’ personal data and privacy. Since the
Cyber Security Law, E-Commerce Law and relevant regulations, rules and measures are relatively new, there are uncertainties as to the
interpretation and application of these laws and regulations, and it is possible that our data protection practices are or will be inconsistent
with regulatory requirements. Any violation of the provisions and requirements under the Cyber Security Law, E-Commerce Law and
other relevant regulations, rules and measures may subject us to warnings, fines, confiscation of illegal gains, revocation of licenses,
suspension of business, shutting down of websites or even criminal liabilities. Complying with such requirements could cause us to incur
substantial expenses or to alter or change our practice in a manner that could harm our business. Any systems failure or security breach
or lapse that results in the unauthorized release of our user data could harm our reputation and brand and, consequently, our business, in
addition to exposing us to potential legal liability.
Our privacy policies and practices concerning the collection, use and disclosure of user data are posted on our mobile app. Any
failure, or perceived failure, by us to comply with our privacy policies or with any applicable regulatory requirements or privacy
protection-related laws, rules and regulations could result in proceedings or actions against us by governmental entities or others. These
proceedings or actions may subject us to significant penalties and negative publicity, require us to change our business model or
practices, increase our costs and severely disrupt our business, which may materially and adversely affect our business, financial
condition, results of operations and prospects.
Our failure to properly manage various participants in our ecosystem may materially and adversely affect our business.
We rely on various participants, including, but not limited to, pharmacies, pharmaceutical companies, marketplace sellers and
medical professionals, in the provision of services and products in our ecosystem, and the success of our business depends on our ability
to properly manage them. See "Item 4. Information on the Company - B. Business Overview - Our Ecosystem."
We consider a variety of factors before entering into contractual arrangements with them. Nevertheless, we have limited control
over the quality of work and performance of our ecosystem participants in their provision of services and products over our website and
mobile platform or otherwise, and they may breach such contractual arrangements and subject us to claims and liabilities that may affect
our business operations.
We have also implemented quality control standards and procedures to manage their work and performance in our ecosystem.
However, there can be no assurance that our monitoring of their work and performance will be sufficient to ensure the quality of their
work. In the event that a third party fails to meet our quality and operating standards contracted in our agreements or as required by
relevant PRC laws and regulations, our operations may suffer and our business, financial condition and results of operations may be
materially and adversely affected. Furthermore, because of the contractual relationships, we could be perceived as responsible for the
actions of such participants and, as a result, suffer reputational damage. This may adversely affect our ability to attract new pharmacies,
pharmaceutical companies, medical professionals and marketplace sellers, and to engage them as providers within our ecosystem.
9
Table of Contents
Any lack of requisite approvals, licenses or permits applicable to our business, or any non-compliance with relevant laws and
regulations, may have a material and adverse effect on our business, financial condition, results of operations and prospects.
Our business is subject to governmental supervision and regulation by various PRC governmental authorities including, but not
limited to, the Ministry of Commerce of the People’s Republic of China, or MOFCOM, the MIIT, the National Health and Family
Planning Commission of the People’s Republic of China, or the NHFPC, which was restructured and integrated into the National Health
Commission of the People’s Republic of China, or the NHC, National Medical Products Administration, formerly China Food and Drug
Administration (“NMPA” or “CFDA”), the State Administration for Industry and Commerce, or the SAIC, which was, together with the
CFDA, integrated into the State Administration for Market Regulation, or the SAMR, the Cyberspace Administration of China, or the
CAC, and the corresponding local regulatory authorities. Such government authorities promulgate and enforce laws and regulations that
cover a variety of business activities that our operations concern, such as provision of internet information, online medical services,
online and offline retail, sales and online operation of pharmaceutical products and medical devices, sales of food, and internet
advertisement, among other things. These regulations in general regulate the entry into, the permitted scope of, as well as approvals,
licenses and permits for, the relevant business activities.
In addition to obtaining necessary approvals, licenses and permits for conducting our business, we must comply with relevant
laws and regulations. Our businesses, such as online and offline pharmaceutical retail and wholesale distribution and online healthcare
services, are subject to various and complex laws and regulations, extensive government regulations and supervision. We may not be
fully informed of all and new requirements under relevant laws and regulations in a timely manner, and even if we become aware of new
requirements, due to uncertainties in their interpretations and implementation, it will be difficult for us to determine what actions or
omissions would be deemed as violations of applicable laws and regulations. We may also not be able to respond to evolving laws and
regulations and take appropriate action in time to adjust our business model. As a result, we may be in violation or non-compliance with
such laws and regulations.
In particular, under the Administrative Measures for the Supervision and Administration of Circulation of Pharmaceuticals
promulgated by the CFDA in 2007, a company is prohibited from selling prescription drugs to consumers without prescription, via
internet or by post. A company in violation of such prohibitions will be instructed to rectify, given a disciplinary warning, and/or
imposed an administrative penalty of no more than RMB30,000 per violation. See “Item 4. Information on the Company—B. Business
Overview— Regulations— Regulations Relating to Online Operation of Drugs and Medical Devices.” The newly revised Drug
Administration Law of the People’s Republic of China, or the Drug Administration Law, abolishes the restriction on online sale of
prescription drugs and adopts the principle of keeping online and offline sales consistent, which allows the qualified pharmaceutical
enterprise to conduct online sale of drugs (including prescription drugs, but not certain special controlled drugs). In addition, the entity
that operates a third-party online drug transaction platform shall be filed with relevant authority for drugs supervision and administration
and responsible to examine the qualifications of the drug marketing permit holders and drug operation enterprises applying to operate on
its platform, ensure that they meet legal requirements, and manage the drug operation behaviors occurring on the platform. However, as
of the date of this annual report, none of the regulations or implementation rules regulating online drug sales have yet been promulgated
and implemented, which may further introduce and impose certain conditions and restrictions to the online sale of drugs. In the past, we
had received disciplinary warnings and administrative penalties due to certain non-compliance incidents in relation to prescription drugs
sales. We have adjusted our sales model and relevant functions of our online platforms in response to such warnings and penalties.
However, it remains uncertain that our sales model and online platforms as adjusted are and will be in full compliance with the relevant
laws and regulations, which are evolving and subject to changes. In addition, due to the complexity of our IT system, its potential errors,
or human errors, mistakes or misconduct by our offline retail pharmacies, we cannot assure you that we can fully comply with and meet
the requirements under all laws and regulations related to the sale of prescription drugs. Any failure to comply with such laws and
regulations could materially and adversely affects our business, results of operations, financial condition and prospects.
Due to the uncertainties in the regulatory environment of the industries in which we operate, there can be no assurance that we
have obtained or applied for all the approvals, permits and licenses required for conducting our business and all activities in the PRC, or
that we would be able to maintain our existing approvals, permits and licenses or obtain any new approvals, permits and licenses if
required by any future laws or regulations. If we fail to obtain and maintain approvals, licenses or permits required for our business, or to
comply with relevant laws and regulations, we could be subject to liabilities, fines, penalties and operational disruptions, or we could be
required to modify our business model, which could materially and adversely affect our business, financial condition and results of
operations.
10
Table of Contents
We may become subject to product liability and medical liability claims, which could cause us to incur significant expenses and
be liable for significant damages if not covered by insurance.
We are exposed to risks inherent in marketing, distributing and selling pharmaceutical and other health and wellness products
and providing online healthcare and medical services in China. Claims, customer complaints or administrative penalties may arise if any
of the products we market and distribute are deemed or proven to be unsafe, ineffective or defective, or they are found to contain illicit
substances. We may also be subject to allegations of having engaged in practices such as improper filling of prescriptions, distribution of
counterfeit and substandard medicines, or providing inadequate warnings or insufficient or misleading disclosures of side effects.
In addition, in the event that any use or misuse of the products we distribute results in personal injury, suicide or death, product
liability claims may be brought against us for damages. If we are unable to defend ourselves against such claims, among other things, we
may be subject to civil liabilities for physical injury, death or other losses caused by our products, to criminal liabilities, and to the
revocation of our business licenses. In addition, we may be required to suspend sales or cease sales of the relevant products.
We face risks of medical liability claims against our in-house medical team, external doctors and us. We only carry insurance
covering medical malpractice claims for our in-house doctors and some of our external doctors. Adequate professional malpractice
insurance coverage may not be available to our in-house medical team, external doctors or us in the future on commercially acceptable
terms, or at all.
Any claims made against us that are not fully covered by insurance could be costly to defend against, result in substantial
damage awards against us and divert the attention of our management and our in-house medical team and external doctors from our
operations, which could have a material adverse effect on our business, financial condition, results of operations and reputation.
If we are unable to implement our strategy to expand our PRC operations by completing an initial public offering and listing on
the STAR Market, our ability to strengthen our market position and operations in the PRC could be materially impaired. Even if
we complete the STAR Market listing, we may not achieve the results contemplated by our business strategy and our strategy for
growth in the PRC may not result in increase in the trading price of our ADSs.
In August 2020 we announced plans to seek to list the shares of 1 Pharmacy Technology (Shanghai) Co., Ltd. (previously
known as Yao Fang Information Technology (Shanghai) Co., Ltd. and 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.), or 1
Pharmacy Technology, on the Science and Technology Innovation Board of Shanghai Stock Exchange (the “STAR Market”) within the
next three years (the “STAR Listing”). 1 Pharmacy Technology is our principal operating company and was a wholly owned subsidiary
of Yao Wang Corporation Limited, or Yao Wang. See “Item 4. Information on the Company – A. History and Development of the
Company.” Since August 20, 2020, 1 Pharmacy Technology has become a majority owned subsidiary of Yao Wang. We may not be able
to complete the STAR Listing for a number of reasons, many of which are outside our control. 1 Pharmacy Technology must succeed in
obtaining PRC governmental approvals required to permit the STAR Listing, and one or more of those approvals may be denied, or
significantly delayed, by the PRC regulators for reasons outside our control or unknown to us. Similarly, the STAR Listing application
may be denied or delayed by the Shanghai Stock Exchange and/or China Securities Regulatory Commission in its discretion.
If we are unable to complete the STAR Listing, we may not otherwise be able to realize the advantages to our PRC operations
contemplated by our business strategy, including accessing a new source of growth capital, raising our profile with Chinese investors and
potential customers, and strengthening our leading digital healthcare platform in China. Because it may be more than three years before
we know whether the STAR Listing will be completed, we may, in the interim, forego or postpone other alternative actions to strengthen
our market position and operations in the PRC.
We cannot assure you that, even if the STAR Listing is completed, we will realize any or all of our anticipated benefits of the
STAR Listing. Our completion of the STAR Listing may not have the anticipated effects of including the strengthening of our market
position and operations in the PRC. If the STAR Listing is completed, 1 Pharmacy Technology will have broad discretion in the use of
the proceeds from the initial sales of shares to investors and the proceeds from the initial public offering, and it may not spend or invest
those proceeds in a manner that results in our operating success or with which our stockholders agree. Our failure to successfully
leverage the completion of the STAR Listing to expand our PRC business could result in a decrease in the trading price of
11
Table of Contents
the ADSs, and we cannot assure you that the success of 1 Pharmacy Technology will have an attendant positive effect on the trading
price of our ADSs.
Additionally, In the event that 1 Pharmacy Technology’s proposed listing on the STAR Market is not completed before June 30,
2023 (or the date otherwise agreed by 1 Pharmacy Technology and the investors in writing), such investors may choose to exercise their
options to require the controlling shareholder of 1 Pharmacy Technology, Yao Wang, to redeem all or part of the equity interests then
owned by such investors. If the investors were to exercise such option, Yao Wang may not have sufficient fund for the redemption, and to
the extent Yao Wang requires additional funding, we cannot assure you that such capital will be available on terms acceptable to us, or at
all. Any such lack of fund may cause our defaults under the agreements between us and the investors and may impair our reputation and
ability to grow its operations, which could have a material adverse effect on our operating results and on the price of the ADSs.
Failure to maintain optimal inventory levels and assortment of products could increase our operating costs or lead to unfulfilled
customer orders, either of which could have a material and adverse effect on our business, financial condition, results of
operations and prospects.
We need to maintain optimal inventory levels in order to operate our pharmaceutical retail and wholesale businesses
successfully and to meet the demands of pharmacy customers and consumers. We manage inventories of pharmaceutical and other health
and wellness products under our direct sales model, while marketplace sellers manage inventories of their products. We are exposed to
inventory risk as a result of rapid changes in product life cycles, changing consumer preferences, uncertainty of product developments
and launches, manufacturer back orders and other vendor-related problems, as well as the volatile economic environment in China. We
cannot assure you that we will accurately predict these trends and events and avoid over-stocking or under-stocking of products.
Furthermore, demand for products could change significantly between the time when the products are ordered and the time when they are
ready for delivery. When we begin to sell a new product, it is particularly difficult to forecast product demand accurately.
As our pharmaceutical retail and wholesale businesses carry a wide range of products and maintain significant inventory levels
for a substantial portion of our merchandise, we may be unable to sell such inventory in sufficient quantities or during the relevant sales
seasons. We had net write-downs of our inventories to their net realizable value of nil, RMB790 thousand and RMB24.2 million (US$3.7
million) in 2018, 2019 and 2020, respectively. Inventory levels in excess of customer demand may result in inventory write-downs,
expiration of products or an increase in inventory holding costs and a potential negative effect on our liquidity.
Conversely, if we underestimate customer demand, or if our suppliers fail to provide products to us in a timely manner, we may
experience inventory shortages, which may, in turn, result in unfulfilled customer orders, leading to a negative impact on our customer
relationships. We cannot assure you that we will be able to maintain proper inventory levels for our pharmaceutical retail and wholesale
operations, and any such failure may have a material and adverse effect on our business, financial condition, results of operations and
prospects.
We closely monitor the inventory levels of other products of which our marketplace sellers manage inventories. However, there
can be no assurance that our monitoring and related measures will be effective in ensuring fulfillment of our customers’ orders at our
online retail pharmacy and online wholesale pharmacy. Our failure to maintain proper inventory levels for our retail and wholesale
businesses may have a material and adverse effect on our business, financial condition, results of operations and prospects.
Third-party logistics and delivery companies are used to fulfill and deliver orders placed on our platform. If these logistics and
delivery companies fail to provide reliable delivery services, our business and prospects, as well as our financial condition and
results of operations, may be materially and adversely affected.
We leverage our large-scale operations and reputation to enter into contractual arrangements with a number of third-party
delivery companies to deliver our products to our pharmacy customers and consumers. We may also use third-party service providers to
ship products from our fulfillment centers to delivery stations or to deliver bulky item products. Interruptions to or failures in these third
parties’ delivery services could prevent the timely or proper delivery of our products to pharmacy customers and consumers. These
interruptions may be due to events that are beyond our control or the control of these delivery companies, such as inclement weather,
natural disasters, transportation disruptions or labor unrest. We may not be able to find alternative delivery companies to
12
Table of Contents
provide delivery services in a timely and reliable manner, or at all. If products are not delivered in proper condition or on a timely basis,
our business and reputation could suffer.
Our self-developed technologies are complex and may contain undetected errors or may not operate properly, which could
adversely affect our business, financial condition and results of operations.
Our self-developed technology platform provides our consumers and other participants in our ecosystem with the ability to
conduct a variety of actions essential to the operations of our business and the delivery of our solution. Technology development is time-
consuming, expensive and complex, and may involve unforeseen difficulties. We may encounter technical obstacles, and it is possible
that we may discover additional problems that prevent our technologies from operating properly and consequently adversely affect our
information infrastructure and other aspects of our business where our technologies are applied. If our solution does not function reliably
in terms of performance, we may lose existing, or fail to attract new participants to our platform, which may damage our reputation and
adversely affect our business.
Moreover, data services, supply chain management systems, and other proprietary technologies we provide to pharmacies,
pharmaceutical companies and other customers are complex and those we offer may develop or contain undetected defects or errors.
Material performance problems, defects or errors in our existing or new software and applications and services may arise in the future
and may result from interface issues between our systems and data that we did not develop and the function of which is beyond our
control or undetected in our testing. These defects and errors, and any failure by us to identify and address them, could result in loss of
revenue or market share, diversion of development resources, harm to our reputation and increased service and maintenance costs.
Defects or errors may discourage existing or potential customers from utilizing our solution. Correction of defects or errors could prove
to be impossible or impracticable. The costs incurred in correcting any defects or errors may be substantial and could have a material
adverse effect on our business, financial condition and results of operations. Defects or errors may also affect our pharmacies,
pharmaceutical companies or other customers who rely on our self-developed technologies in the operation of their businesses, which
may have a material adverse effect on our reputation, business, results of operations and prospects.
We may be subject to penalties or disputes against us for failure to manage the multi-institution practices of our in-house medical
team and external doctors.
The practice of doctors is strictly regulated under PRC laws, rules and regulations. Doctors who practice at medical institutions
must hold practicing licenses and may only practice within the scope of their licenses and at the specific medical institutions as stated in
their licenses. A doctor is required to register the medical institutions at which he or she practices in his or her license. If a doctor is
found practicing at a medical institution not registered in his or her license, the doctor would be subject to regulatory penalties, from
warning to suspension of practice and, in the worst-case scenario, revocation of licenses. A doctor practicing in multiple institutions must
apply to register or file with competent in-charge administrative authorities and can only have the right to prescribe medicine at the
registered or filed practicing institution. If the doctor issues a prescription in a medical institution not registered in his or her license, the
relevant medical institution would also be subject to regulatory penalties, including a fine of up to RMB5,000 and, in the worst-case
scenario, revocation of the medical institution’s Practicing License for Medical Institutions.
We cannot assure you that our in-house and external doctors will complete the registration and relevant government procedures
in a timely manner, or at all, or that our in-house and external doctors will not practice outside the permitted scope of their respective
licenses. Our failure to properly manage the registration of our in-house doctors may subject us to administrative penalties against our
medical institution, including fines, or, in the worst-case scenario, revocation of our Practicing License for Medical Institutions, any of
which could materially and adversely affect our business. Meanwhile, if our in-house and external doctors are found to have deficient
registration or found to be practicing beyond the scope permitted by relevant authorities, they may be disciplined and lose their practicing
licenses. In the event that the multi-institution practices of our in-house and external doctors are in breach of their contractual obligations
owed to other institutions, such as non-compete obligations, we may be exposed to indemnity or other legal liabilities if we are deemed
to have aided in these breaches, and are therefore susceptible to legal disputes and potential damages. As a result, we may no longer be
able to employ them in offering our online consultation services, which could materially and adversely affect our business. In addition,
there can be no assurance that we could timely find qualified replacements on commercially reasonable terms, or at all.
13
Table of Contents
We may not be able to prevent others from unauthorized use of our intellectual property, which could harm our business and
competitive position.
We regard our trademarks, copyrights, patents, domain names, know-how, proprietary technologies, and similar intellectual
property as critical to our success, and we rely on a combination of intellectual property laws and contractual arrangements, including
confidentiality agreements with our employees and third parties, to protect our proprietary rights. Despite these measures, it is often
difficult to enforce intellectual property rights in China. Even where adequate laws exist, certain procedural issues create effective
obstacles to the proper enforcement of intellectual property rights. In addition, the available remedies in both court proceeding and
through administrative enforcement are often inadequate to address infringement or to provide intellectual property rights holders with
full compensation for the losses caused. Accordingly, we may not be able to effectively protect our intellectual property rights or to
enforce confidentiality undertakings in China. In addition any of our intellectual property rights could be challenged, invalidated,
circumvented or misappropriated, or such intellectual property may not be sufficient to provide us with competitive advantages. In
addition, although we are not aware of any copycat websites or mobile apps that attempt to cause confusion or traffic diversion from us at
the moment, we may become an attractive target to such attacks in the future because of our brand recognition.
In addition, there can be no assurance that our patent applications would be approved, that any issued patents would adequately
protect our intellectual property, or that such patents would not be challenged by third parties or found by a judicial authority to be
invalid or unenforceable.
We may be subject to allegations, lawsuits and administrative penalties relating to the sale, distribution, marketing and
advertising of counterfeit or substandard products in our pharmaceutical retail and wholesale businesses, which may damage
our brand and reputation and have a material adverse effect on our business, financial condition, results of operations and
business prospects.
Certain products distributed or sold in the pharmaceutical retail and wholesale markets in China may be manufactured without
proper licenses or approvals and/or fraudulently mislabeled with respect to their content and/or manufacturer. These products are
generally referred to as counterfeit or substandard pharmaceutical products. The current counterfeit and substandard product regulation
control and enforcement system in China is not sufficiently mature to completely eliminate the manufacturing and sales of counterfeit
pharmaceutical products. Counterfeit and substandard pharmaceutical products are generally sold at lower prices than authentic
pharmaceutical products, and, in some cases, are very similar in appearance to the authentic pharmaceutical products. Therefore, the
presence of counterfeit products of pharmaceuticals distributed or sold by us can quickly erode our sales volumes and revenue for the
relevant products.
Furthermore, counterfeit or substandard products may or may not have the same chemical composition as the authentic
counterparts, which may make them less effective than the authentic ones, entirely ineffective, or more likely to cause severe adverse
side effects. We may not be able to identify those counterfeit or substandard products we source from our suppliers. Any unintentional
and unknowing sales of counterfeit or substandard products in our pharmaceutical distribution or retail businesses, or sales of counterfeit
and substandard products by third parties illegally using our brand names, may subject us to negative publicity, fines and other
administrative penalties, or even result in litigation relating to the sale, marketing and advertising of those products. Moreover, the
continuing presence of counterfeit and substandard products may reinforce the negative image of distributors and retail pharmacies
among consumers in general, and may severely harm the reputation and brand names of pharmaceutical companies, including ourselves.
Similarly, consumers may buy counterfeit and substandard products that are in direct competition with products distributed or sold in our
pharmaceutical retail and wholesale businesses, which may materially and adversely affect the sales volumes of the relevant products in
our portfolio and further impact our business, financial condition, results of operations and prospects.
14
Table of Contents
If we fail to provide satisfactory customer experience and continue to increase our retail and wholesale customer base, our
business may be materially and adversely affected.
Our business is highly dependent on the receptiveness of our pharmacy customers and consumers to our services and products
as well as their willingness to use, and to increase the frequency and extent of their utilization of, our solution. Their degree of
receptiveness to our services and products depends on a number of factors, including the demonstrated accuracy and efficacy of our
offerings compared to those of others, turnaround time, cost-effectiveness, convenience and marketing support. In addition, negative
publicity concerning our solution or the internet healthcare market as a whole could limit market acceptance of our solution, especially
that of the online consultation services. Meanwhile, there can be no assurance that our efforts and ability to demonstrate the value of our
solution and the relative benefits of our services and products over those of our competitors to our pharmacy customers and consumers
would be successful. If we fail to achieve an adequate level of acceptance by our pharmacy customers and consumers of our services and
products, or if our solution does not drive their engagement, then our business may not develop as expected, or at all, and our business,
financial condition or results of operations may be materially and adversely affected.
The success of our business also hinges on our ability to provide satisfactory customer experience, which depends on our ability
to continue to deliver quality care to our users, to maintain the quality of our services and products, to source services and products that
are responsive to customer demands, and to provide timely and reliable delivery, flexible payment options and satisfactory after-sales
services. Such ability, in turn, depends on a variety of factors beyond our control. In particular, we rely on a number of third parties in the
provision of our services and products. Their failure to provide a high-quality customer experience to our pharmacy customers and
consumers may adversely affect our pharmacy customers’ and consumers’ receptiveness of, and willingness to utilize our solution, which
may damage our reputation and cause us to lose pharmacy customers and consumers.
In addition, we operate a customer service center to provide assistance to our pharmacy customers and consumers. If our
customer service representatives fail to provide satisfactory service, or if waiting times are too long due to high volume of inquiries from
customers at peak times, our brand and customer loyalty may be adversely affected. Moreover, any negative publicity or poor feedback
on our customer service may harm our brand and reputation and, in turn, cause us to lose pharmacy customers and consumers and market
share.
The failure of in-house medical team and external doctors to provide adequate and proper service to consumers may have a
material and adverse effect on our business, financial condition and results of operations.
Our in-house medical team, external doctors and other employees, may provide sub-standard services, mishandle sensitive
information, engage in other misconduct or commit medical malpractice, which could subject us to medical liability claims. Our
business, financial condition, results of operations and reputation may be materially and adversely affected if any such claims are made
against us in connection with these actions that are not fully covered by insurance. See “—We may become subject to product liability
and medical liability claims, which could cause us to incur significant expenses and be liable for significant damages if not covered by
insurance.” With respect to external doctors, as they often work remotely, we have limited control over them as well as the quality of
their online medical consultation services. There can be no assurance that our risk management procedures will be sufficient to monitor
their performance and control the quality of their work. In the event that the external doctors fail to comply with the contractual
obligations and applicable laws in relation to the provision of our online consultation services, our user experience could deteriorate, and
we may suffer as a result of any actual or alleged misconduct by them, which could materially and adversely affect our business,
financial condition, results of operations and reputation.
15
Table of Contents
The failure of our marketplace sellers to control the quality of products they sell on our platform, or to make timely and accurate
delivery of their products sold on our platform, may have a material and adverse effect on our business, financial condition and
results of operations.
Under the direct sales model, we manage inventories in an integrated process. Under our marketplace model, many of our
marketplace sellers use their own facilities to store their products and utilize their own or third-party delivery systems to deliver their
products to our pharmacy customers and consumers, which makes it difficult for us to ensure that our pharmacy customers and
consumers get consistent quality products and services for all products sold through our online platforms. If any marketplace seller fails
to control the quality of the products that it sells on our platforms, or if it does not deliver the products or delivers them late or delivers
products that are materially different from their description, or if it sells counterfeit or unlicensed products through our platforms, or if it
does not possess requisite licenses or permits as required by relevant laws and regulations despite our online background check for such
licenses or permits on the marketplace seller, the reputation of our retail and wholesale pharmacy and our brand may be materially and
adversely affected and we could face claims and may be held liable for damages in connection with such claims.
Any disruption to the operation of our current fulfillment facilities, or to the development of our new facilities, could reduce or
negatively impact sales and have a material adverse effect on our business, financial condition and results of operations.
We rely on our fulfillment centers for the continuing operation of our pharmaceutical distribution business. Natural disasters or
other unanticipated catastrophic events, including power interruptions, water shortage, storms, fires, earthquakes, terrorist attacks and
wars, as well as changes in governmental planning for the land underlying these facilities, could significantly impair our ability to
operate our business and destroy any inventory located in these facilities. In addition, our fulfillment centers that meet the requirements
of modern logistics operations for guaranteed storage safety, optimal and flexible space utilization and high operational efficiency are in
short supply. We may not be able to replace these facilities and equipment in a timely manner, should any of the foregoing occur.
Furthermore, the leases for our fulfillment centers and our use thereof could be challenged by third parties or government
authorities, which may cause interruptions to our business operations. Certain lessors of our leased fulfillment centers have not provided
us with their property ownership certificates or any other documentation proving their right to lease those properties to us. If our lessors
are not the owners of the properties and they have not obtained consents from the owners or their lessors or permits from the relevant
government authorities, our leases could be invalidated and we may have to renegotiate the leases with the owners or the parties who
have the right to lease the properties, and the terms of the new leases may be less favorable to us. Also, certain of our leasehold interests
in leased properties have not been registered with the relevant PRC government authorities as required by PRC law, which may expose
us to potential fines. Although we are not aware of any claims or actions being contemplated or initiated by government authorities,
property owners or any other third parties with respect to our leasehold interests in or use of such properties, we cannot assure you that
our use of such leased properties will not be challenged. In the event that our use of leased properties is successfully challenged, we may
be subject to fines and forced to relocate the affected operations. We can provide no assurance that we will be able to find suitable
replacement sites on terms acceptable to us on a timely basis, or at all, or that we will not be subject to material liability resulting from
third parties’ challenges on our use of such properties.
16
Table of Contents
Our wide variety of accepted payment methods subjects us to third-party payment processing-related risks.
We accept payments using a variety of methods, including payment on delivery, bank transfers, online payments with credit
cards and debit cards issued by major banks in China, and payment through third-party online payment platforms. For certain payment
methods, including credit and debit cards, we pay interchange and other fees, which may increase over time and raise our operating costs
and lower our profit margins. We may also be subject to fraud and other illegal activities in connection with the various payment methods
we offer, including online payment and cash-on-delivery options. We also rely on third parties to provide payment processing services.
We use third-party couriers to deliver all of the orders. The delivery personnel of our third-party couriers collect payments on our behalf
if our customers opt for the payment-on-delivery option, and we require the third-party couriers to remit the payment collected to us on
the following day. If these companies fail to remit the payment collected to us in a timely fashion, or at all, if they become unwilling or
unable to provide these services to us, or if their service quality deteriorates, our business could be disrupted. We may also be subject to
fraud and other illegal activities in connection with the various payment methods we offer, including online payment and cash-on-
delivery options. Although we rely on third parties to provide payment processing services, we are also subject to various rules,
regulations and requirements, regulatory or otherwise, governing electronic funds transfers, which could change or be reinterpreted to
make it difficult or impossible for us to comply. If we fail to comply with these rules or requirements, we may be subject to fines and
higher transaction fees and lose our ability to accept credit and debit card payments from our pharmacy customers and consumers,
process electronic funds transfers or facilitate other types of online payments, and our business, financial condition and results of
operations could be materially and adversely affected.
Any damage to the reputation and recognition of our brand names, including negative publicity against us, may materially and
adversely affect our business operations and prospects.
We depend on our reputation and brand names in many aspects of our business operations. However, we cannot assure you that
we will be able to maintain a positive reputation or brand name for all of our products in the future. Our reputation and brand names may
be materially and adversely affected by a number of factors, many of which are beyond our control, including:
● adverse associations with the third party-branded products we sell or which are sold in our stores or on our platform,
including with respect to their efficacy or side effects;
● lawsuits and regulatory investigations against us or otherwise relating to our products or industry;
● improper or illegal conduct by our employees, retail and wholesale pharmacies and third-party promoters, that is not
authorized by us; and
● adverse publicity associated with us, our products or our industry, whether founded or unfounded.
Any damage to our brand names or reputation as a result of these or other factors may cause our products to be perceived
unfavorably by pharmacies, doctors, regulators and consumers and the existing and prospective employees, retail and wholesale
pharmacies and third-party promoters, and our business operations and prospects could be materially and adversely affected as a result.
Our business may be materially and adversely affected by adverse news, scandals or other incidents associated with the PRC
general health and wellness industry.
Incidents that reflect doubt as to the quality or safety of pharmaceutical products manufactured, distributed or sold by other
participants in the PRC general health and wellness industry, particularly the internet healthcare industry, including our competitors, have
been, and may continue to be, subject to widespread media attention. Such incidents may damage the reputation of not only the parties
involved, but also the general health and wellness industry in general, even if such parties or incidents have no relation to us, our
management, our employees, our suppliers, our distributors or our retail pharmacies. Such negative publicity may indirectly and
adversely affect our reputation and business operations. In addition, incidents not related to product quality or safety, or other negative
publicity or scandals implicating us or our employees, regardless of merit, may also have an adverse impact on us and our reputation and
corporate image.
17
Table of Contents
If our risk management and internal control system is not adequate or effective, and if it fails to detect potential risks in our
business as intended, our business, financial condition and results of operations could be materially and adversely affected.
We have established our internal control system, such as an organizational framework and, policies and procedures that are
designed to monitor and control potential risk areas relevant to our business operations. However, due to the inherent limitations in the
design and implementation of our internal control system, our internal control system may not be sufficiently effective in identifying,
managing and preventing all risks if external circumstances change substantially or extraordinary events take place.
Furthermore, our new business initiatives may give rise to additional internal control risks that are currently unknown to us,
despite our efforts to anticipate such issues. If our internal control system fails to detect potential risks in our business as intended or is
otherwise exposed to weaknesses and deficiencies, our business, financial condition and results of operations could be materially and
adversely affected.
Our risk management and internal controls also depend on effective implementation by our employees. There can be no
assurance that such implementation by our employees will always function as intended or such implementation will not involve any
human errors, mistakes or intentional misconduct. If we fail to implement our policies and procedures in a timely manner, or fail to
identify risks that affect our business with sufficient time to plan for contingencies for such events, our business, financial condition and
results of operations could be materially and adversely affected, particularly with respect to the maintenance of our relevant approvals
and licenses granted by governments.
We may experience failures in our information technology system, which could materially and adversely affect our business,
financial condition and results of operations.
We depend heavily on our information technology system to manage our business processes, to record and process our
operational and financial data, and to provide reliable services. We have built secure, stable and scalable IT infrastructure. However, our
information technology system may fail due to natural disasters or failures of public infrastructure, our information technology
infrastructure or our applications software systems that are wholly or partially beyond our control. Any material disruption to the
operation of our information technology system could have a material adverse effect on our business. Our failure to address these
problems could result in our inability to perform, or delays in our performance of, critical business operational functions, loss of key
business data, or our failure to comply with regulatory functions, which could materially and adversely affect our business operations and
customer service.
We may be held liable for information or content displayed on, retrieved from or linked to our mobile applications or website,
which may materially and adversely affect our business and operating results.
In addition to our website, we also offer healthcare products and services through our mobile applications, which are regulated
by the Administrative Provisions on Mobile Internet Applications Information Services, or the APP Provisions, promulgated by the
CAC, on June 28, 2016 and effective on August 1, 2016. According to the APP Provisions, the providers of mobile applications shall not
create, copy, publish or distribute information and content that is prohibited by laws and regulations. We have implemented internal
control procedures screening the information and content on our mobile applications to ensure their compliance with the APP Provisions.
However, we cannot assure that all the information or content displayed on, retrieved from or linked to our mobile applications complies
with the requirements of the APP Provisions and other related regulations and rules at all times. If our mobile applications were found to
be violating the APP Provisions, we may be subject to administrative penalties, including warning, service suspension or removal of our
mobile applications from the relevant mobile application store, which may materially and adversely affect our business and operating
results.
18
Table of Contents
We rely on assumptions and estimates to calculate certain key operating metrics, and inaccuracies in such metrics may harm our
reputation and adversely affect our business.
Certain key operating metrics in this annual report are calculated using our internal data that have not been independently
verified by third parties. While these numbers are based on what we believe to be reasonable calculations for the applicable periods of
measurement, there are some challenges in measuring those metrics, such as GMV and repurchase rate. In addition, our key operating
metrics are derived and calculated based on different assumptions and estimates, and you should be cautious of such assumptions and
estimates when assessing our operating performance.
Our operating metrics may differ from estimates published by third parties or from similarly titled metrics used by our
competitors due to differences in data availability, sources and methodology. If third parties do not perceive our user metrics to be
accurate representations of our user base or user engagement, or if we discover material inaccuracies in our operating metrics, our
reputation may be harmed and third parties may be less willing to allocate their resources or spending to us, which could adversely affect
our business and operating results.
Some pharmaceutical products offered by us are subject to price restrictions and will continue to be subject to price competition
in China, but may be pending on changes of the regulations.
Some of our pharmaceutical products were subject to government price controls in the form of fixed retail prices or retail price
ceilings and periodic downward adjustments imposed by National Development and Reform Commission, or the NDRC, and other
authorities. Pursuant to the Notice Regarding the Opinion on Facilitating the Pharmaceutical Pricing Reform jointly issued by the
National Development and Reform Commission, or the NDRC, the NHFPC and five other PRC government agencies in May 2015, the
price ceilings imposed by the PRC government on pharmaceutical products other than narcotic and Class I psychotropic drugs were lifted
on June 1, 2015, and these products would be subject to a more market-based pricing system adopted by medical insurance bureaus and
relevant authorities.
Even prior to the lifting of government price controls on pharmaceutical products, the prices of prescription drugs in China had
been determined by the centralized tender process and the prices of OTC drugs in China had been determined by arm’s-length,
commercial negotiation and market factors such as brand recognition, market competition and consumer demand. There is no assurance
that the application of the more market-based pricing system will result in a higher product pricing compared to the government-
controlled pricing, as competition from other retailers and wholesalers, particularly those offering the same products but with lower
prices, may force us to lower our sales prices to the previous government-controlled price levels. Consequently, our profitability may
suffer and our business, financial condition and results of operations may also be materially and adversely affected.
In addition, the State Council and other relevant authorities issued a series of policies on deepening the reform of medical and
healthcare system in 2019. According to the Notice on Issuance of the Pilot Plan regarding the Organization of Centralized Procurement
and Use of Drugs by the State and the Implementation Opinions on Region Expansion of the Organization of Centralized Procurement
and Use of Drugs by the State, the state planned to organize centralized procurement and use of certain types of pilot drugs to lower drug
price, reduce the burden on patients of drug costs, and lower the transaction costs of pharmaceutical enterprises. The Guidance on
Improving “Internet +” Medical Service Price and Medical Insurance Payment Policies issued by the National Healthcare Security
Administration proposed to improve project management, optimize the pricing mechanism and clarify the payment policy of “Internet +”
medical services. Although such policies may lower the transaction costs of the pharmaceutical enterprises and increase the amount of
drugs purchased, they may also reduce the sales prices of the drugs and increase market competition within the pharmaceutical industry.
There are still uncertainties relating to the actual implementation of such policies. The National Healthcare Security Administration
promulgated the Notice on Accelerating the Implementation of Drug Prices and Bid Invitation and Procurement Credit Assessment
System, which requires that the provincial medical security bureaus and centralized procurement institutions shall establish the drug
prices and bid invitation and procurement credit assessment system before the end of 2020. The General Office of the State Council
promulgated the Opinions on Promoting the Systematism and Normalization of Centralized and Target-quantity Procurement of Drug in
January 2021, to guide the regression of drug prices to reasonable level, reduce the burden of using drugs and promote the healthy
development of pharmaceutical industry.
19
Table of Contents
If we fail to implement and maintain an effective system of internal controls to remediate our material weakness over financial
reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and
investor confidence and the trading price of the ADSs may be materially and adversely affected.
We are subject to reporting obligations under the U.S. securities laws. The SEC, as required by Section 404 of the Sarbanes-
Oxley Act of 2002, adopted rules requiring every public company to include a management report on the company’s internal control over
financial reporting in its annual report, which contains management’s assessment of the effectiveness of our internal control over
financial reporting. Our management has concluded that our internal control over financial reporting was effective as of December 31,
2020. See “Item 15. Controls and Procedures—Management’s Annual Report on Internal Control over Financial Reporting.” Our
independent registered public accounting firm has issued an attestation report, which has concluded that our internal control over
financial reporting is effective as of December 31, 2020.
However, any failure to achieve and maintain effective internal control over financial reporting could result in the loss of
investor confidence in the reliability of our consolidated financial statements, which in turn could harm our business and negatively
impact the trading price of the ADSs. Furthermore, we have incurred and anticipate that we will continue to incur considerable costs,
management time and other resources in an effort to comply with Section 404 and other requirements of the Sarbanes-Oxley Act.
Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets
and subject us to potential delisting from the Nasdaq, regulatory investigations and civil or criminal sanctions.
Competition for employees is intense, and we may not be able to attract and retain the qualified and skilled employees needed to
support our business.
We believe our success depends on the efforts and talent of our employees, including medical professionals, risk management,
software engineering, financial and marketing personnel. Our future success depends on our continued ability to attract, develop,
motivate and retain qualified and skilled employees. Competition for highly skilled technical, risk management and financial personnel is
extremely intense. We may not be able to hire and retain these personnel at compensation levels consistent with our existing
compensation and salary structure. Some of the companies with which we compete for experienced employees have greater resources
than we have and may be able to offer more attractive terms of employment.
In addition, we invest significant time and expenses in training our employees, which increases their value to competitors who
may seek to recruit them. If we fail to retain our employees, we could incur significant expenses in hiring and training new employees,
and the quality of our services and our ability to serve various participants in the pharmaceutical value chain could decline, resulting in a
material adverse effect to our business.
Our business depends on the continued efforts of our senior management. If one or more of our key executives were unable or
unwilling to continue in their present positions, our business may be severely disrupted.
Our future success depends heavily upon the continued services of our senior executives, key research and development
personnel and key sales and marketing personnel. We rely on the expertise and experience of our founders, Dr. Gang Yu and Mr. Junling
Liu, especially in areas of supply chain management and e-commerce. Our research and development team is critical to the development
of proprietary technologies used by our online and offline, retail and wholesale businesses, and realization of the potential benefits of our
intellectual property. In addition, success in the distribution of our products depends on the dedication and skills of our sales and
marketing personnel. Accordingly, our ability to attract and retain key personnel is a critical factor in our competitiveness. Competition
for these individuals could require us to offer higher compensation and other benefits in order to attract and retain them, which could
increase our operating expenses and, in turn, materially and adversely affect our financial condition and results of operations. If we are
unable to attract or retain the personnel required to achieve our business objectives, our business could be severely disrupted.
20
Table of Contents
We do not maintain key-person insurance for members of our management team. If we lose the services of any senior
management, we may not be able to identify suitable or qualified replacements, and may incur additional expenses to recruit and train
new personnel, which could severely disrupt our business and prospects and prolong our expansion strategies and plans. Furthermore, if
any of our executive officers joins a competitor or forms a competing company, we may lose a significant number of our existing
pharmacy customers and consumers and potentially lose our substantial research and development achievements, which could have a
material adverse effect on our business, financial condition, results of operations and prospects.
We may from time to time become party to litigation, other legal or administrative disputes and proceedings that may materially
and adversely affect us.
In the course of our ordinary business operations, we may become a party to litigation, legal proceedings, claims, disputes or
arbitration proceedings from time to time. Any ongoing litigation, legal proceedings, claims, disputes or arbitration proceedings may
distract our senior management’s attention and consume our time and other resources. In addition, even if we ultimately succeed in such
litigation, legal proceedings, claims, disputes or arbitration proceedings, there may be negative publicity attached to such litigation, legal
proceedings, claims, disputes or arbitration proceedings, which may materially and adversely affect our reputation and brand names. In
the case of an adverse verdict, we may be required to pay significant monetary damages, assume significant liabilities or suspend or
terminate parts of our operations. As a result, our business, financial condition, results of operations and prospects may be materially and
adversely affected.
We may not have sufficient insurance to cover our business risks.
We have obtained insurance to cover certain potential risks and liabilities, such as professional liability insurance for our doctors
in connection with their provision of medical consultation services over our platform, and product liability insurance for us and our
suppliers with respect to products sold in our retail pharmacy and online wholesale pharmacy through 1 Medicine Marketplace and 1
Pharmacy, respectively. However, we may not be able to acquire any insurance for certain types of risks such as business liability or
service disruption insurance for all of our operations in the PRC, and our coverage may not be adequate to compensate for all losses that
may occur, particularly with respect to loss of business or operations. For example, we do not maintain business interruption insurance,
nor do we maintain key-man life insurance. Any business disruption, litigation, regulatory action, outbreak of epidemic disease or natural
disaster could also expose us to substantial costs and diversion of resources. There can be no assurance that our insurance coverage is
sufficient to prevent us from any loss or that we will be able to successfully claim our losses under our current insurance policies on a
timely basis, or at all. If we incur any loss that is not covered by our insurance policies, or the compensated amount is significantly less
than our actual loss, our business, financial condition and results of operations could be materially and adversely affected.
21
Table of Contents
We may be subject to intellectual property infringement claims, which may be expensive to defend and may disrupt our business
and operations.
We cannot be certain that our operations or any aspects of our business do not or would not infringe upon or otherwise violate
trademarks, patents, copyrights or other intellectual property rights held by third parties. We may be, from time to time, or in the future,
become subject to legal proceedings and claims relating to the intellectual property rights of others. In addition, there may be other third-
party intellectual property that is infringed by our products, services or other aspects of our business. There could also be existing
intellectual property of which we are not aware that our products may inadvertently infringe. There can be no assurance that holders of
such intellectual property purportedly relating to some aspect of our technology platform or business, if any such holders exist, would not
seek to enforce such intellectual property against us in the PRC or in any other jurisdictions, as applicable. Furthermore, the application
and interpretation of PRC intellectual property related laws and the procedures and standards in the PRC are still evolving and are
uncertain, and there can be no assurance that PRC courts or regulatory authorities would agree with our analysis. If we are found to have
violated the intellectual property rights of others, we may be subject to liability for our infringement activities or may be prohibited from
using such intellectual property, and we may incur licensing fees or be forced to develop alternatives of our own. In addition, we may
incur significant expenses, and may be forced to divert management’s time and other resources from our business and operations to
defend against these third-party infringement claims, regardless of their merits. Successful infringement or licensing claims made against
us may result in significant monetary liabilities and may materially disrupt our business and operations by restricting or prohibiting our
use of the intellectual property in question, which may materially and adversely affect our business, financial condition and results of
operations.
Failure to renew our current leases or locate desirable alternatives for our facilities could materially and adversely affect our
business.
We lease properties for our offices, offline retail pharmacies and fulfillment centers. We may not be able to successfully extend
or renew such leases upon expiration of the current term on commercially reasonable terms or at all, and may therefore be forced to
relocate our affected operations. This could disrupt our operations and result in significant relocation expenses, which could adversely
affect our business, financial condition and results of operations. In addition, we compete with other businesses for premises at certain
locations or of desirable sizes. As a result, even though we could extend or renew our leases, rental payments may significantly increase
as a result of the high demand for the leased properties. In addition, we may not be able to locate desirable alternative sites for our
facilities as our business continues to grow and failure in relocating our affected operations could adversely affect our business and
operations.
Security breaches and attacks against our systems and network, and any potential resultant breach or failure to otherwise protect
confidential and proprietary information, could damage our reputation and adversely affect our business, financial condition
and results of operations.
We rely heavily on technology, particularly the internet, to provide high-quality online services. However, our technology
operations are vulnerable to disruptions arising from human error, natural disasters, power failure, computer viruses, spam attacks,
unauthorized access and other similar events. Disruptions to, or instability of, our technology or external technology that allows our
pharmacy customers and consumers to use our online services and products could materially harm our business and reputation.
22
Table of Contents
Although we have employed significant resources to develop security measures against breaches, our cybersecurity measures
may not detect or prevent all attempts to compromise our systems, including distributed denial-of-service attacks, viruses, malicious
software, break-ins, phishing attacks, social engineering, misconduct or sabotage by our employees, security breaches or other attacks
and similar disruptions that may jeopardize the security of information stored in and transmitted by our systems or that we otherwise
maintain. Breaches of our cybersecurity measures could result in unauthorized access to our systems, misappropriation of information or
data, deletion or modification of user information, or a denial-of-service or other interruption to our business operations. As techniques
used to obtain unauthorized access to or sabotage systems change frequently and may not be known until launched against us, we may be
unable to anticipate, or implement adequate measures to protect against, these attacks. There can be no assurance that we would not in
the future be subject to such attacks that may result in material damages or remediation costs. If we are unable to avert these attacks and
security breaches, we could be subject to significant legal and financial liability, our reputation would be harmed and we could sustain
substantial revenue loss from lost sales and customer dissatisfaction.
In addition, we may not have the resources or technical sophistication to anticipate or prevent rapidly evolving types of cyber-
attacks. Cyber-attacks may target us, our users or other participants of our ecosystem, or the information infrastructure on which we
depend. Actual or anticipated attacks and risks may cause us to incur significantly higher costs, including costs to deploy additional
personnel and network protection technologies, train employees, and engage third-party experts and consultants. Cybersecurity breaches
may harm our reputation and business, and materially and adversely affect our financial condition and results of operations.
Our failure to comply with anti-corruption laws and regulations, or effectively manage our employees, marketplace sellers and
affiliates, could severely damage our reputation, and materially and adversely affect our business, financial condition, results of
operations and prospects.
We are subject to risks in relation to actions taken by us, our employees, marketplace sellers or affiliates that constitute
violations of the anti-corruption laws and regulations. There have been several instances of corrupt practices in the pharmaceutical
industry, including, among other things, receipt of kickbacks, bribes or other illegal gains or benefits by pharmacies, hospitals and
medical practitioners from manufacturers, distributors and retail pharmacies in connection with the prescription of pharmaceutical
products. While we adopt strict internal procedures and work closely with relevant government agencies to ensure compliance of our
business operations with relevant laws and regulations, our efforts may not be sufficient to ensure that we comply with relevant laws and
regulations at all times. If we, our employees, marketplace sellers or affiliates violate these laws, rules or regulations, we could be subject
to fines and/or other penalties. In the case of our retail and wholesale businesses, the products involved may be seized and our operations
may be suspended. Actions by PRC regulatory authorities or the courts to provide an interpretation of PRC laws and regulations that
differs from our interpretation or to adopt additional anti-bribery or anti-corruption related regulations could also require us to make
changes to our operations. Our reputation, corporate image, and business operations may be materially and adversely affected if we fail
to comply with these measures or become the target of any negative publicity as a result of actions taken by us, our employees,
marketplace sellers or affiliates, which may in turn have a material adverse effect on our business, financial condition, results of
operations and prospects.
Our delivery, return and exchange policies may materially and adversely affect our results of operations.
We have adopted shipping policies that do not necessarily pass the full cost of shipping on to our pharmacy customers and
consumers. We have also adopted policies that permit the return and exchange of our products within thirty days in certain circumstances
for specified reasons. We may also be required by law to adopt new or amend existing return and exchange policies from time to time.
For example, pursuant to the Consumer Protection Law and relevant regulations and rules, consumers are generally entitled to return
products purchased within seven days upon receipt without reason when they purchase the products from business operators on the
internet with certain exception, such as pharmaceutical products. These policies subject us to additional costs and expenses which we
may not recoup through increased revenue. Our ability to handle a large volume of returns is unproven. If we revise these policies to
reduce our costs and expenses, our pharmacy customers and consumers may be dissatisfied, which may result in loss of existing
consumers and pharmacy customers or failure to acquire new consumers and pharmacy customers at a desirable pace, which may
materially and adversely affect our results of operations.
23
Table of Contents
If we are subject to higher product return rates, our business, financial condition and results of operations may be materially and
adversely affected.
We have established a thirty-day product return policy in certain circumstances for specified reasons. In addition, pursuant to the
Consumer Protection Law, consumers are generally entitled to return purchased products within seven days upon receipt without giving
any reasons when they purchase the products from business operators on the internet. Although a majority of our products may not be
returned or exchanged under the Administrative Standard of Pharmaceutical Operating Quality, prohibiting returns and exchanges of
pharmaceutical products except for quality reasons, if our product return rates increase or are higher than expected, our revenues and
costs can be negatively impacted. Furthermore, as we cannot return some products to our suppliers pursuant to our contracts with them or
if return rates for such products increase significantly, we may experience an increase in our inventory balance, inventory impairment
and fulfillment cost, which may materially and adversely affect our working capital. As a result, our business, financial condition and
results of operations may be materially and adversely affected.
We may not be able to conduct our marketing activities effectively, properly, or at reasonable costs, and we are subject to
limitations in promoting our services and products, which will have an impact on our business operations.
We invest significant resources in a variety of different marketing and brand promotion efforts designed to enhance our brand
recognition and increase sales of our services and products. However, our brand promotion and marketing activities may not be well
received and may not result in the levels of sales that we anticipate. Meanwhile, marketing approaches and tools in the PRC internet
healthcare market are continually evolving, which may further require us to enhance our marketing approaches and experiment with new
marketing methods to keep pace with industry developments and customer preferences. Failure to refine our existing marketing
approaches or to introduce new marketing approaches in a cost-effective manner could reduce our market share and materially and
adversely affect our financial condition, results of operations and profitability. In addition, we are subject to certain limitations in
promoting services and products. Our in-house medical team and external doctors and other relevant parties in the provision of our
medical and wellness services have to comply with rules and regulations that restrict the promotion or dissemination of information
about the professional healthcare services and practice provided by licensed doctors, and the publication or marketing efforts for the
predominant purpose of promoting the products or services of doctors to consumers or potential consumers. Such restrictions may affect
our ability to further enhance our brand recognition or secure new business opportunities in the future.
Under PRC laws and regulations, all advertisements published online containing drug names, applicable symptoms treated by
such drugs (major functions) or other drug-related content, and advertisements published online containing medical device names and the
applicable scope, performance, structure and composition, function and other contents relevant to medical device are subject to
examination by relevant government authorities. We are prohibited from publishing advertisements of prescription drugs on our website
and must ensure that any advertisement of medical treatment, drugs or medical devices does not include any assertion or guarantee as to
the function and safety or any statement of curative rate and effectiveness of such medical treatment, drugs or medical devices. Any
violation of advertisement-related laws and regulations may subject us to fine, or even suspension of our business or revocation of our
business license. See “Item 4. Information on the Company—B. Business Overview—Regulations—Regulations Relating to Online
Advertising.” Although we have implemented internal procedures to examine the content of advertisements displayed on our website, we
cannot assure you that all such content meets the requirements under PRC advertising-related laws and regulations at all times. In the
past, we have been required to pay penalties for advertisements displayed on our website due to non-compliance with advertising laws.
There can be no assurance that our existing practices of monitoring our information dissemination process and publication
would continue to be effective and would comply fully with laws and regulations. Should there be any change in the relevant rules and
regulations, or change of interpretation thereof, we, our in-house medical team, external doctors and other relevant third parties may be
regarded as breaching the relevant rules and regulations and may be subject to regulatory penalties or disciplinary actions, which may
materially and adversely affect our business and reputation.
We may not be able to detect or prevent fraud or other misconduct committed by our employees or third parties.
Fraud or other misconduct by our employees, such as unauthorized business transactions, bribery and breach of our internal
policies and procedures, unauthorized access to or leakage of the data of our consumers and pharmacy customers, or by third parties,
such as breach of law, may be difficult to detect or prevent. It could subject us to financial loss and sanctions imposed by
24
Table of Contents
governmental authorities while seriously damaging our reputation. This may also impair our ability to effectively attract prospective
users, develop customer loyalty, obtain financing on favorable terms and conduct other business activities.
In particular, we may face risks with respect to fictitious or other fraudulent activities. There can be no assurance that the
measures we have implemented to detect and reduce the occurrence of fraudulent activities would be effective in combating fraudulent
transactions or improving overall satisfaction among our consumers and pharmacy customers, pharmaceutical companies and
marketplace sellers. Our marketplace sellers may also engage in fictitious or “phantom” transactions with themselves or collaborators in
order to artificially inflate their ratings, reputation and search results rankings. This activity may harm other third parties by enabling the
perpetrating marketplace seller to be favored over legitimate ones, may harm consumers by deceiving them into believing that a
marketplace seller is more reliable or trusted than that marketplace seller actually is, and result in inflated GMV from our online
marketplace.
Our risk management systems, information technology systems and internal control procedures are designed to monitor our
operations and overall compliance. However, we may be unable to identify non-compliance or suspicious transactions promptly, or at all.
Furthermore, it is not always possible to detect and prevent fraud or other misconduct committed by our employees, ecosystem
participants or other third parties, and the precautions we take to prevent and detect such activities may not be effective. Therefore, we
are subject to the risk that fraud or other misconduct may have previously occurred but was undetected, or may occur in the future. This
may materially and adversely affect our business, financial condition and results of operations.
Our business operations and financial performance have been adversely affected by the COVID-19 outbreak, may in the future
continue to be affected by the COVID-19 outbreak, and may be affected by other natural disasters, epidemics and other
unforeseeable catastrophes.
Since the end of December 2019, the outbreak of a novel strain of coronavirus, now named as COVID-19, has materially and
adversely affected the global economy. Although the COVID-19 outbreak has increased demand for certain drugs or medical equipment
that we sell, it has caused disruptions to our business operations and those of our customers, suppliers, and logistics providers, to varying
degrees. Our headquarters are located in Shanghai and we currently lease office space in various parts of China to support our operations,
including in Wuhan. We currently operate a fulfilment center in Wuhan and five strategically located, regional fulfillment centers in the
rest of China. The COVID-19 has caused, and may continue to cause, companies in China, including us and certain of our customers and
suppliers, to implement temporary adjustment of work schedules and travel plans or to require employees to work from home and
collaborate remotely. The pandemic has also resulted in the temporary disruption of our fulfillment facilities in Wuhan due to
government-imposed quarantines. While the pandemic has come under control in the PRC since the second quarter of 2020, there remain
significant uncertainties surrounding the COVID-19 outbreak and its further development as a global pandemic. We cannot predict
whether there will be future disruptions in our operations. As a result, we may experience lower efficiency and productivity, internally
and externally, which may adversely affect our business and operations. The extent to which the COVID-19 outbreak impacts our results
of operations will depend on future developments, which are highly uncertain and unpredictable, including new information which may
emerge concerning the severity of this outbreak and future actions we take, if any, to contain this outbreak or treat its impact, among
others.
25
Table of Contents
We may need additional capital but may not be able to obtain it on favorable terms or at all.
We may require additional cash resources due to operating losses or future growth and development of our business, including
any investments or acquisitions we may decide to pursue. If our cash resources are insufficient to satisfy our cash requirements, we may
seek to issue additional equity or debt securities or obtain new or expanded credit facilities. Our ability to obtain external financing in the
future is subject to a variety of uncertainties, including our future financial condition, results of operations, cash flows, share price
performance, liquidity of international capital and lending markets and the PRC governmental regulations over foreign investment and
the PRC healthcare industry. In addition, incurring indebtedness would subject us to increased debt service obligations and could result in
operating and financing covenants that would restrict our operations. There can be no assurance that financing would be available in a
timely manner or in amounts or on terms favorable to us, or at all. Any failure to raise needed funds on terms favorable to us, or at all,
could severely restrict our liquidity as well as have a material adverse effect on our business, financial condition and results of
operations. Moreover, any issuance of equity or equity-linked securities could result in significant dilution to our existing shareholders.
See “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources.”
Our business could be disrupted by network interruptions.
Our business depends on the efficient and uninterrupted operation of our computer and communications systems and our entire
information infrastructure is located in China. Our information infrastructure contains substantial quantities of data relating to our supply
chain information, competitive pricing data and customer base, such as customer behavior, consultation records and transaction data,
among other things, which enable our users to access the full range of our services and other ecosystem participants to conduct their
operations efficiently and effectively over our platforms. Although we have certain precautions to address potential interruptions, such
preparation may not be sufficient and we do not carry business interruption insurance. Furthermore, despite any precautions we may take,
the occurrence of a natural disaster, such as an earthquake, flood or fire, or other unanticipated incidents at our information infrastructure
facilities in China, including power outages, telecommunications delays or failures, break-ins to our systems or computer viruses, could
result in delays or interruptions to our platform and operations as well as loss of our consumers’ and other participants’ data. Any of
these events could damage our reputation, materially disrupt our ecosystem and subject us to liability and claims, which may materially
and adversely affect our business, financial condition and results of operations.
An occurrence of a natural disaster, widespread health epidemic or other outbreaks could have a material adverse effect on our
business, financial condition and results of operations.
Our business could be materially and adversely affected by natural disasters, such as snowstorms, earthquakes, fires or floods,
the outbreak of a widespread health epidemic or other events, such as wars, acts of terrorism, environmental accidents, power shortage,
labor unrest or communication interruptions. The occurrence of such a disaster or prolonged outbreak of an epidemic illness or other
adverse public health developments in the PRC or elsewhere could materially disrupt our business and operations. Such events could also
significantly affect our industry and cause a temporary closure of the facilities we use for our operations, which would severely disrupt
our operations and have a material adverse effect on our business, financial condition and results of operations. Our operations could be
disrupted if any of our employees were suspected of having any of the epidemic illnesses, since this could require us to quarantine some
or all of such employees or disinfect the facilities used for our operations. In addition, our revenue and profitability could be materially
reduced to the extent that a natural disaster, health epidemic or other outbreak harms the global or PRC economy in general. Our
operations could also be severely disrupted if our users or other participants were affected by such natural disasters, health epidemics or
other outbreaks. See also " - Our business operations and financial performance have been adversely affected by the COVID-19
outbreak, may in the future continue to be affected by the COVID-19 outbreak, and may be affected by other natural disasters, epidemics
and other unforeseeable catastrophes."
26
Table of Contents
Risks Related to Our Corporate Structure
If the PRC government deems that the contractual arrangements in relation to our variable interest entities and their subsidiaries
do not comply with PRC regulatory restrictions on foreign investment in the relevant industries, or if these regulations or the
interpretation of existing regulations change in the future, we could be subject to severe penalties or be forced to relinquish our
interests in those operations.
Foreign ownership of internet-based businesses, such as provision of online information and other value-added
telecommunication services, and medical institutions, are subject to restrictions under current PRC laws and regulations. For example,
foreign investors are generally not allowed to own more than 50% of the equity interests in a value-added telecommunication service
provider with the exception relating to e-commerce business, and any such foreign investor must have experience in providing value-
added telecommunications services overseas and maintain a good track record, and the medical institution can only be established as
sino-foreign equity or cooperative joint venture in accordance with the currently-effective Guidance Catalogue of Industries for Foreign
Investment and other applicable laws and regulations.
We are a Cayman Islands company and our PRC subsidiary, 1 Pharmacy Technology, is considered a foreign invested
enterprise. To comply with PRC laws and regulations, we set up a series of contractual arrangements entered into among 1 Pharmacy
Technology, our variable interest entities, and their shareholders to conduct our operations in China. For a detailed description of these
contractual arrangements, see “Item 4. Information on the Company—C. Organizational Structure—Contractual Arrangements with Our
Variable Interest Entities.” As a result of these contractual arrangements, we exert control over our variable interest entities and their
subsidiaries and consolidate their operating results in our financial statements under U.S. GAAP. We conduct our pharmaceutical
wholesale and retail business, online retail pharmacy, 1 Medicine Marketplace, pharmacopoeia and our internet hospital, 1 Clinic, via our
PRC subsidiaries, our variable interest entities and their subsidiaries in China, including Guangdong Yihao Pharmacy Co., Ltd., or Yihao
Pharmacy, Yihao Pharmaceutical Chain Co., Ltd., or Yihao Pharmaceutical Chain, Chongqing Yihao Pharmacy, Hubei Yihao Pharmacy,
Fujian Yaofang Pharmacy, Shanxi Yihao Yaofang Pharmacy, Liaoning Yihao Pharmacy, Chengdu Yizhen Internet Hospital and Anshun
Southwest Internet Hospital Co., Ltd., or Southwest Internet Hospital, respectively.
In the opinion of our PRC legal counsel, Commerce & Finance Law Offices, the ownership structures of our variable interest
entities currently does not, result in any violation of the applicable PRC laws or regulations currently in effect; and the contractual
arrangements among 1 Pharmacy Technology, our variable interest entities and their shareholders, are governed by PRC laws or
regulations, and are currently valid, binding and enforceable in accordance with the applicable PRC laws or regulations currently in
effect, and do not result in any violation of the applicable PRC laws or regulations currently in effect.
However, Commerce & Finance Law Offices has also advised us that there are substantial uncertainties regarding the
interpretation and application of current or future PRC laws and regulations, and there can be no assurance that the PRC government will
ultimately take a view that is consistent with the opinion of our PRC counsel. In January 2015, the MOFCOM published a discussion
draft of the proposed Foreign Investment Law, or the Draft FIL, for public review and comments. Among other things, the Draft FIL
expands the definition of foreign investment and introduces the principle of “actual control” in determining whether a company is
considered a foreign-invested enterprise, or an FIE. Under the Draft FIL, variable interest entities would also be deemed as FIEs, if they
are ultimately “controlled” by foreign investors, and would be subject to restrictions on foreign investments. Subsequently, in December
2018, the standing committee of the National People’s Congress reviewed a draft Foreign Investment Law, and this draft was
subsequently published for public comment. In March 2019, a new draft of Foreign Investment Law was submitted to the National
People’s Congress for review and was approved on March 15, 2019, which will come into effect from January 1, 2020. The approved
Foreign Investment Law does not touch upon the relevant concepts and regulatory regimes that were historically suggested for the
regulation of VIE structures, and thus this regulatory topic remains unclear under the Foreign Investment Law. Since the Foreign
Investment Law is new, there are substantial uncertainties exist with respect to its implementation and interpretation and it is also
possible that the VIE entities will be deemed as foreign invested enterprises and be subject to restrictions in the future. Such restrictions
may cause interruptions to our operations, products and services and may incur additional compliance cost, which may in turn materially
and adversely affect our business, financial condition and results of operations.
If our ownership structure and contractual arrangements with our variable interest entities are found to be in violation of any
existing or future PRC laws or regulations, or we fail to obtain or maintain any of the required permits or approvals, the relevant
governmental authorities would have broad discretion in dealing with such violation, including levying fines, confiscating our income or
the income of our PRC subsidiaries, variable interest entities or their subsidiaries, revoking the business licenses and/or operating
27
Table of Contents
licenses of such entities, shutting down our servers or blocking our online platforms, discontinuing or placing restrictions or onerous
conditions on our operations, requiring us to undergo a costly and disruptive restructuring, and taking other regulatory or enforcement
actions that could be harmful to our business. Any of these actions could cause significant disruption to our business operations and
severely damage our reputation, which would in turn materially and adversely affect our business, financial condition and results of
operations. If any of these occurrences results in our inability to direct the activities of our variable interest entities and their subsidiaries,
and/or our failure to receive economic benefits from our variable interest entities and their subsidiaries, we may not be able to
consolidate their results into our consolidated financial statements in accordance with U.S. GAAP.
We rely on contractual arrangements with our variable interest entities and their shareholders, for a significant portion of our
business operations, which may not be as effective as direct ownership in providing operational control.
We have relied and expect to continue to rely on contractual arrangements with our variable interest entities and their
shareholders to operate our pharmaceutical wholesale and retail business, 1 Medicine Marketplace, pharmacopoeia and our internet
hospital, 1 Clinic, through Yihao Pharmacy, Yihao Pharmaceutical Chain and Southwest Internet Hospital, respectively. For a description
of these contractual arrangements, see “ Item 4. Information on the Company—C. Organizational Structure—Contractual Arrangements
with Our Variable Interest Entities.” These contractual arrangements may not be as effective as direct ownership in providing us with
control over our variable interest entities and their subsidiaries. For example, our variable interest entities or their shareholders may fail
to fulfill their contractual obligations with us, by, among other things, failing to maintain our website and use the domain names and
trademarks in a manner as stipulated in the contractual arrangements, or taking other actions that are detrimental to our interests.
If we had direct ownership of our variable interest entities, we would be able to exercise our rights as shareholders to effect
changes in their board of directors, which in turn could implement changes, subject to any applicable fiduciary obligations, at the
management and operational level. However, under the current contractual arrangements, we rely on the performance by our variable
interest entities and their shareholders of their obligations under the contractual arrangements to exercise control over our variable
interest entities and their subsidiaries. The shareholders of our variable interest entities may not act in the best interests of our company
or may not perform their obligations under these contracts. Such risks exist throughout the period in which we intend to operate certain
portions of our business through the contractual arrangements with our variable interest entities and their shareholders. Although we have
the right to replace any shareholder of such entities under the contractual arrangements, if any of these shareholders are uncooperative or
any dispute relating to these contracts remains unresolved, we will have to enforce our rights under these contracts through the operations
of PRC laws and arbitration, litigation and other legal proceedings, the outcome of which will be subject to uncertainties in the PRC legal
system. Therefore, our contractual arrangements with our variable interest entities and their shareholders may not be as effective in
ensuring our control over the relevant portion of our business operations as direct ownership would be.
Any failure by our variable interest entities or their respective shareholders to perform their obligations under our contractual
arrangements with them would have a material adverse effect on our business.
We have entered into a series of contractual arrangements with our variable interest entities and their shareholders. For a
description of these contractual arrangements, see “ Item 4. Information on the Company—C. Organizational Structure—Contractual
Arrangements with Our Variable Interest Entities.” If our variable interest entities or their shareholders fail to perform their respective
obligations under the contractual arrangements, we may incur substantial costs and expend additional resources to enforce such
arrangements. We may also have to rely on legal remedies under PRC laws, including seeking specific performance or injunctive relief,
and claiming damages, which we cannot assure you will be effective under PRC laws. For example, if the shareholders of our variable
interest entities were to refuse to transfer their equity interests in such entities to us or our designee when we exercise the purchase option
pursuant to these contractual arrangements, or if they were otherwise to act in bad faith toward us, then we may have to take legal action
to compel them to perform their contractual obligations.
All the agreements under our contractual arrangements are governed by PRC laws and provide for the resolution of disputes
through arbitration in China. Accordingly, these contracts would be interpreted in accordance with PRC laws and any disputes would be
resolved in accordance with PRC legal procedures. The legal system in the PRC is not as developed as in some other jurisdictions, such
as the United States. As a result, uncertainties in the PRC legal system could limit our ability to enforce these contractual arrangements.
Meanwhile, there are very few precedents and little formal guidance as to how contractual arrangements in the context of a variable
interest entity should be interpreted or enforced under PRC laws. There remain significant uncertainties regarding the
28
Table of Contents
ultimate outcome of such arbitration should legal action become necessary. In addition, under PRC laws, rulings by arbitrators are final
and parties cannot appeal the arbitration results in court unless such rulings are revoked or determined unenforceable by a competent
court. If the losing parties fail to carry out the arbitration awards within a prescribed time limit, the prevailing parties may only enforce
the arbitration awards in PRC courts through arbitration award recognition proceedings, which would require additional expenses and
delay. In the event that we are unable to enforce these contractual arrangements, or if we suffer significant delay or other obstacles in the
process of enforcing these contractual arrangements, we may not be able to exert effective control over our variable interest entities and
their subsidiaries, and our ability to conduct our business may be negatively affected. See “—Risks Related to Doing Business in China
—Uncertainties in the interpretation and enforcement of PRC laws and regulations could limit the legal protections available to us.”
The shareholders of our variable interest entities may have potential conflicts of interest with us, which may materially and
adversely affect our business and financial condition.
The equity interests of our variable interest entity, Yihao Pharmacy, are held by Mr. Yue Xuan, a family member of Dr. Gang Yu,
and Ms. Jing Liu, a family member of Mr. Junling Liu. These shareholders may have potential conflicts of interest with us. These
shareholders may breach, or cause our variable interest entities to breach, the existing contractual arrangements, which would have a
material adverse effect on our ability to effectively control our variable interest entities and their subsidiaries and receive economic
benefits from them. For example, these shareholders may be able to cause our agreements with our variable interest entities to be
performed in a manner adverse to us by, among other things, failing to remit payments due under the contractual arrangements to us on a
timely basis. We cannot assure you that when conflicts of interest arise, any or all of these shareholders will act in the best interests of
our company or such conflicts will be resolved in our favor.
Currently, we do not have any arrangements to address potential conflicts of interest between these shareholders and our
company, except that we could exercise our purchase option under the exclusive option agreement with these shareholders to request
them to transfer all of their equity interests in our variable interest entities to a PRC entity or individual designated by us, to the extent
permitted by PRC laws. If we cannot resolve any conflict of interest or dispute between us and these shareholders, we would have to rely
on legal proceedings, which could result in the disruption of our business and subject us to substantial uncertainty as to the outcome of
any such legal proceedings.
Contractual arrangements in relation to our variable interest entities, may be subject to scrutiny by the PRC tax authorities and
they may determine that we, or our variable interest entities and their subsidiaries, owe additional taxes, which could negatively
affect our financial condition and the value of your investment.
Under applicable PRC laws and regulations, arrangements and transactions among related parties may be subject to audit or
challenge by the PRC tax authorities. The PRC enterprise income tax law requires every enterprise in China to submit its annual
enterprise income tax return together with a report on transactions with its related parties to the relevant tax authorities. The tax
authorities may impose reasonable adjustments on taxation if they have identified any related party transactions that are inconsistent with
arm’s length principles. We may face material and adverse tax consequences if the PRC tax authorities determine that the contractual
arrangements among 1 Pharmacy Technology, our foreign invested subsidiary in China, our variable interest entities and their
shareholders were not entered into on an arm’s length basis in such a way as to result in an impermissible reduction in taxes under
applicable PRC laws, regulations and rules, and adjust income of our variable interest entities in the form of a transfer pricing
adjustment. A transfer pricing adjustment could, among other things, result in a reduction of expense deductions recorded by our variable
interest entities for PRC tax purposes, which could in turn increase their tax liabilities without reducing 1 Pharmacy Technology’s tax
expenses. Furthermore, the PRC tax authorities may impose late payment fees and other penalties on our variable interest entities for the
adjusted but unpaid taxes according to the applicable regulations. Our financial position could be materially adversely affected if our
variable interest entities’ tax liabilities increase or if they are required to pay late payment fees and other penalties.
If we exercise the option to acquire equity ownership of our variable interest entities, the ownership transfer shall be approved or
filed with PRC governmental authorities and subject to taxation, which may result in substantial costs.
Pursuant to the contractual arrangements, 1 Pharmacy Technology has the exclusive right to purchase all or any part of the
equity interests in our variable interest entities from the respective shareholders for free or at a lowest price as permitted by the then
applicable PRC laws. The equity transfer shall be subject to the approvals from or information reports with the MOFCOM, the MIIT,
29
Table of Contents
the SAMR and/or their local competent branches. In addition, the equity transfer price may be subject to review and tax adjustment by
the relevant tax authority. In particular, the shareholders of our variable interest entities will be subject to PRC individual or enterprise
income tax on the difference between the equity transfer price and the then current registered capital of our variable interest entities and
the payment, after deducting such tax, to 1 Pharmacy Technology may also be subject to enterprise income tax, which may result in
substantial costs.
We may lose the ability to use and benefit from assets held by our variable interest entities that are material to the operation of
our business if the entity goes bankrupt or becomes subject to a dissolution or liquidation proceeding.
Our variable interest entities hold certain assets that are material to the operation of our business, including, among others,
intellectual properties. Under the contractual arrangements, our variable interest entities may not, and the shareholders of our variable
interest entities may not cause them to, in any manner, sell, transfer, mortgage or dispose of their assets or their legal or beneficial
interests in the business without our prior consent. However, in the event these shareholders breach these contractual arrangements and
voluntarily liquidate our variable interest entities, or our variable interest entities declare bankruptcy and all or part of their assets become
subject to liens or rights of third-party creditors, or are otherwise disposed of without our consent, we may be unable to continue some or
all of our business activities, which could materially adversely affect our business, financial condition and results of operations. If our
variable interest entities undergo a voluntary or involuntary liquidation proceeding, the independent third-party creditors may claim
rights to some or all of these assets, thereby hindering our ability to operate our business, which could materially and adversely affect our
business, financial condition and results of operations.
Risks Related to Doing Business in China
Changes in China’s economic, political or social conditions or government policies could have a material adverse effect on our
business and results of operations.
Substantially all of our operations are located in China. Accordingly, our business, prospects, financial condition and results of
operations may be influenced to a significant degree by political, economic and social conditions in China generally and by continued
economic growth in China as a whole.
The Chinese economy differs from the economies of most developed countries in many respects, including the amount of
government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. Although the
Chinese government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state
ownership of productive assets and the establishment of improved corporate governance in business enterprises, a substantial portion of
productive assets in China are still owned by the government. In addition, the Chinese government continues to play a significant role in
regulating industry development by imposing industrial policies. The Chinese government also exercises significant control over China’s
economic growth through allocating resources, controlling payment of foreign currency-denominated obligations, setting monetary
policy and providing preferential treatment to particular industries or companies.
While the Chinese economy has experienced significant growth over the past decades, growth has been uneven, both
geographically and among various sectors of the economy. The Chinese government has implemented various measures to encourage
economic growth and guide the allocation of resources. Some of these measures may benefit the overall Chinese economy, but may have
a negative effect on us. For example, our financial condition and results of operations may be adversely affected by government control
over capital investments or changes in tax regulations. In addition, in the past the Chinese government has implemented certain
measures, including interest rate increases, to control the pace of economic growth. These measures may cause decreased economic
activity in China, and since 2012, the Chinese economy has slowed down. Any prolonged slowdown in the Chinese economy may reduce
the demand for our products and services and materially and adversely affect our business and results of operations.
Uncertainties in the interpretation and enforcement of PRC laws and regulations could limit the legal protections available to us.
The PRC legal system is based on written statutes and prior court decisions have limited value as precedents. Since these laws
and regulations are relatively new and the PRC legal system continues to rapidly evolve, the interpretations of many laws, regulations
and rules are not always uniform and enforcement of these laws, regulations and rules involves uncertainties.
30
Table of Contents
From time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. However, since
PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it
may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in
more developed legal systems. Furthermore, the PRC legal system is based in part on government policies and internal rules (some of
which are not published in a timely manner or at all) that may have retroactive effect. As a result, we may not be aware of our violation
of these policies and rules until sometime after the violation. Such uncertainties, including uncertainty over the scope and effect of our
contractual, property (including intellectual property) and procedural rights, could materially and adversely affect our business and
impede our ability to continue our operations.
We may be adversely affected by the complexity, uncertainties and changes in PRC regulation of pharmaceutical and healthcare
industry and internet-related businesses, and any lack of requisite approvals, licenses or permits applicable to our business may
have a material adverse effect on our business and results of operations.
Our business is subject to governmental supervision and regulation by the relevant PRC governmental authorities, including but
not limited to the MOFCOM, the MIIT, the National Medical Products Administration, or the NMPA, the NHC and the SAMR and their
counterparts. Together, these government authorities promulgate and enforce regulations that cover many aspects of the operation of
pharmaceutical operation, medical and healthcare services and internet-related business, including foreign ownership of, and the
licensing and permit requirements pertaining to, companies in such business. The laws and regulations related to medical and healthcare
services and internet-related business are evolving rapidly, and their interpretation and enforcement involve significant uncertainties. As
a result, in certain circumstances it may be difficult to determine what actions or omissions may be deemed to be in violation of
applicable laws and regulations. Under PRC laws, an entity must obtain the pharmaceutical operation license from the NMPA or its
counterpart for conducting pharmaceutical wholesale and retail business, the value-added telecommunication service operating licenses
from the MIIT or its counterpart for either online information services or third-party e-commerce platform, and a medical institution shall
obtain a practicing license of medical institutions from the NHC for provision of medical diagnosis and treatment services. We have
made great efforts to obtain all applicable licenses and permits necessary to our main business. However, the interpretation and
application of existing PRC laws, regulations and policies and possible new laws, regulations or policies relating to the pharmaceutical
operation, medical and healthcare services and internet-related business have created substantial uncertainties regarding the legality of
existing and future foreign investments in, and the businesses and activities of, pharmaceutical operation, medical and healthcare services
and internet-related business industry in China, including our business, we cannot assure you that we have obtained all the permits or
licenses required for conducting our business or will be able to maintain our existing licenses or obtain new ones. If the PRC government
considers that we were operating without the proper approvals, licenses or permits or promulgates new laws and regulations that require
additional approvals or licenses or imposes additional restrictions on the operation of any part of our business, it has the power, among
other things, to levy fines, confiscate our income, revoke our business licenses, and require us to discontinue our relevant business or
impose restrictions on the affected portion of our business. Any of these actions by the PRC government may have a material adverse
effect on our business and results of operations.
We rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing
requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a
material adverse effect on our ability to conduct our business.
We are a holding company, and we rely on dividends and other distributions on equity paid by our PRC subsidiaries for our cash
and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders and service
any debt we may incur. If our PRC subsidiaries incur debt on their own behalf in the future, the instruments governing the debt may
restrict their ability to pay dividends or make other distributions to us, which may restrict our ability to satisfy our liquidity requirements.
In addition, since we have no direct equity interests in our variable interest entities and only collect the revenue under the contractual
arrangement, the PRC tax authorities may require our PRC subsidiary, 1 Pharmacy Technology, to adjust its taxable income under the
contractual arrangements it currently has in place with our variable interest entities and their subsidiaries, in a manner that would
materially and adversely affect their ability to pay dividends and other distributions to us.
Under PRC laws and regulations, our PRC subsidiaries may pay dividends only out of their accumulated after-tax profits as
determined in accordance with PRC accounting standards and regulations. In addition, Chinese entities are required to set aside at least
10% of their accumulated after-tax profits each year, if any, to fund certain statutory reserve funds, until the aggregate amount of such
funds reaches 50% of their registered capital. These reserve funds are not distributable as cash dividends.
31
Table of Contents
At the end of 2016, the People’s Bank of China, or PBOC, and the State Administration of Foreign Exchange, or SAFE,
implemented a series of capital control measures, including stricter vetting procedures for China-based companies to remit foreign
currency for overseas acquisitions, dividend payments and shareholder loan repayments. For instance, the PBOC issued the Circular on
Further Clarification of Relevant Matters Relating to Offshore Renminbi Loans Provided by Domestic Enterprises, in November 2016,
which provides that offshore Renminbi loans provided by a domestic enterprise to offshore enterprises that are its affiliates in equity shall
not exceed a certain amount that is equal to the most recent audited owner’s equity multiplied by a ratio determined by the PBOC, and
may constrain our PRC subsidiaries’ ability to provide offshore loans to us. The PRC government may continue to strengthen its capital
controls and our PRC subsidiaries’ dividends and other distributions or payment may be subjected to tighter scrutiny in the future. Any
limitation on the ability of our PRC subsidiaries to pay dividends or make other distributions or make payments to us could materially
and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or
otherwise fund and conduct our business. See also “—If we are classified as a PRC resident enterprise for PRC income tax purposes,
such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.”
PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of
currency conversion may delay or prevent us from using the proceeds of our initial public offering to make loans to or make
additional capital contributions to our PRC subsidiaries, which could materially and adversely affect our liquidity and our ability
to fund and expand our business.
We are an offshore holding company conducting our operations in China through our PRC subsidiaries and variable interest
entities. We may make loans to our PRC subsidiaries and variable interest entities subject to the approval from governmental authorities
and limitation of amount, or we may make additional capital contributions to our foreign invested subsidiaries in China.
Any funds we transfer to our PRC subsidiaries, either as a shareholder loan or as an increase in registered capital, are subject to
filing or registration with the relevant governmental authorities in China. According to the relevant PRC regulations on foreign-invested
enterprises in China, capital contributions to our PRC subsidiaries are subject to the requirement of making necessary filings and
registration with other governmental authorities in China. In addition, (a) any foreign loan procured by our PRC subsidiaries is required
to be registered with SAFE, or its local branches, and (b) each of our PRC subsidiaries may not procure loans which exceed the statutory
limit. Any medium or long-term loan to be provided by us to our variable interest entities must be recorded and registered by the NDRC
and SAFE or its local branches. We may not complete such recording or registrations on a timely basis, if at all, with respect to future
capital contributions or foreign loans by us to our PRC subsidiaries. If we fail to complete such recording or registration, our ability to
use the proceeds of our initial public offering and to capitalize our PRC operations may be negatively affected, which could adversely
affect our liquidity and our ability to fund and expand our business.
32
Table of Contents
In 2008, SAFE promulgated the Notice of the General Affairs Department of the State Administration of Foreign Exchange on
the Relevant Operating Issues concerning the Improvement of the Administration of Payment and Settlement of Foreign Currency
Capital of Foreign-invested Enterprises, or Circular 142, which used to regulate the conversion by foreign-invested enterprises of foreign
currency into Renminbi by restricting the usage of converted Renminbi. In March 2015, SAFE promulgated the Notice of the State
Administration of Foreign Exchange on Reforming the Administrative Approach Regarding the Settlement of the Foreign Exchange
Capitals of Foreign-invested Enterprises, or Circular 19. Circular 19 took effect as of June 1, 2015 and superseded Circular 142 on the
same date. Circular 19 launched a nationwide reform of the administration of the settlement of the foreign exchange capitals of foreign-
invested enterprises and allows foreign-invested enterprises to settle their foreign exchange capital at their discretion, but continues to
prohibit foreign-invested enterprises from using the Renminbi fund converted from their foreign exchange capitals for expenditures
beyond their business scopes. In June 2016, SAFE promulgated the Notice of the State Administration of Foreign Exchange on
Reforming and Standardizing the Administrative Provisions on Capital Account Foreign Exchange Settlement, or Circular 16. Circular
16 continues to prohibit foreign-invested enterprises from, among other things, using the Renminbi fund converted from its foreign
exchange capitals for expenditure beyond its business scope, investment and financing (except for guarantee products issued by a bank or
otherwise permitted by laws), providing loans to non-affiliated enterprises or constructing or purchasing real estate not for self-use
(except for real estate enterprise). Pursuant to the Notice of the State Administration of Foreign Exchange on Further Promoting Cross-
border Trade and Investment Facilitation, or Circular 28, promulgated on October 23, 2019, non-investment foreign invested enterprises
are allowed to invest their capital in domestic equity in accordance with laws and regulations on the condition that such investment is not
in violation of the Special Administrative Measures for Admission of Foreign Investment (Negative List) in force and the domestic
projects to be invested shall be authentic and legal. According to the Circular on Optimizing the Administration of Foreign Exchange to
Support the Development of Foreign-related Business, or SAFE Circular 8, issued by the SAFE on April 10, 2020, eligible enterprises
are allowed to make domestic payments using the income under their capital accounts generated from their capital, foreign debt and
overseas listing, without providing materials evidencing the authenticity in advance, provided that the capital usage is authentic and
compliant with the current capital account income usage management regulations. The concerned bank is required to conduct spot checks
in accordance with the relevant requirements. However, as these circulars are relatively new, there are still uncertainties regarding its
interpretation, implementation and enforcement. All of these factors may significantly limit our ability to transfer to and use in China the
net proceeds from our initial public offering, which may adversely affect our business, financial condition and results of operations.
Fluctuations in exchange rates could have a material adverse effect on our results of operations and the price of the ADSs.
The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things,
changes in political and economic conditions in China and by China’s foreign exchange policies. In July 2005, the PRC government
changed its decade-old policy of pegging the value of the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20%
against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate
between the Renminbi and the U.S. dollar remained within a narrow band. Since June 2010, Renminbi has fluctuated against the U.S.
dollar, at certain times significantly and unpredictably. With the development of the foreign exchange market progressing towards
interest rate liberalization and Renminbi internationalization and economic uncertainties in both China and the rest of the world, the PRC
government may in the future announce further changes to the exchange rate system and we cannot assure you that the Renminbi will not
appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or
U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in the future.
All of our revenue and substantially all of our costs are denominated in Renminbi and our reporting currency is Renminbi.
Significant revaluation of the Renminbi may have a material and adverse effect on your investment. For example, to the extent that we
need to convert U.S. dollars we received from our initial public offering into Renminbi for our operations, appreciation of the Renminbi
against the U.S. dollar would reduce the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert
our Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business
purposes, appreciation of the U.S. dollar against the Renminbi would reduce the U.S. dollar amount available to us.
Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not
entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to
enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to
hedge our exposure adequately or at all. In addition, our currency exchange losses may be magnified by PRC exchange control
regulations that restrict our ability to convert Renminbi into foreign currency.
33
Table of Contents
Governmental control of currency conversion may limit our ability to utilize our operating revenue effectively and affect the
value of your investment.
The PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the
remittance of currency out of China. We receive substantially all of our operating revenue in Renminbi. Under our current corporate
structure, our company in the Cayman Islands relies on dividend payments from our PRC subsidiaries to fund any cash and financing
requirements we may have.
Under existing PRC foreign exchange regulations, payments of current account items, such as profit distributions and trade and
service-related foreign exchange transactions, can be made in foreign currencies without prior approval from SAFE by complying with
certain procedural requirements. Therefore, our PRC subsidiary, 1 Pharmacy Technology, is able to pay dividends in foreign currencies to
us without prior approval from SAFE, subject to the certain procedures under PRC foreign exchange regulation. But approval from or
registration with appropriate government authorities is required where Renminbi is to be converted into foreign currency and remitted
out of China to pay capital expenses under capital account items such as overseas investment and the repayment of loans denominated in
foreign currencies.
In light of the substantial capital outflows of China in 2016 due to the weakening of Renminbi, the PRC government has
imposed more restrictive foreign exchange policies and stepped up scrutiny of major outbound capital movement. More restrictions and
substantial vetting processes have been put in place by SAFE to regulate cross-border transactions falling under the capital account. The
PRC government may at its discretion further restrict access to foreign currencies in the future for current account transactions. If the
foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we
may not be able to pay dividends in foreign currencies to our shareholders, including holders of our ADSs.
Failure to make adequate contributions to various employee benefit plans and withhold individual income tax on employees’
salaries as required by PRC regulations may subject us to penalties.
Companies operating in China are required to participate in various government-mandated employee benefit contribution plans,
including certain social insurance, housing funds and other welfare-oriented payment obligations, and contribute to the plans in amounts
equal to certain percentages of salaries, including bonuses and allowances, of our employees up to a maximum amount specified by the
local government from time to time at locations where we operate our businesses. The requirement of employee benefit contribution
plans has not been implemented consistently by the local governments in China given the different levels of economic development in
different locations. Companies operating in China are also required to withhold individual income tax on employees’ salaries based on
the actual salary of each employee upon payment. We may be subject to late fees and fines in relation to the underpaid employee benefits
and under-withheld individual income tax, our financial condition and results of operations may be adversely affected.
The M&A Rules and certain other PRC regulations establish complex procedures for some acquisitions of Chinese companies by
foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China.
The Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors, or the M&A Rules, adopted by six
PRC regulatory agencies in 2006 and amended in 2009, and some other regulations and rules concerning mergers and acquisitions,
established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time-
consuming and complex, including requirements in some instances that the MOFCOM be notified in advance of any change-of-control
transaction in which a foreign investor takes control of a PRC domestic enterprise. Moreover, the Anti-Monopoly Law of the People’s
Republic of China requires that the MOFCOM shall be notified in advance of any concentration of undertaking if certain thresholds are
triggered. On February 7, 2021, the SAMR further issued the Anti-Monopoly Guidelines for the Internet Platform Economy Sector that
aims at specifying some of the circumstances under which an activity of internet platforms may be identified as monopolistic act as well
as setting out merger controlling filing procedures involving variable interest entities.
In addition, a regulation related to security review on mergers and acquisitions of domestic enterprise by foreign investors
issued by the MOFCOM that became effective in September 2011 specifies that mergers and acquisitions by foreign investors that raise
“national defense and security” concerns and mergers and acquisitions through which foreign investors may acquire de facto control over
domestic enterprises that raise “national security” concerns are subject to strict review by the MOFCOM, and the rules prohibit any
activities attempting to bypass a security review, including by structuring the transaction through a proxy or
34
Table of Contents
contractual control arrangement. In December 2020, the NDRC and the MOFCOM further promulgated the Foreign Investment Security
Review Measures, which took effect on January 18, 2021. These measures require direct or indirect investment by foreign investors of
PRC companies engaged in military-related or certain other industries be subject to security review before consummation of any such
investment. "Certain other industries" refer to, among others, important transportation services, important culture products and services,
important information technology and internet products and services, and important finance services that are crucial to national security.
In the future, we may grow our business by acquiring complementary businesses. Complying with the requirements of the above-
mentioned regulations and other relevant rules to complete such transactions could be time-consuming, and any required approval
processes, including obtaining approval from the MOFCOM or its local counterparts may delay or inhibit our ability to complete such
transactions, which could affect our ability to expand our business or maintain our market share.
PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries’ ability to increase
their registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and
penalties under PRC law.
In October 2005, SAFE issued a circular on relevant issues relating to foreign exchange administration in fund financing and
roundtrip investment by domestic residents via offshore special purpose vehicles, or Circular 75, requiring PRC residents, including
individual and entities, to register with the relevant local branch of SAFE before establishing or controlling any company outside of
China, referred to as an offshore special purpose company, for the purpose of raising funds from overseas to acquire or exchange assets
of, or acquiring equity interest in, PRC companies held by such PRC residents.
In July 2014, the SAFE issued a circular on foreign exchange administration involved in overseas investment, financing and
roundtrip investment conducted by PRC residents via offshore special purpose vehicles, or Circular 37, which replaced Circular 75 and
further requires PRC residents or entities to register with SAFE or its local branch in connection with their establishment or control of an
offshore entity established for the purpose of overseas investment or financing by either onshore or offshore assets or equity legally held
by such PRC residents. In February 2015, SAFE released the Notice of the State Administration of Foreign Exchange on Further
Simplifying and Improving the Policies of Foreign Exchange Administration Applicable to Direct Investment, or Circular 13, which
further clarified that offshore individuals who have foreign identification and use their offshore assets or equity to make contributions
into an offshore special purpose vehicle are not subject to the registration under Circular 37.
If our shareholders who are PRC residents or entities do not complete their registration as required, our PRC subsidiary, 1
Pharmacy Technology, may be prohibited from distributing their profits and proceeds from any reduction in capital, share transfer or
liquidation to us, and we may be restricted in our ability to contribute additional capital to our PRC subsidiaries. Moreover, failure to
comply with the SAFE registration described above could result in liability under PRC laws for evasion of applicable foreign exchange
restrictions.
Since Dr. Gang Yu and Mr. Junling Liu are non-PRC citizens with foreign identification who establish and make contributions
to our Cayman Islands holding company by their offshore assets, they are not subject to the foreign exchange registrations for their
offshore investment, financing and roundtrip investment in accordance with Circular 75 then in effect and Circular 37.
However, we may not be informed of the identities of all PRC residents holding direct or indirect interest in our company, nor
can we compel our beneficial owners to comply with the requirements of Circular 37. As a result, we cannot assure you that all of our
shareholders or beneficial owners who are PRC residents or entities have complied with, and will in the future make or obtain any
applicable registrations or approvals required by, Circular 37 or other PRC applicable law and regulations related to outbound
investment. Failure by such shareholders or beneficial owners to comply with Circular 37, or failure by us to amend the foreign exchange
registrations of our PRC subsidiaries, could subject us to fines or legal sanctions, restrict our overseas or cross-border investment
activities and limit our PRC subsidiaries’ ability to make distributions or pay dividends to us or affect our ownership structure, which
could adversely affect our business and prospects.
Any failure to comply with PRC regulations regarding the registration requirements for employee stock incentive plans may
subject the PRC plan participants or us to fines and other legal or administrative sanctions.
Pursuant to the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in
Stock Incentive Plan of Overseas Publicly-Listed Company, promulgated by SAFE in 2012, or SAFE Notices No. 7, PRC citizens and
35
Table of Contents
non-PRC citizens who reside in China for a continuous period of no less than one year who participate in any stock incentive plan of an
overseas publicly listed company offered to the director, supervisor, senior management and other employees of, and any individual who
has labor relationship with its domestic affiliated entities are required to register with SAFE through a domestic qualified agent, which
could be a PRC subsidiary of such overseas listed company, and complete certain other procedures. In addition, an overseas entrusted
institution must be retained to handle matters in connection with the exercise or sale of stock options and the purchase or sale of shares
and interests. We and our directors, executive officers and other employees who are PRC citizens or who reside in the PRC for a
continuous period of no less than one year and who have been granted stock options are subject to these regulations. Failure to complete
the SAFE registrations for our employee incentive plans may subject them to fines and legal sanctions, and may also limit our ability to
contribute additional capital into our PRC subsidiaries and limit our PRC subsidiaries’ ability to distribute dividends to us. We also face
regulatory uncertainties that could restrict our ability to adopt additional incentive plans for our directors, executive officers and
employees under PRC law.
In addition, the State Taxation Administration of the PRC, or STA, has issued certain circulars concerning employee stock
options and restricted shares. Under these circulars, our employees working in China who exercise stock options or are granted restricted
shares will be subject to PRC individual income tax. Our PRC subsidiaries have obligations to file documents related to employee stock
options or restricted shares with relevant tax authorities and to withhold individual income taxes of those employees who exercise their
share options or are granted with restricted shares. If our employees fail to pay or we fail to withhold their income taxes according to
relevant laws and regulations, we may face sanctions imposed by the tax authorities or other PRC governmental authorities.
U.S. regulatory bodies may be limited in their ability to conduct investigations or inspections of our operations in China.
Any disclosure of documents or information located in China by foreign agencies may be subject to jurisdiction constraints and
must comply with China’s state secrecy laws, which broadly define the scope of “state secrets” to include matters involving economic
interests and technologies. There is no guarantee that requests from U.S. federal or state regulators or agencies to investigate or inspect
our operations will be honored by us, by entities who provide services to us or with whom we associate, without violating PRC legal
requirements, especially as those entities are located in China. Furthermore, under the current PRC laws, an on-site inspection of our
facilities by any of these regulators may be limited or prohibited.
If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax
consequences to us and our non-PRC shareholders or ADS holders.
Under the Enterprise Income Tax Law of the PRC, or the EIT Law, and its implementation rules, an enterprise established
outside of the PRC with “de facto management body” within the PRC is considered a resident enterprise and will be subject to the
enterprise income tax on its global income at the rate of 25%. The implementation rules define the term “de facto management body” as
the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and
properties of an enterprise. On April 22, 2009, the STA issued a circular, known as Circular 82, which provides certain specific criteria
for determining whether the “de facto management body” of a PRC-controlled enterprise that is incorporated offshore is located in
China. According to Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be
regarded as a PRC tax resident by virtue of having its “de facto management body” in China and will be subject to PRC enterprise
income tax on its global income only if all of the following conditions are met: (i) the primary location of the day-to-day operational
management is in the PRC; (ii) decisions relating to the enterprise’s financial and human resource matters are made or are subject to
approval by organizations or personnel in the PRC; (iii) the enterprise’s primary assets, accounting books and records, company seals,
and board and shareholder resolutions, are located or maintained in the PRC; and (iv) at least 50% of voting board members or senior
executives habitually reside in the PRC.
Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those
controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the STA’s general position on how the “de
facto management body” text should be applied in determining the tax resident status of all offshore enterprises. If the PRC tax
authorities determine that we should be classified as a PRC resident enterprise for PRC tax purposes, our global income will be subject to
income tax at a uniform rate of 25%, which may have a material adverse effect on our financial condition and results of operations.
Notwithstanding the foregoing provision, the EIT Law also provides that, if a PRC resident enterprise directly invests in another PRC
resident enterprise, the dividends received by the investing PRC resident enterprise from the invested PRC resident enterprise are
exempted from income tax, subject to certain conditions. However, it remains unclear how the PRC tax authorities will interpret the
36
Table of Contents
PRC tax resident treatment of an offshore company with indirect ownership interests in PRC resident enterprises through intermediary
holding companies.
Moreover, if the PRC tax authorities determine that our company is a PRC resident enterprise for PRC enterprise income tax
purposes, gains realized on the sale or other disposal of ADSs or ordinary shares may be subject to PRC tax, at a rate of 10% in the case
of non-PRC enterprises, or 20% in the case of non-PRC individuals (in each case, subject to the provisions of any applicable tax treaty),
if such gains are deemed to be from PRC sources. Any such tax may reduce the returns on your investment in the ADSs.
We may not be able to obtain certain benefits under the relevant tax treaty on dividends paid by our PRC subsidiaries to us
through our Hong Kong subsidiary.
Pursuant to the EIT Law and its implementation rules, if a non-resident enterprise has not set up an organization or
establishment in the PRC, or has set up an organization or establishment but the income derived has no actual connection with such
organization or establishment, it will be subject to a withholding tax on its PRC-sourced income at a rate of 10%. Pursuant to the
Arrangement between Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and
Tax Evasion on Income, or the Double Taxation Arrangement, the withholding tax rate in respect to the payment of dividends by a PRC
enterprise to a Hong Kong enterprise is reduced to 5% from a standard rate of 10% if the Hong Kong enterprise directly holds at least
25% of the PRC enterprise. There are also other conditions for enjoying the reduced withholding tax rate according to other relevant tax
rules and regulations.
In February 2009, STA issued STA Notice No. 81, pursuant to which an enterprise must be the “beneficial owner” of the
relevant dividend income in order to enjoy the preferential withholding tax rates on dividend. If, however, such enterprise otherwise
qualifies for such preferential withholding tax rates through any transaction or arrangement, whose main purpose is to qualify for such
preferential withholding tax rates, the enterprise nevertheless cannot enjoy the preferential withholding tax rates and the competent tax
authority has the power to adjust the applicable withholding tax rates if it so determines. A STA Notice No. 9 issued by STA that took
effect in April 2018 indicated that “beneficial owner” refers to a person who has ownership and disposal rights to the income or any
rights and assets arising from such income, and the tax authority has discretion to determine whether or not an enterprise is determined as
a “beneficial owner.” However, since the STA Notice No. 9 is newly issued, it remains unclear how the PRC tax authorities will
implement STA Notice No. 9 in practice and to what extent they will affect the dividend withholding tax rates for dividends distributed
by our PRC subsidiaries to our Hong Kong subsidiary. If the relevant tax authority determines that our Hong Kong subsidiary is a
conduit company and does not qualify as the “beneficial owner” of the dividend income it receives from our PRC subsidiaries, the higher
10% withholding tax rate will apply to such dividends.
Entitlement to a lower tax rate on dividends according to tax treaties or arrangements between the PRC central government and
governments of other countries or regions is further subject to the Administrative Measures for Non-Resident Taxpayers to Enjoy
Treatments under Tax Treaties promulgated by the STA on October 14, 2019 and became effective from January 1, 2020, which provides
that non-resident enterprises are not required to obtain pre-approval from the relevant tax authority in order to enjoy the reduced
withholding tax. Instead, non-resident enterprises and their withholding agents may, by self-assessment and on confirmation that the
prescribed criteria to enjoy the tax treaty benefits are met, directly apply the reduced withholding tax rate, collect and retain relevant
materials for reference in accordance with these treaties, and accept supervision and management from the tax authorities. Therefore, we
cannot assure you that our determination regarding our qualification to enjoy the preferential tax treatment will not be challenged by the
relevant PRC tax authority or we will be able to complete the necessary filings with the relevant PRC tax authority and enjoy the
preferential withholding tax rate of 5% under the Double Taxation Arrangement with respect to dividends to be paid by our PRC
subsidiaries to Yao Wang Corporation Limited, our Hong Kong subsidiary.
We face uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding
companies.
We face uncertainties regarding the reporting on and consequences of previous private equity financing transactions involving
the transfer and exchange of shares in our company by non-PRC resident investors.
According to the Notice on Strengthening Administration of Enterprise Income Tax for Share Transfers by Non-PRC Resident
Enterprises issued by STA on December 10, 2009, or STA Circular 698, where a non-PRC resident enterprise transfers the equity
interests in a PRC resident enterprise indirectly through a disposition of equity interests in an offshore holding company (other
37
Table of Contents
than the sale on a public stock market of shares of an offshore enterprise purchased on a public stock market), or an Indirect Transfer, the
non-PRC resident enterprise, as the seller, may be subject to PRC enterprise income tax of up to 10% of the gains derived from the
Indirect Transfer in certain circumstances.
On February 3, 2015, the STA issued the Announcement on Several Issues Concerning the Enterprise Income Tax on Indirect
Property Transfers by Non-PRC Resident Enterprises, or STA Notice No. 7, to supersede the existing tax rules in relation to the tax
treatment of the Indirect Transfer, while the other provisions of STA Circular 698 are irrelevant to the Indirect Transfer remain in force.
STA Notice No. 7 introduces a new tax regime that is significantly different from that under a notice issued by STA Circular 698. It
extends STA’s tax jurisdiction to capture not only the Indirect Transfer as set forth under STA Circular 698 but also transactions
involving indirect transfer of (i) real properties in China and (ii) assets of an “establishment or place” situated in China, by a non-PRC
resident enterprise through a disposition of equity interests in an offshore holding company. STA Notice No. 7 also extends the
interpretation with respect to the disposition of equity interests in an offshore holding company broadly. In addition, STA Notice No. 7
further clarifies how to assess reasonable commercial purposes and introduces safe harbors applicable to internal group restructurings.
However, it also brings challenges to both offshore transferor and transferee as they are required to make self-assessments on whether an
Indirect Transfer or similar transaction should be subject to PRC tax and whether they should file or withhold any tax payment
accordingly. On October 17, 2017, the STA issued a Notice Concerning Withholding Income Tax of Non-Resident Enterprise, or STA
Notice No. 37, which abolished STA Circular 698 and certain provisions of STA Notice No. 7 and STA Notice No. 37 further reduced
the burden of the withholding obligator, such as revocation of contract filing requirements and tax liquidation procedures, strengthened
the cooperation of tax authorities in different places, and clarified the calculation of tax payable and mechanism of foreign exchange.
There is uncertainty as to the application of STA Notice No. 7 and STA Notice No. 37. In the event that non-PRC resident
investors were involved in our private equity financing transactions and such transactions were determined by the competent tax
authorities as lacking reasonable commercial purposes, we and our non-PRC resident investors may become at risk of being taxed under
and STA Notice No. 7 and STA Notice No. 37 and may be required to expend costly resources to comply with STA Notice No. 7 and
STA Notice No. 37, or to establish a case to be tax exempt under STA Notice No. 7 and STA Notice No. 37, which may cause us to incur
additional costs and may have a negative impact on the value of your investment in us.
The PRC tax authorities have discretion under STA Notice No. 7 and STA Notice No. 37 to adjust the taxable capital gains
based on the difference between the fair value of the transferred equity interests and the investment cost. We may pursue acquisitions in
the future that may involve complex corporate structures. If we are deemed as a non-PRC resident enterprise under the EIT Law and if
the PRC tax authorities adjust the taxable income of the transactions under STA Notice No. 7 and STA Notice No. 37, our income tax
expenses associated with such potential acquisitions will increase, which may have an adverse effect on our financial condition and
results of operations.
The audit report included in this annual report is prepared by an auditor who is not inspected by the Public Company
Accounting Oversight Board and, as such, our investors are deprived of the benefits of such inspection.
As a public company with securities listed on a national exchange, we are required to have our financial statements audited by
an independent registered public accounting firm registered with the Public Company Accounting Oversight Board (United States), or
the PCAOB. A requirement of being registered with the PCAOB is that if requested by the SEC or PCAOB, such accounting firm is
required to make its audits and related audit work papers be subject to regular inspections to assess its compliance with the applicable
professional standards. Since our auditor is located in China, a jurisdiction where the PCAOB has been unable to conduct inspections
without the approval of the Chinese authorities due to various state secrecy laws and the revised Securities Law, the PCAOB currently
does not have free access to inspect the work of our auditor. This lack of the PCAOB inspections in China prevents the PCAOB from
fully evaluating audits and quality control procedures of our auditor. As a result, we and investors in our ordinary shares are deprived of
the benefits of such PCAOB inspections, which could cause investors in our stock to lose confidence in our audit procedures and the
quality of our financial statements.
38
Table of Contents
The recent enactment of the Holding Foreign Companies Accountable Act, the SEC’s ongoing rulemaking with respect to such
law, and other legislative developments in the United States may result in delisting of the ADSs.
Over the past decade, U.S. SEC and PCAOB and the Chinese counterparts, namely, the China Securities Regulatory
Commission, or the CSRC, and PRC Ministry of Finance have been in an impasse over the ability of the PCAOB to have access to the
audit work papers and inspect the audit work of China based accounting firms, including our auditor. In May 2013, the PCAOB entered
into a Memorandum of Understanding on Enforcement Cooperation (the “MOU”) with the CSRC, and the PRC Ministry of Finance,
which establishes a cooperative framework between the parties for the production and exchange of audit documents relevant to
investigations undertaken by the PCAOB, the CSRC or the PRC Ministry of Finance in the United States and the PRC, respectively.
Despite the MOU, on December 7, 2018, the SEC and the PCAOB issued a joint statement highlighting continued challenges faced by
the U.S. regulators in their oversight of financial statement audits of U.S.-listed companies with significant operations in China. On April
21, 2020, the SEC and the PCAOB reiterated in another joint statement the greater risk associated with the PCAOB’s inability to inspect
audit work paper and practices of accounting firms in China, with respect to their audit work of U.S. reporting companies.
As part of a continued regulatory focus in the United States on access to audit and other information currently protected by laws
in China, on December 2, 2020, U.S. Congress passed S. 945, the Holding Foreign Companies Accountable Act, or the HFCAA. The
HFCAA has been signed by the President into law. Pursuant to the HFCAA, the SEC is required to propose rules to prohibit the
securities of any registrant from being listed on any of the U.S. securities exchanges or traded “over the counter” if the PCAOB is unable
to inspect the work of the accounting firm for three consecutive years. On March 24, 2021, the SEC issued amendments to Form 20-F
and sought public comments in response to the HFCAA. Consistent with the HFCAA, these amendments require the submission of
documentation to the SEC establishing that a “commission-identified registrant” (as defined in the amendments) is not owned or
controlled by a governmental entity in that foreign jurisdiction and also require disclosure in a foreign issuer’s annual report regarding
the audit arrangements of, and governmental influence on, such registrant. As of the date of this annual report, the SEC is also actively
assessing how best to implement other requirements of the HFCAA, including the identification process and the trading prohibition
requirements.
The enactment of the HFCAA and other efforts to increase U.S. regulatory access to audit work papers could cause investor
uncertainty for affected issuers, including us, and the market price of the ADSs could be adversely affected as uncertainty remains over
whether there will be a compromise solution. In the worst case, our ADSs could be delisted if we were unable to cure the situation to
meet the PCAOB inspection requirement in time.
In addition, on August 6, 2020, the President’s Working Group on Financial Markets, or PWG, released a report recommending
that the SEC take steps to implement the five recommendations, including enhanced listing standards on U.S. stock exchanges with
respect to PCAOB inspection of accounting firms. This would require, as a condition to initial and continued listing on a U.S. stock
exchange, PCAOB access to work papers of the principal audit firm for the audit of the listed company. The report permits the new
listing standards to provide for a transition period until January 1, 2022 for listed companies, but would apply immediately to new
listings once the necessary rulemakings and/or standard-setting are effective. It is unclear if and when the SEC will make rules to
implement the recommendations proposed in the PWG report, especially in light of its ongoing rulemaking pursuant to the HFCAA. Any
of these factors and developments could potentially lead to a material adverse effect on our business, prospects, financial condition and
results of operations.
Proceedings instituted by the SEC against Chinese affiliates of the “big four” accounting firms, including our independent
registered public accounting firm, could result in financial statements being determined to not be in compliance with the
requirements of the Exchange Act.
In December 2012, the SEC instituted administrative proceedings against the Big Four PRC-based accounting firms, including
our independent registered public accounting firm, alleging that these firms had violated U.S. securities laws and the SEC’s rules and
regulations thereunder by failing to provide to the SEC the firms’ audit work papers with respect to certain PRC-based companies that
are publicly traded in the United States.
39
Table of Contents
On January 22, 2014, the administrative law judge presiding over the matter rendered an initial decision that each of the firms
had violated the SEC’s rules of practice by failing to produce audit papers and other documents to the SEC. The initial decision censured
each of the firms and barred them from practicing before the SEC for a period of six months.
On February 6, 2015, the four China-based accounting firms each agreed to a censure and to pay a fine to the SEC to settle the
dispute and avoid suspension of their ability to practice before the SEC and audit U.S.-listed companies. The settlement required the
firms to follow detailed procedures and to seek to provide the SEC with access to Chinese firms’ audit documents via the CSRC. Under
the terms of the settlement, the underlying proceeding against the four China-based accounting firms was deemed dismissed with
prejudice four years after entry of the settlement. The four-year mark occurred on February 6, 2019. While we cannot predict if the SEC
will further challenge the four China-based accounting firms’ compliance with U.S. law in connection with U.S. regulatory requests for
audit work papers or if the results of such a challenge would result in the SEC imposing penalties such as suspensions, if the accounting
firms are subject to additional remedial measures, our ability to file our financial statements in compliance with SEC requirements could
be impacted. A determination that we have not timely filed financial statements in compliance with the SEC requirements could
ultimately lead to the delisting of our ADSs from the Nasdaq or the termination of the registration of our ordinary shares under the
Securities Exchange Act of 1934, or both, which would substantially reduce or effectively terminate the trading of our ADSs in the
United States.
Risks Related to American Depositary Shares
The trading price for the ADSs may be volatile.
Since the ADSs became listed on Nasdaq on September 12, 2018, the trading price of the ADSs has ranged from US$2.65 to
US$45.88. The trading prices of the ADSs are likely to be volatile and could fluctuate widely due to factors beyond our control. This
may happen because of broad market and industry factors, like the performance and fluctuation in the trading prices or the
underperformance or deteriorating financial results of internet or other companies based in China that have listed their securities in the
United States in recent years. The securities of some of these companies have experienced significant volatility since their initial public
offerings, including, in some cases, substantial price declines in their trading prices. The trading performances of other Chinese
companies’ securities after their offerings, including internet and e-commerce companies, may affect the attitudes of investors toward
Chinese companies listed in the United States, which consequently may impact the trading performance of the ADSs, regardless of our
actual operating performance. In addition, any negative news or perceptions about inadequate corporate governance practices or
fraudulent accounting, corporate structure or other matters of other Chinese companies may also negatively affect the attitudes of
investors towards Chinese companies in general, including us, regardless of whether we have conducted any inappropriate activities. In
addition, securities markets may from time to time experience significant price and volume fluctuations that are not related to our
operating performance, which may have a material adverse effect on the trading price of the ADSs.
In addition to the above factors, the price and trading volume of the ADSs may be highly volatile due to multiple factors,
including the following:
● regulatory developments affecting us, our consumers or our industry;
● conditions in the online healthcare industry and the public perception of the legitimacy and ethics of certain business
practices of our competitors or other market players within the industry;
● announcements of studies and reports relating to the quality of our product and service offerings or those of our
competitors;
● changes in the economic performance or market valuations of other online healthcare platforms;
● actual or anticipated fluctuations in our quarterly results of operations and changes or revisions of our expected results;
● changes in financial estimates by securities research analysts;
40
Table of Contents
● announcements by us or our competitors of new product and service offerings, acquisitions, strategic relationships, joint
ventures or capital commitments;
● additions to or departures of our senior management;
● detrimental negative publicity about us, our management or our industry;
● fluctuations of exchange rates between the Renminbi and the U.S. dollar;
● allegations of a lack of effective internal control over financial reporting resulting in financial and accounting irregularities
and mistakes; inadequate corporate governance policies, or allegations of fraud, among other things, involving China-based
issuers;
● release or expiry of any transfer restrictions on our outstanding ordinary shares or the ADSs; and
● sales or perceived potential sales of additional ordinary shares or ADSs.
The trading market for the ADSs will depend in part on the research and reports that securities or industry analysts publish
about us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts
who cover us downgrade the ADSs or publish inaccurate or unfavorable research about our business, the trading price for our ADSs
would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could
lose visibility in the financial markets, which, in turn, could cause the trading price or trading volume for the ADSs to decline.
Techniques employed by short sellers may drive down the trading price of the ADSs.
Short selling is the practice of selling securities that the seller does not own but rather has borrowed from a third party with the
intention of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from a decline in the
value of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects
to pay less in that purchase than it received in the sale. As it is in the short seller’s interest for the price of the security to decline, many
short sellers publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects in order
to create negative market momentum and generate profits for themselves after selling a security short. These short attacks have, in the
past, led to selling of shares in the market.
Public companies that have substantially all of their operations in China have been the subject of short selling. Most of the
scrutiny and negative publicity raised in the short seller reports has centered on allegations of a lack of effective internal control over
financial reporting resulting in financial and accounting irregularities and mistakes, inadequate or ineffective disclosure controls and
procedures or a lack of adherence thereto, related party transactions at the cost of the public investors, and, in many cases, allegations of
fraud. As a result, many of these companies are now conducting internal and external investigations into the allegations and, in the
interim, are subject to shareholder lawsuits or enforcement actions by the SEC, Department of Justice and other U.S. regulatory
authorities.
It is not clear what effect such negative publicity could have on us. If we were to become the subject of any unfavorable
allegations, whether such allegations are proven to be true or untrue, we could have to expend a significant amount of resources to
investigate such allegations or defend ourselves in shareholder litigation or regulatory enforcement actions. While we would strongly
defend against any such short seller attacks, we may be constrained in the manner in which we can proceed against the relevant short
seller by principles of freedom of speech, applicable state law or issues of commercial confidentiality. Such a situation could be costly
and time-consuming, and could distract our management from growing our business. Even if such allegations are ultimately proven to be
groundless, allegations against us could severely impact our business operations, and any investment in the ADSs could be greatly
reduced or even rendered worthless.
41
Table of Contents
Our dual-class share structure with different voting rights will limit your ability to influence corporate matters and could
discourage others from pursuing any change of control transactions that holders of our Class A ordinary shares and ADSs may
view as beneficial.
We have a dual-class share structure such that our ordinary shares consists of Class A ordinary shares and Class B ordinary
shares. In respect of matters requiring the votes of shareholders, holders of Class A ordinary shares will be entitled to one vote per share,
while holders of Class B ordinary shares will be entitled to fifteen votes per share based on our dual-class share structure. Each Class B
ordinary share is convertible into one Class A ordinary share at any time by the holder thereof, while Class A ordinary shares are not
convertible into Class B ordinary shares under any circumstances. Upon any sale, transfer, assignment or disposition of any Class B
ordinary share by our Founders (defined in our memorandum and articles of association to mean Dr. Gang Yu and Mr. Junling Liu) or
Founder Affiliate (as defined in our memorandum and articles of association) to any person who is not a “Founder Affiliate,” or upon a
change of ultimate beneficial ownership of any Class B ordinary share to any person who is not a Founder Affiliate, such Class B
ordinary share shall be automatically and immediately converted into one Class A ordinary share.
As of March 31, 2021, our founders, Dr. Gang Yu and Mr. Junling Liu, beneficially own all of our issued and outstanding Class
B ordinary shares. These Class B ordinary shares constitute approximately 43.44% of our total outstanding share capital and 92.01% of
the aggregate voting power of our total outstanding share capital due to the disparate voting powers associated with our dual-class share
structure. See “Item 6. Directors, Senior Management and Employees—E. Share Ownership.” As a result of the dual-class share structure
and the concentration of ownership, holders of Class B ordinary shares will have considerable influence over matters such as decisions
regarding mergers, consolidations and the sale of all or substantially all of our assets, election of directors and other significant corporate
actions. Such holders may take actions that are not in the best interest of us or our other shareholders. This concentration of ownership
may discourage, delay or prevent a change in control of our company, which could have the effect of depriving our other shareholders of
the opportunity to receive a premium for their shares as part of a sale of our company and may reduce the price of our ADSs. This
concentrated control will limit your ability to influence corporate matters and could discourage others from pursuing any potential
merger, takeover or other change of control transactions that holders of Class A ordinary shares and ADSs may view as beneficial.
The dual-class structure of our ordinary shares may adversely affect the trading market for our ADSs.
S&P Dow Jones and FTSE Russell have recently announced changes to their eligibility criteria for inclusion of shares of public
companies on certain indices, including the S&P 500, to exclude companies with multiple classes of shares and companies whose public
shareholders hold no more than 5% of total voting power from being added to such indices. In addition, several shareholder advisory
firms have announced their opposition to the use of multiple class structures. As a result, the dual-class structure of our ordinary shares
may prevent the inclusion of our ADSs representing Class A ordinary shares in such indices and may cause shareholder advisory firms to
publish negative commentary about our corporate governance practices or otherwise seek to cause us to change our capital structure. Any
such exclusion from indices could result in a less active trading market for our ADSs. Any actions or publications by shareholder
advisory firms critical of our corporate governance practices or capital structure could also adversely affect the value of our ADSs.
Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of the ADSs for return
on your investment.
We currently intend to retain most, if not all, of our available funds and any future earnings to fund the development and growth
of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an
investment in the ADSs as a source for any future dividend income.
42
Table of Contents
Our board of directors has discretion as to whether to distribute dividends, subject to certain restrictions under Cayman Islands
law, namely that our company may only pay dividends out of profits or share premium account; provided that in no circumstances may a
dividend be paid if this would result in our company being unable to pay its debts as they fall due in the ordinary course of business. In
addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our
board of directors. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends,
if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, the
amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors
deemed relevant by our board of directors. Accordingly, the return on your investment in our ADSs will likely depend entirely upon any
future price appreciation of our ADSs. There is no guarantee that our ADSs will appreciate in value in the future or even maintain the
price at which you purchased the ADSs. You may not realize a return on your investment in our ADSs and you may even lose your entire
investment in our ADSs.
Substantial future sales or perceived potential sales of ADSs in the public market could cause the price of the ADSs to decline.
Sales of ADSs in the public market, or the perception that these sales could occur, could cause the trading price of the ADSs to
decline. As of March 31, 2021, we have 165,353,402 ordinary shares outstanding, including 93,353,402 Class A ordinary shares. All of
our ADSs are freely transferable without restriction or additional registration under the Securities Act of 1933, as amended, or the
Securities Act. The remaining Class A ordinary shares will be available for sale subject to volume and other restrictions as applicable
under Rules 144 and 701 under the Securities Act.
Certain holders of our Class A ordinary shares may cause us to register, under the Securities Act, the sale of their shares.
Registration of these shares under the Securities Act would result in ADSs representing these shares becoming freely tradable without
restriction under the Securities Act immediately upon the effectiveness of the registration. Sales of ADSs representing these registered
shares in the public market could cause the price of the ADSs to decline.
43
Table of Contents
The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise your
right to direct the voting of the underlying Class A ordinary shares which are represented by your ADSs.
As a Cayman Islands exempted company, we are not obliged by the Companies Act (As Revised) of the Cayman Islands to call
shareholders’ annual general meetings. As a holder of ADSs, you will not have any direct right to attend general meetings of our
shareholders or to cast any votes at such meetings. You will only be able to exercise the voting rights that attach to the underlying Class
A ordinary shares represented by your ADSs indirectly by giving voting instructions to the depositary in accordance with the provisions
of the deposit agreement. Under the deposit agreement, you may vote only by giving voting instructions to the depositary, as the holder
of the underlying Class A ordinary shares that are represented by your ADSs. If we ask the depositary to solicit your instructions, upon
receipt of your voting instructions, the depositary will endeavor to vote the underlying Class A ordinary shares in accordance with your
instructions. If we do not instruct the depositary to solicit, you can still send voting instructions to the depositary, and the depositary may,
but is not required, to endeavor to carry out those instructions. You will not be able to directly exercise any right to vote with respect to
the underlying Class A ordinary shares unless you withdraw the shares and become the registered holder of such shares prior to the
record date for the general meeting. Under our memorandum and articles of association, the minimum notice period required to be given
by our company to our registered shareholders for convening a general meeting is ten calendar days. When a general meeting is
convened, you may not receive sufficient advance notice to enable you to withdraw the underlying shares which are represented by your
ADSs and become the registered holder of such shares prior to the record date for the general meeting to allow you to attend the general
meeting or to vote directly with respect to any specific matter or resolution which is to be considered and voted upon at the general
meeting. In addition, under our memorandum and articles of association, for the purposes of determining those shareholders who are
entitled to attend and vote at any general meeting, our directors may close our register of members and/or fix in advance a record date for
such meeting, and such closure of our register of members or the setting of such a record date may prevent you from withdrawing the
underlying shares which are represented by your ADSs and becoming the registered holder of such shares prior to the record date, so that
you would not be able to attend the general meeting or to vote directly. Where any matter is to be put to a vote at a general meeting, the
depositary will endeavor to notify you of the upcoming vote and to deliver our voting materials to you if we ask it to. We cannot assure
you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the underlying shares which
are represented by your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or
for their manner of carrying out your voting instructions. This means that you may not be able to exercise your right to direct the voting
of the underlying shares that are represented by your ADSs, and you may have no legal remedy if the underlying shares are not voted as
you requested.
The depositary for our ADSs may give us a discretionary proxy to vote the Class A ordinary shares underlying your ADSs if you
do not give voting instructions, which could adversely affect your interests.
Under the deposit agreement for the ADSs, if (i) we timely instruct the depositary to solicit your voting instructions, the
depositary does not receive your instructions by the specified date and (ii) we confirm to the depositary that:
● we wish a discretionary proxy to be given;
● we reasonably believe there is no substantial opposition as to a matter to be voted on at the meeting; and
● a matter to be voted on at the meeting would not have a material adverse impact on shareholders,
then the depositary will give us a proxy to vote the shares represented by your ADSs. The effect of this discretionary proxy is
that, if you fail to give voting instructions to the depositary as to how to vote the Class A ordinary shares underlying your ADSs at any
particular shareholders’ meeting, you cannot prevent our ordinary shares underlying your ADSs from being voted at that meeting, and it
may make it more difficult for shareholders to influence our management. Holders of our Class A ordinary shares are not subject to this
discretionary proxy.
The deposit agreement may be amended or terminated without your consent.
We and the depositary may amend the deposit agreement, and we may initiate termination of it, without your consent. If you
continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit agreement as amended.
See “Item 12. Description of Securities Other Than Equity Securities—Description of American Depositary Shares” for more
information.
44
Table of Contents
Your right to participate in any future rights offerings may be limited, which may cause dilution of your holdings.
We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot
make such rights available to you in the United States unless we register the securities to which the rights relate under the Securities Act
or an exemption from the registration requirements is available. Under the deposit agreement, the depositary will not make rights
available to you unless the underlying securities to be distributed to ADS holders are either registered under the Securities Act or exempt
from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or
securities or to endeavor to cause such a registration statement to be declared effective and we may not be able to establish a necessary
exemption from registration under the Securities Act. Accordingly, you may be unable to participate in our rights offerings in the future
and may experience dilution in your holdings.
You may not receive dividends or other distributions on our Class A ordinary shares and you may not receive any value for them,
if it is illegal or impractical to make them available to you.
The depositary has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our Class A
ordinary shares or other deposited securities underlying our ADSs, after deducting its fees and expenses. You will receive these
distributions in proportion to the number of Class A ordinary shares your ADSs represent. However, the depositary is not responsible if it
decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to
make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act but that are not
properly registered or distributed under an applicable exemption from registration. The depositary may also determine that it is not
feasible to distribute certain property through the mail. Additionally, the value of certain distributions may be less than the cost of
mailing them. In these cases, the depositary may determine not to distribute such property. We have no obligation to register under U.S.
securities laws any ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to
take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that you
may not receive distributions we make on our Class A ordinary shares or any value for them if it is illegal or impractical for us to make
them available to you. These restrictions may cause a material decline in the value of the ADSs.
Holders of ADS may experience difficulties in effecting service of legal process, enforcing foreign, including U.S., judgments or
bringing actions in China against us or our directors and management named in this offering memorandum based on foreign
laws, including U.S. securities law.
We are an exempted company limited by shares incorporated under the laws of the Cayman Islands. We conduct substantially
all of our operations in China and substantially all of our assets are located in China. In addition, a majority of our directors and
executive officers reside within China, and most of the assets of these persons are located within China. As a result, it may be difficult or
impossible for you to effect service of process within the United States upon these individuals, or to bring an action against us or against
these individuals in the United States in the event that you believe your rights have been infringed under the U.S. federal securities laws
or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands and of the PRC may render
you unable to enforce a judgment against our assets or the assets of our directors and officers. However, the deposit agreement gives you
the right to submit claims against us to binding arbitration, and arbitration awards may be enforceable against us and our assets in China
even when court judgments are not.
45
Table of Contents
Shareholder claims that are common in the United States, including securities law class actions and fraud claims, generally are
difficult to pursue as a matter of law or practicality in China. In particular, in China, there are significant legal, regulatory and other
obstacles to obtaining information needed for shareholder investigations or litigation outside China or otherwise involving foreign
persons or entities as plaintiffs. Although the local authorities in China may establish a regulatory cooperation mechanism with the
securities regulatory authorities of foreign jurisdictions to implement cross-border supervision and litigation, such regulatory cooperation
with the securities regulatory authorities in the Unities States have not been efficient in the absence of mutual and practical
implementation mechanism. Under the PRC Securities Law, no PRC entity or individual may provide the documents and materials
relating to securities trading and market activities to overseas parties without prior consent of the competent securities regulatory
authority in China.
You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited,
because we are incorporated under Cayman Islands law.
We are an exempted company limited by shares incorporated under the laws of the Cayman Islands. Our corporate affairs are
governed by our memorandum and articles of association, the Companies Act (As Revised) of the Cayman Islands and the common law
of the Cayman Islands. The rights of shareholders to take action against our directors, actions by our minority shareholders and the
fiduciary duties of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman
Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands
as well as from the common law of England, the decisions of whose courts are of persuasive authority, but are not binding, on a court in
the Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly
established as they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman
Islands has a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully
developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not
have standing to initiate a shareholder derivative action in a federal court of the United States.
Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect
corporate records (other than copies of our memorandum and articles of association, register of mortgages and charges, and any special
resolutions passed by our shareholders) or to obtain copies of lists of shareholders of these companies. Our directors will have discretion
under our memorandum and articles of association to determine whether or not, and under what conditions, our corporate records may be
inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to
obtain the information needed to establish any facts necessary for a shareholder resolution or to solicit proxies from other shareholders in
connection with a proxy contest.
As a result of all of the above, our public shareholders may have more difficulty in protecting their interests in the face of
actions taken by our management, members of the board of directors or controlling shareholders than they would as public shareholders
of a company incorporated in the United States.
We may need additional capital and may sell additional ADSs or other equity securities or incur indebtedness, which could result
in additional dilution to our shareholders or increase our debt service obligations.
We may require additional cash resources due to changed business conditions or other future developments, including any
investments or acquisitions we may decide to pursue. If our cash resources are insufficient to satisfy our cash requirements, we may seek
to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity securities or equity-linked debt
securities could result in additional dilution to our shareholders. The incurrence of indebtedness would result in debt service obligations
and could result in operating and financing covenants that would restrict our operations. We cannot assure you that financing will be
available in amounts or terms acceptable to us, if at all.
Our memorandum and articles of association contains anti-takeover provisions that could discourage a third party from
acquiring us and adversely affect the rights of holders of our Class A ordinary shares and the ADSs.
Our memorandum and articles of association contains certain provisions that could limit the ability of others to acquire control
of our company, including a provision that grants authority to our board of directors to establish and issue from time to time one or more
series of preferred shares without action by our shareholders and to determine, with respect to any series of preferred shares, the terms
and rights of that series. These provisions could have the effect of depriving our shareholders and holders of the
46
Table of Contents
ADSs of the opportunity to sell their shares or ADSs at a premium over the prevailing trading price by discouraging third parties from
seeking to obtain control of our company in a tender offer or similar transactions. In addition, our dual-class structure could discourage
others from pursuing any change of control transactions. See “—Our dual-class share structure with different voting rights will limit your
ability to influence corporate matters and could discourage others from pursuing any change of control transactions that holders of our
Class A ordinary shares and the ADSs may view as beneficial.”
Certain existing shareholders have substantial influence over our company and their interests may not be aligned with the
interests of our other shareholders.
As of March 31, 2021, our directors and officers collectively owned an aggregate of 92.0% of the total voting power of our
outstanding ordinary shares. As a result, they have substantial influence over our business, including significant corporate actions such as
mergers, consolidations, election of directors and other significant corporate actions.
They may take actions that are not in the best interest of us or our other shareholders. This concentration of ownership may
discourage, delay or prevent a change in control of our company, which could deprive our shareholders of an opportunity to receive a
premium for their shares as part of a sale of our company and may reduce the price of the ADSs. These actions may be taken even if they
are opposed by our other shareholders. In addition, the significant concentration of share ownership may adversely affect the trading
price of the ADSs due to investors’ perception that conflicts of interest may exist or arise. For more information regarding our principal
shareholders and their affiliated entities, see “Item 6. Directors, Senior Management and Employees—E. Share Ownership.”
47
Table of Contents
We have granted, and may continue to grant, share incentive awards, which may result in increased share-based compensation
expenses.
We adopted our 2016 share incentive plan, or the 2016 Plan, in 2016 to promote our success and the interests of our
shareholders by providing a means through which we may grant equity-based incentives to attract, motivate, retain and reward certain
officers, employees, directors, consultants and other eligible persons and to further link the interests of recipients with those of our
shareholders generally. We adopted certain share incentive policies in December 2013 and August 2014, or the 2013 Policy and the 2014
Policy, respectively. Since the adoption of the 2016 Plan, we stopped granting awards under the 2013 Policy or the 2014 Policy, although
the outstanding awards under the 2013 Policy and the 2014 Policy are still being administered under their respective policies. In August
2018, we adopted our 2018 Share Incentive Plan, or the 2018 Plan, which replaced the 2016 Plan in its entirety. Upon the effectiveness of
the 2018 Plan, we no longer grant any awards under the 2016 Plan. Outstanding awards granted under the 2016 Plan will remain
effective and be subject to the terms and conditions of the 2018 Plan. Under the 2016 Plan, we were authorized to grant options to
purchase ordinary shares of our company. The maximum number of ordinary shares which may be issued pursuant to all awards under
the 2013 Policy, the 2014 Policy and the 2016 Plan is 13,671,109. Under the 2018 Plan, the maximum number of our shares that may be
issued pursuant to all awards is 13,671,109, plus an annual increase on the first day of each fiscal year during the ten-year term of the
2018 Plan commencing with the fiscal year beginning January 1, 2019, by an amount equal to the lesser of (i) 1.0% of the total number
of shares issued and outstanding on the last day of the immediately preceding fiscal year, and (ii) such number of shares as may be
determined by our board of directors. As of the date of this annual report, options to purchase 7,235,287 Class A ordinary shares and
60,000 restricted share units are granted and outstanding under the 2013 Policy, the 2014 Policy and the 2016 Plan, and options to
purchase 2,319,697 Class A ordinary shares and 4,447,828 restricted share units are granted and outstanding under the 2018 Plan. We
recognized share-based compensation expenses in the amount of RMB51.4 million, RMB54.3 million and RMB75.7 million (US$11.6
million) in 2018, 2019 and 2020, respectively. See “Item 6. Directors, Senior Management and Employees—B. Compensation.” We
believe the granting of share-based compensation is of significant importance to our ability to attract, retain and incentivize key
personnel and employees, and we will continue to grant share-based compensation to employees in the future. As a result, our expenses
associated with share-based compensation may increase, which may have an adverse effect on our results of operations.
We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain
provisions applicable to U.S. domestic public companies.
Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the securities
rules and regulations in the United States that are applicable to U.S. domestic issuers, including:
● the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q or current reports on
Form 8-K;
● the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security
registered under the Exchange Act;
● the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and
liability for insiders who profit from trades made in a short period of time; and
● the selective disclosure rules by issuers of material nonpublic information under Regulation FD.
We are required to file an annual report on Form 20-F within four months of the end of each fiscal year. In addition, we intend
to publish our results on a quarterly basis as press releases, distributed pursuant to the rules and regulations of the Nasdaq Global Market.
Press releases relating to financial results and material events will also be furnished to the SEC on Form 6-K. However, the information
we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC
by U.S. domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you
were you investing in a U.S. domestic issuer.
48
Table of Contents
As a company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to
corporate governance matters that differ significantly from the Nasdaq Global Market corporate governance requirements; these practices
may afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq Global Market corporate
governance requirements.
We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.
As discussed above, we are a foreign private issuer, and therefore, we are not required to comply with all of the periodic
disclosure and current reporting requirements of the Exchange Act. The determination of foreign private issuer status is made annually
on the last business day of an issuer’s most recently completed second fiscal quarter. We would lose our foreign private issuer status if,
for example, more than 50% of our ordinary shares are directly or indirectly held by residents of the U.S. and we fail to meet additional
requirements necessary to maintain our foreign private issuer status. In the future, if we lose our foreign private issuer status as of the last
date of our second fiscal quarter, we would be required to file with the SEC periodic reports and registration statements on U.S. domestic
issuer forms beginning on the following January 1, which are more detailed and extensive than the forms available to a foreign private
issuer. We would also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal
shareholders would become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In
addition, we would lose our ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq Global
Market listing rules. As a U.S. listed public company that is not a foreign private issuer, we would incur significant additional legal,
accounting and other expenses that we will not incur as a foreign private issuer, and accounting, reporting and other expenses in order to
maintain a listing on a U.S. securities exchange.
There can be no assurance that we will not be a passive foreign investment company, or PFIC, for any taxable year, which could
result in adverse U.S. federal income tax consequences to U.S. investors in the ADSs or ordinary shares.
In general, a non-U.S. corporation is a passive foreign investment company for U.S. federal income tax purposes, or PFIC, for
any taxable year in which (i) 75% or more of its gross income consists of passive income; or (ii) 50% or more of the value of its assets
(generally determined on an average quarterly basis) consists of assets that produce, or are held for the production of, passive income.
For purposes of the above calculations, a non-U.S. corporation that owns (or is treated as owning for U.S. federal income tax purposes),
directly or indirectly, at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets
of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally
includes dividends, interest, rents, royalties and certain gains. Cash is generally a passive asset for these purposes. Goodwill (the value of
which generally may be determined by reference to the excess of the sum of the corporation’s market capitalization and liabilities over
the value of its assets) is generally characterized as a non-passive or passive asset based on the nature of the income produced in the
activity to which the goodwill is attributable.
Based on the composition of our income and assets and the estimated value of our assets, including goodwill, which is based on
the price of our ADSs, we believe that we were not a PFIC for our taxable year ended on December 31, 2020. However, our PFIC status
for any taxable year will depend on the composition of our income and assets and the value of our assets from time to time (which may
be determined, in large part, by reference to the market price of the ADSs, which has been and may continue to be volatile). Therefore,
the risk of us being or becoming a PFIC will increase if during any taxable year our ADS price declines significantly.
Moreover, it is not entirely clear how the contractual arrangements between our subsidiary, our variable interest entities and the
shareholders of our variable interest entities will be treated for purposes of the PFIC rules, and we may be or become a PFIC if our
variable interest entities are not treated as owned by us for these purposes. In addition, the extent to which our goodwill should be
characterized as an active asset is not entirely clear. We also hold a substantial amount of cash. Accordingly, there can be no assurance
that we will not be a PFIC for our 2021 or any future taxable year. If we were a PFIC for any taxable year during which a U.S. taxpayer
holds ADSs or ordinary shares, the U.S. taxpayer generally would be subject to adverse U.S. federal income tax consequences, including
increased tax liability on disposition gains and “excess distributions,” and additional reporting requirements. See “Item 10. Additional
Information—10.E. Taxation—Material U.S. Federal Income Tax Considerations—Passive Foreign Investment Company Rules.”
49
Table of Contents
Item 4. Information on the Company
A. History and Development of the Company
In 2010, our founders launched 1 Drugstore, one of the first online retail pharmacies in China. In January 2013, Yihao
Pharmaceutical Chain established its subsidiary Shanghai Yaowang E-Commerce Co., Ltd., or Shanghai Yaowang. In May 2013, Yao
Wang Holdings Ltd. was incorporated under the laws of the Cayman Islands as our offshore holding company, which changed its name to
New Peak Group in June 2015, and subsequently changed its name to 111, Inc. in April 2018. In June 2013, Yao Wang Corporation
Limited, or Yao Wang, was incorporated in Hong Kong as a wholly owned subsidiary of 111, Inc. 1 Pharmacy Technology (Shanghai)
Co., Ltd. (previously known as Yao Fang Information Technology (Shanghai) Co., Ltd. and 1 Pharmacy Yao Fang Technology
(Shanghai) Co., Ltd.), or 1 Pharmacy Technology, was established in August 2013 as a wholly owned subsidiary of Yao Wang in the
PRC. In September 2013, 1 Pharmacy Technology entered into a series of contractual agreements with Guangdong Yihao Pharmacy
Co., Ltd., or Yihao Pharmacy, Yihao Pharmaceutical Chain and Shanghai Yaowang and their respective shareholders such that Yihao
Pharmacy, Yihao Pharmaceutical Chain and Shanghai Yaowang were each treated as a variable interest entity of 1 Pharmacy Technology,
and 1 Pharmacy Technology consolidated the financial results of Yihao Pharmacy, Yihao Pharmaceutical Chain and Shanghai Yaowang
in its consolidated financial statements in accordance with U.S. GAAP.
Through 1 Pharmacy Technology, we obtained control over Yihao Pharmacy, Yihao Pharmaceutical Chain and Shanghai
Yaowang, or collectively, our variable interest entities, based on a series of contractual arrangements. See “—C. Organizational Structure
—Contractual Arrangements with Our Variable Interest Entities.”
In May 2018, Chongqing Yihao Pharmacy Co., Ltd. was established as a wholly owned subsidiary of Yihao Pharmacy in the
PRC. In December 2018, Yihao Pharmacy transferred 100% equity interests in Chongqing Yihao Pharmacy Co., Ltd. to 1 Pharmacy
Technology. In June 2018, Tianjin Yihao Pharmacy Co., Ltd. was established as a wholly owned subsidiary of Yihao Pharmacy in the
PRC. In July 2018 and August 2019, Kunshan Yifang Pharmacy Co., Ltd. and Fujian Yaofang Pharmacy Co., Ltd. were also established
as a wholly owned subsidiary of Yihao Pharmacy and Chongqing Yihao Pharmacy Co., Ltd. in the PRC, respectively. In August 2019,
Chongqing Yihao Pharmacy Co., Ltd. purchased 100% of the equity interests in Hubei Yihao Pharmacy Co., Ltd. In March 2020,
Chengdu Yizhen Internet Hospital Co., Ltd. was established as a wholly owned subsidiary of Kunshan Yihua Hospital Co., Ltd., a wholly
owned subsidiary of Yihao Pharmaceutical Chain. In April 2020, Shanghai Hanhong Medical Technology Co., Ltd. (previously known as
Shanghai Hanhong Pharmacy Co., Ltd.) was established as a wholly owned subsidiary of 1 Pharmacy Technology in the PRC. In August
2020, 1 Pharmacy Technology transferred 20% of the equity interests in Shanghai Hanhong Medical Technology Co., Ltd. to Shanghai
Pade Enterprise Management Partnership (L.P.). In October 2020 and November 2020, Shanxi Yihao Yaofang Pharmacy Co., Ltd. and
Liaoning Yihao Pharmacy Co., Ltd. were established as wholly owned subsidiaries of Chongqing Yihao Pharmacy Co., Ltd. in the PRC.
On September 15, 2018, our ADSs commenced trading on Nasdaq under the symbol “YI.” We raised from our initial public
offering approximately US$ 101.2 million in net proceeds (including the net proceeds generated from the offering of additional 809,555
ADSs upon the underwriters’ partial exercise of their over-allotment option), after deducting underwriting commissions and the offering
expenses payable by us.
On August 17, 2020, 1 Pharmacy Technology completed the capital injection from new investors with an aggregate of RMB
419.82 million (approximately US$60.49 million). On December 22, 2020, 1 Pharmacy Technology completed another round of
financing with an aggregate of RMB515 million (approximately US$78.75 million). In connection with each round of the capital
injection, the investors agreed to take all necessary and reasonable steps to facilitate the proposed listing of 1 Pharmacy Technology on
the STAR Market. In the event that 1 Pharmacy Technology’s proposed listing on the STAR Market is not completed before June 30,
2023 or the date otherwise agreed by 1 Pharmacy Technology and the investors in writing, such investors may choose to exercise their
options to require the controlling shareholder of 1 Pharmacy Technology, Yao Wang, to redeem all or part of the equity interests then
owned by such investors.
50
Table of Contents
Our principal executive offices are located at 3-5/F, No.295 ZuChongZhi Road, Pudong New Area, Shanghai, the People’s
Republic of China. Our telephone number at this address is +86 21 2053 6666. Our registered office in the Cayman Islands is located at
the offices of Vistra (Cayman) Limited, P.O. Box 31119, Grand Pavilion Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205,
Cayman Islands. Our agent for service of process in the United States is Puglisi & Associates, located at 850 Library Avenue, Suite 204,
Newark, Delaware 19711.
B. Business Overview
In 2010, our founders launched 1 Medicine Marketplace (1 药网 ), one of the first online retail pharmacies in China. Today, we
provide hundreds of millions of consumers with better access to pharmaceutical products and medical services, directly through our
online retail pharmacy and indirectly through our offline pharmacy network. In 2016, we commenced our online medical services
through our internet hospital, 1 Clinic (1 诊 ), to provide consumers with cost-effective and convenient online consultation and electronic
prescription services. Our online wholesale pharmacy, 1 Pharmacy (1 药城 ), serves as a one-stop shop for pharmacies, clinics, hospitals
and etc. to source a vast selection of pharmaceutical products.
Our New Retail Platform
New Retail aims to improve the efficiency of selling and buying, as well as customer experience, by integrating e-commerce,
brick-and-mortar retail, and logistics with data throughout the value chain. In 2016, we began the transformation from a pure B2C
business to a New Retail platform, integrating our online retail pharmacy and offline pharmacy network by leveraging our smart supply
chain and cloud-based solutions. This model allows us to collect and analyze data from a large number of transactions, which we use to
continuously increase the efficiency of our smart supply chain, and the intelligence of our cloud-based solutions.
Our Ecosystem
We connect pharmacies, pharmaceutical companies, medical professionals, insurance companies and consumers in our
ecosystem, and we improve the efficiency and transparency of the pharmaceutical value chain. We create value for various participants in
our integrated online and offline platform in the healthcare ecosystem in China: (i) consumers who purchase pharmaceutical and other
health and wellness products and seek medical services; (ii) pharmacies, including independent pharmacies, pharmacy chains and in-
house pharmacies within clinics and private hospitals who purchase pharmaceutical products and interact with consumers through our
platform; (iii) suppliers, such as pharmaceutical companies and distributors; (iv) marketplace sellers, who use our platform to distribute
and sell their products; (v) insurance companies, which are integral to the roll out of our new closed-loop internet “healthcare + pharma”
pharmacy benefits management model and (vi) medical professionals who provide healthcare services through our platform.
Our Omni-channel Model
Our omni-channel model plays an important role in facilitating the commercialization of drugs across the nation. Partners in this
model include pharmacies, public and private hospitals, clinics, community health centers, distributors, medical representatives and our 1
Medicine Marketplace app. This model offers multiple channels for pharmaceutical companies to simultaneously reach healthcare
providers nationwide and educates them about new drugs and therapies. This model significantly reduces time, resources and cost, which
allow drugs to be distributed quickly and efficiently.
Our S2B2C Model
Our S2B2C model refers to “Supply Chain Platform” to enable “Business” to better serve “Customers”.
51
Table of Contents
“S” refers to supply-chain infrastructure that encompasses our network of suppliers, i.e., pharmaceutical companies, distributors,
market-place vendors and other service providers. Then “S” is digitally connected to our “B”s, pharmacies and doctors, and offers them
a series of services including cloud CRM, speedy home delivery services, cloud clinic, cloud pharmacy, doctor-patient platform and etc.
Based on these robust foundations, we have brought value to patients, the “C”, by digitally connecting them with medicines and
healthcare services. Through our supply chain platform, doctors and pharmacies are able to leverage different service modules to offer a
variety of services to patients that never existed before.
Our Products and Services to Consumers
Our Online Retail Pharmacy
Our online retail pharmacy is an integral part of our holistic online and offline platform. In 2010, our founders launched our
online retail pharmacy, 1 Medicine Marketplace, to fulfill the healthcare needs of consumers. 1 Medicine Marketplace is currently
available through our 1 Medicine Marketplace app or website. We provide consumers with a wide variety of pharmaceutical products and
other merchandise, including drugs, nutritional supplements, contact lenses, medical supplies and devices, personal care products as well
as baby products. We operate our online retail pharmacy under either direct sales model or the marketplace model.
Our Direct Sales Model
In our online direct sales model, we acquire products from suppliers and sell them directly to consumers. For this model, we
need to manage inventories to ensure effective inventory management and may adjust inventory level based on fluctuation in supply and
prices, seasonality, popularity of a particular product, and we also take into consideration the shelf life. See “—Supply Chain
Management—Inventory Management.” Under this model, we also operate our independent branded storefronts in leading e-commerce
platforms in China such as Tmall.com, JD.com and PDD.com. We pay these third-party e-commerce platforms commissions as a
percentage of sales.
Our Marketplace Model
We introduced an online marketplace in 2016 to leverage our brand recognition, large and growing customer base, and
proprietary technology platform. Under our marketplace model, third-party sellers offer products to consumers over our online
marketplace.
We facilitate transactions between marketplace sellers and consumers through our marketplace. We provide transaction
processing and billing services on all orders on our online marketplace, while the marketplace sellers are responsible for inventory
management, fulfillment and delivery. We require marketplace sellers to meet our standards for authenticity and reliability. We aim to
offer consumers the same high quality customer experience regardless of the source of the products they choose.
We collect commission fees and platform usage fees from marketplace sellers according to the terms of our individual contracts
with them. The commission fees are generally charged as a percentage of sales, depending on product category, among other things. We
also charge a fixed annual platform usage fees to marketplace sellers for maintaining storefronts on our platform. We provide order
processing services for all orders on our online marketplace.
Our Offline Retail Pharmacy
We also operate a network of offline retail pharmacies branded as “Yi Hao Pharmacy,” mainly in Guangdong province, which
enables us, as required by the relevant laws and regulations, to operate our online pharmaceutical retail businesses. As of December 31,
2020, we had 13 offline retail pharmacies in Guangzhou, Tianjin, Kunshan and Wuhan. Revenue contribution from our Yi Hao
Pharmacies was insignificant in 2018, 2019 and 2020.
52
Table of Contents
Our Drug Benefit Plan
We provide our drug benefit plan for our chronic patients. Under this plan, our online doctors and pharmacists maintain regular
contact with members to provide them with systemized online consultation, on-line prescription refill, medication guidance, information
on symptoms, outreach for feedback, and real-time drug and nutrition recommendation. Members may also purchase brand-name drugs
at a discount. This plan significantly improves medication adherence rates and repurchase rate.
Our Product Offerings to Consumers
We carry diverse and comprehensive products in our online retail and offline retail pharmacies. Our unique integrated retail and
wholesale supply chain and inventory management combines the management of retail and wholesale SKUs. The merchandise offered by
us and the marketplace sellers can be broadly classified into the following major categories:
Drugs. We display drugs, including prescription drugs and over-the counter, or OTC, drugs such as western medicines and
traditional Chinese medicines.
Nutritional supplements. We display nutritional supplements, including a variety of vitamins, and dietary products.
Contact lenses. We offer a comprehensive selection of contact lenses that cover all major brands.
Medical supplies and devices. We offer a variety of general-purpose medical supplies and devices such as bandages and
thermometers.
Other products. Our other products include personal care products such as skin care, birth control, sexual wellness products as
well as baby products.
We also sell seasonal and promotional items tailored to local consumer demand for convenience and quality. In 2017, we further
expanded our product offerings by introducing more health and wellness products and smart wearable devices. We believe that offering
these products increases the order size spend per visit by meeting the growing demand for one-stop shopping convenience.
Consumers can browse our products by category or scan barcodes of drugs they find in store and easily find them on our online
retail pharmacy.
Pricing and Payment of Products
We offer competitive pricing to attract and retain consumers. Under the direct sales model, prices are set by us with reference to
major online and offline competitors, taking into account our overall pricing strategy for different categories. We believe our prices are
generally lower than those of offline pharmacy chains and independent pharmacies. We constantly monitor the prices of products offered
by our competitors through our pricing intelligence system. See “—Technology and IT Infrastructure— Cloud-based Applications.”
Under our marketplace model, sellers are free to set their own prices, but are encouraged to set comparable and competitive prices. We
also occasionally offer significant discounts on certain products for a limited time in flash sales or other promotional activities, including
our anniversary sale and “November 11 sale.” We make continuous efforts to maintain and improve an efficient cost structure and create
incentives for our suppliers to provide us with competitive prices.
We provide our consumers flexible payment options for both direct sales and marketplace models. Our payment options include
in-person settlement (which is required and the only option for the purchase of prescription drugs), bank transfers, online payments with
credit cards and debit cards, and payment through third-party online payment platforms, such as WeChat Payment and Alipay. For
fulfillment and delivery options, please see “—Supply Chain Management—Fulfillment and Delivery.”
Our Online Consultation and E-prescription Services
We strive to provide our consumers with convenient access not only to pharmaceutical products, but also to medical services.
We commenced our online consultation services, through 1 Clinic, a licensed internet hospital operated by us, in 2016, to address the
need for cost-effective and convenient evaluation of health and medical conditions. Our online consultation utilizes a user-friendly
53
Table of Contents
interface embedded in 1 Medicine Marketplace website and app designed to empower consumers to remotely access healthcare. This
service covers a wide range of conditions and cases, with a primary focus on common and chronic illnesses. For conditions that require
in person or further examination or laboratory testing, we generally refer our consumers to hospitals.
Consumers access our online consultations primarily through photo and text consultations, phone calls and video consultations.
They can select a doctor of their choosing based on the doctor’s availability and his/her profile displayed on our platform. Our photo and
text consultation sessions are offered to consumers for free. We typically charge a fixed amount of fees per consultation session for
consultations through video and online assisted telephone calls, which differ based on the type of consultation used and are paid through
our convenient online payment system.
The first step to utilize our services is to provide basic personal information, descriptions of conditions and any medical records
or laboratory test results through our online platform. Based on the consumer’s response to inquiries on the condition at issue, the doctor
provides medical recommendations, issues prescriptions, or advises the consumer to have an examination conducted at a hospital and
uploads the results to our system.
We provide ongoing training and professional development programs to our in-house medical professionals. We conduct weekly
evaluations of our in-house doctors and medical assistants in respect of quality of service, user feedback and efficiency. We have also
adopted a quality control system with standardized protocols for our services performed by our in-house medical team. We contract
services from external doctors who practice at reputable hospitals with significant experience and appropriate credentials. We require
external doctors to register with us and to agree to our terms of use, pursuant to which they must comply with both our specified work
scope and quality requirements, and the applicable rules and regulations. See “—Risk Management and Internal Control—Healthcare
Service Quality and Safety.”
We offer e-prescription services to consumers as an integral part of the online consultation process, subject to our stringent
compliance procedures. Each of our prescriptions is issued by qualified doctors. The e-prescription services is also available when a
consumer needs to purchase a prescription drug through the offline pharmacy network. See “—Our Products and Services to Pharmacies
—Our Cloud Prescription Services.”
Customer Service and Satisfaction
Providing satisfactory customer services is a high priority. Our commitment to consumers is reflected in the high service quality
provided by our customer service staff and speedy fulfillment and delivery services. We have high levels of customer satisfaction, as
evidenced by a customer satisfaction rate over 99.4% on 1 Medicine Marketplace in 2020.
Our Products and Services to Pharmacies
We have enabled more than 13 offline pharmacies, as of December 31, 2020, to better serve their consumers. The pharmacy
customers we serve include small and medium-sized retail pharmacy chains, independent pharmacies and in-house pharmacies within
clinics and private hospitals, spanning across 31 provinces in China.
Our Online Wholesale Pharmacy
We provide comprehensive, intelligent and integrated distribution solutions through our online wholesale pharmacy, 1
Pharmacy, available both through our 1 Pharmacy app and website. Overall, our business involves a process of sourcing from suppliers,
warehousing, processing orders and invoicing, payment collection and delivering to pharmacies. These pharmacy customers include
independent pharmacies, pharmacy chains, in-house pharmacies within clinics and private hospitals, as well as certain select distributors
that have both retail and wholesale businesses.
1 Pharmacy features an extensive selection of pharmaceutical and other health and wellness products sourced from
pharmaceutical companies and other suppliers. A substantial majority of prescription and OTC drugs displayed on 1 Pharmacy are
available under our direct sales model. Our broad and fast-growing product offerings enable us to satisfy the purchasing needs of our
pharmacy customers. Meanwhile, our strong sourcing capability, coupled with our highly cost-effective distribution model, enables us to
bypass traditional layers of the distribution network to provide competitive prices to our pharmacy customers.
54
Table of Contents
Our Direct Sales Model
We primarily conduct our wholesale distribution business through our direct sales model, where we procure pharmaceutical
products from pharmaceutical companies or distributors and sell to our pharmacy customers. As of December 31, 2020, we directly
sourced from 333 pharmaceutical companies and 1,339 distributors. Leveraging our strong relationship with our suppliers, we offer a
comprehensive selection of pharmaceutical products at market-competitive pricing. Under the direct sales model, we are responsible for
the fulfillment and delivery of the products sold.
Our Marketplace Model
We also operate an online marketplace where third-party sellers can directly sell to pharmacies. These marketplace sellers
primarily consist of traditional offline distributors. They leverage our platform and customer base to grow their business, while at the
same time complementing our product offerings under our direct sales model. Our marketplace business model under our wholesale
business is similar in many respects to our retail business, including the charging model. For a detailed discussion, please see “—Our
Products and Services to Consumers—Our Marketplace Model.”
Payment, Exchange and Return
We generally require advance payment or payment-upon-delivery for purchases. For certain select pharmacy customers, we may
grant a credit period of up to a month. We generally do not offer product return and exchange service unless the damages are caused by
our fault.
Supply Chain Finance Service
We offer convenient online loan application services to the clients of 1 Pharmacy, including pharmacies and wholesalers, when
they purchase drugs on 1 Pharmacy. Our service provides access to credit loans from a third party at low interest rates, which can
effectively alleviate the clients’ cash flow pressures, subsequently increasing their purchase frequency and order size.
Our Cloud-based Inventory Management Services
Most of our pharmacy customers, in particular, independent pharmacies and in-house pharmacies within clinics and private
hospitals, do not have a comprehensive inventory and demand forecast system. Purchases by these customers are primarily made based
on historical experience, and their inventory turnover days are generally long due to a lack of detailed, precise planning and bulk
purchase patterns. In addition, their inventory level is subject to fluctuations as a result of seasonal or other factors beyond their control.
Our online wholesale pharmacy, featuring a vast selection of pharmaceutical products and speedy delivery, enables cloud-based
inventory management. Pharmacy customers, rather than relying on advance but often imprecise planning, can collaborate with us for
inventory visibility and on-demand offering. We simplify and streamline the procurement process and shorten the procurement cycle.
Our pharmacy customers typically do not need to negotiate or enter into any purchase and sale agreement or make any purchase
commitment. The purchase orders of our pharmacy customers on 1 Pharmacy are processed in real time. Typically, the order processing
will take within 15 minutes, after which orders will be dispatched for delivery through our fulfillment network. The inventory on demand
and just-in-time delivery offer significant benefits to our pharmacy customers. Instead of bulk purchases and maintaining large inventory,
pharmacies procure their inventory with more precision, reducing their working capital needs and enabling them to quickly respond to
market demand. As a result, we are able to improve the inventory turnover of our pharmacy customers.
Our Cloud Pharmacy Services
We help offline pharmacies to build their online presence effectively and to extend the reach of their products to cover a broader
consumer base through the Internet, thus expanding their market coverage and improving their service capabilities.
55
Table of Contents
Our Cloud Clinic Services
We enable offline pharmacies to provide online consultation and e-prescription services through our cloud clinic services to
patients.
Our Cloud Prescription Services
Pharmacies, especially independent pharmacies and small-to-medium sized pharmacy chains, often lack onsite doctors to offer
prescriptions to consumers with minor ailments or chronic diseases visiting their stores. In 2018, we began to use our cloud prescription
services to leverage our existing online consultation and e-prescription service platform to offer convenient online consultation services
to these consumers onsite. Once consumers obtain their prescriptions from us, they will be able to purchase prescription drugs from our
pharmacy customers. In return for our services, we charge our pharmacy customers a fixed amount of annual service fees. The annual
service fees vary, depending on the number of online consultations performed, the number of e-prescriptions issued, and the number of
drugs purchased in connection with our services.
Our Smart Procurement Services
Leveraging our extensive experience in inventory management and our data analytics capabilities, we launched our smart
procurement services in the first quarter of 2018 to cooperate with pharmacies to collect their historical purchase orders and inventory
data. We then typically analyze historical purchase patterns, the location of the pharmacy and regional supply and demand information,
any epidemic status and trend, and current pricing and promotions. Through our proprietary big data analytic platform and sophisticated
prediction model, we can make individualized purchase recommendations for our pharmacy customers’ review.
Given our broad reach within the pharmaceutical value chain, we believe that we will be able to detect trends in the industry and
forecast demand, therefore, meeting the procurement needs of pharmacies through our customized generated purchase orders. Our smart
procurement service is also capable of comparing prices across different sellers on our platform to ensure the best pricing for our
pharmacy customers. As pharmacy customers gradually increase the use of our services, we believe that we can accumulate data to
optimize our own supply chain management, while providing better solutions to both pharmacies and upstream suppliers with more
relevant service offerings.
Our Automated Salesforce Tool
Hawkeye is an automated tool that we provide to our on-the-ground sales team to better serve customers. This tool captures the
behavior of every pharmacy customer that surfs the 111 website, and monitors the supply chain status on a real-time basis. For example,
upon replenishment of an SKU, Hawkeye will immediately generate a task for our sales team to engage customers who have researched,
or who have searched for this SKU in the past. This tool enables our sales team to identify the purchase intent of pharmacies more
intuitively and to offer more customized recommendations. As a result, our on-the-ground sales coverage efficiency improved threefold.
Customer Experience
We are committed to optimizing and achieving satisfaction of our pharmacy customers. This commitment drives every aspect of
our operations, which are focused on five core components: extensive product offerings, competitive pricing, transformational online
procurement processes and frequent customer engagement, as well as timely and accurate fulfillment. We also build customer loyalty and
encourage pharmacies to make repurchases by actively engaging with them. After assisting our pharmacy customers to open accounts
and establishing initial relationships, our on-the-ground sales force frequently liaise with these pharmacies via in-person visits, telephone
calls or other social network tools to share the latest promotional information and drive repeat purchases.
Our Services to Pharmaceutical Companies
We source products from pharmaceutical companies and distributors, while at the same time providing them with data services
and other value-added services.
56
Table of Contents
Data Services
Leveraging our direct reach to many touchpoints of the healthcare and pharmaceutical value chain, we launched our data
services in 2018 on a pilot basis to help our pharmaceutical companies expand their reach and gain valuable insights to the distribution
channel and consumers. We compile, aggregate and analyze our detailed sales data to uncover purchase patterns and predict future
purchase behaviors and demand. With our broad consumer base, we can extract valuable information from our extensive database. For a
particular product, we analyze the regional and seasonal sales patterns, the amounts of orders, the frequency of purchases, any particular
preference for packaging, and other factors that may affect sales. Data mining of our available data is a powerful tool to predict consumer
behaviors and market trends, allowing pharmaceutical companies to make knowledge-driven decisions in their sales forecasts and
budgeting. For a discussion of our pricing intelligence system, see “—Technology and IT Infrastructure—Cloud-based Applications.”
Supply Chain Integration Services
Leveraging our established supply chain system, we provide supply chain integration services to help pharmaceutical companies
manage their products through online and offline distribution channels. In addition to our supply chain integration service, we also
provide product promotion services, customer analytic services, patient education services and brand awareness services.
Our Services to Medical Professionals
We provide medical professionals with services to enable them to better serve patients and improve service quality.
E-medical Record and Patient Management
We create and maintain, in secured electronic storage, a copy of electronic medical records for certain consumers. These e-
medical records allow consumers to access past consultation history and communicate with doctors for follow-up or new consultations.
Our cloud-based platform and e-medical record services also enable more efficient patient management by doctors. Doctors use our
system for reviewing e-medical records with the patient’s consent.
Suppliers
We have an extensive network of suppliers, consisting primarily of pharmaceutical companies and distributors. As of
December 31, 2020, we directly sourced from 333 pharmaceutical companies and 1,339 distributors. We believe that competitive sources
are readily available for substantially all of the merchandise we carry on our platform, and we have diversified our procurement sources
to obtain more favorable terms and minimize our inventory risk.
57
Table of Contents
Supplier Selection
When choosing suppliers, we take into consideration, among other things, whether their products complement our overall
product offering, the quality and prices of their products, market reputation, production and/or distribution capacity and the market
potential of their products. Before we engage with any new supplier, we also examine their qualifications and licenses to verify that they
operate their businesses in compliance with applicable laws, rules and regulations.
Our Relationship with Pharmaceutical Companies and Key Suppliers
We have dedicated teams that work closely with our top suppliers, especially pharmaceutical companies, to strengthen our
relationships with them. For the same product, the price from a pharmaceutical company is generally lower than from a distributor. We
aim for qualification by major pharmaceutical companies as a “tier one” distributor so as to directly source from them. As of
December 31, 2020, we have obtained such qualifications from 333 pharmaceutical companies and directly source from them. We also
seek to cooperate with other “tier one” distributors who may have negotiated attractive prices for particular products. Our cooperation
with these suppliers allows us to expand our product offerings and procure products manufactured by pharmaceutical companies without
an established relationship with us. We intend to help pharmaceutical companies expand their end user base by leveraging our network of
pharmacies. We also provide them with customized channel management services, as well as data flow, operational support, marketing,
user data analysis and other value-added services. Together with pharmaceutical companies, we work to develop medical know-how
including academic content and product trainings.
Supply Chain Management
We combine advanced technologies and supply chain optimization techniques to integrate the front and the back end of the
supply chain and optimize our inventory management. Our unique integrated retail and wholesale supply chain and inventory
management allow us to share inventories among 1 Medicine Marketplace, 1 Pharmacy, and Yi Hao Pharmacy, significantly increasing
our operational efficiency. Supported by our proprietary supply chain management systems, efficiently designed supply chain protocols
and processes, strategically located fulfillment centers and nationwide fulfillment network, our supply chain enables inventory on
demand and just-in-time delivery for our consumers. As a result of our advanced supply chain management system, we have seen
tangible improvements in our own and our customers’ efficiency levels.
Supply Chain Technologies and Systems
Our supply chain management system consists of four separate subsystems supported by proprietary software that allows us to
effectively collaborate with third-party service providers and interact with our consumers and pharmacy customers. All of our systems
are designed to comply with Good Supply Practices (GSP) for pharmaceutical products, and connect with provincial food and drug
administrations for real-time monitoring.
Warehouse Management System (WMS). We customize our proprietary warehouse management system to meet the specific
needs of our pharmaceutical distribution business. Our WMS enables us to closely monitor each step of the fulfillment process from
guiding inventory receiving and put-away, optimizing picking and shipping of orders and advising on inventory replenishment. Our
advanced WMS software optimizes our warehouse space and employees’ time, supports paperless material handling in a digital WMS
environment and automates the interaction between our employees and material handling equipment, such as conveyor belts. For
example, we developed advanced algorithms to optimize picking, packing and shipping. At each fulfillment center, inventory is bar-
coded and tracked through our management information system, allowing real-time monitoring of inventory levels across our fulfillment
network and item tracking at each fulfillment center. Our shelf space hosts the same inventory for both our wholesale and retail
businesses, while the assignment and allocation logics are designed to cater to the different requirements for fast-moving and long-tail
products, optimizing fulfillment efficiency. The seamless connection with our other supply chain management modules has led to
increased inventory accuracy, greater space utilization, increased warehouse productivity and improved customer service.
Transportation Management System (TMS). Our transportation management system enables full operational control and
visibility from dispatch to delivery, and from invoicing to receivables collections. Our TMS is integrated with third-party accounting
systems. All of these systems are customer-oriented and allow for full shipment tracking and visibility, as well as for customer shipment
input.
58
Table of Contents
Procurement Management System (PMS). Our procurement management system promotes transparency and compliance. It
consists of various modules with different levels of authorizations to different personnel. We are in the process of developing our data
platform that is fully compatible with and can connect to many of our suppliers’ ordering systems to allow seamless information
exchange. We expect the new system to enhance the efficiency of various aspects of our purchase process, such as stocking and account
settlement.
Order Management System (OMS). Our order management system allows us to manage inventory cost and pricing, and process
orders from both pharmacy customers and consumers. It also provides us with flexible pricing and promotions to satisfy our customers’
needs. Our order management system enhances our visibility into our customers’ preferences, merchandise and supply chain, resulting in
improved customer service, improved operational efficiency, enhanced management analytics and increased inventory synergies.
Price Intelligence System (PIS). Our price intelligence system generates price indexes and optimal pricing recommendations for
products on 1 Pharmacy and 1 Medicine Marketplace by analyzing product information collected from online and offline channels, and
makes automatic adjustments to prices based on optimal pricing strategies. Our PIS also provides clients with pricing data intelligence
generated from our collection and analysis of products and prices on the market, useful in our clients’ product procurement and pricing
processes.
Inventory Management
We manage our inventory, both retail and wholesale, in an integrated manner. Our inventory, fulfillment and delivery services
are centrally managed from our headquarters. Our inventory management allows our retail and wholesale businesses to access and share
all of our inventory resources.
We continually seek to improve our inventory control and minimize inventory risk. We analyze historical sales data and days in
inventory to establish inventory management plans. We may adjust our inventory management plans based on factors such as
fluctuations in supply and prices, seasonality and sales of a particular product. Our inventory optimization model uses sophisticated
algorithms to help determine when to replenish an SKU. We also perform regular spot inventory counts in our fulfillment centers. We
monitor the shelf life of our pharmaceutical products by conducting periodic reviews, and either make sales promotion plans or make
inventory write-downs depending on the status of the inventory.
Our inventory includes high level of stock for certain products that we consider as strategic reserves. These products are
generally purchased at favorable price terms, and have a long shelf life. They also help us preempt possible industry-wide shortages.
Fulfillment and Delivery
As of December 31, 2020, our fulfillment network consists of eight regional fulfillment centers strategically located in
Guangzhou in Guangdong Province in Southern China, Kunshan in Jiangsu Province in Eastern China (which is within close proximity
of Shanghai), Tianjin in Northern China, Chongqing in Western China, Wuhan in Central China, Fuzhou in Fujian Province in Southern
China, Xi'an in northwest China and Shenyang in northeast China. In the future, we plan to selectively establish additional fulfillment
centers to improve our geographical coverage while maintaining our operational efficiency.
We leverage our large-scale operations and reputation to obtain favorable contractual terms from third-party delivery
companies. To reduce the risk of reliance on any single delivery company, we typically contract with two or more regional delivery
companies in each major city. We regularly monitor and review the delivery companies’ performance and their compliance with our
contractual terms. In addition, we typically require the delivery companies to pay deposits or provide payment guarantees before
providing services to us. We typically negotiate and enter into logistics agreements on an annual basis.
We are generally able to deliver to major cities in 31 provinces within 24 hours, and nationwide within 72 hours.
Risk Management and Internal Control
We have adopted and implemented various policies and procedures to ensure rigorous risk management and internal control,
and we are dedicated to continually improving these policies and procedures.
59
Table of Contents
Our risk management and internal control policies and procedures cover various aspects of our business operations such as
product safety, healthcare quality and safety, regulatory risk management, government affairs and regulatory compliance.
Product Quality and Safety
We place strong emphasis on quality and safety of the products we sell on our platform. We conduct random quality inspections
of products we procure, and reject the shipment if it fails to meet our quality standards. Our quality control department rigorously
implements quality control procedures.
Healthcare Service Quality and Safety
We value the quality and safety of the healthcare services we provide. We strive to minimize medical risks arising from our
operations. We have never received any written notice or penalty for material non-compliance or violation of healthcare service quality
and safety laws or regulations, nor have we received any recommendation for improvement with respect to healthcare service quality and
safety from any government authority.
The skills, competence and attitude of our in-house medical team are essential for the quality of care that our users receive. We
continually monitor the risk in relation to services provided by our in-house medical team to ensure the risk management policies and
procedures have been strictly followed, so as to achieve effective and efficient governance, risk and control processes.
We have adopted stringent hiring procedures for doctors, pharmacists and medical assistants, which involve in-person
interviews and assessments of technical knowledge. Our in-house medical team receives regular training on relevant safety policies,
standards, protocols and procedures and is required to strictly comply with them in all aspects of our operations. We conduct frequent
evaluations of our in-house doctors, pharmacists and medical assistants.
For external doctors, we generally require them to provide us with their qualifications and licenses and to strictly adhere to the
work scope and quality requirements specified in their service agreements in compliance with applicable legal and regulatory
requirements.
For healthcare institutions to which we refer our consumers, we consider a variety of factors such as reputation, scale of
business, service quality and capability, as well as their facilities. We typically require healthcare institutions who cooperate with us to
maintain requisite licenses, comply with relevant laws and regulations and follow our service guidelines. We also carefully monitor
feedback from our consumers on the services provided by these healthcare institutions, and take that into consideration when determining
our continued cooperation with such healthcare institutions. We are not responsible for any losses to our consumers resulting from
disputes or breach of obligations in relation to the provision of the relevant services.
Regulatory Compliance and Risk Management
We have a dedicated public relations department, consisting of government relations and public relations teams and with a
leader who has over 10 years of experience in regulatory compliance and risk management in Fortune 500 companies. We have designed
and adopted strict internal procedures to ensure compliance of our business operations with all relevant laws and regulations and have
established a code of conduct to regulate employee behavior and activities. In addition, we continually review the implementation of our
risk management policies and measures to ensure our policies and implementation are effective and sufficient.
We work closely with relevant government agencies that have jurisdiction over our business. We maintain frequent
communications with government agencies before implementing new business initiatives or when regulatory uncertainties arise as new
laws or regulations are promulgated. We actively provide our inputs on proposed regulations that are subject to public comments. We are
often invited to comment on proposed regulations by relevant government authorities during the comment solicitation process.
As part of our risk management and internal control measures, we have adopted a series of internal regulations against corrupt
and fraudulent activities, which include measures against receiving bribes and kickbacks, and misuse of company assets. We have anti-
corruption and anti-bribery clauses in a majority of our major business contracts, and we require our suppliers and other third parties who
cooperate with us to comply with relevant laws and regulations.
60
Table of Contents
Data Privacy and Protection
We are committed to protecting information and privacy of our consumers and other participants on our platform. We have
developed a company-wide policy on data security to preserve individual personal information and privacy. We strictly comply with laws
and regulations and do not distribute or sell our users’ personal data for any purpose. We encrypt user data in network transmissions and
in backend storage to ensure confidentiality. To minimize the risk of data loss, we conduct regular data backup and data recovery tests.
Our database can only be accessed by certain designated and authorized personnel after assessment and approval procedures, whose
actions are recorded and monitored.
Technology and IT Infrastructure
Our proprietary technology is one of our core competitive advantages. As of December 31, 2020, our technology and IT team
consisted of 292 employees, including core team members with extensive experience with leading internet, online retail and e-commerce
companies in China. We have built our technology platform primarily relying on proprietary software and systems that we have
developed in-house. We develop and maintain various online platforms that connect the respective systems of various participants in the
healthcare ecosystem, enabling them to access our services and connect with other participants in the ecosystem. As a result, they are
able to conveniently share information and conduct their operations efficiently over our platform.
Data Collection, Aggregation and Analytics and Transaction Support
Our data assets are the backbone of our data analytics capabilities. We collect data under various scenarios across the entire
pharmaceutical value chain. The high volumes of traffic over our platform have brought us large amounts of data, collected with the
consumer’s due authorization. Our strong data mining and user behavior analytics capabilities allow us to build a comprehensive profile
for each consumer. Data analytics is extensively used in various aspects of our operations.
In addition, we collect a wealth of data on our supply chain, such as cost per delivery, delivery time requirements, positive
customer feedback and other similar indicators. Based on our extensive database of supply chain information, we create operational goals
and insights, including optimal time by which deliveries must be made to elicit positive consumer feedback and optimal delivery routes
that minimize cost per delivery. We use the data we possess to simplify supply chain management, enabling our business to operate more
efficiently, giving us more visibility and control over our inventory and reducing our operational costs. For discussion of our supply
chain management and related technologies, please see “—Supply Chain Management.”
Cloud-based Applications
Our platform is built on highly scalable and reliable cloud-based technology architecture that can accommodate the increasing
scale and complexity of our business operations. Our IT framework includes service-oriented architecture, business intelligence, single
sign-on, ERP Open API, pay component, image recognition, message-oriented middleware, task scheduling center and radio frequency
identification, or RFID. Service-oriented architecture is a style of software design where services are provided to the other components
by application components. ERP Open API is standardized API, or application programming interface, that is compatible with different
ERP systems adopted by pharmacy customers. Message-oriented middleware is a software or hardware infrastructure that supports
sending and receiving messages between distributed systems, allowing application modules to be distributed over heterogeneous
platforms and reducing the complexity of developing applications that span across multiple operating systems and network protocols. We
are able to rapidly enroll consumers, pharmacy customers and suppliers onto our platform and seamlessly include them in our system.
Our sophisticated CRM system enables us to effectively gather, analyze and use customer data to plan customized marketing
activities. In addition, we also provide our data insights to pharmacies and marketplace sellers to help them optimize their sales and
marketing strategies. Our CRM system enables us to reduce costs and increase profitability through increased customer loyalty and
attention. Our online platform for doctors also has a CRM system and lays the foundation of patient management and assists the
interaction between medical professionals.
Our business intelligence system provides operational analysis, sales forecasts and other application-oriented intelligent
products that facilitate data-driven decision making. One such application is our pricing intelligence system, which applies data mining
techniques to discover, match, extract and report on competitive pricing data to optimize our pricing strategy relative to our
61
Table of Contents
competition. This pricing intelligence system helps us gain a better understanding of our price position in the market and make automatic
adjustments to thousands of our SKUs. We also use our pricing intelligence system to provide data services to pharmaceutical
companies. See “—Our Services to Pharmaceutical Companies.”
Our IT Infrastructure
We are committed to maintaining a secure online platform. We have built a firewall that monitors and controls incoming and
outgoing traffic on our platform 24/7. Once any abnormal activity is detected, our system will immediately notify our IT team and
simultaneously take automatic protective and remedial measures, such as activating third-party traffic control services, to prevent any
harm to our platform. We conduct periodic reviews of our technology platform identifying and correcting problems that may undermine
our system security.
Our stable IT infrastructure is hosted by two separate cloud service providers. We achieve redundancy and reliability of our
network through a real-time multi-layer data backup system. Our platform adopts modular architecture that consists of multiple
connected components, each of which can be separately upgraded and replaced without compromising the functioning of other
components. This makes our platform both highly reliable and scalable.
Our platform is scalable and can be easily expanded as data storage requirements and user visits increase. In addition, load
balancing technology helps us improve distribution of workloads across multiple computing components, optimizing resource utilization
and minimizing response time.
Environmental, Social and Governance (ESG) Initiatives
We are committed to corporate social responsibility and meeting society’s changing needs despite the recent challenging
economic environment. We are committed to supporting and participating in socially responsible projects that align with our core values
and mission, and to extend the benefits of our products and services through our technology-driven platform to the community at large.
In response to the recent coronavirus (COVID-19) outbreak, we have taken a series of initiatives.
We were among the leaders in combatting the COVID-19 outbreak both domestically and overseas. On January 20, 2020, we
established an anti-epidemic command team and our senior executives led their teams to the front lines of the epidemic in Hubei
province to provide medical supplies and resources. All of our employees worked overtime during the Chinese New Year holiday to meet
the needs of the nation.
Starting on January 24, 2020, our Internet hospital was one of the first Internet-based healthcare companies to offer free online
medical consultations to the public in Wuhan and subsequently to the entire Hubei province. It was also among the first to provide free
online drug refill services to individuals with chronic conditions. We worked with both pharmaceutical manufacturers and logistics
companies to deliver supplies to those in need, whether in Wuhan, Hubei province, or nationwide. Our swift and effective actions
alleviated some of the pressure on overburdened hospitals and helped to curtail the further spread of COVID-19 by allowing patients
with chronic illnesses and COVID-19 patients without life-threatening symptoms to receive medical care without visiting a hospital. In
addition, we donated 100,000 protective masks and other protective materials to the people in Wuhan. We also launched a channel
featuring real-time information on COVID-19, with news updates and advice from medical professionals on containing the virus and
preventing infection, and we set up a “Medical Supply Assurance Service” to help companies protect their employees when they begin to
resume their operations and recover from the impact of the epidemic.
62
Table of Contents
Beginning on March 17, 2020, we offered a free online consultation service in Chinese through our Internet hospital globally. In
April 2020, we delivered approximately 40,000 N95 masks to Weill Cornell Medicine in New York City and the first batch of 2.3 million
medical gloves and 75,000 medical coats to the State of Washington. We also provided online appointment service of COVID-19 testing
in collaboration with Adicon in China. In May 2020, we launched our Overseas Direct Delivery service in collaboration with leading
logistic and delivery companies including UPS, FedEx and DHL to provide direct delivery of masks, disposable gloves, protective gowns
and other equipment to over 200 countries globally, including the hardest hit countries such as United States, Italy, Spain and Japan.
Sales and Marketing
Our marketing and promotion strategy is to build brand recognition, increase customer traffic, attract new customers, build
strong customer loyalty and develop incremental revenue opportunities.
We employ a variety of methods to attract potential consumers. Generally, we expand our user base on our marketplace through
search engines, social media and word-of-mouth referrals. We offer incentives to new consumers and pharmacy customers who make
purchases for the first time on our platform. We also offer flash sales and brand promotion events on our website and mobile application
to engage with existing consumers in an effort to increase retention and repurchases. Our principal marketing programs include
advertising our company and our solutions through our mobile platform and other media.
We acquire pharmacy customers primarily through our effective on-the-ground sales operation to allow rapid expansion of our
wholesale business. We have full-time employees who visit independent pharmacies, pharmacy chains and in-house pharmacies within
clinics and private hospitals to promote our online wholesale pharmacy and our inventory management services. We also hire
independent contractors who work for us on a commission-basis to promote our products and services to pharmacies through our “City
Partners” program. We also coordinate market development and promotion efforts for our pharmacy customers, which may include flash
sales, seasonal sales discounts and rebates.
Competition
We believe our business model is unique and our services encompass the entire pharmaceutical value chain. We believe there
are no comparable companies that directly compete with us. However, we face intense competition in certain business segments and
verticals:
● we compete against other pharmaceutical retail companies including traditional offline pharmacies and online platforms,
such as Ali Health and JD.com; and
● we also face competition from numerous B2B platforms and traditional pharmaceutical distributors.
We believe that our ability to compete effectively depends on many factors, including the variety of our products, our pricing
competitiveness, user experience on our platform, our technological leadership, effectiveness of our risk management, our partnership
with third parties, our marketing and selling efforts and the strength and reputation of our brands.
Furthermore, as our business continues to grow rapidly, we face significant competition for highly skilled personnel, including
management, engineers, product managers and risk management personnel. The success of our growth strategy depends in part on our
ability to retain existing personnel and add additional highly skilled employees. We believe that our early mover advantage and leading
market position help us to compete efficiently against our competitors.
63
Table of Contents
Intellectual Property
We rely on a combination of copyright, trademark and trade secret laws and restrictions on disclosure to protect our intellectual
property rights. We have registered 28 software copyrights with the PRC National Copyright Administration. We have 33 registered
domain names, including 111.com.cn and yaoex.com. As of December 31, 2020, we had 271 registered trademarks, including our “1药
网” trademark. As of the same date, we had 7 authorized patents with the PRC State Intellectual Property Office.
Insurance
We maintain property insurance policies covering certain equipment and other property that are essential to our business
operations to safeguard against risks and unexpected events. We also provide social security insurance including pension, medical
insurance, unemployment insurance, maternity insurance, on-the-job injury insurance and housing fund plans through a PRC
government-mandated benefit contribution plan for our employees. We maintain product liability insurance. We also maintain
professional malpractice insurance for our in-house licensed medical practitioners and some of our external doctors. We do not maintain
business interruption insurance. We consider our insurance coverage to be sufficient for our business operations in China.
Regulations
This section sets forth a summary of the most significant rules and regulations that affect our business activities in China.
Regulation Relating to Foreign Investment
Investment in the PRC conducted by foreign investors and foreign-owned enterprises shall comply with the Guidance Catalogue
of Industries for Foreign Investment, or the Catalogue, which was first issued in 1995 and amended from time to time. The current
effective Catalogue was promulgated by the MOFCOM and the NDRC in June 2017 and became effective in July 2017, and contains
specific provisions guiding market access of foreign capital and stipulates in detail the areas of entry pertaining to the categories of
encouraged foreign-invested industries, restricted foreign-invested industries and prohibited foreign-invested industries. The latter two
categories are included in the negative list, which was first introduced into the Catalogue in 2017, and listed, in a unified manner, the
restrictive measures for the entry of foreign investment. On June 23, 2020 and December 27, 2020, the MOFCOM and the NDRC jointly
promulgated the Special Administrative Measures for Access of Foreign Investment (Negative List) (2020 Edition) and the Catalog of
Industries for Encouraged Foreign Investment (2020 Edition) respectively, to replace the former negative lists and the Catalogue, which
took effect on July 23, 2020 and January 27, 2021 respectively. Any industry not listed in the Catalogue and the Negative List is a
permitted industry and generally open to foreign investment unless specifically prohibited or restricted by PRC laws and regulations.
According to the Negative List, value-added telecommunications services (with the proportion of foreign investment not exceeding 50%,
except for e-commerce) and medical institutions (limited to sino-foreign equity joint venture or sino-foreign cooperative joint venture)
are restricted for foreign investment. 1 Pharmacy Technology, our PRC subsidiary, is a foreign-invested enterprise and conducts technical
services and consultation and sale of goods that falls in permitted industries for foreign investment. Wuhan Central China, our 70%
owned PRC subsidiary, is an entity invested by a foreign-invested enterprise and conducts online B2B pharmaceutical e-commerce
business which is classified as a type of value-added telecommunications services. It falls in the restricted foreign-invested industry but
is not subject to the 50% foreign investment restriction.
In September 2016, the SCNPC, passed a decision in connection with the revision of four laws, including the trio of laws
regulating foreign investment in China, which became effective in October 2016. According to this decision, establishment of a foreign-
invested enterprise, or the FIE, in a sector not subject to special entry administrative measures will be simplified by going through
government filing instead of a government approval process, which applies to its establishment, separation, merger or other major
modifications and operation duration and extension; but the special entry administrative measures are to be separately promulgated or
approved to be promulgated by the State Council. According to a notice issued by the NDRC and the MOFCOM in October 2016, the
special entry administrative measures shall be applicable and implemented to the restricted foreign-invested industries, prohibited
foreign-invested industries and encouraged foreign-invested industries which have requirements as to shareholding and qualifications of
senior management stipulated in the then-effective Catalogue.
In March 2019, a new draft of Foreign Investment Law was submitted to the National People’s Congress for review and was
approved on March 15, 2019, which has come into effect on January 1, 2020 and replaced the trio of laws regulating foreign investment
in China. Its implementation of regulations promulgated by the State Council in December 2019 also came into effect on
64
Table of Contents
January 1, 2020. Under new Foreign Investment Law, foreign investment refers to investment activity directly or indirectly conducted by
foreign natural persons, enterprises or other organizations, including the following circumstances: (i) a foreign investor establishes a
foreign-funded enterprise within the territory of China, independently or jointly with any other investor; (ii) a foreign investor acquires
shares, equities, property shares or any other similar rights and interests of an enterprise within the territory of China; (iii) a foreign
investor makes investment to initiate a new project within the territory of China, independently or jointly with any other investor; and
(iv) a foreign investor makes investment in any other way stipulated by laws, administrative regulations or provisions of the State
Council. Foreign investors shall not invest in any field forbidden by the negative list for access of foreign investment and shall conform
to the investment conditions stipulated under the negative list for any field restricted by the negative list. Fields not included in the
negative list shall be managed under the principle that domestic investment and foreign investment shall be treated uniformly. In
addition, a foreign investment information reporting system shall be established and foreign investors or foreign-funded enterprises shall
submit the investment information to competent departments for commerce through the enterprise registration system and the enterprise
credit information publicity system.
Our PRC subsidiary, 1 Pharmacy Technology, as a foreign-invested enterprise, is not subject to the special entry administrative
measures and has filed with the competent commerce authority for its establishment and modification as requested. Our PRC subsidiary,
Wuhan Central China, an entity invested by a foreign-invested enterprise and conducts business which falls in the restricted foreign-
invested industry, has obtained the approval from and made filing with the competent commerce authority for its modifications. Our
variable interest entities which are not foreign-invested enterprises are not required to be filed with commercial authorities under such
measures.
In August 2006, six PRC regulatory agencies, including the MOFCOM, jointly adopted the M&A Rules, which became
effective in September 2006 and were amended in 2009. The M&A Rules also establish procedures and requirements that could make
certain acquisitions of PRC companies by foreign investors more time-consuming and complex, including requirements in some
instances that MOFCOM be notified in advance of any change-of-control transaction in which a foreign investor takes control of a PRC
domestic enterprise. In addition, according to the Notice on Establishing the Security Review System for Mergers and Acquisitions of
Domestic Enterprises by Foreign Investors issued by the General Office of the State Council in February 2011, the Rules on
Implementation of Security Review System for the Merger and Acquisition of Domestic Enterprises by Foreign Investors issued by the
MOFCOM in August 2011, mergers and acquisitions by foreign investors that raise “national defense and security” concerns and
mergers and acquisitions through which foreign investors may acquire de facto control over domestic enterprises that raise “national
security” concerns are subject to strict review by the MOFCOM, and the regulations prohibit any activities attempting to bypass such
security review, including by structuring the transaction through a proxy or contractual control arrangement.
Regulation Relating to Value-added Telecommunications Services
Telecommunications Regulations
The Telecommunications Regulations of the People’s Republic of China, or the Telecom Regulations, promulgated in
September 2000 and amended in July 2014 and February 2016 respectively, are the primary PRC laws governing telecommunication
services, and set out the general framework for the provision of telecommunication services by domestic PRC companies. The Telecom
Regulations require that telecommunications service providers obtain operating licenses prior to commencing operations. The Telecom
Regulations draw a distinction between “basic telecommunications services” and “value-added telecommunications services.” The
catalogue of Telecommunications Business, or the Telecom Catalogue, issued as an attachment to the Telecom Regulations, identifies
information services and online data and transaction processing services as value-added telecommunications services.
65
Table of Contents
In July 2017, the MIIT issued the revised Measures on the Administration of Telecommunications Business Operating Permits,
or the Telecom License Measures, which became effective in September 2017, to supplement the Telecom Regulations. The Telecom
License Measures require that an operator of value-added telecommunications services obtain a value-added telecommunications
business operating license, from the MIIT or its provincial level counterparts. The term of a license for value-added telecommunication
business is five years and subject to annual inspection. Yihao Pharmaceutical Chain has obtained the Value-Added Telecommunications
Services Operating License for conducing information services and online data and transaction processing services (e-commerce only),
while Wuhan Central China has obtained the value-added telecommunications services operating license to conduct online data and
transaction processing services (e-commerce only).
Foreign Investment in Value-Added Telecommunications
Foreign direct investment in telecommunications companies in China is also regulated by the Regulations for the
Administration of Foreign-Invested Telecommunications Enterprises, or the FITE Regulations, which were issued by the State Council in
December 2001 and amended in September 2008 and February 2016, respectively. The FITE Regulations stipulate that a foreign invested
telecommunications enterprise in the PRC, or the FITE, must be established as a sino-foreign equity joint venture for operations in the
PRC. Under the FITE Regulations and in accordance with WTO-related agreements, the foreign party investing in a FITE engaging in
value-added telecommunications services may hold up to 50% of the equity interests of the FITE. In addition, the major foreign party to
be the shareholder of the FITE must satisfy a number of stringent performance and operational experience requirements, including
demonstrating a good track record and experience in operating a value-added telecommunications business. The FITE that meets these
requirements must obtain approvals from the MIIT and the MOFCOM or its counterparts, which retain considerable discretion in
granting approvals. Furthermore, the foreign party investing in e-commerce business, as a type of value-added telecommunication
services, has been allowed to hold up to 100% of the equity interests of the FITE based on the Notice of the Ministry of Industry and
Information Technology on Removing the Restrictions on Foreign Equity Ratios in Online Data Processing and Transaction Processing
(Operating E-commerce) Business issued on in June 2015 and the current effective Telecom Catalogue.
In July 2006, the Ministry of Information Industry, which was restructured and integrated into the MIIT, promulgated the Notice
of the Ministry of Information Industry on Intensifying the Administration of Foreign Investment in Value-added Telecommunications
Services, or the MII Notice, which reiterates certain requirements of the FITE Regulations and strengthens the administration by the MII.
Under the MII Notice, if a foreign investor intends to invest in a PRC value-added telecommunications business, the FITE must be
established to apply for a telecommunications business license applicable to the business. In addition, a domestic company that holds a
license for the provision of value-added telecommunications services is prohibited from leasing, transferring or selling the license to
foreign investors in any form, and from providing any assistance, including providing resources, sites or facilities, to foreign investors to
conduct value-added telecommunications businesses illegally in China. Trademarks and domain names that are used in the provision of
value-added telecommunications services must be owned by the license holder or its shareholders. The MII Notice also requires that each
value-added telecommunications services license holder have appropriate facilities for its approved business operations and to maintain
such facilities in the business regions covered by its license. Yihao Pharmaceutical Chain and Yihao Pharmacy, our variable interests
entity holding the value-added telecommunications services license, owns the domain names, trademarks, and facilities which are
appropriate for the telecommunication business provided by Yihao Pharmaceutical Chain and Yihao Pharmacy.
Internet Information Services
In September 2000, the State Council promulgated the Measures for the Administration of Internet Information Services, or the
ICP Measures, as amended in 2011. Under the ICP Measures, the internet information services are divided into commercial internet
information services and non-commercial internet services. The operators of non-commercial internet information services must file with
relevant governmental authorities and operators of commercial internet information services in China must obtain a license for internet
information provision, or ICP license, from the relevant governmental authorities, and the provision of particular information services,
such as news, publishing, education, healthcare, medicine and medical device, and must also comply with relevant laws and regulations
and obtain the approval from competent governmental authorities.
Mobile Internet Applications Information Services
In June 2016, the CAC promulgated the APP Provisions, which became effective in August 2016. Under the APP Provisions,
mobile application providers and application store service providers are prohibited from engaging in any activity that may endanger
66
Table of Contents
national security, disturb the social order, or infringe the legal rights of third parties, and may not produce, copy, issue or disseminate
through internet mobile applications any content prohibited by laws and regulations. The APP Provisions also require application
providers to procure relevant approval to provide services through such applications and require application store service providers to
register with local branches of the CAC within 30 days after they start providing application store services.
Regulations Relating to Pharmaceutical Operation and Service
Pharmaceutical Operation
In September 1984, the SCNPC promulgated the Drug Administration Law, which was amended in 2001, 2013, 2015 and 2019
respectively to regulate all entities or individuals engaging in research, manufacture, operation, use, supervision and management of
drugs within the PRC. According to the Drug Administration Law, no pharmaceutical operation, including pharmaceutical wholesale and
pharmaceutical retail business, is permitted without obtaining the Pharmaceutical Operation License. The Implementation Rules for the
Drug Administration Law, was promulgated by the State Council in August 2002 and amended in 2016 and 2019, which emphasized the
detailed implementation rules of drugs administration. The CFDA promulgated the Measures for the Administration of Pharmaceutical
Operation License in February 2004 as amended in 2017, which stipulate the procedures for applying the Pharmaceutical Operation
License and the requirements and qualifications for pharmaceutical wholesalers or pharmaceutical retailers with respect to their
management system, personnel, facilities and etc. The valid term of the Pharmaceutical Operation License is five years and shall be
renewed six months prior to its expiration date. Yihao Pharmacy, Yihao Pharmaceutical Chain and its branches, Chongqing Yihao
Pharmacy Co., Ltd., Fujian Yaofang Pharmacy Co., Ltd,. Hubei Yihao Pharmacy Co., Ltd, Kunshan Yifang Pharmacy Co., Ltd., Tianjin
Yihao Pharmacy Co., Ltd., Shanxi Yihao Yaofang Pharmacy and Liaoning Yihao Pharmacy have obtained the Pharmaceutical Operation
License, respectively.
According to the Measures on Prescription Drugs and OTC Drugs Classification Management and the Interim Provisions on the
Circulation of Prescription and OTC Drugs (Trial), which were both promulgated by the State Drug Administration, which was
restructured and integrated into the CFDA, in 1999 and became effective in January 2000, drugs are divided into prescription drugs and
over-the-counter drugs, or OTC drugs. For prescription drugs, the dispensing, purchase and use can only be based on the prescription
issued by the certified medical practitioner or certified medical assistant practitioner. In addition, the prescription drugs can only be
advertised and promoted in professional medical magazines. OTC drugs, on the other hand, are further divided into Class A and Class B
and they both can be purchased and used without a prescription and promoted in public upon approval by the relevant governmental
authorities. The pharmaceutical wholesale enterprises distributing prescription drugs and/or OTC drugs, as well as pharmaceutical retail
enterprises selling prescription drugs and/or Class A OTC drugs are required to obtain the Pharmaceutical Operation License.
67
Table of Contents
According to the Administrative Measures for the Supervision and Administration of Circulation of Pharmaceuticals,
promulgated by the CFDA in January 2007 and effective in May 2007, pharmaceutical manufacture and operation enterprises and
medical institutions shall be responsible for the quality of pharmaceuticals they manufacture, provide or use. The operation of
prescription drugs is highly regulated under these rules. Prescription drugs may not be sold by pharmaceutical retail enterprises without
valid prescriptions and an enterprise in violation of such restriction will be instructed to rectify any violation, given a disciplinary
warning, and/or imposed a fine of no more than RMB1,000. In addition, a pharmaceutical manufacture or operation enterprise shall not
sell prescription drugs directly to the public by post or over internet, and the enterprise in violation of such restriction shall be instructed
to rectify, given a disciplinary warning, and fined the lesser of (i) two times the value of the pharmaceuticals sold and (ii) RMB 30,000.
The Drug Administration Law abolishes the restriction on online sale of prescription drugs and adopts the principle of keeping online
and offline sales consistent, which allows the qualified pharmaceutical enterprise to conduct online sale of drugs (including prescription
drugs, but not certain special controlled drugs). In addition, the entity that operates a third-party online drug transaction platform shall be
filed with relevant authority for drugs supervision and administration and responsible to examine the qualifications of the drug marketing
permit holders and drug operation enterprises applying to operate on its platform, ensure that they meet legal requirements, and manage
the drug operation behaviors occurring on the platform. However, as of the date of this annual report, none of the regulations or
implementation rules regulating online drug sales have yet been promulgated and implemented, which may further introduce and impose
certain conditions and restrictions to the online sale of drugs. Furthermore, the Administrative Standard of Pharmaceutical Operating
Quality, promulgated by the CFDA in April 2000 and amended in 2012, 2015 and 2016, respectively, and the Administrative Measures
for Identification of Pharmaceutical Operating Quality Administrative Standards, promulgated by the CFDA in April 2003, the
pharmaceutical operation enterprise shall take effective quality control measures over the process of procurement, storage, transportation
and sale of drugs in order to ensure their quality.
Medical Devices Operation
According to the Regulations on the Supervision and Administration of Medical Devices, which was promulgated by the State
Council in January 2000 and amended in 2014 and 2017, respectively, and the Supervision and Management Measures on Medical
Devices Operation, which was promulgated by the CFDA in July 2014 and amended in 2017, business operations of medical devices are
regulated based on the degree of risks involving the medical devices, which are divided into three categories. Operation of Class I
medical devices does not require a license or record-filing, while operations of Class II medical devices and Class III medical devices are
subject to record-filing and licensing requirements, respectively. An entity engaging in the operation of medical devices shall meet
certain requirements with respect to its management system, personnel, facilities etc., and shall apply for approval to operate Class III
medical devices and make record-filing with relevant governmental authority to operate Class II medical devices. The valid term of
medical devices operation permit is five years. Yihao Pharmacy, Yihao Pharmaceutical Chain and its branches, Chongqing Yihao
Pharmacy Co., Ltd., Fujian Yaofang Pharmacy Co., Ltd,. Hubei Yihao Pharmacy Co., Ltd, Kunshan Yifang Pharmacy Co., Ltd., Tianjin
Yihao Pharmacy Co., Ltd. and Shanxi Yihao Yaofang Pharmacy have obtained the record-filing certificates for the business operations of
Class II medical devices and the business permits for the business operations of Class III medical devices, which are necessary to cover
their current business.
Regulations Relating to Online Operation of Drugs and Medical Devices
Internet Drug Information Service
The Administrative Measures on Internet Drug Information Service, or Internet Drug Measures, was promulgated by the CFDA
in July 2004 and amended in 2017, pursuant to which the internet drug information services is to provide drug (including medical device)
information services to online users, which is divided into commercial internet drug information services and non-commercial internet
drug information services. The website operator that provides drugs (including medical devices) information services must obtain an
Internet Drug Information Service Qualification Certificate from the competent counterpart of the CFDA. The valid term for an Internet
Drug Information Service Qualification Certificate is five years and may be renewed at least six months prior to its expiration date upon
a re-examination by the relevant governmental authorities. Yihao Pharmacy, Yihao Pharmaceutical Chain and Wuhan Central China have
each obtained the Internet Drug Information Service Qualification Certificate to provide commercial internet drug information services.
Furthermore, as requested by Internet Drug Measures, the information relating to drugs shall be accurate and scientific in nature,
and its provision shall comply with the relevant laws and regulations. No product information of stupefacient, psychotropic drugs,
medicinal toxic drugs, radiopharmaceutical, detoxification drugs and pharmaceutics made by medical institutes shall be
68
Table of Contents
distributed on the website. In addition, advertisements relating to drugs (including medical devices) shall be approved by the NMPA or
its competent counterparts.
Internet Drug Transaction Services
The Interim Provisions on the Examination and Approval of Internet Drug Transaction Services, or Interim Portions of Internet
Drug Transaction, were promulgated by the CFDA in September 2005 and became effective in December 2005, and regulate transaction
of drugs (including medical devices and packing materials and containers that are in direct contact with drugs) over internet, including
the provision of transaction services among pharmaceutical manufacturers, pharmaceutical operation enterprises and medial institutes,
the services provided by pharmaceutical manufacturers and pharmaceutical wholesale enterprises to other third parties via their own
websites and services provided by pharmaceutical retail chain enterprises to individual consumers. According to Interim Portions of
Internet Drug Transaction enterprises engaging in providing drug transaction services over the internet must obtain an Internet Drug
Transaction Qualification Certificate. Such certificates have a term of five years and have three types: A certificate, B certificate and C
certificate. They are only issued to three kinds of enterprises: (i) enterprises that provide drug transaction services to pharmaceutical
manufactures, pharmaceutical operation enterprises and medical institutions, but do not participate in pharmaceutical manufacture and
operation and do not own, have no property relationship or other economic interest with the administrative organizations, medical
institutions or pharmaceutical manufacture and operation enterprises; (ii) pharmaceutical manufacturers and pharmaceutical wholesale
enterprises that deal with other third-party enterprises via their own websites; (iii) the pharmaceutical retail chain enterprises that provide
OTC drug transaction services for individual consumers via the internet. Wuhan Central China and Yihao Pharmacy have obtained the
Internet Drug Transaction Qualification Certificates for A certificate, B certificate and C certificate, respectively.
However, according to the Decision on the Cancellation of the Third Batch of Items Subject to Administrative Permission by
Local Governments Designated by the Central Government, promulgated by the State Council in January 2017, except for third-party
platforms, all approval of internet drug transaction service enterprises implemented by counterparts of CFDA at the provincial level are
cancelled. In April 2017, the General Office of the CFDA promulgated a notice on implementing the above mentioned decision, pursuant
to which pharmaceutical manufacture enterprises and pharmaceutical wholesale enterprises may carry out internet drug (including
medical device) transactions with other enterprises through their own websites, but shall not provide internet drug (including medical
device) transaction services to individual consumers. In addition, pharmaceutical retail chain enterprises may provide internet drug
(including medical device) transaction services to individual consumers, but they shall not exceed the business scope permitted by
license and filings and display information of prescription drugs on related transaction webpages, or sell prescription drugs or the OTC
drugs under special administrative requirements; as indicated in such decision, the CFDA will promulgate subsequently the relevant
rules on supervision of internet drug (including medical device) transaction.
Furthermore, according to the Decision on the Cancellation of Various Items Subject to Administrative Permission promulgated
by the State Council in September 2017, the enterprises engaging in internet drug transaction service as a third-party platform shall no
longer be subject to the examination and approval of the CFDA before carrying out such business. In November 2017 the General Office
of the CFDA promulgated a Notice on Strengthening the Administration and Supervision of Internet Drug and Medical Devices
Transaction, which specify the approval to conduct internet drug transaction service as the third-party platform is cancelled, but
enterprises carrying out internet drug (including medical) transaction services shall establish a comprehensive supervision system in
general and also request local counterparts of CFDA to implement day-to-day supervision and examination with respect to qualification
access examination, products inspection, storage of transaction data and legal liabilities etc.
Online Sales of Drugs and Medical Device
Under PRC laws and regulations, the drugs and medical devices are allowed to be sold online in general except the prescription
drugs that cannot be sold by pharmaceutical manufacture and operating enterprise or medical institution directly to the public by post or
via internet.
In November 2017, the CFDA released a draft of the Administrative Measures for Supervision and Regulation of Online Drug
Sales for public consultation, which aims to regulate online drug sales in the PRC. In February 2018 and November 2020, the CFDA also
released two drafts for online drug sales for public consultation. All of the drafts stipulate that sellers and online platforms engaging in
this business shall obtain relevant certificates or satisfy relevant conditions to guarantee the safety and quality of the drugs. Furthermore,
according to the latest draft, the platform shall make record-filing with the counterparts of NMPA at provincial
69
Table of Contents
level. In particular, only drug retail enterprises who satisfy the conditions for online sales of prescription drugs are allowed to display
prescription drugs information to the public, and shall expressly indicate that the prescription drugs must be bought and used with
prescriptions under the guidance of licensed pharmacist and other risk warning information. The newly revised Drug Administration Law
in 2019 abolishes the restrictions on online sale of prescription drugs and only prohibits special types of drugs to be sold via the internet,
including vaccines, blood products, anesthesia and psychiatric drugs, toxic drugs for medical use, radiative drugs, pharmaceutical
precursor chemicals or other drugs subject to special administration. This new law adopts the principle of keeping the online and offline
sales consistent, under which the entity conducting online sale of drug shall possess a valid license for medicine operation and the third-
party platform provider shall examine the qualifications of the drug marketing permit holders and drug operation enterprises applying to
operate on its platform, ensure that they meet legal requirements, and manage the drug operation behaviors occurring on the platform.
The SAMR released a draft of the Administrative Measures for the Supervision and Administration of Pharmaceutical Operations, or the
Draft Pharmaceutical Operations Measures, in October 2019, which stipulates that only a drug marketing license holder or drug
operation enterprise is allowed to sell drugs online. The online sales of drugs shall be compliant with relevant requirements of the
Administrative Standard of Pharmaceutical Operating Quality, and specific regulations will be draw up by the NMPA together with other
relevant authorities. The third-party platform for online sales of drugs is required to review the qualifications for the operators who apply
to enter its platform and perform its management responsibilities in accordance with relevant laws and regulations. The drug marketing
license holder, drug operation enterprise and drug retail enterprise shall make filing with relevant counterparts of NMPA for their online
sales of drugs. However, as of the date of this annual report, the Draft Pharmaceutical Operations Measures has yet to come into effect. It
is uncertain when it will be signed into law and whether the final version will deviate substantially from the draft. In addition, as of the
date of this annual report, none of the regulations or implementation rules regulating online drug sales have yet been promulgated and
implemented, which may further introduce and impose certain conditions and restrictions to the online sale of drugs, including but not
limited to the transaction method, qualifications and type of drugs, and there are substantial uncertainties with respect to their enactment
timetable and final provisions.
In December 2017, the CFDA promulgated the Administration and Supervision Measures of Online Sales of Medical Devices,
or the Online Medical Devices Sales Measures, which became effective in March 2018. According to the Online Medical Devices Sales
Measures, enterprises engaged in online sales of medical devices must be medical device manufacture and operation enterprises with
medical devices production licenses or operation licenses or being filed for record in accordance with laws, unless such licenses or
record-filing is not required by laws and regulations, and the third-party platform for provision of online medical devices transaction
services shall obtain an Internet Drug Information Services Qualification License. Either enterprises for online sales of medical devices
or enterprises for provision of medical devices online transaction services shall take technical measures to ensure the data and materials
of medical devices online sales are authentic, completed and retrospective, for example the records of sale information of medical
devices shall be kept for two years after the valid period of the medical devices, and for no less than five years in case of no valid period,
or be kept permanently in case of implanted medical devices.
70
Table of Contents
Regulations Relating to Online Trading
In January 2014, the SAIC promulgated the Administrative Measures for Online Trading, or Online Trading Measures, which
became effective in March 2014, to regulate all operating activities for products sale and services provision via the internet (including
mobile internet). It stipulates the obligations of online products operators and services providers and certain special requirements
applicable to third-party platform operators. The MOFCOM promulgated the Provisions on the Procedures for Formulating Transaction
Rules of Third Party Online Retail Platforms (Trial) in December 2014, which became effective in April 2015, to guide and regulate the
formulation, revision and enforcement of transaction rules by online retail third-party platforms operators. These measures impose more
stringent requirements and obligations on third-party platform operators. For example, third-party platform operators are obligated to
make public and file their transaction rules with MOFCOM or their respective provincial counterparts, examine and register the legal
status of each third-party merchant selling products or services on their platforms and display on a prominent location on a merchant’s
webpage the information stated in the merchant’s business license or a link to its business license. Where third-party platform operators
also act as online distributors, these third-party platform operators must make a clear distinction between their online direct sales and
sales of third-party merchant products on their third-party platforms. Furthermore, in August 2018, the SCNPC promulgated the E-
Commerce Law, which took effect on January 1, 2019 and aims to regulate the e-commerce activities conducted within the territory of
the PRC. According to the E-Commerce Law, e-commerce operators shall comply with the principles of voluntariness, equality, fairness,
and good faith, abide by laws, observe business ethics, equally participate in market competition. It further strengthened the performing
obligations of e-commerce operators regarding to the protection of consumers’ rights and interests, environmental protection, intellectual
property protection, and the protection of cyberspace safety and personal information, and also emphasized the commitment by e-
commerce operators over the quality of products and services.
After the issuance of Online Trading Measures, the SAIC has issued a number of guidelines and implementing rules aimed at
adding greater specificity to these regulations and continues to consider and issue guidelines and implementing rules in this industry. For
example, three PRC governmental authorities (the Ministry of Finance of the People’s Republic of China, or the MOF, General
Administration of Customs, or the GAC, and the STA) issued the New Cross-Border E-commerce Retail Imports Tax Notice in
March 2016, which became effective in April 8, 2016 and was amended in November 2018, to regulate cross-border e-commerce trading
and introduced the concept of the cross-border e-commerce retail importation goods inventory, or the Cross-Border E-Commerce Goods
Inventory, which has been issued and updated by the three authorities together with other relevant authorities from time to time. Two
batches of the Cross-Border E-Commerce Goods Inventory and the Cross-Border E-Commerce Goods Inventory (2018 Edition) issued in
April 2016 and November 2018 have been replaced by the Cross-Border E-Commerce Goods Inventory (2019 Edition) issued in
December 2019 and the Notice of Relevant Matters on Implementation of New Cross-Border E-Commerce Retail Importation
Supervision and Administration Requirements has been issued by the GAC in May 2016 to further implement the rules. According to the
Notice of Relevant Work on improving Cross-Border E-Commerce Retail Importation Supervision and Administration issued in
November 2018, retail imported goods on cross-border e-commerce platforms will be temporarily treated as personal items which are not
subject to stricter regulations and higher tax rates applicable to normal imported goods in 37 cross-border e-commerce trial areas.
Regulations Relating to the Medical Industry
Medical Institution
The Administrative Regulations on Medical Institutions was promulgated by the State Council in February 1994 and amended
in 2016 to regulate all medical institutions, such as hospitals, health centers, sanatoriums, out-patient departments, clinics and health
posts (rooms) as well as first-aid stations. The establishment of medical institutions by the entity or individual shall be subject to
examination and approval of the health administrative authorities at the county level or above and medical institutions must obtain the
approval certificate to establish the medical institution. Furthermore, the medical institution shall also register with competent health
administrative authorities for practice and operation, and obtain the License for Practicing of Medical Institutions after examination by
competent health administrative authorities. Southwest Internet Hospital and Chengdu Yizhen Internet Hospital Co., Ltd. have
respectively obtained a License for Practicing of Medical Institutions, and Guangdong Yihao Pharmaceutical Chain Co., Ltd. Dongshan
Branch Traditional Chinese Medicine Clinic has obtained Licenses for Practicing of Medical Institution only for traditional Chinese
medicine and internal medicine.
71
Table of Contents
According to the Notice on Issuance of the Opinions on the Pilot of Promoting Clinics Development issued by the MOF, the
MOHRSS and the National Healthcare Security Administration in April 2019, the pilot program of promoting clinic development was
suggested be implemented in 10 cities, where the establishment of such clinics would not be subject to examination and approval but
filing with relevant health administrative authorities. The clinics would be allowed to practice after completing filing procedures and
obtaining the License for Practicing of Medical Institutions.
Internet Medical Services
On May 1, 2009, the Ministry of Health of the People’s Republic of China, which was restructured and integrated into the
NHFPC and subsequently to the NHC, promulgated the Administrative Measures on Internet Medical and Healthcare Information
Services to regulate the business relating to providing online medical and healthcare information; but such measures were abolished in
January 2016.
In August 2014, the NHFPC issued an opinion to promote medical institution’s remote diagnosis and treatment services. Under
this opinion, the medical institutions shall possess qualified personnel, technology, facilities to carry out remote diagnosis and treatment
services, and shall also satisfy certain requirements. Non-medical institutions are prohibited from providing remote diagnosis and
treatment services.
In July 2015, the State Council issued a guiding opinion to promote activities of the concept of “Internet +”, including
popularizing the model of online medical services to develop the medical services via internet and support medical information sharing
service platform. In December 2016, the State Council promulgated the 13th Five-Year sanitation and health planning, which suggests to
comprehensively implement “Internet +” Healthcare service, and encourages the establishment of regional remote medical service
platform and promotes the vertical flow of high quality medical resources.
According to an official reply to a proposal put forward in the fourth meeting of the twelfth committee of the Chinese People’s
Political Consultative Conference in June 2016 and released in November 2016 on the website of NHFPC, it indicates that no online
diagnosis and treatment shall be allowed except for remote diagnosis and treatment; but it allows online health consultation provided by
practitioners or other personnel via network platform operated by internet companies and medical consultation made by practitioners
without provision of written diagnosis and prescription and other implementation of doctors’ advice. As indicated in another official
reply to a recommendation made in the fifth meeting of China’s twelfth National People’s Congress issued in December 2017 by the
NHFPC, the administration measures for internet diagnosis and treatment are under research and formulation, which aims to specify the
business scope of internet diagnosis and treatment, information security, patient privacy protection, supervision and legal liabilities.
In April, 2018, the General Office of State Council promulgated the opinions concerning development of “internet + healthcare”
that specifies that both medical institutions and qualified enterprises could set up and operate “internet hospital” to offer approved
services and the prescription drugs for common and chronic disease prescribed by pharmacist could be delivered by third parties
designated by pharmaceutical operating entities, which would allow the pharmaceutical enterprise to sell the prescription drugs to
individual by mail. In July 2018, the NHC and the State Administration of Traditional Chinese Medicine, or the SATCM, jointly
promulgated the Notice of Carrying Out In-depth Activities for the Benefit of the People regarding “Internet + Healthcare”, which
further specified that after e-prescriptions have been approved by pharmacists, pharmaceutical enterprises can designate qualified third
party couriers to deliver the prescription drugs.
In July 2018, the NHC and the SATCM issued the Administrative Measures for Online Diagnosis and Treatment (Trial), the
Administrative Measures for Internet Hospitals (Trial), or the Internet Hospital Administrative Measures and the Administrative
Standards for Remote Diagnosis (Trial). According to these measures and standards, internet hospitals including the internet hospitals
used as second name of a physical medical institution and the internet hospitals established independently while relying on a physical
medical institution, and are subject to access restrictions. The application for establishment of internet hospitals shall be submitted to the
registration department of the physical medical institution. The Internet Hospital Administrative Measures also provide the basic
standards for internet hospitals, including the requirements for diagnosis subjects, department settings, staffs, buildings and facilities,
rules and regulations.
In June 2019, a Notice on Issuance of the Opinions on Promotion of the Sustained, Healthy and Normalized Development of
Social Medical was issued, which supports social medical to develop “Internet + Healthcare”, encourages medical institutions to use
72
Table of Contents
internet and other information technology in expanding the medical service space and building an integrated medical service model, and
supports medical and healthcare institutions and qualified third-party institutions to build internet information platform and provide
remote medical services, healthcare consultation and health management services.
In 2020, the NHC, together with relevant authority, promulgated a series of policies such as the Circular on Further Promoting
the Development and Standardized Administration of Online Medical Services, the Guiding Opinions on Promoting the “Internet”
Medical Insurance Services during the Period of COVID-19 Prevention and Control, the Circular Relating to Internet Diagnosis and
Treatment Consultation Services in COVID-19 Prevention and Control, to further promote the integrated development of internet
technologies and medical services, facilitate medical services seeking and drugs purchasing by insured people, reduce the risk of crowd
gathering and cross-infection, provide high-quality and convenient medical consultation services for broad masses by using the
advantages of “internet + Healthcare”.
Medical Practitioners
In June 1998, the SCNPC promulgated the Law on Licensed Medical Practitioners of the People’s Republic of China, or the
Licensed Medical Practitioners Law, which became effective in May 1999 and was amended in 2009. According to the Licensed Medical
Practitioners Law, registered doctors can work in medical or healthcare institutions according to the registered place, category and scope
of business to engage in the relevant services of medical treatment, prevention or healthcare. Person who fails to register as a doctor and
obtain the practicing certificate shall not practice medicine. In February 2017, the NHFPC promulgated the Administrative Measures for
the Registration of Medical Practitioners, or the Medical Practitioners Registration Measures, which became effective in April 2017 and
stipulate that medical practitioners shall obtain the Practice License for Medical Practitioners to practice upon registration.
In November 2014, the NHFPC, the NDRC, the MOHRSS, the SATCM and the China Insurance Regulatory Commission
jointly promulgated Several Opinions on Promoting and Standardizing Multi-Institution Practice of Medical Practitioners. According to
these opinions, the clinical, dental and traditional Chinese medicine practitioners are allowed to practice in multiple places. The medical
practitioners who meet certain requirements and conditions shall register with competent health administrative authorities and obtain the
consent from the medical institution where he or she first practices before practicing in other places. Moreover, under the Medical
Practitioners Registration Measures, a medical practitioner practicing in multiple institutions at the same place of practice shall determine
one institution as his or her primary practicing institution, and apply for registration to the competent administrative authorities of health
and family planning that approve the practice at such institution, and for other institutions where a medical practitioner intends to
practice, he or she should apply for the record at the relevant administrative authorities of health and family planning that approve the
practice of such institutions, which names should be indicated in the record. In addition, a medical practitioner intends to add the
practicing institution beyond the place of practice, he or she should apply for registering such institution to the relevant administrative
authorities of health and family planning authority that approve the practice of such institutions.
According to the Measures for the Administration of Prescriptions issued by the NHFPC in February 2007, a registered medical
practitioner shall obtain the corresponding prescription right at the registered practice place and the registered medical practitioner shall
issue prescriptions according to the relevant requirements. The prescriptions issued by a registered assistant medical practitioner shall not
become effective until it is signed by a registered medical practitioner.
73
Table of Contents
Regulations Relating to Food Business
General Administration on Food Operation
The Food Safety Law of the People’s Republic of China, which was effective as from June 2009 and amended by the SCNPC in
April 2015 and December 2018 and became effective in December 2018, and the Implementation Regulations of the Food Safety Law of
the PRC, which took effect as from July 2009 and were amended by the State Council in 2016 and 2019, regulate food safety and set up a
system of the supervision, monitoring and evaluation of food safety and adopt food safety standards. The State Council implements a
licensing system for the food production and transaction. To engage in food production, sale or catering services, the business operator
shall obtain a license in accordance with the laws. Furthermore, the State Council implements strict supervision and administration for
special categories of foods such as healthcare food, special formula foods for medical purposes and infant formula.
The Administrative Measures for Food Business Licensing, promulgated by the CFDA in August 2015 and amended in 2017
regulates the food business licensing activities, strengthens the supervision and management of food business and ensures food safety.
Food business operators shall obtain one Food Business License for one business venue where they engage in food business activities.
The valid term of a food business license is five years. 1 Pharmacy Technology (Shanghai) Co., Ltd., Yihao Pharmacy, Yihao
Pharmaceutical Chain and its branches, Chongqing Yihao Pharmacy Co., Ltd., Fujian Yaofang Pharmacy Co., Ltd., Hubei Yihao
Pharmacy Co., Ltd, Kunshan Yifang Pharmacy Co., Ltd., Tianjin Yihao Pharmacy Co., Ltd., Shanxi Yihao Yaofang Pharmacy Co., Ltd.,
and Liaoning Yihao Pharmacy have obtained the Food Business Licenses.
Regulations Relating to Product Quality and Consumers Protection
According to the Product Quality Law of the People’s Republic of China, which was effective as from September 1993 and
amended by the SCNPC in 2000, 2009 and 2018, respectively, products for sale must satisfy relevant safety standards and sellers shall
adopt measures to maintain the quality of products for sale. Sellers may not sell mix impurities or imitations into products, or substitute
fake products for genuine ones, or substitute defective products for good ones or substitute substandard products for standard ones. For
sellers, any violation of state or industrial standards for health and safety or other requirements may result in civil liabilities and
administrative penalties, such as compensation for damages, fines, confiscation of products illegally sold and the proceeds from such
sales and even revoking business license; in addition, severe violations may subject the responsible individual or enterprise to criminal
liabilities.
According to the Consumers Rights and Interests Protection Law of the People’s Republic of China, or Consumers Rights and
Interests Protection Law, which became effective in January 1994 and was amended by the SCNPC in 2009 and 2013 respectively,
business operators should guarantee that the products and services they provide satisfy the requirements for personal or property safety,
and provide consumers with authentic information about the quality, function, usage and term of validity of the products or services. The
consumers whose interests have been damaged due to the products or services that they purchase or accept on the internet trading
platforms may claim damages to sellers or service providers. Where the operators of the online trading platforms are unable to provide
the real names, addresses and valid contact details of the sellers or service providers, the consumers may also claim damages to the
providers of the online trading platforms. Operators of online trading platforms that clearly knew or should have known that sellers or
service providers use their platforms to infringe upon the legitimate rights and interests of consumers but fail to take necessary measures
must bear joint and several liabilities with the sellers or service providers. Moreover, if business operators deceive consumers or
knowingly sell substandard or defective products, they should not only compensate consumers for their losses, but also pay additional
damages equal to three times the price of the goods or services.
In January 2017, the SAIC issued the Interim Measures for No Reason Return of Online Purchased Products within Seven Days,
which became effective in March 2017 and was amended in October 2020, further clarifying the scope of consumers’ rights to make
returns without a reason, including exceptions, return procedures and online trading platform operators’ responsibility to formulate
seven-day no-reason return rules and related consumer protection systems, continuously display such rules and systems on a notable
location of the homepage, and ensure that consumers are able to read and download them conveniently and completely, and supervise the
merchants for compliance with these rules.
74
Table of Contents
Regulations Relating to Online Advertising
Foreign Investment on Advertising
The principal regulation governing foreign-invested advertising agencies in China are the Administrative Measures for Foreign
Invested Advertising Enterprise, which was abolished due to the decision on Repealing the Administrative Measures for Foreign
Invested Advertising Enterprise issued by SAIC in June 2015. According to the Negative List and the Catalog, foreign investors are
allowed to own 100% of an advertising agency in China subject to certain qualification requirements. However, foreign investment in
advertising agencies that provide online advertising services is still subject to restrictions of foreign investment in the value-added
telecommunications business.
Administration on Internet Advertisement
In April 2015, the SCNPC enacted the Advertising Law of the People’s Republic of China, or the Advertising Law, which
became effective in September 2015 and was amended in October 2018. The Advertising Law regulates commercial advertising
activities in the PRC and sets out the obligations of advertisers, advertising operators, advertising publishers and advertising
spokespeople, and prohibits any advertisement from containing any obscenity, pornography, gambling, superstition, terrorism or
violence-related content. Any advertiser in violation of such requirements to advertisement content will be ordered to cease publishing
such advertisements and imposed a fine ranging from RMB200,000 to RMB1,000,000; in severe circumstances, the business license of
such advertiser may be revoked, and the relevant authorities may revoke the approval document for advertisement examination and
refuse to accept applications submitted by such advertiser for one year. In addition, any advertising operator or advertising publisher in
violation of such requirements will be imposed a fine ranging from RMB200,000 to RMB1,000,000, and the advertisement fee received
will be confiscated; in severe circumstances, the business license of such advertising operator or advertising publisher may be revoked.
Except that certain prescription drugs are prohibited from advertising, the advertisement of prescription drugs can be only made
on designated medical or pharmaceutical journals. Any display of prescription drugs advertisements outside the designated media
channels may result in violations of such restrictions by the advertising operator, confiscation of advertising fees and a fine ranging from
RMB200,000 to RMB1,000,000, or, in severe circumstances, revocation of business license. In addition, any advertisement for medical
treatment, pharmaceutical or medical devices must not contain any assertion or guarantee on the function and safety, or any statement on
curative rate or effectiveness of such medical treatment, pharmaceutical or medical devices, and any violation of such requirements will
result in a fine equivalent to an amount up to three times the amount of the advertising fees, or a fine ranging from RMB100,000 to
RMB200,000 if the advertising fees cannot be calculated or are significantly low; and in severe circumstances, a fine equivalent to the
amount up to five times the amount of the advertising fees will be imposed, or a fine ranging from RMB200,000 to RMB1,000,000 if the
advertising fees cannot be calculated or are significantly low. Moreover, the Advertising Law also provides that the internet information
service providers must not publish advertisements related to medical treatments, drugs, medical devices or health foods in the disguised
form of providing healthcare and health maintenance knowledge.
The Interim Measures for Administration of Internet Advertising, or the Internet Advertising Measures regulating the internet-
based advertising activities, were adopted by the SAIC in July 2016 and became effective in September 2016. According to the Internet
Advertising Measures, internet advertisers are responsible for the authenticity of the advertisements content and all online advertisements
must be marked “Advertisement” so that viewers can easily identify them as such.
75
Table of Contents
Pursuant to the Interim Administrative Measures on Drugs, Medical Devices, Health Foods and Foods for Special Medical
Purposes Advertisements Examination, which took effect in March 2020, and replaced the Measures for Drug Advertisements
Examination and the Measures for Medical Device Advertisement Examination, the drugs, medical devices, health foods and foods for
special medical purposes advertisements shall be examined according to such measures. The applicants for such advertisements must be
the holders of the registration certificate or record-filing certificate of the drugs, medical devices, health foods and foods for special
medical purposes or the production or operation enterprises it authorized. The valid period of drugs, medical devices, health foods and
foods for special medical purposes advertisement license numbers shall be consistent with the shortest one of the valid periods of the
registration certificate, record-filing certificate or production license of the product. In the case of no valid period stipulated in such
documents, the valid period of the advertisement license numbers shall be two years. And the content of approved advertisement may not
be altered without prior approval, otherwise a new examination shall be reapplied for the revised content of drug and medical device
advertisement.
Regulations relating to Internet Information Security and Privacy Protection
PRC government authorities have enacted laws and regulations with respect to internet information security and protection of
personal information from any abuse or unauthorized disclosure. Internet information in China is regulated and restricted from a national
security standpoint.
In June 2017, the Cyber Security Law of the People’s Republic of China, or the Cyber Security Law, promulgated by SCNPC
took effect, which is formulated to maintain the network security, safeguard the cyberspace sovereignty, national security and public
interests, protect the lawful rights and interests of citizens, legal persons and other organizations, and requires that a network operator,
which includes, among others, internet information services providers, take technical measures and other necessary measures to
safeguard the safe and stable operation of the networks, effectively respond to the network security incidents, prevent illegal and criminal
activities, and maintain the integrity, confidentiality and availability of network data. The Cyber Security Law reaffirms the basic
principles and requirements set forth in other existing laws and regulations on personal information protections and strengthens the
obligations and requirements of internet service providers, which include but are not limited to: (i) keeping all user information collected
strictly confidential and setting up a comprehensive user information protection system; (ii) abiding by the principles of legality,
rationality and necessity in the collection and use of user information and disclosure of the rules, purposes, methods and scopes of
collection and use of user information; and (iii) protecting users’ personal information from being leaked, tampered with, destroyed or
provided to third parties. Any violation of the provisions and requirements under the Cyber Security Law and other related regulations
and rules may result in administrative liabilities such as warnings, fines, confiscation of illegal gains, revocation of licenses, suspension
of business, and shutting down of websites, or, in severe cases, criminal liabilities.
In July 2013, the MIIT issued the Provisions on Protecting Personal Information of Telecommunication and Internet Users to
further define the personal information of user to include user name, birthday, identification number, address, phone number, account,
passcode, and others that may be used to identify the user solely in addition to other information such as location and service time of
users. Furthermore, according to the interpretations issued by the Supreme People’s Court and the Supreme People’s Procuratorate in
May 2017, personal information means various information recorded electronically or through other manners, which may be used to
identify individuals or activities of individuals, including but not limited to the name, identification number, contact information, address,
user account and passcode, property ownership and location tracking. According to the Announcement on Launching Special Crackdown
against Illegal Collection and Use of Personal Information by Apps promulgated by the CAC, the MIIT and the Ministry of Public
Security of the People’s Republic of China in January 2019, application operators shall strictly perform their obligations under the Cyber
Security Law when collecting and using personal information, be responsible for the security of personal information obtained, and take
effective measures to strengthen personal information protection.
In November 2015, the Ninth Amendment to the Criminal Law issued by the SCNPC became effective, pursuant to which, any
internet service provider that fails to comply with obligations related to internet information security administration as required by
applicable laws and refuses to rectify upon order is subject to criminal penalty for (i) any large-scale dissemination of illegal information;
(ii) any severe consequences due to the leakage of the user information; (iii) any serious loss of criminal evidence; or (iv) other severe
circumstances. Furthermore, any individual or entity that (i) sells or distributes personal information in a manner which violates relevant
regulations, or (ii) steals or illegally obtain any personal information is subject to criminal penalty in severe circumstances.
76
Table of Contents
Regulations Relating to Intellectual Property
Copyright
China has adopted comprehensive legislation governing intellectual property rights, including trademarks and copyrights. China
is a signatory to the primary international conventions on intellectual property rights and has been a member of the Agreement on Trade
Related Aspects of Intellectual Property Rights since its accession to the WTO in December 2001.
In September 1990, the SCNPC promulgated the Copyright Law of the People’s Republic of China, effective in June 1991 and
amended in 2001, 2010 and 2020 respectively and the latest amendment will take effect on June 1, 2021. The amended Copyright Law
extends copyright protection to internet activities, products disseminated over the internet and software products. In addition, there is a
voluntary registration system administered by the Copyright Protection Centre of China.
In order to further implement the Computer Software Protection Regulations, promulgated by the State Council in
December 2001 and amended in 2011 and 2013 respectively, the National Copyright Administration issued Computer Software
Copyright Registration Procedures in February 2002, which specify detailed procedures and requirements with respect to the registration
of software copyrights.
Trademark
According to the Trademark Law of the People’s Republic of China, promulgated by the SCNPC in August 1982, and amended
in 1993, 2001, 2013 and 2019 respectively, the Trademark Office of the SAMR is responsible for the registration and administration of
trademarks in China. The SAMR under the State Council has established a Trademark Review and Adjudication Board for resolving
trademark disputes. Registered trademarks are valid for ten years from the date the registration is approved. A registrant may apply to
renew a registration within twelve months before the expiration date of the registration. If the registrant fails to apply in a timely manner,
a grace period of six additional months may be granted. If the registrant fails to apply before the grace period expires, the registered
trademark shall be deregistered. Renewed registrations are valid for ten years. In April 2014, the State Council issued the revised
Implementation of the Trademark Law, which specified the requirements of applying for trademark registration and review.
Patent
According to the Patent Law of the People’s Republic of China promulgated by the SCNPC in 1984 and amended in 1992, 2000
and 2008, respectively, a patentable invention or a utility model must meet three criteria: novelty, inventiveness and practicability. A
patent is valid for a twenty-year term for an invention and a ten-year term for a utility model or design, starting from the application date.
Domain Names
In May 2012 and June 2019, the China Internet Network Information Center issued the Implementing Rules for Domain Name
Registration and the Implementing Rules for National Top-level Domain Name Registration setting forth the detailed rules for
registration of domain names and top-level domain names. In August 2017, the MIIT promulgated the Administrative Measures on
Internet Domain Names, or the Domain Name Measures. The Domain Name Measures regulate the registration of domain names, such
as the top-level domain name “.cn”.
77
Table of Contents
Regulations Relating to Foreign Exchange and Dividend Distributions
The principal regulations governing foreign currency exchange in China are the Foreign Exchange Administration Regulations,
which was promulgated by the State Council in January 1996, which became effective in April 1996 and was subsequently amended in
1997 and 2008 and the Regulations on the Administration of Foreign Exchange Settlement, Sale and Payment which was promulgated by
the PBOC in June 1996 and became effective in July 1996. Under these regulations, the Renminbi for current account items is freely
convertible, including the distribution of dividends, interest payments, trade and service-related foreign exchange transactions, but not
for capital account items, such as direct investments, loans, and investments in securities outside of the PRC, unless the prior approval of
the SAFE or its local counterpart is obtained. Foreign invested enterprises are permitted to convert their after-tax dividends into foreign
exchange and to remit such foreign exchange out of their foreign exchange bank accounts in the PRC.
The principal regulations governing distribution of dividends of foreign holding companies include the Foreign Investment
Enterprise Law and the Administrative Rules under the Foreign Investment Enterprise Law, which have been abolished by the Foreign
Investment Law on January 1, 2020. Under current regulations, all PRC enterprises, including foreign investment enterprises, are
required to allocate at least 10% of their after-tax profits to statutory reserve funds unless these reserve funds have reached 50% of the
registered capital of the enterprises. These reserve funds are not distributable as cash dividends and dividends shall not be distributed
until any losses from prior fiscal years have been offset. Furthermore, under the EIT Law, which became effective in January 2008 and
amended in 2018, the maximum tax rate for the withholding tax imposed on dividend payments from PRC foreign invested companies to
their overseas investors that are not regarded as “resident” for tax purposes is 20%. The rate was reduced to 10% under the Implementing
Regulations for the EIT Law issued by the State Council. However, a lower withholding tax rate might be applied if there is a tax treaty
between China and the jurisdiction of the foreign holding companies, such as tax rate of 5% in the case of Hong Kong companies that
holds at least 25% of the equity interests in the foreign-invested enterprise, and certain requirements specified by PRC tax authorities are
satisfied.
Regulations Relating to Stock Incentive Plans
According to the Notice of Issues Related to the Foreign Exchange Administration for Domestic Individuals Participating in
Stock Incentive Plan of Overseas Listed Company, or the Share Incentive Rules, which was issued by the SAFE in February 2012 and
other regulations, directors, supervisors, senior management and other employees participating in any share incentive plan of an overseas
publicly-listed company who are PRC citizens or non-PRC citizens residing in China for a continuous period of not less than one year,
subject to certain exceptions, are required to register with the SAFE. All such participants need to authorize a qualified PRC agent, such
as a PRC subsidiary of overseas publicly-listed company to register with the SAFE and handle foreign exchange matters such as opening
accounts, transferring and settlement of the relevant proceeds. The Share Incentive Rules further require an offshore agent to be
designated to handle matters in connection with the exercise of share options and sale of proceeds for the participants of share incentive
plans.
Failure to complete the SAFE registrations for our employee incentive plans after our listing may subject them to fines and legal
sanctions, and may also limit our ability to contribute additional capital into our PRC subsidiaries and limit our PRC subsidiaries’ ability
to distribute dividends to us.
Regulations Relating to Employment
The Labor Law of the People’s Republic of China, or the Labor Law, which became effective in January 1995 and was amended
in 2009 and 2018, and the Employment Contract Law of the People’s Republic of China, or the Employment Contract Law, effective in
January 2008 and amended in 2012, require employers to provide written contracts to their employees, restrict the use of temporary
workers and aim to give employees long-term job security. Employers must pay their employees wages equal to or above local minimum
wage standards, establish labor safety and workplace sanitation systems, comply with state labor rules and standards and provide
employees with appropriate training on workplace safety. In September 2008, the State Council promulgated the Implementing
Regulations for the PRC Employment Contract Law which became effective immediately and interprets and supplements the provisions
of the Employment Contract Law.
Under the Labor Contract Law, an employer shall limit the number of dispatched workers so that they do not exceed a certain
percentage of its total number of workers. In January 2014, the MOHRSS issued the Interim Provisions on Labor Dispatching, which
78
Table of Contents
became effective in March 2014, pursuant to which it provides that the number of dispatched workers used by an employer shall not
exceed 10% of the total number of its employees.
The PRC governmental authorities have passed a variety of laws and regulations regarding social insurance and housing funds
from time to time, including, among others, the Social Insurance Law of the People’s Republic of China, the Regulation of Insurance for
Labor Injury, the Regulations of Insurance for Unemployment, the Provisional Insurance Measures for Maternal Employees and the
Administrative Regulations on the Housing Provident Fund. Pursuant to these laws and regulations, PRC companies must make
contributions at specified levels for their employees to the relevant local social insurance and housing fund authorities. Failure to comply
with such laws and regulations may result in various fines and legal sanctions and supplemental contributions to the local social
insurance and housing fund regulatory authorities.
Regulation Relating to Taxation
Enterprise Income Tax
Pursuant to the EIT Law promulgated by the National People’s Congress on March 16, 2007, which became effective from
January 1, 2008 and was amended in 2017 and 2018, the income tax rate for both domestic and foreign-invested enterprises incorporated
in the PRC is 25% commencing from January 1, 2008. In order to clarify certain provisions in the EIT Law, the State Council
promulgated the Implementation Rules of the Enterprise Income Tax Law of the PRC, or the EIT Implementation Rules, on December 6,
2007, which became effective on January 1, 2008 and was amended in 2019. Under the EIT Law and the EIT Implementation Rules,
enterprises are classified as either “resident enterprises” or “non-resident enterprises”. Pursuant to the EIT Law and the EIT
Implementation Rules, besides enterprises established within the PRC, enterprises established outside of the PRC whose “de facto
management bodies” are located in the PRC are considered as “resident enterprises” and subject to the uniform enterprise income tax rate
of 25% for their global income. In addition, the EIT Law provides that a non-resident enterprise refers to an entity established under
foreign law whose “de facto management bodies” are not within the PRC but which have an establishment or place of business in the
PRC, or which do not have an establishment or place of business in the PRC but have income sourced within the PRC.
Enterprises that are recognized as high and new technology enterprises in accordance with the Administrative Measures
Recognition of High and New Technology Enterprises are entitled to enjoy the preferential enterprise income tax rate of 15%. The
validity period of the high and new technology enterprise qualification shall be three years from the date of issuance of the certificate of
high and new technology enterprise. The enterprise can re-apply for such recognition as a high and new technology enterprise before or
after the previous certificate expires. The enterprise shall, after being recognized as a high and new technology enterprise, fill out and
submit annually the statements on annual development conditions for the previous year. Besides, if a high and new technology enterprise
has changed its name or has undergone any major change concerning the recognition conditions (such as a division, merger,
reorganization or change of business), it shall report the change within three months and recognition institution will review whether it
continues to be qualified as high and new technology enterprise. 1 Pharmacy Technology has obtained the certificate of high and new
technology enterprise on December 6, 2019.
Dividend Withholding Tax
The EIT Implementation Rules provide that, from January 1, 2008, an income tax rate of 10% will normally be applicable to
dividends declared to non-PRC resident enterprise shareholders that do not have an establishment or place of business in the PRC, or that
have such establishment or place of business but whose relevant income is not effectively connected with the establishment or place of
business, to the extent such dividends are derived from sources within the PRC. The income tax on dividends may be further reduced
pursuant to a tax treaty between the PRC and the jurisdictions in which non-PRC shareholders reside.
Value-Added Tax
Pursuant to the Provisional Regulation of the PRC on Value-Added Tax, which was promulgated by the State Council on
December 13, 1993 and amended in 2008, 2016 and 2017 and its implementation rules, entities or individuals engaging in the sale of
goods, the provision of processing services, repairs and replacement services, sale of services, intangible assets or real property, or the
importation of goods within the territory of the PRC must pay value-added tax.
79
Table of Contents
C. Organizational Structure
The following diagram illustrates our corporate structure, including our principal subsidiaries, consolidated affiliated entities
and subsidiaries of consolidated affiliated entities as of the date of this annual report on Form 20-F:
(1) The shareholders of 1 Pharmacy Technology include Yao Wang Corporation Limited (86)% and various investors (14)% who
purchased shares in 1 Pharmacy in connection with capital injection. See "Item 4. Information on the Company - A. History and
Development of the Company."
(2) The shareholders of Wuhan Central China Drug Trading Co., Ltd. include 1 Pharmacy Technology (70%) and Wuhan Zall Venture
Capital Co., Ltd. (30%).
(3) Guangdong Yihao Pharmacy Co., Ltd. is our variable interest entity. The shareholders of Guangdong Yihao Pharmacy Co., Ltd.
include Mr. Yue Xuan (50%) and Ms. Jing Liu (50%). Mr. Yue Xuan is a family member of Dr. Gang Yu, our co-founder and co-
chairman. Ms. Jing Liu is a family member of Mr. Junling Liu, our co-founder, co-chairman and chief executive officer. See “—
Contractual Arrangements with Our Variable Interest Entities.”
80
Table of Contents
(4) Guangdong Yihao Pharmaceutical Chain Co., Ltd. is our variable interest entity and is wholly owned by Guangdong Yihao
Pharmacy Co., Ltd. See “—Contractual Arrangements with Our Variable Interest Entities.”
(5) Shanghai Yaowang E-Commerce Co., Ltd. is our variable interest entity and is wholly owned by Guangdong Yihao Pharmaceutical
Chain Co., Ltd. See “—Contractual Arrangements with Our Variable Interest Entities.”
Contractual Arrangements with Our Variable Interest Entities
PRC laws and regulations impose restrictions on foreign ownership and investment in internet-based businesses such as
provision of online information and other value-added telecommunications services. We are a Cayman Islands company and our PRC
subsidiary, 1 Pharmacy Technology, is considered a foreign invested enterprise. To comply with PRC laws and regulations, we have
entered into a series of contractual arrangements, through 1 Pharmacy Technology, with our variable interest entities and the shareholders
of our variable interest entities to obtain effective control over our variable interest entities and their subsidiaries.
We currently conduct our business through our variable interest entities and their subsidiaries based on these contractual
arrangements, which allow us to:
● exercise effective control over our variable interest entities and their subsidiaries;
● receive substantially all of the economic benefits from our variable interest entities and their subsidiaries; and
● have an exclusive option to purchase all or part of the equity interest in our variable interest entities when, and to the
extent, permitted by PRC law.
As a result of these contractual arrangements, we have become the primary beneficiary of our variable interest entities under
U.S. GAAP. We have consolidated the financial results of our variable interest entities and their subsidiaries in our consolidated financial
statements in accordance with U.S. GAAP.
The following is a summary of the currently effective contractual arrangements in relation to our foreign invested subsidiary, 1
Pharmacy Technology, our variable interest entities and their shareholders.
Agreements that Allow Us to Receive Economic Benefits from Our Variable Interest Entities
Exclusive Support Services Agreements. 1 Pharmacy Technology entered into exclusive support services agreements with each
of our variable interest entities. Pursuant to these agreements, 1 Pharmacy Technology has the exclusive right to provide our variable
interest entities with support services, including training, financial support, equipment and asset support, labor support, intellectual
property support and other services relating to the day-to-day operations of our variable interest entities. Without 1 Pharmacy
Technology’s prior written consent, our variable interest entities shall not accept any services or similar services covered by these
agreements from any third party. Pursuant to the amended exclusive support services agreements entered into with each of our variable
interest entities in July 2019, our variable interest entities agree to pay service fees in an amount equivalent to the balance calculated as
3% of quarterly revenue (exclusive of revenue from related parties) of our variable interest entities on a quarterly basis. 1 Pharmacy
Technology has the right to delay or waive payment of service fees at its discretion and the service fee level is subject to adjustment at
any time upon mutual agreement between 1 Pharmacy Technology and our variable interest entities. 1 Pharmacy Technology owns the
intellectual property rights arising out of the services performed under these agreements. Unless 1 Pharmacy Technology terminates these
agreements or pursuant to other provisions of these agreements, these agreements will remain effective for ten years to be automatically
extended for another ten years thereafter.
Agreements that Provide Us with Effective Control over Our Variable Interest Entities
Proxy Agreement. Pursuant to the proxy agreement, each shareholder of our variable interest entities irrevocably authorizes 1
Pharmacy Technology to act as its attorney-in-fact to exercise all of such shareholder’s voting and other rights associated with the
shareholder’s equity interest in our variable interest entities, including but not limited to, the right to attend shareholder meetings on
behalf of such shareholder, the right to vote, the right to manage the variable interest entities and the right to appoint legal
81
Table of Contents
representatives, directors and other management. The proxy agreement remains in force for the same period as the exclusive support
services agreements.
Equity Pledge Agreement. 1 Pharmacy Technology has entered into an equity pledge agreement with each shareholder of our
variable interest entities. Pursuant to these equity pledge agreements, each shareholder of our variable interest entities has pledged all of
his, her or its respective equity interest in our variable interest entities to 1 Pharmacy Technology to guarantee the performance by such
shareholder and our variable interest entities of their respective obligations under the exclusive support services agreements, the proxy
agreement, the exclusive option agreements, and payment of all accounts payable to 1 Pharmacy Technology from time to time. If our
variable interest entities or any of their shareholders breach any obligations under these agreements, 1 Pharmacy Technology, as pledgee,
will be entitled to dispose of the pledged equity and have priority to be compensated by the proceeds from the disposal of the pledged
equity. Each of the shareholders of variable interest entities agrees that he, she or it will not dispose of the pledged equity interests, create
or allow any encumbrance on the pledged equity interests, or engage in any activities that may have adverse effects on the pledger’s asset
conditions without the prior written consent of 1 Pharmacy Technology. These equity pledge agreements will remain effective until our
variable interest entities and their shareholders discharge all their respective obligations under the contractual arrangements which shall
include, among other things, full payment of services fees to the WFOE under the exclusive support services agreement, and granting
exclusive option to the WFOE or any third party designated by the WFOE to purchase all or part of their respective equity interests at the
lowest price permitted by law under the exclusive option agreements, and repay all accounts payable to the WFOE. The equity pledge for
all of our variable interest entities has been registered with local PRC authorities.
Rights and Obligations Assignment Agreement. Shuhong Yuan’s 50% equity interests in Yihao Pharmacy were transferred to
Jing Liu pursuant to a share transfer agreement dated July 13, 2017. As a result, Jing Liu has become a shareholder of Yihao Pharmacy,
our variable interest entity. In connection with this transaction, Jing Liu and Yue Xuan, both shareholders of our variable interest entity,
Yihao Pharmacy, and Shuhong Yuan, a party to the contractual arrangements with Yihao Pharmacy, entered into the rights and
obligations assignment agreement with 1 Pharmacy Technology and Yihao Pharmacy on July 13, 2017. Pursuant to this agreement,
Shuhong Yuan assigned all of her rights and obligations under the exclusive option agreement, proxy agreement and equity pledge
agreement to Jing Liu. As such, Jing Liu is deemed to have entered into and is currently bound by the contractual arrangements with this
variable interest entity.
Agreements that Provide Us with the Option to Purchase the Equity Interest in Our Variable Interest Entities
Exclusive Option Agreements. 1 Pharmacy Technology has entered into exclusive option agreements with shareholders of our
variable interest entities. Pursuant to these exclusive option agreements, the shareholders of our variable interest entities have irrevocably
granted 1 Pharmacy Technology or any third party designated by 1 Pharmacy Technology an exclusive option to purchase all or part of
their respective equity interests in our variable interest entities. The purchase price shall be the lowest price permitted by law. Without 1
Pharmacy Technology’s prior written consent, our variable interest entities shall not, among other things, supplement or amend their
articles of association, increase or decrease the registered capital, sell, dispose of or set any encumbrance on their assets or revenue, enter
into any material contracts, merge with any other persons or make any investments, or distribute dividends. The shareholders of our
variable interest entities also jointly and severally undertake that they will not transfer, pledge or otherwise dispose of their respective
equity interests in our variable interest entities to any third party or create or allow any encumbrance on their equity interests without 1
Pharmacy Technology’s prior written consent within the term of these agreements. These agreements will remain effective for the same
period as the exclusive support services agreements.
In the opinion of Commerce & Finance Law Offices, our PRC counsel, the ownership structures of our variable interest entities,
currently do not result in any violation of the applicable PRC laws or regulations currently in effect; and the agreements under the
contractual arrangements among 1 Pharmacy Technology, our variable interest entities and their shareholders, are governed by PRC laws
or regulations, and are currently valid, binding and enforceable in accordance with the applicable PRC laws or regulations currently in
effect, and do not result in any violation of the applicable PRC laws or regulations currently in effect.
However, our PRC counsel, Commerce & Finance Law Offices, advised us that there are substantial uncertainties regarding the
interpretation and application of current and future PRC laws, regulations and rules and there can be no assurance that the PRC
government will ultimately take a view that is consistent with the opinion of our PRC counsel. If the PRC government finds that the
agreements that establish the structure for operating our online pharmaceutical and medical business do not comply with PRC
government restrictions on foreign investment in value-added telecommunications services business, such as the internet content
82
Table of Contents
provision services, we could be subject to severe penalties, including being prohibited from continuing operations. See “Item 3. Key
Information—D. Risk Factors—Risks Related to Our Corporate Structure” and “—Risks Related to Doing Business in China.”
A. Property, Plant and Equipment
As of December 31, 2020, we leased office space in Shanghai with an area of approximately 5,553.50 square meters. As of
December 31, 2020, we also leased office space in Guangzhou, Wuhan, Beijing, Chengdu, Chongqing, Tianjin, Hefei, Fuzhou, Xi’an,
Shenyang, Guangdong and Anshun with a total area of approximately 5,528.67 square meters. In addition, we leased properties in
various locations in China for operations of Yi Hao Pharmacies, with a total area of approximately 2,486.15 square meters as of
December 31, 2020. With respect to our fulfillment centers, we leased these facilities with a total area of approximately 164,658.07
square meters in Kunshan, Guangzhou, Tianjin, Chongqing, Wuhan, Fuzhou, Xi’an and Shenyang as of December 31, 2020. We lease
our premises from unrelated third parties under operating lease agreements. We believe that our existing facilities are generally adequate
to meet our current needs, but we expect to seek additional space as needed to accommodate future growth, especially as we expand our
fulfillment network and establish more fulfillment centers.
Item 4A. Unresolved Staff Comments
None.
Item 5. Operating and Financial Review and Prospects
The following discussion of our financial condition and results of operations is based upon, and should be read in conjunction
with, our audited consolidated financial statements and the related notes included in this annual report on Form 20-F. This report contains
forward-looking statements. See “Forward-Looking Information.” In evaluating our business, you should carefully consider the
information provided under the caption “Item 3. Key Information—D. Risk Factors” in this annual report on Form 20-F. We caution you
that our businesses and financial performance are subject to substantial risks and uncertainties.
A. Operating Results
Overview
We are dedicated to digitally connecting patients with drugs and healthcare services in China. We are a leading integrated online
and offline healthcare platform with the largest virtual pharmacy network in China. By applying advanced Internet and enabling
technology, we deliver a broad range of products and services ranging from medical consultations to prescription drugs, from health and
wellness products to tools from one-time fix to life-cycle chronic disease management, from off-line to online, as well as support services
that help them better manage their conditions, through optimized supply chain and cloud services, to increase the efficiency and
transparency of drug retail and distribution. Today, we provide hundreds of millions of consumers with better access to pharmaceutical
products and medical services, bridging medical providers and patients. Our integrated business model is hallmarked by our flagship
technology platforms:
● 1 Medicine Marketplace: Our virtual retail pharmacy provides consumers with a wide variety of pharmaceutical products
and other merchandise.
● 1 Clinic: Our internet hospital provides consumers with cost-effective and convenient online consultation and electronic
prescription services.
● 1 Pharmacy: Our online wholesale pharmacy serves as a one-stop shop for pharmacies to source a vast selection of
pharmaceutical products.
We are building our core competencies in the areas of smart supply chain, cloud-based solutions, big data and medical expertise,
and are reshaping the pharmaceutical value chain in China using our New Retail platform. Not only do we serve consumers directly
through our online retail pharmacy, we also enable more than 13 offline pharmacies to better serve their consumers as of December 31,
2020. Our online wholesale pharmacy, 1 Pharmacy, serves as a one-stop shop for pharmacies to source a vast selection of
pharmaceutical products.
83
Table of Contents
We connect pharmacies, pharmaceutical companies, medical professionals and consumers in our ecosystem, and we improve the
efficiency and transparency of the pharmaceutical value chain. Our omni-channel e-commerce platform plays an important role in
facilitating the commercialization of drugs across the nation. This model offers multiple channels for pharmaceutical companies to
simultaneously reach healthcare providers nationwide and educates them about new drugs and therapies. This model significantly
reduces time, resources and cost, which allows drugs to be distributed quickly and efficiently.
Our revenue was RMB1.79 billion in 2018, RMB3.95 billion in 2019 and RMB8.20 billion (US$1.26 billion) in 2020, of which
product revenues from the B2B segment were RMB1,061.6 million, RMB3.29 billion and RMB7.49 billion (US$1.15 billion),
respectively. Our net loss margin improved from 21.4% in 2018 to 12.7% in 2019 and further to 5.7% in 2020.
Key Factors Affecting Our Results of Operations
Our results of operations are affected by general factors driving China’s general health and wellness industry, especially
pharmaceutical retail and wholesale distribution and internet healthcare industries in China.
Our business expansion and revenue growth have been and will continue to be affected by the development of the general health
and wellness industry in China, which is in turn driven by increasing disposable income and healthcare spending, rising awareness of
health, an aging population, increasing life expectancy, increasing penetration of mobile internet, favorable government policies and
increasing coverage of medical insurance. Unfavorable changes in any of these general industry conditions could negatively affect
demand for our products and services and negatively and materially affect our results of operations.
We are affected by government policies and regulations that address all aspects of our operations, including qualifications and
licensing requirements for online and offline sales and distribution of pharmaceutical and other health and wellness products, online
healthcare services and online hospitals, among other things. See also “Item 3. Key Information—D. Risk Factors—Risks Related to Our
Business and Industry—We are subject to extensive and evolving regulatory requirements, non-compliance with which, or changes in
which, may materially and adversely affect our business and prospects.” We have benefitted from certain recent favorable regulatory and
policy changes in China, especially various policy initiatives that have promoted the distribution of pharmaceutical products. We expect
that the implementation of these measures relating to the distribution of pharmaceutical products will also affect market competition and
drive industry consolidation.
While our business is influenced by general factors driving the general health and wellness market in China, we believe our
results of operations are more directly affected by company-specific factors, including the following major factors.
Our Ability to Attract and Retain Consumers and Pharmacies
Our net revenues are dependent on our ability to attract and retain our consumers and pharmacies.
● Consumers . Historically, our revenue growth was primarily driven by the sale of pharmaceutical and other health and
wellness products through our online retail pharmacy to consumers. Steady and continued growth of our consumer base
and their stickiness to our platform allows us to maintain a solid foundation for our business to continue to expand.
● Pharmacies . Since we launched our online wholesale pharmacy, 1 Pharmacy, in May 2017, we have significantly
increased the scale of our B2B business through the sale of pharmaceutical products to pharmacies. As of December 31,
2020, we have served more than 329,000 pharmacies, compared to over 235,000 pharmacies as of December 31, 2019 and
150,000 pharmacies as of December 31, 2018. We have also diversified the types of pharmacy customers we serve and
have expanded our reach not only to independent pharmacies and pharmacy chains, but also to in-house pharmacies within
clinics and private hospitals. We have thus far accumulated considerable offline pharmacy resources, which contributed to
the increase of product revenues from the B2B segment to RMB7.49 billion (US$1.15 billion) in 2020. We expect to
further expand our offline pharmacy market and to develop this revenue stream. Product revenues from the B2B segment
contributed 59.4%, 83.3% and 91.3% to our total net revenues in 2018, 2019 and 2020, respectively.
We rely on a diverse array of online marketing channels to attract consumers, including using social media such as WeChat and
Weibo and paid placement on major online search engines in China. With respect to growing our pharmacy customers, we rely on
84
Table of Contents
the effective operation of our on-the-ground sales force to promote our products and services. Our ability to continue to reach more
consumers and pharmacies will affect the growth of our business and our net revenues.
Our Ability to Create Value for Participants in the Healthcare Ecosystem and Increase Monetization
We are a pioneer in developing and applying technologies to create an integrated online and offline platform in the healthcare
ecosystem in China. Our results of operations depend on our ability to create value for various participants in the healthcare ecosystem
and increase monetization for these participants. Consumers and pharmacies are drawn to our platform because we offer a wide selection
of competitively priced pharmaceutical and other health and wellness products, as well as efficient and comprehensive services. In
addition, we offer to suppliers, pharmaceutical companies, medical professionals and other participants in the ecosystem our innovative
cloud-based solutions, such as data service, CSO, smart supply chain services and other value-added services. Our success depends on
our ability to continuously offer attractive products and services, therefore increasing user stickiness and attracting more participants to
our close-loop online and offline platform. We have also implemented various initiatives and invested significantly to ramp up our cloud-
based solutions and improve our smart supply chain services. As we further enhance our technologies and IT infrastructure, we aim to
create more value for these participants, increasing their engagement and connection and deepening our penetration in the healthcare
ecosystem, which we anticipate will create additional monetization venues for us to drive our revenue growth.
Our Ability to Manage Our Mix of Product and Service Offerings
Our results of operations are also affected by the mix of products and services we offer. We currently derive our revenues
primarily from the sale and distribution of pharmaceutical and other health and wellness products to our pharmacy customers and
consumers. We also earn commissions and service fees from marketplace sellers on our online marketplace. Different products and
services have different cost structures. For example, the various services we provide generally have higher fixed costs. The revenue
contributions from our online direct sales model, our online marketplace model and our services have a major influence on our
profitability. We intend to better manage the mix of our product and service offerings in order to improve our profitability.
Our Ability to Control Operating Costs and Expenses and Improve Efficiency
Our cost of products sold represents primarily the purchase price of products and inbound shipping charges if any, as well as
inventory write-downs. In 2020, we sourced our products from over 2,045 suppliers, including pharmaceutical companies and
distributors. As our business further grows in scale, we expect to obtain more favorable terms from suppliers, including pricing terms,
credit period and volume-based rebates. In addition, we aim to create value for our suppliers, especially pharmaceutical companies, by
providing an effective and transparent channel for selling large volumes of their products online and by offering them valuable data
insights on market demand, customer preferences and supply chain information. We believe this value proposition will also help us
deepen our relationships with suppliers, obtain favorable terms and reduce our procurement costs. Our selling and marketing expenses
are a significant contributor to our operating costs and expenses, and they primarily consist of payroll, bonus and employee benefits of
sales and marketing staff, advertising costs, agency fees and costs for promotional materials. In 2018, 2019 and 2020, selling and
marketing expenses amounted to 14.6%, 8.6% and 4.9% of our total net revenues, respectively. We expect our selling and marketing
expenses to remain substantial in absolute terms as we implement new business initiatives, such as deploying additional sales personnel
to promote our 1 Pharmacy and our value-added services to pharmacies. As our business grows, we anticipate that our technology and
fulfillment expenses will increase in absolute terms in the foreseeable future in light of our anticipated expansion and investment plans.
In 2020, we continued to expand our B2B business with the increase in our marketing and sales and, as a result, our cost of
products sold increased.
We continuously seek to streamline our operations and improve our supply chain and inventory management. Controlling costs
and operating expenses to achieve optimal operating efficiency is important to our success. As our business grows in scale, we expect to
have significant operating leverage and realize structural cost savings.
85
Table of Contents
Key Components of Results of Operations
Net Revenues
The following table sets forth the components of our net revenues by amounts and percentages of our total net revenues for the
periods presented:
Product revenues
B2C
B2B
Sub total
Service revenues
Total
2018
2019
For the Year Ended December 31,
RMB
%
RMB
%
(in thousands, except for percentages)
RMB
2020
US$
%
709,585
1,061,559
1,771,144
14,826
1,785,970
39.7
59.4
99.1
0.9
100.0
636,430
3,293,268
3,929,698
22,355
3,952,053
16.1
83.3
99.4
0.6
100.0
666,223
7,490,449
8,156,672
46,485
8,203,157
102,103
1,147,960
1,253,349
7,124
1,257,189
8.1
91.3
99.4
0.6
100.0
Product revenues. We historically reported our product revenues under our direct sales model from two reportable segments: the
B2C segment and the B2B segment. Product revenues from our B2C segment are generated from the sale of pharmaceutical and other
health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers
and certain enterprise customers. We also generate product revenues from the B2B segment through the sale of pharmaceutical products
to pharmacies on 1 Pharmacy.
In the first quarter of 2020, we began to report our product revenues from E-Channel business representing revenue from
product sales to e-commerce companies, such as Ali Health, JD Health, Ping An Good Doctor, among others, in the B2B segment.
Revenue from these sources was historically included in the B2C segment, accounting for between 15% and 20% of our B2C revenue. In
the fourth quarter of 2020, the revenue from E-Channel which was previously reported as a separate segment, was incorporated into the
B2B segment. As a result, as of December 31, 2020, we had two reporting segments, i.e. B2B segment and B2C segment. In this annual
report, we present the year-on-year comparison of results of operation using the updated two segment and we have also revised our
financial information for 2018 and 2019 to conform to our current reportable segments presentation.
Our product revenues, in particular, those from B2B segment, have grown significantly and we expect continued growth as we
attract more pharmacies as customers. Our product revenue from the B2B business segment in 2020 reached RMB7.49 billion (US$1.15
billion), representing a 127.4% increase from 2019, and our product revenue from the B2C business segment in 2020 reached RMB666.2
million (US$102.1 million), representing a 4.7% increase from 2019.
Service revenues. Service revenues primarily consist of marketplace (MP) service fees we charge to marketplace sellers to
which we provide access to 1 Medicine Marketplace where they are able to effectively sell their products. We charge marketplace sellers
commission fees equal to an agreed percentage of the sales price of the product when a sale is completed and also charge marketplace
sellers an annual non-refundable up-front fee for platform usage. We refer to these fees as MP service revenue. Since we launched our
MP service, it has made substantial contribution to our service revenues. Our service revenues increased significantly by 107.6% from
RMB22.4 million in 2019 to RMB46.5 million (US$7.1 million) in 2020, which was primarily attributable to an increase of RMB11.8
million (US$1.8 million) in B2B MP service revenues. We also generate service revenues by providing other ancillary services, mainly
online medical consultation services for patients and digital marketing services for pharmaceutical companies. We expect our service
revenues, although not a material contribution to our net revenues currently or in the near future, to grow as we expand our online
marketplace and increase the service coverage of our cloud-based solutions, such cloud prescription services and data services to more
pharmacies and pharmaceutical companies.
86
Table of Contents
Operating costs and expenses
The following table sets forth the components of our operating costs and expenses by amounts and percentages of total
operating costs and expenses for the periods presented:
2018
2019
For the Year Ended December 31,
RMB
%
RMB
%
(in thousands, except for percentages)
RMB
2020
US$
%
Operating costs and expenses:
Cost of products sold
Fulfillment expenses
Selling and marketing expenses
General and administrative expenses
Technology expenses
Other operating income (expenses), net
Total
(1,681,700)
(73,930)
(260,040)
(98,759)
(71,248)
(668)
(2,186,345)
76.9
3.4
11.9
4.5
3.3
0.0
100.0
(3,786,870)
(128,996)
(340,562)
(123,501)
(61,902)
(3,735)
(4,445,566)
85.2
2.9
7.6
2.8
1.4
0.1
100.0
(7,837,325)
(226,930)
(399,610)
(128,226)
(92,080)
7,703
(8,676,468)
(1,201,123)
(34,779)
(61,243)
(19,651)
(14,112)
1,181
(1,329,727)
90.3
2.6
4.6
1.5
1.1
0.1
100.0
Cost of products sold. Cost of products sold consists of the purchase price of products and inbound shipping charges, as well as
inventory write-downs, less rebates earned from vendors in the form of credits that we can apply against trade amounts owed to these
vendors pursuant to binding arrangements when we complete a specified cumulative level of purchases within a specified time period.
Cost of products does not include other direct costs related to costs of product sales such as shipping and handling expense, payroll and
employee benefits for logistic staff, logistic centers rental expenses and depreciation expenses. Therefore, our cost of products sold may
not be comparable to that of other companies, which include such expenses in their costs of products sold. We expect our cost of
products sold to grow in absolute terms as our business continues to grow.
Fulfillment expenses. Fulfillment expenses primarily consist of payroll, bonus and employee benefits for logistics staff, logistics
centers rental expenses, shipping and handling expenses and packaging expenses. We expect our fulfillment expenses as a percentage of
our total net revenues to decrease because larger B2B orders reduce our cost as a percentage as a result of the way pricing is undertaken
by the logistics business. In addition, we have implemented more cost-saving initiatives and continue to expand our fulfillment network
to leverage our scale.
Selling and marketing expenses. Selling and marketing expenses primarily consist of payroll, bonus and employee benefits for
sales and marketing staff, advertising costs, agency fees and costs for promotional materials. We expect our selling and marketing
expenses to remain substantial in absolute terms as we implement new business initiatives, such as deploying additional sales personnel
to promote our 1 Pharmacy and our value-added services to pharmacies.
General and administrative expenses. General and administrative expenses primarily consist of payroll, bonus and employee
benefit costs for corporate employees, legal, finance, rental expenses, and other corporate overhead costs. We expect our general and
administrative expenses to increase in absolute terms in the foreseeable future due to the anticipated growth of our business as well as
accounting, insurance, investor relations and other public company costs, but to decrease as a percentage of our total net revenues as we
leverage the scale of our business.
Technology expenses. Technology expenses primarily consist of payroll, bonus and employee benefits for our technology and
system department staffs and expenses incurred for the development and enhancement of our websites, technology platforms and
applications. We expect our technology expenses to grow in absolute terms as we expand our technology team, enhance our big data
analytics capabilities and develop new features and applications to better serve various participants in the healthcare ecosystem, but to
decrease as a percentage of our total net revenues as we are able to leverage the scale of our business as we continue to grow.
87
Table of Contents
Results of Operations
The following table sets forth a summary of our consolidated results of operations for the periods indicated. The period-to-
period comparisons of results of operations should not be relied upon as indicative of future performance. This information should be
read together with our audited consolidated financial statements and related notes included elsewhere in this annual report.
Net Revenues:
Product revenues
Service revenues
Total net revenues
Operating costs and expenses:
Cost of products sold
Fulfillment expenses
Selling and marketing expenses(1)
General and administrative expenses(1)
Technology expenses(1)
Other operating income (expenses), net
Total operating costs and expenses
Loss from operations
Interest income
Interest expense
Foreign exchange gain (loss)
Other income, net
Loss before income taxes
Income tax expense
Net loss
For the Year Ended December 31,
2018
2019
2020
RMB
%
RMB
%
(in thousands)
RMB
US$
%
1,771,144
14,826
1,785,970
99.2
0.8
100.0
3,929,698
22,355
3,952,053
99.4
0.6
100.0
8,156,672
46,485
8,203,157
1,250,063
7,124
1,257,189
99.4
0.6
100.0
(1,681,700)
(73,930)
(260,040)
(98,759)
(71,248)
(668)
(2,186,345)
(400,375)
4,352
—
2,459
11,531
(382,033)
(8)
(382,041)
(94.2)
(4.1)
(14.6)
(5.5)
(4.0)
(0.0)
(122.4)
(22.4)
0.2
—
0.1
0.6
(21.4)
(0.0)
(21.4)
(3,786,870)
(128,996)
(340,562)
(123,501)
(61,902)
(3,735)
(4,445,566)
(493,513)
4,802
(3,622)
(10,328)
834
(501,827)
—
(501,827)
(95.8)
(3.3)
(8.6)
(3.1)
(1.6)
(0.1)
(112.5)
(12.5)
0.1
(0.1)
(0.2)
0.0
(12.7)
—
(12.7)
(7,837,325)
(226,930)
(399,610)
(128,226)
(92,080)
7,703
(8,676,468)
(473,311)
6,312
(8,817)
5,547
3,161
(467,108)
—
(467,108)
(1,201,123)
(34,779)
(61,243)
(19,651)
(14,112)
1,181
(1,329,727)
(72,538)
967
(1,351)
850
484
(71,588)
—
(71,588)
95.5
(2.8)
(4.9)
(1.6)
(1.1)
0.1
(105.8)
(5.8)
0.1
(0.1)
0.1
0.0
(5.7)
—
(5.7)
(1) Share-based compensation expenses are allocated to operating expense line items as follows:
General and administrative expenses
Selling and marketing expenses
Technology expenses
Total
2018
RMB
22,477
23,561
5,321
51,359
For the Year Ended December 31,
2019
RMB
2020
RMB
US$
(in thousands)
25,412
24,772
4,097
54,281
22,727
40,562
12,406
75,695
3,483
6,216
1,901
11,601
The Year Ended December 31, 2020 Compared to the Year Ended December 31, 2019
Net Revenues
Our net revenues increased by 107.6% from RMB3.95 billion in 2019 to RMB8.20 billion (US$1.26 billion) in 2020. This
increase was primarily due to the significant increase in product revenues from B2B segment. Our net revenues experienced consistent
monthly growth and are significantly impacted by the annual and mid-year e-commerce festivals.
Product Revenues by Segment. Product revenues increased by 107.6% from RMB3.93 billion in 2019 to RMB8.16 billion
(US$1.25 billion) in 2020, due to an increase in the number of offline pharmacies through which more products were sold. We
experienced a significant increase in product revenues from B2B segment, which increased by 127.7% to RMB7.49 billion (US$1.15
88
Table of Contents
billion) from RMB3.29 billion last year. Product revenues from B2C segment increased by 4.7% to RMB666.2 million (US$102.1
million) from RMB636.4 million last year.
Service revenues. Our service revenues increased by 107.6% from RMB22.4 million in 2019 to RMB46.5 million (US$7.1
million) in 2020, which was primarily attributable to the expansion of our B2B MP service in 2020.
Segment Cost of Products Sold
Cost of products sold increased by 107.0% from RMB3,786.9 million in 2019 to RMB7,837.3 million (US$1,201.1 million) in
2020, in line with our overall revenue growth, which is primarily attributable to growth in sales and a change in revenue mix with a much
higher proportion of B2B business.
Segment Profit/Loss
As a result of the foregoing, our segment profit from our B2C segment increased by 17.4% from RMB118.7 million in 2019 to
RMB139.3 million (US$21.3 million) in 2020, while our segment profit from our B2B segment increased by 387.1% from RMB46.5
million in 2019 to RMB226.6 million (US$34.7 million) in 2020.
Operating Costs and Expenses
Our operating costs and expenses increased by 95.1% from RMB4.45 billion in 2019 to RMB8.68 billion (US$1,33 billion) in
2020, with increases in the following categories of operating expenses.
Cost of Products Sold. Our cost of products sold increased by 106.9% from RMB3.79 billion in 2019 to RMB7.84 billion
(US$1.20 billion) in 2020, primarily due to growth in sales and a change in revenue mix with a much higher proportion of B2B business.
Fulfillment Expenses. Our fulfillment expenses increased by 75.9% from RMB129.0 million in 2019 to RMB226.9 million
(US$34.8 million) in 2020, primarily as a result of growth in B2B business. Fulfillment expenses accounted for 2.8% of net revenue in
2020 as compared to 3.3% last year.
Selling and Marketing Expenses. Our selling and marketing expenses increased by 17.3% from RMB340.6 million in 2019 to
RMB399.6 million (US$61.2 million) in 2020. The increase was primarily attributable to increase in sales staff and expenses associated
with the expansion of B2B business. Selling and marketing expenses accounted for 4.9% of net revenue in 2020 as compared to 8.6%
last year.
General and Administrative Expenses. Our general and administrative expenses increased by 3.8% from RMB123.5 million in
2019 to RMB128.2 million (US$19.7 million) in 2020. The increase was primarily due to increases in managerial staff and professional
service fees. General and administrative expenses accounted for 1.6% of net revenue in 2020 as compared to 3.1% last year.
Technology Expenses. Our technology expenses increased by 48.8% from RMB61.9 million in 2019 to RMB92.1 million
(US$14.1 million) in 2020, mainly due to increase in our technology staff and expenses associated with expansion of our business.
Technology expenses accounted for 1.1% of net revenue in 2020 as compared to 1.6% last year.
Net Loss
As a result of the foregoing, we recorded a net loss of RMB467.1 million (US$71.6 million) in 2020 and a net loss of
RMB501.8 million in 2019.
89
Table of Contents
The Year Ended December 31, 2019 Compared to the Year Ended December 31, 2018
Net Revenues
Our net revenues increased by 121.3% from RMB1.79 billion in 2018 to RMB3.95 billion in 2019. This increase was primarily
due to the significant increase in product revenues from B2B segment. Our net revenues experienced consistent monthly growth and are
significantly impacted by the annual and mid-year e-commerce festivals.
Product Revenues by Segment. Product revenues increased by 122.0% from RMB1.77 billion in 2018 to RMB3.93 billion in
2019, due to an increase in the number of offline pharmacies through which more products were sold. We experienced a significant
increase in product revenues from B2B segment, which increased by 210.4% to RMB3.29 billion in 2019 from RMB1.06 billion in 2018.
Product revenues from B2C segment decreased by 10.3% to RMB636.4 million in 2019 from RMB709.6 million in 2018.
Service revenues. Our service revenues increased by 51.4% from RMB14.8 million in 2018 to RMB22.4 million in 2019, which
was primarily attributable to the launch of our B2B MP service in 2018 and the expansion of our B2C MP services.
Segment Cost of Products Sold
Cost of products sold increased by 125.2% from RMB1,681.7 million in 2018 to RMB3,786.9 million in 2019, in line with our
overall revenue growth, which is primarily attributable to growth in sales and a change in revenue mix with a much higher proportion of
B2B business.
Segment Profit/Loss
As a result of the foregoing, our segment profit from our B2C segment increased by 25.6% from RMB94.5 million in 2018 to
RMB118.7 million in 2019, while our segment profit from our B2B segment increased by 374.5% from RMB9.8 million in 2018 to
RMB46.5 million in 2019.
Operating Costs and Expenses
Our operating costs and expenses increased by 103.3% from RMB2,186.3 million in 2018 to RMB4,445.6 million in 2019, with
increases in the following categories of operating expenses.
Cost of Products Sold. Our cost of products sold increased by 125.2 % from RMB1,681.7 million in 2018 to RMB3,786.9
million in 2019, primarily due to growth in sales and a change in revenue mix with a much higher proportion of B2B business.
Fulfillment Expenses. Our fulfillment expenses increased by 74.6% from RMB73.9 million in 2018 to RMB129.0 million in
2019, primarily as a result of growth in B2B business. Fulfillment expenses accounted for 3.3% of net revenue in 2019 as compared to
4.1% in 2018.
Selling and Marketing Expenses. Our selling and marketing expenses increased by 31.0% from RMB260.0 million in 2018 to
RMB340.6 million in 2019. The increase was primarily attributable to increase in sales staff and expenses associated with the expansion
of B2B business. Selling and marketing expenses accounted for 8.6% of net revenue in 2019 as compared to 14.6% in 2018.
General and Administrative Expenses. Our general and administrative expenses increased by 25.0% from RMB98.8 million in
2018 to RMB123.5 million in 2019. The increase was primarily due to increases in managerial staff and professional service fees.
General and administrative expenses accounted for 3.1% of net revenue in 2019 as compared to 5.5% in 2018.
Technology Expenses. Our technology expenses decreased by 13.1% from RMB71.2 million in 2018 to RMB61.9 million in
2019, mainly due to improvements in our system development efficiency and implementation of automation tools. Technology expenses
accounted for 1.6% of net revenue in 2019 as compared to 4.0% in 2018.
90
Table of Contents
Net Loss
As a result of the foregoing, we recorded a net loss of RMB501.8 million in 2019 and a net loss of RMB382.0 million in 2018.
Taxation
Cayman Islands
We are incorporated in the Cayman Islands. The Cayman Islands currently has no income, corporation or capital gains tax and
no estate duty, inheritance tax or gift tax. The Cayman Islands does not impose a withholding tax on payments of dividends to
shareholders.
Hong Kong
Our subsidiary incorporated in Hong Kong is subject to Hong Kong profit tax at a rate of 16.5%. No Hong Kong profit tax has
been levied as we did not have assessable profit that was earned in or derived from the Hong Kong subsidiary during the periods
presented. Hong Kong does not impose a withholding tax on dividends.
China
Enterprise Income Tax. According to the EIT Law, which was promulgated on March 16, 2007 and amended in 2017 and 2018,
and its implementing regulation, an income tax rate of 25% generally applies to all enterprises incorporated in the PRC, including our
PRC subsidiaries, our variable interest entities and their subsidiaries. Under the EIT Law, an enterprise established outside the PRC with
“de facto management bodies” within the PRC is considered a resident enterprise for PRC enterprise income tax purposes and is
generally subject to a uniform 25% enterprise income tax rate on its worldwide income. Although we do not believe that 111, Inc. or Yao
Wang Corporation Limited should be considered as a PRC resident enterprise for PRC tax purposes, PRC income tax at a rate of 25%
would generally be applicable to our worldwide income if we were to be considered a PRC resident enterprise.
Dividend Withholding Tax. According to the EIT Law and its implementation rules, the profits of a foreign-invested enterprise
arising in 2008 and thereafter that are distributed to its immediate holding company outside the PRC are subject to withholding tax at a
rate of 10%, but a lower withholding tax rate will be applied if there is a beneficial tax treaty between the PRC and the jurisdiction of the
foreign holding company. A holding company in Hong Kong, for example, will be eligible, with approval of the PRC local tax authority,
to be subject to a 5% withholding tax rate under the Double Taxation Arrangement, if such holding company is considered to be a non-
PRC resident enterprise and holds at least 25% of the equity interests in the PRC foreign-invested enterprise distributing the dividends.
However, the PRC tax authorities will review preferential tax treatment under the “substance over form” principle and grant such
treatment on a case-by-case basis. Therefore, if such Hong Kong holding company is not considered to be the beneficial owner of such
dividends under applicable PRC tax regulations, such dividend will remain subject to withholding tax at a rate of 10%.
91
Table of Contents
Value-Added Tax. According to the Provisional Regulations of the PRC on Value-added Tax promulgated by the State council on
December 13, 1993 and amended in 2008, 2016 and 2017, and the Detailed Rules for the Implementation of the Provisional Regulations
of the PRC on Value-added Tax which was promulgated by the MOF, and the STA on December 18, 2008 and became effective on
January 1, 2009 and amended on October 28, 2011, all enterprises and individuals that engage in the sale of goods and services, the
provision of tangible personal property leasing services or importation of goods shall pay value-added tax at different tax rates of 0%,
6%, 11% or 17% due to different business; in addition, the small-scale taxpayers shall be subject to tax rate of 3%, except as otherwise
specified by the State Council. On April 4, 2018, the MOF and the STA issued the Notice on Adjusting Value-added Tax Rate, which
became effective from May 1, 2018 and stipulates that the previous tax rate of 17%, 11% for the taxable sale activities or importing
goods will be adjusted to 16% and 10% respectively. Moreover, on the same date, the MOF and the STA issued another notice to unify
the criteria of small-scale value-added tax payers, which became effective from May 1, 2018. On November 16, 2011, the MOF and the
STA promulgated a Pilot Plan for Imposition of Value-Added Tax to Replace Business Tax in Shanghai, or Pilot Plan, which became
effective on January 1, 2012 and stipulates that any entity in Shanghai that falls in the category of “selected modern service industries”
was required to switch from being a business tax payer to become a value-added tax payer, who is permitted to offset expenses incurred
in providing the relevant services it provides from the taxable income. The Pilot Plan was expanded to other regions in September 2012,
and was further expanded nationwide beginning on August 1, 2013. The MOF and the STA subsequently promulgated several circulars
in December 2013, April 2014 and March 2016 to further expand the scope of services which are to be subject to value-added tax instead
of business tax.
Inflation
To date, inflation in China has not materially affected our results of operations. According to the National Bureau of Statistics of
China, the year-over-year percent changes in the consumer price index for December 2018, 2019 and 2020 were increases of 1.9%, 4.5%
and 0.2%, respectively. Although we have not been materially affected by inflation in the past, we may be affected if China experiences
higher rates of inflation in the future.
Critical Accounting Policies, Judgments and Estimates
We prepare our financial statements in conformity with U.S. GAAP, which requires us to make judgments, estimates and
assumptions. We continually evaluate these estimates and assumptions based on the most recently available information, our own
historical experience and various other assumptions that we believe to be reasonable under the circumstances. Since the use of estimates
is an integral component of the financial reporting process, actual results could differ from our expectations as a result of changes in our
estimates. Some of our accounting policies require a higher degree of judgment than others in their application and require us to make
significant accounting estimates.
The following descriptions of critical accounting policies, judgments and estimates should be read in conjunction with our
consolidated financial statements and other disclosures included in this annual report. When reviewing our financial statements, you
should consider (i) our selection of critical accounting policies, (ii) the judgments and other uncertainties affecting the application of such
policies and (iii) the sensitivity of reported results to changes in conditions and assumptions.
Revenue Recognition
We follow five steps to recognize revenue under ASC 606: (i) identify the contract(s) with a customer; (ii) identify the
performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
We report revenue net of discount, business tax, value added tax and related surcharges. Our net revenue consists of product
revenues and service revenues.
Product Revenues
We generate our product revenues from the sale of pharmaceutical and other health and wellness products through our online
platforms and offline pharmacies to our consumers. We also generate revenues from the sale of drugs to pharmacies through 1 Pharmacy,
our online wholesale pharmacy.
92
Table of Contents
For both our B2B business and B2C business, we utilize delivery service providers to deliver goods to our consumers and
pharmacy customers. The delivery service is not considered as a separate obligation as it is an integral process for us to fulfill our
promises to transfer the products, the costs of which are recorded as fulfillment expenses. As a result, revenue is recognized at the point
in time when the goods are delivered to the designated address and received by consumers and pharmacy customers. In 2020, revenues
generated from our corporate customers (mainly E-channel customers) that place orders through 1 Medicine Marketplace were
reclassified to the B2B segment given the business nature and accordingly the business segmentation classification in prior periods has
been revised to conform to the current year presentation.
For both our B2C business and B2B business, revenues from product sales are recognized at the point in time when the delivery
is made and when the title and risk of loss transfer to the individual consumers and pharmacy customers. Revenues are measured as the
amount of consideration we expect to receive in exchange for transferring products to individual consumers and pharmacy customers
(the "transaction price"). To the extent that the transaction price includes variable consideration, we estimate the amount of variable
consideration that should be included in the transaction price utilizing the most likely amount method. Variable consideration is included
in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will
not occur. We provide the right of return in circumstances where there is package or delivery damage or other quality problems identified
within 30 days which is considered to be a form of variable consideration. We estimate sales returns based on historical experience and
as such, the amount of sales returns accrued was insignificant as of December 31, 2019 and 2020, respectively.
We voluntarily provide discount coupons through our websites during our marketing activities. These coupons are not related to
prior purchases, and can only be utilized in conjunction with subsequent purchases on our platforms. These discount coupons are
recorded as a reduction of revenues at the time of use.
Product revenue was recorded net of surcharges and value added tax which ranges from 0% to 13% for different kinds of
products based on sales amount. Surcharges are sales related taxes representing the City Maintenance and Construction Tax and
Education Surtax. We record revenue on a gross basis because we control the products before they are transferred to consumers and
pharmacy customers. We have made this determination on the basis that: we are primarily responsible for fulfilling our promise to
deliver the specified products to consumers and pharmacy customers, we have inventory risk before the specified products are transferred
to a customer or after transfer of control to consumers and pharmacy customers, and we also have discretion in establishing the price for
the specified products.
Contract Assets and Liabilities
Contract assets include unbilled receivables, which were recorded in accounts receivable.
Contract liabilities consist of advance payments, which were recorded in accrued expenses and other current liabilities.
Service Revenues
Service revenues primarily consist of MP service fees we charge to marketplace sellers to which we provide access to
1 Medicine Marketplace for sales of their products. We refer these fees as MP service revenue. We have determined that we are not the
principal in the arrangement as we are not responsible for fulfilling the order for the specified products we do not bear the inventory risk
for the products, nor do we have the ability to establish prices. We charge marketplace sellers commission fees equal to an agreed
percentage of the sales price of the product when a sale is completed and also charge marketplace sellers an annual non-refundable up-
front fee for platform usage. The promise to the customer, which is the marketplace seller, is to arrange for the sale which is considered
as one performance obligation. Therefore, we recognize the up-front fee and commission at the point in time when the sale is completed.
Cost of Products Sold
Cost of products sold consists of the purchase price of products and inbound shipping charges if any. We periodically receive
rebates of a specified amount of cash consideration from certain vendors in the form of credits that we can apply against trade amounts
owed to vendors pursuant to a binding arrangement only if we complete a specified cumulative level of purchases within a specified time
period. The rebates do not represent a payment for assets or services delivered to the vendor or a reimbursement of costs incurred
93
Table of Contents
by us to sell vendors’ products. We account for the rebates received from our vendors as a reduction to the price we pay for the products
purchased and therefore records such amounts as a reduction of cost of products sold when recognized in the consolidated financial
statements. Rebates are earned based on reaching minimum purchase thresholds within a specified period. When volume rebates can be
reasonably estimated based on our experience and current forecasts, a portion of the rebate is recognized as we make progress towards
the purchase threshold. Cost of products does not include other direct costs related to cost of product sales such as shipping and handling
expense, payroll and employee benefits of logistics staff, logistics centers rental expenses and depreciation expenses. Therefore, our cost
of products sold may not be comparable to other companies which include such expenses in their costs of products.
Income taxes
Current income taxes are provided for in accordance with the laws of the relevant taxing authorities. As part of the process of
preparing financial statements, we are required to estimate the income taxes in each of the jurisdictions in which it operates. We account
for income taxes using the liability method. Under this method, deferred income taxes are recognized for tax consequences in future
years of differences between the tax bases of assets and liabilities and their reported amounts in the financial statements at each year-end
and tax loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable for the differences that are
expected to affect taxable income. Deferred tax assets are reduced by a valuation allowance when, based upon the weight of available
evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Share-based Compensation
Awards Granted to Employees
We grant employee share options to eligible employees and account for these share based awards in accordance with ASC 718
Compensation—Stock Compensation .
Employees’ share-based awards are measured at the grant date fair value of the awards and recognized as expenses
a) immediately at grant date if no vesting conditions are required; or b) using the straight-line vesting method over the requisite service
period, which is the vesting period. To the extent the required vesting conditions are not met, resulting in the forfeiture of the share-based
awards, previously recognized compensation expense relating to those awards are reversed.
Prior to our initial public offering, the fair value of the stock options granted to employees was determined with the assistance of
an independent third-party valuation firm. The Black-Scholes option pricing model was applied in determining the estimated fair value of
such options granted to employees.
After our initial public offering, in determining the fair value of the share options and restricted share units, the closing market
price of the underlying shares on the grant date is applied.
The Group estimates the Company’s subsidiary's enterprise value for purposes of recording sharebased compensation, and the
information considered by the Company mainly include but are not limited to the pricing of recent rounds of financing, future cash flow
forecasts, discount rates, and liquidity factors.
The compensation expense for the awards with performance conditions is based upon the Group’s judgement of likely future
performance and may be adjusted in future periods depending on actual performance.
Awards Granted to Non-Employees
Prior to the adoption of Accounting Standard Update 2018-07 Compensation — Stock Compensation (Topic
718), Improvements to Nonemployee Share-Based Payment Accounting on January 1, 2019, we have accounted for equity instruments
issued to non-employees in accordance with the provisions of ASC 505, Equity-based payments to nonemployees. All transactions in
which goods or services are received in exchange for equity instruments are accounted for based on the fair value of the consideration
received or the fair value of the equity instrument issued, whichever is more reliably measurable. As there is no performance
commitment associated with the equity instrument issued to non-employees, we re-measure the awards using the then-current fair value
at each reporting date until the measurement date, generally when the services are completed and awards are vested,
94
Table of Contents
and attribute the changes in those fair values over the service period by the straight-line method. Details are included in note 2 to our
consolidated financial statements included elsewhere in this annual report.
Recent Accounting Pronouncements
A list of recently issued accounting pronouncements that are relevant to us is included in note 2 to our consolidated financial
statements included elsewhere in this annual report.
B. Liquidity and Capital Resources
To date, we have financed our operations primarily through cash generated by the issuance of preferred shares in private
placements and our initial public offering in 2018. As of December 31, 2018, 2019 and 2020, we had RMB853.7 million, RMB581.3
million and RMB1.19 billion (US$182.3 million), respectively, in cash and cash equivalents. Our cash and cash equivalents primarily
consist of cash on hand and demand deposits.
In addition, as of December 31, 2018, 2019 and 2020, we had RMB252.8 million, nil and RMB300.2 million (US$46.0
million), respectively, in short-term investments. Our short-term investments consist of wealth management products, which are financial
products with variable interest rates purchased from financial institutions with an original maturity period of less than one year. Our
operating cash flow and cash are also affected by our ability to manage our inventory effectively and to enhance our overall supply chain
efficiency. We believe that our supply chain and effective inventory management, which have resulted in reduced inventory turnover
days, support the growing scale of our business, free our valuable working capital and improve our liquidity.
In December 2018, certain of our subsidiaries entered into a revolving credit facility that allows us to borrow up to
RMB500,000 for working capital purpose which will expire in two years. Any draw down on the credit facility will mature within 6
months. Cash deposits or notes receivable are required to be pledged for any draw down. As of December 31, 2018, no amounts had been
drawn on the line of credit facility. During the year ended December 31, 2019, RMB112,334 were drawn down and RMB47,253 were
repaid with the balance of RMB65,081 outstanding as of December 31, 2019. As of December 31, 2019, RMB116,441 restricted cash
deposits and RMB14,264 notes receivable were pledged to the bank.
In September 2019, 1 Pharmacy Technology entered into a credit agreement which provides a revolving credit facility that
allows 1 Pharmacy Technology to borrow up to RMB100,000 for working capital purpose in one year. Any draw down on the credit
facility will be charged with interest at six-month loan prime rate published by People’s Bank of China. The borrowings were guaranteed
by Yihao Pharmacy. During the year ended 2020, RMB229,666 were drawn down and RMB159,666 were repaid with the balance of
RMB100,000 outstanding as of December 31, 2020.
In June 2020, 1 Pharmacy Technology entered into a credit agreement with Industrial Bank (IB) which provides a revolving
credit facility that allows 1 Pharmacy Technology to borrow up to RMB100,000 for working capital purpose in one year. Any draw down
on the credit facility will be charged with interest at one-year loan prime rate published by People’s Bank of China minus 0.35%. The
borrowings were guaranteed by Yihao Pharmacy. During the year ended December 31, 2020, RMB9,850 was drawn on this credit facility
and nil were repaid, with the balance of RMB9,850 outstanding as of December 31, 2020.
In May 2020, we obtained new loan of RMB 40,000 from Shanghai Pudong Technology Financial Service Co., Ltd. with annual
interest rate of 8.5%. The borrowing was guaranteed by Guangdong Yihao Pharmacy Co., Ltd.. No repayment was incurred during year
2020 and its balance remained RMB 40,000 as of December 31, 2020. We also borrowed RMB10,000 from China Construction Bank
(CCB). The loan agreement includes covenants that Debt to Asset Ratio of 1 Pharmacy Technology should be no more than 70%, and the
Liquidity Ratio should be no less than 1.0. No repayment incurred during year 2020. We were in compliance with the covenants as of
December 31, 2020. The interest rate for the borrowings in 2020 was approximately 8.50 % per annum.
In 2020, we also obtained loans from several other financial institutions. During the year ended December 31, 2020,
RMB109,250 were borrowed and RMB39,850 were repaid, with the balance of RMB 69,400 outstanding as of December 31, 2020. The
interest rate range for the borrowings in 2020 was from 3.50 % to 4.6% per annum.
95
Table of Contents
After considering all facts available to us as of the date of this annual report, we believe that our current cash and cash
equivalents, short-term investments and our anticipated cash flows from operations will be sufficient to meet our anticipated working
capital requirements and capital expenditures for the next 12 months.
We may, however, need additional capital in the future to fund our continued operations in light of the perceived or actual
impact of COVID-19 pandemic on domestic and global economy. If we determine that our cash requirements exceed the amount of cash
and cash equivalents we have on hand at the time, we may seek to issue equity or debt securities or obtain credit facilities. The issuance
and sale of additional equity or the incurrence of convertible debt would result in further dilution to our shareholders. The incurrence of
indebtedness would result in increased fixed obligations and could result in operating covenants that might restrict our operations. We
cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all, and the availability of financing
options will be affected by the slowdown in the growth or contraction of the global or Chinese economies or any liquidity or credit
drainage in the global or Chinese finance sectors if triggered by the COVID-19 pandemic.
We expect that substantially all of our future net revenues will be denominated in Renminbi. Under existing PRC foreign
exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related
foreign exchange transactions, can be made in foreign currencies without prior SAFE approval as long as certain routine procedural
requirements are fulfilled. Therefore, our PRC subsidiary, 1 Pharmacy Technology, is allowed to pay dividends in foreign currencies to
us without prior SAFE approval by following certain routine procedural requirements. However, approval from or registration with
competent government authorities is required where the Renminbi is to be converted into foreign currency and remitted out of China to
pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may at its discretion
restrict access to foreign currencies for current account transactions in the future.
The following table sets forth material amounts of cash and short-term investments disaggregated by currency denomination as
of December 31, 2020 in each jurisdiction in which our affiliated entities are domiciled:
Cash in RMB
Cash in US$
Cash Flows
PRC
1,102,876
2,674
Hong Kong
(RMB in thousands)
90,904
14,193
Cayman Islands
6,500
1,256
The following table sets forth a summary of our cash flows for the periods presented:
Summary Consolidated Cash Flow Data:
Net cash used in operating activities
Net cash provided by (used in) investing activities
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents, and restricted cash
Cash and cash equivalents, and restricted cash at the beginning of period
Cash and cash equivalents, and restricted cash at the end of period
Operating Activities
For the Year Ended December 31,
2018
RMB
2019
RMB
2020
RMB
US$
(in thousands)
(343,018)
44,454
972,697
686,080
167,660
853,740
(512,382)
237,675
108,987
(156,018)
853,740
697,722
(116,777)
(324,669)
1,070,408
620,812
697,722
1,318,534
(17,897)
(49,757)
164,048
95,145
106,929
202,074
Net cash used in operating activities in 2020 was RMB116.8 million (US$17.9 million) and primarily consisted of our net loss
of RMB467.1 million (US$71.6 million), as adjusted for non-cash items and the effects of changes in operating assets and liabilities.
Adjustment for non-cash items primarily included RMB75.7 million (US$11.6 million) of share-based compensation, RMB24.2 million
(US$3.7 million) of inventory write-down and RMB39.3 million (US$6.0 million) of noncash lease expense, partially offset by an
increase in exchange loss of RMB5.5 million (US$0.9 million). In 2020, the principal items accounting for the
96
Table of Contents
changes in operating assets and liabilities were increase in inventories of RMB304.5 million (US$46.7 million), partially offset by an
increase of RMB629.0 million (US$96.4 million) in accounts payble and an increase in accrued expenses and other current liabilities of
RMB111.3 million (US$17.1 million). The increases in accounts payable and inventory were primarily due to an increase in our
inventory storage level to meet increased demands.
Net cash used in operating activities in 2019 was RMB512.4 million and primarily consisted of our net loss of RMB501.8
million, as adjusted for non-cash items and the effects of changes in operating assets and liabilities. Adjustment for non-cash items
primarily included RMB54.3 million of share-based compensation expenses, RMB11.7 million of depreciation and amortization
expenses and RMB11.0 million of investment loss and RMB25.4 million of noncash lease expense, partially offset by an increase in
investment income of RMB9.6 million. In 2019, the principal items accounting for the changes in operating assets and liabilities were an
increase in inventory of RMB276.2 million, partially offset by an increase of RMB232.1 million in accounts payable and an increase in
accrued expenses and other current liabilities of RMB74.4 million. The increases in accounts payable and inventory were primarily due
to an increase in our inventory storage level to meet increased demands.
Net cash used in operating activities in 2018 was RMB343.0 million and primarily consisted of our net loss of
RMB382.0 million, as adjusted for non-cash items and the effects of changes in operating assets and liabilities. Adjustment for non-cash
items primarily included RMB51.4 million of share-based compensation expenses and RMB11.3 million of depreciation and
amortization expenses, partially offset by an increase in investment income of RMB10.9 million. In 2018, the principal items accounting
for the changes in operating assets and liabilities were an increase of RMB84.1 million in accounts payable, partially offset by an
increase in inventory of RMB66.8 million and an increase in prepayments and other current assets of RMB56.3 million. The increases in
accounts payable and inventory were primarily due to an increase in our inventory storage level to meet increased demands.
Investing Activities
Net cash used in investing activities in 2020 was RMB324.7 million (US$49.8 million), consisting primarily of purchases of
short-term investments of RMB500.0 million (US$76.6 million), partially offset by proceeds from sale or maturity of short-term
investments of RMB201.0 million (US$30.8 million).
Net cash provided by investing activities in 2019 was RMB237.7 million, consisting primarily of proceeds from sale or maturity
of short-term investments of RMB863.1 million, partially offset by purchases of short-term investments of RMB601.0 million.
Net cash provided by investing activities in 2018 was RMB44.5 million, consisting primarily of proceeds from sale or maturity
of short-term investments of RMB578.4 million, partially offset by purchases of short-term investments of RMB519.2 million.
Financing Activities
Net cash provided by financing activities in 2020 was RMB1,070.4 million (US$164.0 million), consisting of proceeds from
redeemable non-controlling shareholders of a subsidiary of RMB934.8 million (US$143.3 million), proceeds from short-term bank
borrowings of RMB398.8 million (US$61.1 million), proceeds from non-controlling shareholders of a subsidiary of RMB32.5 million
(US$5.0 million) and proceeds from ordinary shareholders of RMB6.3 million (US$1.0 million), partially offset by repayment of short-
term bank borrowings of RMB264.6 million (US$40.6 million), net proceeds used in other financing activities of RMB25.4 million
(US$3.9 million) and payment of share repurchase of RMB12.0 million (US$1.8 million).
Net cash provided by financing activities in 2019 was RMB109.0 million, consisting of proceeds from short-term bank
borrowings of RMB150.9 million, net proceeds from issuance of other financing activities of RMB25.6 million and proceeds from
ordinary shareholders of RMB11.3 million, partially offset by repayment of short-term bank borrowings of RMB55.8 million and
payments for share repurchases of RMB23.0 million.
Net cash provided by financing activities in 2018 was RMB972.7 million, consisting of proceeds from preferred shareholders of
RMB277.8 million and net proceeds from our initial public offering of RMB694.9 million.
97
Table of Contents
Capital Expenditures
We made capital expenditures of RMB14.8 million, RMB24.6 million and RMB25.8 million (US$4.0 million) in 2018, 2019
and 2020, respectively. In these periods, our capital expenditures were primarily used for purchases of property, equipment and software.
We will continue to make capital expenditures, including establishing more fulfillment centers to meet the expected growth of our
business.
Holding Company Structure
111, Inc. is a holding company with no material operations of its own. We conduct our operations primarily through our PRC
subsidiaries, our variable interest entities and their subsidiaries in China. As a result, 111, Inc.’s ability to pay dividends depends upon
dividends paid by our PRC subsidiaries. If our existing PRC subsidiaries or any newly formed ones incur debt on their own behalf in the
future, the instruments governing their debt may restrict their ability to pay dividends to us. In addition, 1 Pharmacy Technology, our
subsidiary in China is permitted to pay dividends to us only out of their retained earnings, if any, as determined in accordance with PRC
accounting standards and regulations. Under PRC law, each of our PRC subsidiaries and our variable interest entities in China is required
to set aside at least 10% of its after-tax profits each year, if any, to fund certain statutory reserve funds until such reserve funds reach 50%
of their registered capital. In addition, our subsidiaries in China and variable interest entities may allocate a portion of their after-tax
profits based on PRC accounting standards to a surplus fund at their discretion. The statutory reserve funds and the discretionary funds
are not distributable as cash dividends. Remittance of dividends by a foreign invested company out of China is subject to examination by
the banks designated by SAFE. Our PRC subsidiary, 1 Pharmacy Technology, has not paid dividends and will not be able to pay
dividends until they generate accumulated profits and meet the requirements for statutory reserve funds.
C. Research and Development, Patents and Licenses, etc.
See “Item 4. Information on the Company—B. Business Overview—Technology and IT Infrastructure” and “Item 4.
Information on the Company—B. Business Overview—Intellectual Property.”
D. Trend Information
Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or
events for the year ended December 31, 2020 that are reasonably likely to have a material and adverse effect on our net revenues,
income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily
indicative of future results of operations or financial conditions.
E. Off-Balance Sheet Commitments and Arrangements
We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third
parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are
not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets
transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable
interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging
or product development services with us.
F. Tabular Disclosure of Contractual Obligations
The following table sets forth our contractual obligations, including interest payments, as of December 31, 2020:
Operating lease commitments
Total
109,481
109,481
98
Total
Less than 1
year
1-3 years
(in RMB thousands)
47,608
47,608
41,893
41,893
More than 5
3-5 years
years
19,364
19,364
616
616
Table of Contents
Our operating lease commitments relate to our leases of certain offices and fulfillment centers. Our lease expenses for the years
ended December 31, 2018, 2019 and 2020 were RMB27.1 million, RMB29.7 million and RMB41.9 million (US$6.4 million),
respectively.
Other than those shown above, we did not have any significant capital and other commitments, long-term obligations or
guarantees as of December 31, 2020.
G. Safe Harbor
See “Forward-Looking Information” on page 3 of this annual report.
99
Table of Contents
Item 6. Directors, Senior Management and Employees
A. Directors and Executive Officers
The following table sets forth information regarding our directors and executive officers as of the date of this annual report.
Directors and Executive Officers
Gang Yu
Junling Liu
Leon Lian Yong Chen
Nee Chuan Teo
Jian Sun
Jun Luo
Age
61
56
58
50
57
53
Position/Title
Co-founder and Co-Chairman
Co-founder, Co-Chairman and Chief Executive Officer
Director
Independent Director
Independent Director
Independent Director
Dr. Gang Yu is our co-founder and has served as our executive chairman since 2015. Since September 2018, Dr. Yu has served
as our co-chairman. Dr. Yu has over 23 years of experience in the technology sector and 14 years of experience in the e-commerce
industry. He is a recipient of numerous prestigious international awards, including the 2002 Franz Edelman Management Science
Achievement Award from INFORMS and the 2012 Martin K. Starr Excellence in Production and Operations Management Practice
Award from POMS. Dr. Yu co-founded and served as chairman of YHD.com, a leading e-commerce company in China. Dr. Yu currently
serves as a director of Midea Group Co., Ltd. (SZSE: 000333), LightInTheBox Holding Co., Ltd. (NYSE: LITB) and Chindata Group
Holdings Limited (NASDAQ: CD), and as the co-chairman of the board of Zall Group (02098.HK). Prior to founding YHD.com, Dr. Yu
served as the vice president of Worldwide Procurement at Dell Inc. from 2006 to 2007 and the vice president of Worldwide Supply Chain
at Amazon.com from 2004 to 2006. Before Amazon, Dr. Yu was the chair professor at McCombs School of Business at The University
of Texas at Austin from 1989 to 2004. Dr. Yu received his bachelor’s degree in science from Wuhan University in 1982, master’s degree
in physics from Cornell University in 1986 and Ph.D. degree in decision sciences from The Wharton School of the University of
Pennsylvania in 1990. Dr. Yu has been a member of the Board of Overseers of The Wharton School of the University of Pennsylvania
since 2019. Dr. Yu has published 6 books and over 80 journal articles. Dr. Yu also holds three U.S. patents related to airline optimization
solutions.
Mr. Junling Liu is our co-founder and has served as our chairman and chief executive officer since 2015. Since September 2018,
Mr. Liu has served as our co-chairman. He co-founded and served as chief executive officer of YHD.com from 2008 to 2015. Prior to
founding YHD.com, Mr. Liu served as the global vice president and president for mainland China and Hong Kong at Dell Inc. from 2006
to 2007. He also held numerous executive positions at internationally renowned technology companies such as Avaya China, Openwave
Systems and Lucent Technologies Asia. Since January 2015, he has been an independent director of Autohome Inc. (NYSE: ATHM), the
leading online destination for automobile consumers. Mr. Liu also serves as an independent director of Hua Medicine (02552.HK).
Mr. Liu received his bachelor’s degree in education from Flinders University in Australia in 1991 and master’s degree in international
business administration from Flinders University in 1998.
100
Table of Contents
Dr. Leon Lian Yong Chen has served as our director since May 2019. He is currently the founding managing partner and CEO of
6 Dimensions Capital. He has over 20 years of experience in the life science industry in China and the United States as a venture
capitalist, senior management executive, entrepreneur, and scientific inventor. He was the founder and managing partner at Frontline Bio
Ventures and a partner at FIL Capital Management (Hong Kong) Limited in Asia from May 2008 to March 2014. Dr. Chen has been an
executive director and the chairman of the board of Ocumension Therapeutics since May 2018, a company listed on the Stock Exchange
(01477.HK). Since August 2018, he has served as a director at CStone Pharmaceuticals, a company listed on the main board of the Stock
Exchange (02616.HK). Since May 2018, he has served as a non-executive Director at Hua Medicine, a company listed on the main board
of the Stock Exchange (02552.HK). He served as a director of Shanghai Hile Bio-Pharmaceutical Co. Ltd., a company listed on the
Shanghai Stock Exchange (6037180.SS) since December 2014. Save as disclosed above, Dr. Lian Yong Chen is not and has not been a
director of any other listed companies in the past three years. Dr. Lian Yong Chen conducted postdoctoral research at the Massachusetts
Institute of Technology after obtaining his Ph.D. degree in Chemistry (with top honor) from the University of Louvain, Louvain-La-
Neuve in Belgium in July 1991. He obtained his Bachelor of Science degree in Chemistry from Peking University in June 1984.
Mr. Nee Chuan Teo has served as our independent director since September 2018. Mr. Teo is the chief financial officer of
Huazhu Group Limited (formerly China Lodging Group Limited, Nasdaq: HTHT), a leading fast-growing multi-brand hotel group in
China. Prior to joining Huazhu Group Limited, Mr. Teo served as chief financial officer of Rnomac International Group from 2011 to
2015, the largest Volvo construction equipment distributor in China. He also served as financial controller in Focus Media Group from
2007 to 2009. Mr. Teo received his bachelor of science in accounting and financial analysis from Warwick University, the United
Kingdom. He is a chartered certified accountant in the United Kingdom and a certified public accountant in the United States and Hong
Kong.
Mr. Jian Sun has served as our independent director since September 2018. Mr. Sun is an executive director and the general
manager of BTG Hotels (Group) Co., Ltd. (Shanghai Stock Exchange Stock Code: 600258), a top tourism service company in China.
Prior to joining BTG Hotels Group, Mr. Sun served as executive director and chief executive officer of Home Inns Group, a leading
economy hotel chain in China previously listed on Nasdaq, from 2004 to 2016. From 2010 to 2014, Mr. Sun served as independent
director, chairman of the compensation committee and a member of the audit committee of Mecox Lane Limited, an online platform for
apparel and accessories listed on Nasdaq. Since 2014, Mr. Sun has served as an independent director and a member of the compensation
committee of two companies listed on the New York Stock Exchange, including Leju Holdings Limited, a leading online-to-offline real
estate services provider in China, and eHi Car Services Limited, a leading car services and car rental provider in China. Mr. Sun holds a
bachelor’s degree from Shanghai Medical University in China.
Mr. Jun Luo has served as our independent director since September 2018. Mr. Luo is the co-founder and chief executive officer
of Tujia & Sweetome Group, a leading short-term property rental firm in China. Prior to co-founding Tujia & Sweetome Group, Mr. Luo
served as general manager of Shanghai SINA Leju and executive president at China Real Estate Information Corporation. Mr. Luo
received his bachelor’s degree in accounting from Shanghai University of Finance and Economics in 1994 and master’s degree in
software engineering from Beihang University in China in 2010.
B. Compensation
For the year ended December 31, 2020, we paid an aggregate of approximately RMB8.1 million (US$1.2 million) in cash and
other benefits to our directors and executive officers. For share incentive grants to our officers and directors, see “—Share Incentives.”
We have not set aside or accrued any amount to provide pension, retirement or other similar benefits to our executive officers and
directors. Our PRC subsidiaries are required by law to make contributions equal to certain percentages of each employee’s salary for his
or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing provident fund.
101
Table of Contents
Share Incentives
Share Incentive Policies
We adopted certain share incentive policies in December 2013 and August 2014, or the 2013 Policy and the 2014 Policy,
respectively, for the purpose of granting share based compensation awards to our officers, employees, directors, consultants and other
eligible persons to incentivize their performance and promote the success of our business.
Share Incentive Plans
2016 Plan
We adopted our 2016 Share Incentive Plan, or the 2016 Plan, in January 2016, to promote our success and the interests of our
shareholders by providing a means through which we may grant equity-based incentives to attract, motivate, retain and reward certain
officers, employees, directors, consultants and other eligible persons to further link the interests of recipients with those of our
shareholders generally. Since the adoption of the 2016 Plan, we stopped granting awards under the 2013 Policy or the 2014 Policy,
although the outstanding awards under the 2013 Policy and the 2014 Policy are still being administered under their respective policies.
The following paragraphs summarize the terms of the 2016 Plan.
Types of Awards. The 2016 Plan permits awards of options, share appreciation rights, restricted shares and restricted share units.
Plan Administration. The 2016 Plan will be administered by our board of directors or by a committee designated by our board
of directors. The committee or the full board of directors, as applicable, will determine the participants to receive awards, the type and
number of awards to be granted to each participant, and the terms and conditions of each award grant.
Award Agreement. Generally, awards granted under the 2016 Plan are evidenced by an award agreement that sets forth terms,
conditions and limitations for each award, which must be consistent with the plan.
Exercise Price. The plan administrator determines the exercise price for each award, which is stated in the award agreement.
Eligibility. We may grant awards only to those persons that the plan administrator determines to be eligible persons, which may
include our employees, directors and consultants.
Term of the Awards. The term of each award granted under the 2016 Plan may not exceed ten years from the date of the grant.
Vesting Schedule. In general, the plan administrator determines the vesting schedule, which is set forth in the award agreement.
Acceleration of Awards upon Change in Control. The plan administrator may determine, at the time of grant or thereafter, that
an award will become vested and exercisable, in full or in part, in the event that a change in control of our company occurs.
Transfer Restrictions. Awards may not be transferred in any manner by the recipient other than by will or the laws of descent
and distribution, except as otherwise provided by the plan administrator.
Termination. Unless terminated earlier, the 2016 Plan has a term of fifteen years.
102
Table of Contents
Under the 2013 Policy, the 2014 Policy and the 2016 Plan, the maximum aggregate number of shares which may be issued
pursuant to all awards is 13,671,109 ordinary shares. As of the date of this annual report, options to purchase a total of 7,235,287
ordinary shares and 60,000 restricted share units were granted and outstanding under the 2013 Policy, the 2014 Policy and the 2016 Plan.
2018 Plan
In August 2018, we adopted our 2018 Share Incentive Plan, or the 2018 Plan, which became effective on September 15, 2018,
one day after the completion of our initial public offering, replacing the 2016 Plan in its entirety. The 2018 Plan allows us to offer share-
based incentive awards to employees, officers, directors and individual consultants who render services to us. The 2018 Plan permits the
grant of options, restricted shares and restricted share units, or other types of awards, in the form of cash or otherwise, as approved by
our board of directors or a committee thereof. The maximum number of Class A ordinary shares that may be issued pursuant to all
awards under the 2018 Plan is 13,671,109, plus an annual increase on the first day of each fiscal year of our company during the ten-year
term of the 2018 Plan commencing with the fiscal year beginning January 1, 2019, by an amount equal to the lesser of (i) 1.0% of the
total number of shares issued and outstanding on the last day of the immediately preceding fiscal year, and (ii) such number of shares as
may be determined by our board of directors. Upon the effectiveness of the 2018 Plan, we no longer grant any awards under the 2016
Plan. Outstanding awards granted under the 2016 Plan will remain effective and be subject to the terms and conditions of the 2018 Plan.
As of the date of this annual report, options to purchase a total of 2,319,697 Class A ordinary shares and 4,447,828 restricted share units
were granted and outstanding under the 2018 Plan. The following paragraphs summarize the terms of the 2018 Plan:
Plan Administration. Our board of directors, or a committee designated by our board of directors, will administer the plan. The
plan administration committee will determine the provisions and terms and conditions of each grant.
Award Agreements. Options and other awards granted under the plan are evidenced by an award agreement that sets forth the
terms, conditions and limitations for each grant, which may include the term of the award and the provisions applicable in the event the
grantee’s employment or service terminates.
Exercise Price. The exercise price of an option will be determined by the plan administration committee, which may be a fixed
price or a variable price related to the fair market value on the grant date of the respective option. The exercise price of granted options
may be amended or adjusted in the absolute discretion of the plan administration committee without the approval of our shareholders or
the recipients of the options.
Eligibility. We may grant awards to employees, directors and consultants of our company and our majority-owned subsidiaries
as determined by the plan administration committee.
Vesting Schedule. In general, the plan administration committee determines the vesting schedule, which is specified in the
relevant award agreement.
Acceleration of Awards upon Change in Control. If a change-of-control corporate transaction occurs, the plan administration
committee may, in its sole discretion, provide for (i) all awards outstanding to terminate at a specific time in the future and give each
participant the right to exercise the vested portion of such awards during a specific period of time, or (ii) the purchase of any award for
an amount of cash equal to the amount that could have been attained upon the exercise of such award, or (iii) the replacement of such
award with other rights or property selected by the plan administration committee in its sole discretion, or (iv) payment of award in cash
based on the value of ordinary shares on the date of the change-of-control corporate transaction plus reasonable interest.
Term of the Options. The term of each option grant shall be stated in the award agreement, provided that the term shall not
exceed ten years from the date of the grant.
Transfer Restrictions. Subject to certain exceptions, awards may not be transferred by the recipient.
Termination of the Plan. The 2018 Plan shall terminate in 2028, provided that our board of directors may terminate the plan at
any time and for any reason.
103
Table of Contents
Our Employee Share Holding Platform
In November 2014, we established Gold Prized Investment Limited, or Gold Prized, a company incorporated in the British
Virgin Islands, as an offshore employee shareholding platform to allow our employees in China to receive share incentives.
Gold Prized is wholly owned by Shanghai Yiyao Enterprise Management Partners, or Yiyao Partners, a limited partnership
formed in the PRC and owned by Ms. Jing Liu (0.81%), a family member of Mr. Junling Liu, and Ms. Ying Song (99.19%), a family
member of Dr. Gang Yu. Ms. Ying Song is the general partner while Ms. Jing Liu is the sole limited partner of Yiyao Partners.
We issued class C ordinary shares to Gold Prized, and did not grant any rights associated with the class C ordinary shares held
by Gold Prized to our directors and executive officers or any other employees. We have transferred the class C ordinary shares issued to
Gold Prized back to our company and have reserved those shares for the 2016 Plan. Gold Prized has since ceased to be a shareholder of
our company.
1 Pharmacy Technology Share Incentive Plan
In November 2020, our subsidiary, 1 Pharmacy Technology issued 32,500,000 ordinary shares to 13 limited liability
partnerships (“LLPs”) founded by the employees of 1 Pharmacy Technology with the total consideration of RMB32.5 million. The shares
issued to the employees in each LLP are not outstanding shares but are restricted with 50% of the shares vesting within two years from
the issuance date and the remaining 50% vesting evenly on an annual basis over the two years thereafter, which are also subject to
adjustment based on performance condition. Such arrangement was entered into to provide a share incentive plan to the employees of 1
Pharmacy Technology. For more details, see Notes 13 and 16 to our consolidated financial statements included elsewhere in this annual
report.
The following table summarizes, as of the date of this annual report, the outstanding share incentive awards we have granted to
our directors and executive officers under the 2013 Policy, the 2014 Policy, the 2016 Plan and the 2018 Plan:
Ordinary
Shares
Underlying
Outstanding
Share
Incentive
Awards
Exercise
Price
($/Share)
*
†
*
*
*
*
*
1,541,464
†
†
†
†
†
Name
Gang Yu
Junling Liu
Leon Lian Yong Chen
Nee Chuan Teo
Jian Sun
Jun Luo
All directors and executive officers as a group
* Less than one percent of our total outstanding shares.
† Restricted share units.
104
Grant Date
4/13/2020
5/13/2020
6/13/2020
7/13/2020 and
Expiration
Date
4/12/2030
5/12/2030
6/12/2030
7/12/2030
1/1/2021 12/31/2030
4/12/2030
5/12/2030
6/12/2030
7/12/2030
5/12/2030
5/31/2029
9/11/2028
9/11/2028
9/11/2028
4/13/2020
5/13/2020
6/13/2020 and
7/13/2020
5/13/2020
6/1/2019
9/12/2018
9/12/2018
9/12/2018
Table of Contents
C. Board Practices
Board of Directors
Our board of directors consists of six directors. A director is not required to hold any shares in our company to qualify to serve
as a director. A director who is in any way, whether directly or indirectly, interested in a contract or transaction or proposed contract or
transaction with our company is required to declare the nature of his interest at a meeting of our directors. A director may vote with
respect to any contract or transaction or proposed contract or transaction notwithstanding that he may be interested therein, and if he does
so his vote shall be counted and he may be counted in the quorum at any meeting of our directors at which any such contract or
transaction is considered. Our directors may exercise all the powers of our company to borrow money, mortgage or charge its
undertaking, property and uncalled capital and to issue debentures or other securities whenever money is borrowed or as security for any
debt, liability or obligation of our company or of any third party.
Committees of the Board of Directors
We have three committees under the board of directors: an audit committee, a compensation committee and a nominating and
corporate governance committee. We have adopted a charter for each of the three committees. Each committee’s members and functions
are described below.
105
Table of Contents
Audit Committee
Our audit committee consists of Nee Chuan Teo, Jian Sun and Jun Luo, and is chaired by Nee Chuan Teo. Nee Chuan Teo, Jian
Sun and Jun Luo each satisfies the “independence” requirements of Rule 5605(c)(2) of the Nasdaq Stock Market Rules and meet the
independence standards under Rule 10A-3 under the Exchange Act. We have determined that Nee Chuan Teo qualifies as an “audit
committee financial expert.” The audit committee oversees our accounting and financial reporting processes and the audits of the
financial statements of our company. The audit committee is responsible for, among other things:
● selecting the independent registered public accounting firm and pre-approving all auditing and non-auditing services
permitted to be performed by the independent registered public accounting firm;
● reviewing with the independent auditors any audit problems or difficulties and management’s response;
● reviewing and approving all proposed related party transactions, as defined in Item 404 of Regulation S-K under the
Securities Act;
● discussing the annual audited financial statements with management and the independent registered public accounting firm;
● reviewing major issues as to the adequacy of our internal controls and any special audit steps adopted in light of material
control deficiencies;
● annually reviewing and reassessing the adequacy of our audit committee charter;
● meeting separately and periodically with management and the independent registered public accounting firm; and
● reporting regularly to the board.
Compensation Committee
Our compensation committee consists of Gang Yu, Nee Chuan Teo and Jian Sun, and is chaired by Gang Yu. Nee Chuan Teo
and Jian Sun each satisfies the “independence” requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The compensation
committee assists the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our
directors and executive officers. Our chief executive officer may not be present at any committee meeting during which his compensation
is deliberated upon. The compensation committee is responsible for, among other things:
● reviewing the total compensation package for our executive officers and making recommendations to the board with
respect to it;
● reviewing the compensation of our non-employee directors and making recommendations to the board with respect to it;
and
● periodically reviewing and approving any long-term incentive compensation or equity plans, programs or similar
arrangements, annual bonuses, and employee pension and welfare benefit plans.
106
Table of Contents
Nominating and Corporate Governance Committee
Our nominating and corporate governance committee consists of Junling Liu, Jian Sun and Jun Luo, and is chaired by Junling
Liu. Jian Sun and Jun Luo each satisfies the “independence” requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The
nominating and corporate governance committee assists the board in selecting individuals qualified to become our directors and in
determining the composition of the board and its committees. The nominating and corporate governance committee is responsible for,
among other things:
● recommending nominees to the board for election or re-election to the board, or for appointment to fill any vacancy on the
board;
● reviewing annually with the board the current composition of the board with regards to characteristics such as
independence, age, skills, experience and availability of service to us;
● selecting and recommending to the board the names of directors to serve as members of the audit committee and the
compensation committee, as well as of the nominating and corporate governance committee itself; and
● monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness
of our procedures to ensure proper compliance.
Terms of Directors and Executive Officers
Our board of directors may, by the affirmative vote of a simple majority of the remaining directors present and voting at a
meeting of our board, which shall include the affirmative vote of at least one Founder as long as either Founder is a director, appoint any
person as a director, to fill a vacancy on the board arising from the office of any director being vacated. Our shareholders may also
appoint any person to be a director by way of ordinary resolution. Our directors are not subject to a term of office and hold office until
such time as they are removed from office by ordinary resolution of the shareholders. A director will cease to be a director if, among
other things, the director (i) becomes bankrupt or makes any arrangement or composition with his creditors; (ii) dies or is found by our
company to be or becomes of unsound mind, (iii) resigns his office by notice in writing to the company, or (iv) without special leave of
absence from our board, is absent from three consecutive board meetings and our directors resolve that his office be vacated.
Our founders serve as co-chairmen of our board of directors. For so long as each of our founders is a director of our company,
he shall be a co-chairman of our board of directors, until he resigns as co-chairman or ceases to be a director (in which event he shall
automatically cease to be a co-chairman). If either founder ceases to be a co-chairman, the other founder shall continue as the sole
chairman of our board (unless our board, with the consent of the other founder, elects and appoints another director to be another co-
chairman). Upon both founders ceasing to be co-chairmen or chairman, our board shall elect and appoint the co-chairmen or chairman at
their discretion.
Subject to the foregoing, our officers are elected by and serve at the discretion of our board of directors.
Employment Agreements and Indemnification Agreements
We have entered into employment agreements with our senior executive officers. Pursuant to these agreements, we are entitled
to terminate a senior executive officer’s employment for cause at any time without remuneration for certain acts of the officer, such as
being convicted of any criminal conduct, any act of gross or willful misconduct or any serious, willful, grossly negligent or persistent
breach of any employment agreement provision, or engaging in any conduct which may make the continued employment of such officer
detrimental to our company. In connection with the employment agreements, each senior executive officer agrees to hold all information,
know-how and records in any way connected with the products of our company, including, without limitation, all software and computer
formulas, designs, specifications, drawings, data, manuals and instructions and all customer and supplier lists, sales and financial
information, business plans and forecasts, all technical solutions and the trade secrets of our company, in strict confidence perpetually.
Each officer also agrees that we shall own all the intellectual property developed by such officer during his or her employment.
107
Table of Contents
We have entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we
agree to indemnify them against certain liabilities and to reimburse them for expenses in connection with claims made by reason of their
being a director or officer of our company.
D. Employees
The following table sets forth the numbers of our employees categorized by function as of December 31, 2020.
Functions:
Wholesale pharmacy business
Retail pharmacy business
Supply chain
Procurement
Research and development and IT
General and administrative
Total
As of December 31, 2020
Number
% of Total
1,198
220
144
227
292
108
2,189
54.7
10.1
6.6
10.4
13.3
4.9
100
As required by laws and regulations in China, we participate in various employee social security plans that are organized by
municipal and provincial governments including, among other things, pension, medical insurance, unemployment insurance, maternity
insurance, on-the-job injury insurance and housing fund plans through a PRC government-mandated benefit contribution plan. We are
required under PRC law to make contributions to employee benefit plans at specified percentages of the salaries, bonuses and certain
allowances of our employees, up to a maximum amount specified by the local government from time to time.
We typically enter into standard employment agreements and confidentiality agreements or clauses with our senior management
and core personnel. These contracts include a standard non-compete covenant that prohibits the employee from competing with us,
directly or indirectly, during his or her employment and for two years after termination of his or her employment.
We maintain a good working relationship with our employees and the labor union in Guangzhou, and we have not experienced
any material labor disputes.
E. Share Ownership
The following table sets forth information with respect to the beneficial ownership of our shares as of March 31, 2021 by:
● each of our current directors and executive officers; and
● each person known to us to own beneficially more than 5% of our shares.
The calculations in the table below are based on 165,746,714 ordinary shares outstanding as of March 31, 2021, comprising of
(i) 93,746,714 Class A ordinary shares, and (ii) 72,000,000 Class B ordinary shares.
108
Table of Contents
Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares
beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to
acquire within 60 days after March 31, 2021, including through the exercise of any option, warrant or other right or the conversion of any
other security. These shares, however, are not included in the computation of the percentage ownership of any other person.
Directors and Executive Officers:*
Gang Yu(1)(9)
Junling Liu(2)(7)
Leon Lian Yong Chen(3)
Nee Chuan Teo(4)
Jian Sun(5)
Jun Luo(6)
All directors and executive officers as a group
Principal Shareholders:
Sunny Bay Global Limited(7)
ClearVue Partners, L.P.(8)
Infinity Cosmo Limited(9)
First Pharmacia International(10)
Notes:
Class A
Ordinary
Shares
Class B
Ordinary
Shares
Percentage
of total
ordinary
shares on an
as-converted
basis
Percentage
of aggregate
voting
power†
—
1,066,686
—
—
**
—
1,101,686
36,000,000
36,000,000
—
—
**
—
72,000,000
—
18,946,636
—
8,690,562
36,000,000
—
11,494,252
—
21.7
22.4
—
—
**
—
44.1
21.7
11.4
6.9
5.2
46.0
46.1
—
—
**
—
92.1
46.0
1.5
14.7
0.7
* Except for Dr. Leon Lian Yong Chen, Mr. Nee Chuan Teo, Mr. Jian Sun and Mr. Jun Luo, the business address of our directors and
executive officers is 3-5/F, No. 295 ZuChongZhi Road, Pudong New Area, Shanghai, the People’s Republic of China.
** Less than 1% of our total outstanding shares.
† For each person or group included in this column, percentage of aggregate voting power represents voting power based on both
Class A and Class B ordinary shares held by such person or group with respect to all outstanding shares of our Class A and Class B
ordinary shares as a single class. Each holder of our Class A ordinary shares is entitled to one vote per share. Each holder of our
Class B ordinary shares is entitled to fifteen votes per share. Our Class B ordinary shares are convertible at any time by the holder
into Class A ordinary shares on a one-for-one basis.
(1) Represents 24,505,748 Class B ordinary shares held by Dr. Gang Yu, and 11,494,252 Class B ordinary shares held by Infinity
Cosmo Limited, a company incorporated in the British Virgin Islands. Infinity Cosmo Limited is controlled by Gang Yu Irrevocable
Trust.
(2) Represents 1,066,686 Class A ordinary shares held by Mr. Junling Liu and 36,000,000 Class B ordinary shares held by Sunny Bay
Global Limited, a company incorporated in the British Virgin Islands. Sunny Bay Global Limited is wholly owned by Mr. Liu.
(3) The business address of Dr. Leon Lian Yong Chen is Block 6, No. 999 Huanke Road, Pudong New District, Shanghai, China.
(4) The business address of Mr. Nee Chuan Teo is 2266, HongQiao Road, Shanghai, China.
(5) The business address of Mr. Jian Sun is 124 Caobao Road, Xuhui District, Shanghai, China.
(6) The business address of Mr. Jun Luo is Room 101, K Unit, No. 8 Liuying Road, Hongkou District, Shanghai, China.
109
Table of Contents
(7) Represents 36,000,000 Class B ordinary shares held by Sunny Bay Global Limited, a company incorporated in the British Virgin
Islands. Sunny Bay Global Limited is wholly owned by Mr. Junling Liu. The registered office address of Sunny Bay Global Limited
is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.
(8) Beneficial ownership calculation is based solely on a review of a Schedule 13G filed with the SEC on February 5, 2021. Represents
(i) 15,100,646 Class A ordinary shares and (ii) 1,922,995 ADSs (representing 3,845,990 Class A ordinary shares) held by ClearVue
YW Holdings, Ltd. ClearVue YW Holdings, Ltd. is wholly owned by ClearVue Partners, L.P., and as such, ClearVue Partners, L.P.
may exercise voting and dispositive power over these shares held by ClearVue YW Holdings, Ltd. ClearVue Partners GP, L.P. is the
general partner of ClearVue Partners, L.P., and as such, may exercise voting and dispositive power over the shares held by ClearVue
YW Holdings, Ltd. by way of ClearVue Partners, L.P. and the shares held by ClearVue Partners, L.P. ClearVue Partners Ltd. is the
general partner of ClearVue Partners GP, L.P., and as such, may exercise voting and dispositive power over the shares held by
ClearVue YW Holdings, Ltd. and ClearVue Partners, L.P. by way of ClearVue Partners GP, L.P. The registered office address of
ClearVue YW Holdings, Ltd. is Harneys Services (Cayman) Limited, 4th Floor, Harbour Place, 103 South Church Street, George
Town, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands.
(9) Represents 5,747,126 ADSs (representing 11,494,252 Class B ordinary shares) held by Infinity Cosmo Limited, a company
incorporated in the British Virgin Islands. Infinity Cosmo Limited is controlled by Gang Yu Irrevocable Trust, a trust managed by
Zedra Asia Limited, as the trustee. Dr. Gang Yu is the settlor of the Gang Yu Irrevocable Trust, and Dr. Yu’s family members are the
trust’s beneficiaries. Under the terms of this trust, a family member of Gang Yu has the power to direct the trustee with respect to the
disposal of, and the exercise of any voting and other rights attached to, the shares held by Infinity Cosmo Limited in our company.
The registered office address of Infinity Cosmo Limited is Sertus Chambers, P.O. Box 905, Quastisky Building, Road Town, Tortola,
British Virgin Islands.
(10) Represents 4,345,281 ADSs (representing 8,690,562 Class A ordinary shares) directly held by First Pharmacia International, a
Cayman Islands exempted company. First Pharmacia International is held by BVCF III L.P. (92.38%) and BVCF III-A L.P. (7.62%),
each a Cayman Islands exempted limited partnership. The registered office address of First Pharmacia International is Walkers
Corporate Limited, Cayman Corporate Centre, 27 Hospital Road, George Town, Grand Cayman, KY1-9008, Cayman Islands.
Our ordinary shares are divided into Class A ordinary shares and Class B ordinary shares. Holders of Class A ordinary shares
are entitled to one vote per share, while holders of Class B ordinary shares are entitled to fifteen votes per share. We issued Class A
ordinary shares represented by the ADSs in our initial public offering in September 2018. Holders of our Class B ordinary shares may
choose to convert their Class B ordinary shares into the same number of Class A ordinary shares at any time. Class A ordinary shares are
not convertible into Class B ordinary shares under any circumstance.
To our knowledge, as of March 31, 2021, a total of 118,646,062 ordinary shares, representing approximately 71.6% of our total
outstanding ordinary shares, were held by two record shareholders in the United States, including The Bank of New York Mellon, the
depositary of our ADS program. The number of beneficial owners of our ADSs in the United States is likely to be much larger than the
number of record holders of our ordinary shares in the United States.
Except for the above, we are not aware of any arrangement that may, at a subsequent date, result in a change of control of our
company.
Item 7. Major Shareholders and Related Party Transactions
A. Major Shareholders
Please refer to “Item 6. Directors, Senior Management and Employees—E. Share Ownership.”
110
Table of Contents
B. Related Party Transactions
Contractual Arrangements with Our Variable Interest Entities and Their Shareholders
PRC laws and regulations currently restrict foreign ownership and investment in value-added telecommunications services
(except for e-commerce) in China. As a result, we operate our relevant business through our variable interest entities and their
subsidiaries based on a series of contractual arrangements. For a description of these contractual arrangements, see “Item 4. Information
on the Company—C. Organizational Structure—Contractual Arrangements with Our Variable Interest Entities.”
Shareholders Agreement
We entered into our tenth amended and restated shareholders agreement on June 19, 2018 with our then-existing shareholders.
The shareholders agreement provides for board representation rights to certain shareholders, which terminated upon our initial public
offering. The shareholders agreement also provides for certain information and inspection rights, board observer rights, preferential
rights, including right of participation, right of first refusal, co-sale rights and redemption rights. All information and inspection rights
and preferential rights terminated upon our initial public offering.
Registration Rights
Pursuant to our current shareholders agreement, we have granted certain registration rights to our shareholders. Set forth below
is a description of the registration rights granted under the agreement.
Demand Registration Rights. At any time after six months following a QIPO as defined in the shareholders agreement, holders
of at least 25% of our registrable securities have the right to demand in writing that we file a registration statement covering the
registration of their registrable securities. We have the right to defer filing of a registration statement for a period of not more than 90
days if our board of directors determines in good faith that filing of a registration statement in the near future will be materially
detrimental to us and our shareholders, but we cannot exercise the deferral right more than once during any twelve-month period. We are
not obligated to effect more than two demand registrations. Further, if the registrable securities are offered by means of an underwritten
offering, and the underwriters advise us in writing that marketing factors require a limitation of the number of share to be underwritten,
the underwriters may reduce as required and allocate the shares to be included in the registration statement among holders of our
registrable securities on a pro rata basis, subject to certain limitations.
Piggyback Registration Rights. If we propose to file a registration statement for a public offering of our securities, we must offer
holders of our registrable securities an opportunity to be included in such registration. If the underwriters determine in good faith that
marketing factors require a limitation of the number of shares to be underwritten, the registrable securities shall allocate first to us,
second, to each holder of our registrable securities requesting inclusion of their registrable securities pursuant to the piggyback
registration, on a pro rata basis, and third, to other holders of our securities.
Form F-3 or Form S-3 Registration Rights. After our initial public offering, we shall use our best efforts to qualify for
registration on Form F-3 or Form S-3. Holders of 10% or more of our registrable securities may request us in writing to file a registration
statement on Form F-3 or Form S-3 if we qualify for registration on such forms, subject to certain limitations. We have the right to defer
filing for a period of not more than 60 days if our board of directors determines in good faith that effecting registration at such time
would be materially detrimental to us and our shareholders, but we cannot exercise the deferral right more than once during any twelve-
month period, and we may not register any of our other shares during such 60-day period. The holders of our registrable securities are
entitled to an unlimited number of registrations on Form F-3 or Form S-3. We, however, are not obligated to effect such registration if we
have effected two such registrations within any twelve-month period.
111
Table of Contents
Expenses of Registration. We will bear all registration expenses, other than underwriting discounts and selling commissions
applicable to the sale of registrable securities, incurred in connection with registrations, filings or qualification pursuant to the
shareholders agreement. We will not be required to pay for any expenses of any registration proceeding begun pursuant to demand
registration rights, unless subject to certain exception, if the registration request is subsequently withdrawn at the request of a majority of
the holders of the registrable securities to be registered.
Termination of Obligations. We have no obligation to effect any demand, piggyback or Form F-3 or Form S-3 registration upon
the earlier of (i) the fifth anniversary from the date of closing of a QIPO, (ii) a Trade Sale as defined in the shareholders agreement, and
(iii) with respect to any holder of our registrable securities, the date following a QIPO on which such holder holds less than 1% of our
total outstanding share capital.
Employment Agreements and Indemnification Agreements
See “ Item 6—Directors, Senior Management and Employees—C. Board Practices”
Share Incentive Plans
See “ Item 6. Directors, Senior Management and Employees—B. Compensation”
Transactions with Other Related Parties
In September 2018, we purchased electronic equipment for RMB157,000 from Zhejiang Youzhan Information Technology
Co., Ltd., an entity controlled by our chief operating officers. No similar purchases were made in 2019 or 2020.
C. Interests of Experts and Counsel
Not applicable.
Item 8. Financial Information
A. Consolidated Statements and Other Financial Information
We have appended consolidated financial statements filed as part of this annual report.
Legal Proceedings
We are currently not a party to any material legal or administrative proceedings. We may from time to time be subject to various
legal or administrative claims and proceedings arising in the ordinary course of business. Litigation or any other legal or administrative
proceeding, regardless of the outcome, is likely to result in substantial cost and diversion of our resources, including our management’s
time and attention.
Dividend Policy
We have not previously declared or paid cash dividends and we have no plan to declare or pay any dividends in the near future
on our shares. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our
business.
We are a holding company incorporated in the Cayman Islands. We rely principally on dividends from our PRC subsidiaries for
our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC
subsidiaries to pay dividends to us. See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—We
rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may
have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material adverse effect on our ability
to conduct our business.”
112
Table of Contents
Our board of directors has discretion as to whether to distribute dividends, subject to certain restrictions under Cayman Islands
law, namely that our company may only pay dividends either out of profits or share premium account, and provided always that in no
circumstances may a dividend be paid if this would result in our company being unable to pay its debts as they fall due in the ordinary
course of business. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount
recommended by our board of directors. Even if our board of directors decides to pay dividends, the form, frequency and amount will
depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions
and other factors that the board of directors may deem relevant. If we pay any dividends on our ordinary shares, we will pay those
dividends which are payable in respect of the Class A ordinary shares underlying ADSs to the depositary, as the registered holder of such
Class A ordinary shares, and the depositary will then pay such amounts to ADS holders in proportion to the Class A ordinary shares
underlying the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable
thereunder. See “Item 12. Description of Securities Other Than Equity Securities—D. American Depositary Shares.” Cash dividends on
our ordinary shares, if any, will be paid in U.S. dollars.
B. Significant Changes
Except as disclosed elsewhere in this annual report, we have not experienced any significant changes since the date of our
audited consolidated financial statements included in this annual report.
Item 9. The Offer and Listing
A. Offering and Listing Details
Our ADSs, each representing two Class A ordinary shares, have been listed on The Nasdaq Global Market under the symbol
“YI” since September 12, 2018.
B. Plan of Distribution
Not applicable.
C. Markets
The ADSs have been listed on Nasdaq since September 12, 2018 under the symbol “YI.”
D. Selling Shareholders
Not applicable.
E. Dilution
Not applicable.
F. Expenses of the Issue
Not applicable.
Item 10. Additional Information
A. Share Capital
Not applicable.
113
Table of Contents
B. Memorandum and Articles of Association
We are a Cayman Islands exempted company and our affairs are governed by our memorandum and articles of association and
the Companies Act (As Revised) of the Cayman Islands, referred to as the Companies Act below, and the common law of the Cayman
Islands. The following are summaries of material provisions of our twelfth amended and restated memorandum and articles of
association, as well as the Companies Act insofar as they relate to the material terms of our ordinary shares.
Registered Office and Objects
Our registered office in the Cayman Islands is located at the offices of Vistra (Cayman) Limited, P.O. Box 31119, Grand
Pavilion Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205, Cayman Islands. Our agent for service of process in the United
States is Puglisi & Associates. The objects of our company are unrestricted and we have the full power and authority to carry out any
object not prohibited by the law of the Cayman Islands.
Board of Directors
See “Item 6. Directors, Senior Management and Employees—C. Board Practices—Board of Directors.”
Ordinary Shares
General
Our ordinary shares are divided into Class A ordinary shares and Class B ordinary shares. Holders of our Class A ordinary
shares and Class B ordinary shares will have the same rights except for voting and conversion rights, as described below. All of our
outstanding ordinary shares are fully paid and non-assessable. Certificates representing the ordinary shares are issued in registered form.
Our ordinary shares are issued in registered form and are issued when registered in our register of members. Our shareholders who are
non-residents of the Cayman Islands may freely hold and vote their ordinary shares. Our company will issue only non-negotiable shares,
and will not issue bearer or negotiable shares.
Conversion
Each Class B ordinary share may be converted into one Class A ordinary share at any time at the option of the holder thereof,
while Class A ordinary shares cannot be converted into Class B ordinary shares under any circumstances.
Upon any sale, transfer, assignment or disposition of any Class B ordinary share by our Founders (defined in our memorandum
and articles of association to mean Dr. Gang Yu and Mr. Junling Liu) or Founder Affiliate (as defined in our memorandum and articles of
association) to any person who is not a “Founder Affiliate,” or upon a change of ultimate beneficial ownership of any Class B ordinary
share to any person who is not a Founder Affiliate, such Class B ordinary share shall be automatically and immediately converted into
one Class A ordinary share. However, the creation of any pledge, charge, encumbrance or other third party right on any Class B ordinary
share to secure a holder’s contractual or legal obligations shall not be deemed as a sale, transfer, assignment or disposition unless and
until any such pledge, charge, encumbrance or other third party right is enforced and results in the third party holding legal title to the
relevant Class B ordinary shares, in which case all the related Class B ordinary shares shall be automatically converted into the same
number of Class A ordinary shares.
Furthermore, if at any time the Founders and the Founder Affiliates collectively own less than 5% of the total number of the
issued and outstanding shares of our company, all of the issued and outstanding Class B ordinary shares shall be automatically converted
into the same number of Class A ordinary shares.
Register of Members
Under Cayman Islands law, we must keep a register of members and there should be entered therein:
● the names and addresses of the members, a statement of the shares held by each member, and of the amount paid or agreed
to be considered as paid, on the shares of each member;
114
Table of Contents
● confirm the number and category of shares held by each member, and confirm whether each relevant category of shares
held by a member carries voting rights under the articles of association of the company, and if so, whether such voting
rights are conditional;
● the date on which the name of any person was entered on the register as a member; and
● the date on which any person ceased to be a member.
Under Cayman Islands law, the register of members of our company is prima facie evidence of the matters set out therein (i.e.,
the register of members will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the
register of members is deemed as a matter of Cayman Islands law to have legal title to the shares as set against its name in the register of
members. Once our register of members has been updated, the shareholders recorded in the register of members should be deemed to
have legal title to the shares set against their name.
If the name of any person is incorrectly entered in or omitted from our register of members, or if there is any default or
unnecessary delay in entering on the register the fact of any person having ceased to be a member of our company, the person or member
aggrieved (or any member of our company or our company itself) may apply to the Cayman Islands Grand Court for an order that the
register be rectified, and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for
the rectification of the register.
Dividends
The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors or shareholders in
a general meeting (provided always that dividends may be declared and paid only out of funds legally available therefor, namely out of
either profit or our share premium account, and provided further that a dividend may not be paid if this would result in our company
being unable to pay its debts as they fall due in the ordinary course of business). Our shareholders may by ordinary resolution declare a
dividend, but no dividend may exceed the amount recommended by our board of directors.
Voting Rights
Holders of ordinary shares have the right to receive notice of, attend, speak and vote at general meetings of our company.
Holders of Class A ordinary shares and Class B ordinary shares shall, at all times, vote together as one class on all matters submitted to a
vote by the members at any general meeting of our company. Each Class A ordinary share shall entitle the holder thereof to one vote on
all matters subject to the vote at general meetings of our company, and each Class B ordinary share shall entitle the holder thereof to
fifteen votes on all matters subject to the vote at general meetings of our company. Voting at any meeting of shareholders is by show of
hands unless a poll is demanded. A poll may be demanded by the chairman of such meeting or any one shareholder present in person or
by proxy.
Maples and Calder (Hong Kong) LLP, our counsel as to Cayman Islands law, has advised that such voting structure is in
compliance with current Cayman Islands law as in general terms, a company and its shareholders are free to provide in the articles of
association for such rights as they consider appropriate, subject to such rights not being contrary to any provision of the Companies Act
and not inconsistent with common law. Maples and Calder (Hong Kong) LLP has confirmed that the inclusion in our memorandum and
articles of association of provisions giving weighted voting rights to specific classes of shareholders generally or to specific classes of
shareholders on specific resolutions is not prohibited by the Companies Act. Further, weighted voting provisions have been held to be
valid as a matter of English common law and therefore it is expected that such would be upheld by a Cayman Islands court.
An ordinary resolution to be passed by the shareholders requires the affirmative vote of a simple majority of the votes attached
to the ordinary shares cast by those shareholders who are present in person or by proxy at a general meeting, while a special resolution
requires the affirmative vote of no less than two-thirds of the votes attached to the ordinary shares cast by those shareholders who are
present in person or by proxy at a general meeting. Both ordinary resolutions and special resolutions may also be passed by a unanimous
written resolution signed by all the shareholders of our company, as permitted by the Companies Act and our memorandum and articles
of association. A special resolution will be required for important matters such as a change of name or making changes to our
memorandum and articles of association.
115
Table of Contents
Transfer of Ordinary Shares
Any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or
common form or any other form approved by our board of directors. However, our board of directors may, in its absolute discretion,
decline to register any transfer of any ordinary share which is not fully paid up or on which our company has a lien. Our board of
directors may also decline to register any transfer of any ordinary share unless:
● the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and
such other evidence as our board of directors may reasonably require to show the right of the transferor to make the
transfer;
● the instrument of transfer is in respect of only one class of shares;
● the instrument of transfer is properly stamped, if required;
● any fee related to the transfer has been paid to us; and
● in the case of a transfer to joint holders, the transfer is not to more than four joint holders.
If our directors refuse to register a transfer, they are required, within three calendar months after the date on which the
instrument of transfer was lodged, to send to each of the transferor and the transferee notice of such refusal. The registration of transfers
of shares may, on ten calendar days’ notice being given by advertisement in such one or more newspapers, by electronic means or by any
other means in accordance with the relevant code, rules and regulations of the Nasdaq Global Market, be suspended and the register of
members closed at such times and for such periods (not exceeding thirty calendar days in any calendar year) as our directors may
determine.
Liquidation
On a return of capital on winding up or otherwise (other than on conversion, redemption or purchase of ordinary shares), assets
available for distribution among the holders of ordinary shares will be distributed among the holders of the ordinary shares on a pro rata
basis. If our assets available for distribution are insufficient to repay all of the paid-up capital, the assets will be distributed so that the
losses are borne by our shareholders proportionately. We are a “limited liability” company registered under the Companies Act, and
under the Companies Act, the liability of our members is limited to the amount, if any, unpaid on the shares respectively held by them.
Our memorandum and articles of association contains a declaration that the liability of our members is so limited.
Calls on Ordinary Shares and Forfeiture of Ordinary Shares
Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their ordinary shares.
The ordinary shares that have been called upon and remain unpaid are subject to forfeiture.
116
Table of Contents
Redemption, Repurchase and Surrender of Ordinary Shares
We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders thereof, on
such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by a special resolution
of our shareholders. Our company may also repurchase any of our shares provided that the manner and terms of such purchase have been
approved by our board of directors or by an ordinary resolution of our shareholders or are otherwise authorized by our memorandum and
articles of association. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company’s profits or
out of the proceeds of a fresh issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share
premium account and capital redemption reserve) if our company can, immediately following such payment, pay its debts as they fall
due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a) unless it
is fully paid up, (b) if such redemption or repurchase would result in there being no shares outstanding, or (c) if the company has
commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.
Variations of Rights of Shares
If at any time, our share capital is divided into different classes of shares, all or any of the rights attached to any class of shares
may, subject to any rights or restrictions for the time being attached to any class, only be materially adversely varied with the consent in
writing of the holders of two-thirds of the issued shares of that class or with the sanction of a special resolution passed at a separate
meeting of the holders of shares of that class. The rights conferred upon the holders of the shares of any class issued with preferred or
other rights will not, subject to any rights or restrictions for the time being attached to the shares of that class, be deemed to be materially
adversely varied by, inter alia, the creation, allotment or issue of further shares ranking pari passu with or subsequent to them or the
redemption or purchase of any shares of any class by our company. The rights of the holders of shares shall not be deemed to be
materially adversely varied by the creation or issue of shares with preferred or other rights including, without limitation, the creation of
shares with enhanced or weighted voting rights.
General Meetings of Shareholders and Shareholder Proposals
As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders’ annual general
meetings.
Shareholders’ annual general meetings and any other general meetings of our shareholders may be convened by the chairman of
our board of directors, or any co-chairman of our board of directors, or by a majority of our board of directors. Advance notice of at least
ten calendar days is required for the convening of our annual general shareholders’ meeting and any other general meeting of our
shareholders. A quorum required for a general meeting of shareholders consists of one or more shareholders present in person or by
proxy (or, if a corporation or other non-natural person, by its duly authorized representative), holding shares which carry in aggregate not
less than one-third of the total number of votes attaching to all issued and outstanding shares in our company which are entitled to vote at
the meeting.
Cayman Islands law provides shareholders with only limited rights to requisition a general meeting, and does not provide
shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company’s articles
of association. Our memorandum and articles of association allow any shareholders holding shares which carry in aggregate not less than
one-third of the total number of votes attaching to all issued and outstanding shares in our company, that carry the right to vote at general
meetings of our company to requisition an extraordinary general meeting of our shareholders, in which case our directors are obliged to
call such meeting and to put the resolutions so requisitioned to a vote at such meeting; however, our memorandum and articles of
association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general
meetings not called by such shareholders.
117
Table of Contents
Election and Removal of Directors
Our memorandum and articles of association provide that, unless otherwise determined by our company in general meeting, our
board will consist of not less than three directors. There are no provisions relating to retirement of directors upon reaching any age limit.
Our board of directors may, by the affirmative vote of a simple majority of the remaining directors present and voting at a meeting of our
board, which shall include the affirmative vote of at least one Founder as long as either Founder is a director, appoint any person as a
director, to fill a vacancy on the board arising from the office of any director being vacated. In the event of a vacancy arising from the
office of an independent director being vacated, our board may only appoint another independent director to fill such vacancy.
Our shareholders may also appoint any person to be a director by way of ordinary resolution. A director may be removed with
or without cause by ordinary resolution. A vacancy on the board created by the removal of a director by ordinary resolution of our
shareholders may be filled by an ordinary resolution or by the affirmative vote of a simple majority of the remaining directors present
and voting at a meeting of our board. The notice of any meeting at which a resolution to remove a director shall be proposed or voted
upon must contain a statement of the intention to remove that director and such notice must be served on that director not less than ten
calendar days before the meeting. Such director is entitled to attend the meeting and be heard on the motion for his removal. In addition,
a director will cease to be a director if, among other things, the director (i) becomes bankrupt or makes any arrangement or composition
with his creditors, (ii) dies or is found by our company to be or becomes of unsound mind, (iii) resigns his office by notice in writing to
the company, or (iv) without special leave of absence from our board, is absent from three consecutive board meetings and our directors
resolve that his office be vacated.
Chairman and Co-chairmen of our Board
For so long as each of our founders is a director of our company, he shall be a co-chairman of our board of directors, until he
resigns as co-chairman or ceases to be a director (in which event he shall automatically cease to be a co-chairman). If either founder
ceases to be a co-chairman, the other founder shall continue as the sole chairman of our board (unless our board, with the consent of the
other founder, elects and appoints another director to be another co-chairman). Upon both founders ceasing to be co-chairmen or
chairman, our board shall elect and appoint the chairman or co-chairmen at their discretion.
Proceedings of Board of Directors
Our memorandum and articles of association provide that our business is to be managed and conducted by our board of
directors. The quorum necessary for board meetings may be fixed by the board and, unless so fixed at another number, will be a majority
of the directors. Our memorandum and articles of association provide that the board may from time to time at its discretion exercise all
powers of our company to raise or borrow money, to mortgage or charge all or any part of the undertaking, property and assets (present
and future) and uncalled capital of our company and issue debentures, bonds and other securities of our company, whether outright or as
collateral security for any debt, liability or obligation of our company or of any third party.
Inspection of Books and Records
Holders of our ordinary shares have no general right under Cayman Islands law to inspect or obtain copies of our list of
shareholders or our corporate records (other than copies of our memorandum and articles of association, our register of mortgages and
charges, and any special resolutions passed by our shareholders). However, we intend to provide our shareholders with annual audited
financial statements.
Changes in Capital
Our shareholders may from time to time by ordinary resolution:
● increase our share capital by such sum, to be divided into shares of such amount, as the resolution shall prescribe;
● consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares;
118
Table of Contents
● sub-divide our existing shares, or any of them into shares of a smaller amount than that fixed by our memorandum of
association; or
● cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any
person and diminish the amount of our share capital by the amount of the shares so cancelled.
Our shareholders may by special resolution, subject to confirmation by the Grand Court of the Cayman Islands on an
application by our company for an order confirming such reduction, reduce our share capital or any capital redemption reserve in any
manner permitted by law.
Exempted Company
We are an exempted company incorporated with limited liability under the Companies Act. The Companies Act distinguishes
between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts
business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted
company are essentially the same as for an ordinary company except for the exemptions and privileges listed below:
● an exempted company does not have to file an annual return of its shareholders with the Registrar of Companies of the
Cayman Islands;
● an exempted company’s register of members is not required to be open to inspection;
● an exempted company does not have to hold an annual general meeting;
● an exempted company may issue no par value, negotiable or bearer shares;
● an exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are
usually given for 20 years in the first instance);
● an exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman
Islands;
● an exempted company may register as a limited duration company; and
● an exempted company may register as a segregated portfolio company.
“Limited liability” means that the liability of each shareholder is limited to the amount unpaid by the shareholder on that
shareholder’s shares of the company (except in exceptional circumstances, such as involving fraud, the establishment of an agency
relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate
veil).
We are subject to reporting and other informational requirements of the Exchange Act, as applicable to foreign private issuers.
Except as otherwise disclosed in this annual report, we currently comply with the Nasdaq Global Market rules in lieu of following home
country practice.
Differences in Corporate Law
The Companies Act is derived, to a large extent, from the older Companies Acts of England but does not follow recent United
Kingdom statutory enactments, and accordingly there are significant differences between the Companies Act and the current Companies
Act of England. In addition, the Companies Act differs from laws applicable to United States corporations and their shareholders. Set
forth below is a summary of certain significant differences between the provisions of the Companies Act applicable to us and the laws
applicable to companies incorporated in the United States and their shareholders.
119
Table of Contents
Mergers and Similar Arrangements
The Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands
companies and non-Cayman Islands companies. For these purposes, (a) “merger” means the merging of two or more constituent
companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company and (b) a
“consolidation” means the combination of two or more constituent companies into a combined company and the vesting of the
undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation,
the directors of each constituent company must approve a written plan of merger or consolidation, which must then be authorized by (a) a
special resolution of the shareholders of each constituent company, and (b) such other authorization, if any, as may be specified in such
constituent company’s articles of association. The written plan of merger or consolidation must be filed with the Registrar of Companies
of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a list of the assets and
liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the
members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman
Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory
procedures.
A merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a
resolution of shareholders. For this purpose a subsidiary is a company of which at least 90% of the issued shares entitled to vote are
owned by the parent company.
The consent of each holder of a fixed or floating security interest of a constituent company is required unless this requirement is
waived by a court in the Cayman Islands.
Except in certain limited circumstances, a shareholder of a Cayman Islands constituent company who dissents from the merger
or consolidation is entitled to payment of the fair value of his or her shares (which, if not agreed between the parties, will be determined
by the Cayman Islands court) upon dissenting from a merger or consolidation, provided the dissenting shareholder complies strictly with
the procedures set out in the Companies Act. The exercise of such dissenter rights will preclude the exercise by the dissenting
shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, except for the right to seek
relief on the grounds that the merger or consolidation is void or unlawful.
Separate from the statutory provisions relating to mergers and consolidations, the Companies Act also contains statutory
provisions that facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the
arrangement is approved by a majority in number of each class of shareholders or creditors with whom the arrangement is to be made
and who must, in addition, represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are
present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and
subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the
right to express to the court the view that the transaction ought not to be approved, the court can be expected to approve the arrangement
if it determines that:
● the statutory provisions as to the required majority vote have been met;
● the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide
without coercion of the minority to promote interests adverse to those of the class;
● the arrangement is such that may be reasonably approved by an intelligent and honest man of that class acting in respect of
his interest; and
● the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act.
120
Table of Contents
The Companies Act also contains a statutory power of compulsory acquisition which may facilitate the “squeeze out” of
dissentient minority shareholders upon a tender offer. When a tender offer is made and accepted by holders of 90% of the shares affected
within four months, the offeror may, within a two-month period commencing on the expiration of such four month period, require the
holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can be made to the Grand
Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of
fraud, bad faith or collusion.
If an arrangement and reconstruction by way of scheme of arrangement is thus approved and sanctioned, or if a tender offer is
made and accepted, in accordance with the foregoing statutory procedures, a dissenting shareholder would have no rights comparable to
appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to
receive payment in cash for the judicially determined value of the shares.
Shareholders’ Suits
In principle, we will normally be the proper plaintiff to sue for a wrong done to us as a company, and as a general rule a
derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be
of persuasive authority in the Cayman Islands, the Cayman Islands court can be expected to apply and follow the common law principles
(namely the rule in Foss v. Harbottle and the exceptions thereto) which permit a minority shareholder to commence a class action against,
or derivative actions in the name of, a company to challenge the following:
● an act which is illegal or ultra vires;
● an act which, although not ultra vires, could only be effected duly if authorized by a special or qualified majority vote that
has not been obtained; and
● an act which constitutes a fraud on the minority where the wrongdoers are themselves in control of the company.
Indemnification of Directors and Executive Officers and Limitation of Liability
Cayman Islands law does not limit the extent to which a company’s articles of association may provide for indemnification of
officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy,
such as to provide indemnification against civil fraud or the consequences of committing a crime. Our memorandum and articles of
association provide that we shall indemnify our directors and officers against all actions, proceedings, costs, charges, expenses, losses,
damages or liabilities incurred or sustained by such director or officer, other than by reason of such person’s own dishonesty, willful
default or fraud, in or about the conduct of our company’s business or affairs or in the execution or discharge of his duties, powers,
authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred
by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs
in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware
General Corporation Law for a Delaware corporation. In addition, we have entered into indemnification agreements with our directors
and senior executive officers that will provide such persons with additional indemnification beyond that provided in our memorandum
and articles of association.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons
controlling us under the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is therefore unenforceable.
Anti-Takeover Provisions in the Memorandum and Articles of Association
Some provisions of our memorandum and articles of association may discourage, delay or prevent a change in control of our
company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue
preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares
without any further vote or action by our shareholders.
121
Table of Contents
However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our
memorandum and articles of association, as amended and restated from time to time, for a proper purpose and for what they believe in
good faith to be in the best interests of our company.
Directors’ Fiduciary Duties
Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders.
This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with
the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of
and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty
requires that a director act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use
his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best
interests of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling
shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an
informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this
presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a
transaction by a director, a director must prove the procedural fairness of the transaction and that the transaction was of fair value to the
corporation.
As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the
company and therefore he owes the following duties to the company—a duty to act in good faith in the best interests of the company, a
duty not to make a personal profit based on his or her position as director (unless the company permits him to do so), a duty not to put
himself in a position where the interests of the company conflict with his or her personal interest or his or her duty to a third party and a
duty to exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the
company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his or her
duties a greater degree of skill than may reasonably be expected from a person of his or her knowledge and experience. However,
English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these
authorities are likely to be followed in the Cayman Islands.
Shareholder Proposals
Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of
shareholders, provided it complies with the notice provisions in the governing documents. The Delaware General Corporation Law does
not provide shareholders an express right to put any proposal before the annual meeting of shareholders, but in keeping with common
law, Delaware corporations generally afford shareholders an opportunity to make proposals and nominations provided that they comply
with the notice provisions in the certificate of incorporation or bylaws. A special meeting may be called by the board of directors or any
other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.
Cayman Islands law provides shareholders with only limited rights to requisition a general meeting, and does not provide
shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company’s articles
of association. Our memorandum and articles of association provide that, on the requisition of any shareholders holding shares which
carry in aggregate not less than one-third of the total number of votes attaching to all issued and outstanding shares in our company that
carry the right to vote at general meetings of our company, our board of directors shall convene an extraordinary general meeting and put
the resolutions so requisitioned to a vote at such meeting. However, our memorandum and articles of association do not provide our
shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such
shareholders. As an exempted Cayman Islands company, we are not obliged by law to call shareholders’ annual general meetings.
122
Table of Contents
Cumulative Voting
Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the
corporation’s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of
minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is
entitled on a single director, which increases the shareholder’s voting power with respect to electing such director. Cayman Islands law
does not prohibit cumulative voting, but our articles of association do not provide for cumulative voting. As a result, our shareholders are
not afforded any less protections or rights on this issue than shareholders of a Delaware corporation.
Removal of Directors
Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for
cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.
Under our memorandum and articles of association, any of our directors may be removed by ordinary resolution of our shareholders.
Transactions with Interested Shareholders
The Delaware General Corporation Law contains a business combination statute applicable to Delaware public corporations
whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of
incorporation or bylaws that is approved by its shareholders, it is prohibited from engaging in certain business combinations with an
“interested shareholder” for three years following the date that such person becomes an interested shareholder. An interested shareholder
generally is a person or a group who or which owns or owned 15% or more of the target’s outstanding voting stock or who or which is an
affiliate or associate of the corporation and owned 15% or more of the corporation’s outstanding voting stock within the past three years.
This has the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would
not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an
interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person
becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any
acquisition transaction with the target’s board of directors.
Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the
Delaware business combination statute. However, although Cayman Islands law does not regulate transactions between a company and
its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the company and
for a proper corporate purpose and not with the effect of constituting a fraud on the minority shareholders.
Dissolution; Winding Up
Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must
be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board
of directors may it be approved by a simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware
corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by
the board. Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a
special resolution of its members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members.
The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just
and equitable to do so.
123
Table of Contents
Variation of Rights of Shares
Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a
majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under our memorandum and
articles of association, if our share capital is divided into more than one class of shares, the rights attached to any such class may, subject
to any rights or restrictions for the time being attached to any class, only be materially adversely varied with the consent in writing of the
holders of two-thirds of the issued shares of that class or with the sanction of a special resolution passed at a separate meeting of the
holders of the shares of that class.
Amendment of Governing Documents
Under the Delaware General Corporation Law, a corporation’s certificate of incorporation may be amended only if adopted and
declared advisable by the board of directors and approved by a majority of the outstanding shares entitled to vote and the bylaws may be
amended with the approval of a majority of the outstanding shares entitled to vote and may, if so provided in the certificate of
incorporation, also be amended by the board of directors. Under the Companies Act, our memorandum and articles of association may
only be amended by special resolution of our shareholders.
Rights of Non-Resident or Foreign Shareholders
There are no limitations imposed by our memorandum and articles of association on the rights of non-resident or foreign
shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our memorandum and articles of
association governing the ownership threshold above which shareholder ownership must be disclosed.
Directors’ Power to Issue Shares
Under our memorandum and articles of association, our board of directors is empowered to issue or allot shares or grant options
and warrants with or without preferred, deferred, qualified or other special rights or restrictions.
C. Material Contracts
We have not entered into any material contracts other than in the ordinary course of business and other than those described in
“Item 4. Information on the Company” or elsewhere in this annual report on Form 20-F.
D. Exchange Controls
See “Item 4. Information on the Company—B. Business Overview—Regulations—Regulations Relating to Foreign Exchange
and Dividend Distributions.”
E. Taxation
The following summary of material Cayman Islands, PRC and U.S. federal income tax consequences of an investment in ADSs
or ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this annual report, all of which are
subject to change. This summary does not deal with all possible tax consequences relating to an investment in ADSs or ordinary shares,
such as the tax consequences under state, local and other tax laws.
Cayman Islands Taxation
The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation
and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to investors levied by
the government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or, after execution,
brought within the jurisdiction of the Cayman Islands. The Cayman Islands is not party to any double tax treaties which are applicable to
any payments made by our company. There are no exchange control regulations or currency restrictions in the Cayman Islands.
124
Table of Contents
Payments of dividends and capital in respect of ordinary shares and ADSs will not be subject to taxation in the Cayman Islands
and no withholding will be required on the payment of a dividend or capital to any holder of ordinary shares or ADSs, nor will gains
derived from the disposal of ordinary shares or ADSs be subject to Cayman Islands income or corporation tax.
No stamp duty is payable in respect of the issue of our ordinary shares or on an instrument of transfer in respect of our ordinary
shares.
People’s Republic of China Taxation
Although we are incorporated in the Cayman Islands, we may be treated as a PRC resident enterprise for PRC tax purposes
under the EIT Law. The EIT Law provides that an enterprise established outside the PRC but whose “de facto management body” is
located in the PRC is treated as a PRC resident enterprise for PRC tax purposes. The implementing rules of the EIT Law merely define
the location of the “de facto management body” as “organizational body which effectively manages and controls the production and
business operation, personnel, accounting, properties and other aspects of operations of an enterprise.” Based on a review of the facts and
circumstances, we do not believe that 111, Inc. or Yao Wang Corporation Limited should be considered a PRC resident enterprise for
PRC tax purposes. However, there is limited guidance and implementation history of the EIT Law. If 111, Inc. were to be considered a
PRC resident enterprise, then PRC income tax at a rate of 10% would generally be applicable to any gain realized on the transfer of our
ADSs or ordinary shares by investors that are “non-resident enterprises” of the PRC and to any interest or dividends payable by us to
such investors. See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—If we are classified as a
PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our
non-PRC shareholders or ADS holders.”
Furthermore, pursuant to the EIT Law and its implementation rules, if a non-resident enterprise has not set up an organization or
establishment in the PRC, or has set up an organization or establishment but the income derived has no actual connection with such
organization or establishment, it will be subject to a withholding tax on its PRC-sourced income at a rate of 10%. On February 3, 2015,
the STA issued the Announcement on Several Issues Concerning the Enterprise Income Tax on Indirect Property Transfers by Non-PRC
Resident Enterprises, pursuant to which the indirect transfer of assets of an “establishment or place” situated in China, by a non-PRC
resident enterprise through a disposition of equity interests in an offshore holding company may also be treated as a transfer of PRC
taxable assets and, as a result, the gain derived from this indirect transfer by a non-PRC enterprise shareholder (other than the sale at
public stock market of shares that purchased by an offshore enterprise in public stock market) may be subject to PRC enterprise income
tax at a rate of 10%. Therefore, the deposition of ADSs or ordinary shares acquired not at public stock market by investors in private
transaction may subject to withholding tax rate at a rate of 10%.
Material U.S. Federal Income Tax Considerations
The following are material U.S. federal income tax consequences to the U.S. Holders described below of owning and disposing
of the ADSs or Class A ordinary shares, but this discussion does not purport to be a comprehensive description of all of the tax
considerations that may be relevant to a particular person’s decision to hold the ADSs or Class A ordinary shares.
This discussion applies to a U.S. Holder that holds the ADSs or Class A ordinary shares as capital assets for U.S. federal income
tax purposes (generally, property held for investment). It does not describe all of the tax consequences that may be relevant in light of a
U.S. Holder’s particular circumstances, including the alternative minimum tax, the Medicare contribution tax on net investment income
and tax consequences applicable to U.S. Holders subject to special rules, such as:
● certain financial institutions;
● dealers or traders in securities that use a mark-to-market method of tax accounting;
● persons holding ADSs or ordinary shares as part of a straddle, integrated or similar transaction;
● persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;
● entities classified as partnerships for U.S. federal income tax purposes and their partners;
125
Table of Contents
● tax-exempt entities, “individual retirement accounts” or “Roth IRAs”;
● insurance companies;
● certain U.S. expatriates;
● persons that own or are deemed to own ADSs or ordinary shares representing 10% or more of our voting power or value;
● persons holding ADSs or ordinary shares in connection with a trade or business outside the United States; or
● persons who acquired our ADSs or ordinary shares pursuant to the exercise of an employee stock option or otherwise as
compensation.
If a partnership (or other entity that is classified as a partnership for U.S. federal income tax purposes) owns ADSs or ordinary
shares, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the
partnership. Partnerships owning ADSs or ordinary shares and their partners should consult their tax advisers as to their particular U.S.
federal income tax consequences of owning and disposing of ADSs or ordinary shares.
This discussion is based on the Internal Revenue Code of 1986, as amended, (the “Code”), administrative pronouncements,
judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between the United States and the PRC,
or the Treaty, all as of the date hereof, any of which is subject to change, possibly with retroactive effect.
As used herein, a “U.S. Holder” is a person that for U.S. federal income tax purposes is beneficial owner of our ADSs or Class
A ordinary shares that is:
● a citizen or individual resident of the United States;
● a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any
state therein or the District of Columbia; or
● an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.
In general, a U.S. Holder that owns ADSs will be treated as the owner of the underlying ordinary shares represented by those
ADSs for U.S. federal income tax purposes. Accordingly, no gain or loss will be recognized if a U.S. Holder exchanges ADSs for the
underlying ordinary shares represented by those ADSs.
This discussion does not address any U.S. federal taxes (such as estate or gift taxes) other than income taxes, nor does it address
any state, local or non-U.S. considerations. U.S. Holders should consult their tax advisers concerning the U.S. federal, state, local and
non-U.S. tax consequences of owning and disposing of ADSs or ordinary shares in their particular circumstances.
Taxation of Distributions
This discussion is subject to the discussion below under “—Passive Foreign Investment Company Rules.”
126
Table of Contents
Distributions paid on the ADSs or ordinary shares, other than certain pro rata distributions of ADSs or ordinary shares, will be
treated as dividends to the extent paid out of our current or accumulated earnings and profits, as determined under U.S. federal income
tax principles. Because we do not maintain calculations of our earnings and profits under U.S. federal income tax principles, it is
expected that distributions generally will be reported to U.S. Holders as dividends. Dividends will not be eligible for the dividends-
received deduction generally available to U.S. corporations under the Code. Subject to applicable limitations, dividends paid to certain
non-corporate U.S. Holders may be taxable at a favorable rate. Non-corporate U.S. Holders should consult their tax advisers regarding
the availability of this favorable rate in their particular circumstances.
Dividends will be included in a U.S. Holder’s income on the date of the U.S. Holder’s, or in the case of ADSs, the depositary’s,
receipt. The amount of any dividend income paid in foreign currency will be the U.S. dollar amount calculated by reference to the spot
rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars on such
date. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder generally should not be required to recognize
foreign currency gain or loss in respect of the amount received. A U.S. Holder may have foreign currency gain or loss if the dividend is
converted into U.S. dollars after the date of receipt.
Dividends will be treated as foreign-source income and will constitute passive category income or in certain cases, general
category income, for foreign tax credit purposes. As described in “—People’s Republic of China Taxation,” dividends paid by us may be
subject to PRC withholding tax. For U.S. federal income tax purposes, the amount of the dividend income will include any amounts
withheld in respect of PRC withholding tax. Subject to applicable limitations, which vary depending upon the U.S. Holder’s
circumstances, PRC taxes withheld from dividend payments (at a rate not exceeding the applicable rate provided in the Treaty in the case
of a U.S. Holder that is eligible for Treaty benefits) generally will be creditable against a U.S. Holder’s U.S. federal income tax liability.
The rules governing foreign tax credits are complex, and U.S. Holders should consult their tax advisers regarding the creditability of
foreign taxes in their particular circumstances. In lieu of claiming a credit, a U.S. Holder may elect to deduct such PRC taxes in
computing its taxable income, subject to applicable limitations. An election to deduct foreign taxes instead of claiming foreign tax credits
must apply to all foreign taxes paid or accrued in the relevant taxable year.
Sale or Other Taxable Disposition of ADSs or Ordinary Shares
This discussion is subject to the discussion below under “—Passive Foreign Investment Company Rules.”
A U.S. Holder will generally recognize capital gain or loss on a sale or other taxable disposition of ADSs or ordinary shares in
an amount equal to the difference between the amount realized on the sale or disposition and the U.S. Holder’s tax basis in the ADSs or
ordinary shares disposed of, in each case as determined in U.S. dollars. The gain or loss will be long-term capital gain or loss if, at the
time of the sale or disposition, the U.S. Holder has owned the ADSs or ordinary shares for more than one year. Long-term capital gains
recognized by non-corporate U.S. Holders are subject to tax rates that are lower than those applicable to ordinary income. The
deductibility of capital losses is subject to limitations.
As described in “—People’s Republic of China Taxation,” gains on the sale of ADSs or ordinary shares may be subject to PRC
taxes. A U.S. Holder is entitled to use foreign tax credits to offset only the portion of its U.S. federal income tax liability that is
attributable to foreign-source income. Because under the Code capital gains of U.S. persons are generally treated as U.S.-source income,
this limitation may preclude a U.S. Holder from claiming a credit for all or a portion of any PRC taxes imposed on any such gains.
However, U.S. Holders that are eligible for the benefits of the Treaty may be able to elect to treat the gain as PRC-source and therefore
claim foreign tax credits in respect of PRC taxes on such disposition gains. U.S. Holders should consult their tax advisers regarding their
eligibility for the benefits of the Treaty and the creditability of any PRC tax on disposition gains in their particular circumstances.
127
Table of Contents
Passive Foreign Investment Company Rules
In general, a non-U.S. corporation is a passive foreign investment company for U.S. federal income tax purposes, or PFIC, for
any taxable year in which (i) 75% or more of its gross income consists of passive income; or (ii) 50% or more of the value of its assets
(generally determined on an average quarterly basis) consists of assets that produce, or are held for the production of, passive income.
For purposes of the above calculations, a non-U.S. corporation that owns (or is treated as owning for U.S. federal income tax purposes),
directly or indirectly, at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets
of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally
includes dividends, interest, rents, royalties and certain gains. Cash is generally a passive asset for these purposes. Goodwill (the value of
which generally may be determined by reference to the excess of the sum of the corporation’s market capitalization and liabilities over
the value of its assets) is generally characterized as a non-passive or passive asset based on the nature of the income produced in the
activity to which the goodwill is attributable.
Based on the composition of our income and assets and the estimated value of our assets, including goodwill, which is based on
the price of our ADSs, we believe that we were not a PFIC for our taxable year ended on December 31, 2020. However, our PFIC status
for any taxable year will depend on the composition of our income and assets and the value of our assets from time to time (which may
be determined, in large part, by reference to the market price of the ADSs, which has been and may continue to be volatile). Therefore,
the risk of us being or becoming a PFIC will increase if during any taxable year our ADS price declines significantly.
Moreover, it is not entirely clear how the contractual arrangements between our subsidiary, our variable interest entities and the
shareholders of our variable interest entities will be treated for purposes of the PFIC rules, and we may be or become a PFIC if our
variable interest entities are not treated as owned by us for these purposes. In addition, the extent to which our goodwill should be
characterized as an active asset is not entirely clear. We also hold a substantial amount of cash. Accordingly, there can be no assurance
that we will not be a PFIC for our 2021 or any future taxable year.
If we were a PFIC for any taxable year and any of our subsidiaries, variable interest entities or other companies in which we
own or are treated as owning equity interests were also a PFIC (any such entity, a “Lower-tier PFIC”), U.S. Holders would be deemed to
own a proportionate amount (by value) of the shares of each Lower-tier PFIC and would be subject to U.S. federal income tax according
to the rules described in the subsequent paragraphs on (i) certain distributions by a Lower-tier PFIC and (ii) dispositions of shares of
Lower-tier PFICs, in each case as if the U.S. Holders held such shares directly, even though the U.S. Holders would not receive the
proceeds of those distributions or dispositions.
In general, if we were a PFIC for any taxable year during which a U.S. Holder held ADSs or ordinary shares, gain recognized
by such U.S. Holder on a sale or other disposition (including certain pledges) of its ADSs or ordinary shares would be allocated ratably
over that U.S. Holder’s holding period. The amounts allocated to the taxable year of the sale or disposition and to any year before we
became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the
highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed on the
resulting tax liability for each such year. Furthermore, to the extent that distributions received by a U.S. Holder in any year on its ADSs
or ordinary shares exceed 125% of the average of the annual distributions on the ADSs or ordinary shares received during the preceding
three years or the U.S. Holder’s holding period, whichever is shorter, such distributions would be subject to taxation in the same manner.
If we are a PFIC for any taxable year during which a U.S. Holder owns ADSs or ordinary shares, we will generally continue to
be treated as a PFIC with respect to the U.S. Holder for all succeeding years during which the U.S. Holder owns the ADSs or ordinary
shares, even if we cease to meet the threshold requirements for PFIC status. If we are a PFIC for any taxable year but cease to be PFIC
for subsequent years, U.S. Holders should consult their tax advisers regarding the advisability of making a “deemed sale” election that
would allow them to eliminate the continuing PFIC status under certain circumstances.
128
Table of Contents
Alternatively, if we were a PFIC and if the ADSs were “regularly traded” on a “qualified exchange,” a U.S. Holder of ADSs
could make a mark-to-market election that would result in tax treatment different from the general tax treatment for PFICs described
above. The ADSs would be treated as “regularly traded” for any calendar year in which more than a de minimis quantity of the ADSs
were traded on a qualified exchange on at least 15 days during each calendar quarter. The Nasdaq, where the ADSs are listed, is a
qualified exchange for this purpose. If a U.S. Holder made the mark-to-market election, the U.S. Holder generally would recognize as
ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted tax basis, and would
recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value at the end of the
taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S.
Holder made the election, the U.S. Holder’s tax basis in the ADSs will be adjusted to reflect the income or loss amounts recognized. Any
gain recognized on the sale or other disposition of ADSs in a year in which we were a PFIC would be treated as ordinary income and any
loss would be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-
to-market election, with any excess treated as capital loss). If a U.S. Holder made the mark-to-market election, distributions paid on
ADSs would be treated as discussed under “—Taxation of Distributions” above (but subject to the discussion in the immediately
subsequent paragraph). U.S. Holders will not be able to make a mark-to-market election with respect to our ordinary shares or Lower-tier
PFICs, if any. U.S. Holders should consult their tax advisers regarding the availability and advisability of a mark-to-market election if we
were a PFIC for any taxable year.
We do not intend to provide information necessary for U.S. Holders to make qualified electing fund elections, which if available
could materially affect the tax consequences of the ownership and disposition of ADSs.
If we were a PFIC (or with respect to a particular U.S. Holder were treated as a PFIC) for a taxable year in which we paid a
dividend or for the prior taxable year, the favorable tax rate described above with respect to dividends paid to certain non-corporate U.S.
Holders would not apply.
If we were a PFIC for any taxable year during which a U.S. Holder owned any ADSs or ordinary shares, the U.S. Holder would
generally be required to file annual reports with the Internal Revenue Service. U.S. Holders should consult their tax advisers regarding
the determination of whether we are a PFIC for any taxable year and the potential application of the PFIC rules to their ownership of
ADSs or ordinary shares.
Information Reporting and Backup Withholding
Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related intermediaries
may be subject to information reporting and backup withholding, unless (i) the U.S. Holder is a corporation or other “exempt recipient”
or (ii) in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not
subject to backup withholding. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a
U.S. Holder will be allowed as a credit against the U.S. Holder’s U.S. federal income tax liability and may entitle it to a refund, provided
that the required information is timely furnished to the Internal Revenue Service.
Certain U.S. Holders who are individuals (or certain specified entities) may be required to report information relating to their
ownership of ADSs or ordinary shares, unless the ADSs or ordinary shares are held in accounts at financial institutions (in which case the
accounts may be reportable if maintained by non-U.S. financial institutions). U.S. Holders should consult their tax advisers regarding
their reporting obligations with respect to the ADSs or ordinary shares.
B. Dividends and Paying Agents
Not applicable.
C. Statement by Experts
Not applicable.
129
Table of Contents
D. Documents on Display
We are subject to periodic reporting and other informational requirements of the Exchange Act as applicable to foreign private
issuers, and are required to file reports and other information with the SEC. Specifically, we are required to file annually an annual report
on Form 20-F within four months after the end of each fiscal year, which is December 31. All information filed with the SEC can be
obtained over the internet at the SEC’s website at www.sec.gov or inspected and copied at the public reference facilities maintained by
the SEC at 100 F Street, N.E., Washington, D.C. 20549. You can request copies of documents, upon payment of a duplicating fee, by
writing to the SEC. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and
content of quarterly reports and proxy statements, and officers, directors and principal shareholders are exempt from the reporting and
short-swing profit recovery provisions contained in Section 16 of the Exchange Act.
We will furnish the Bank of New York Mellon, the depositary of the ADSs, with our annual reports, which will include a review
of operations and annual audited consolidated financial statements prepared in conformity with U.S. GAAP, and all notices of
shareholders’ meetings and other reports and communications that are made generally available to our shareholders. The depositary will
make such notices, reports and communications available to holders of ADSs and, upon our request, will mail to all record holders of
ADSs the information contained in any notice of a shareholders’ meeting received by the depositary from us.
E. Subsidiary Information
Not applicable.
Item 11. Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Risk
Our exposure to interest rate risk primarily relates to the interest income generated by excess cash, which is mostly held in
interest-bearing bank deposits and financial instruments. These interest-bearing bank deposits and financial instruments carry a degree of
interest rate risk. We have not been exposed to material risks due to changes in interest rates, and we have not used any derivative
financial instruments to manage our interest risk exposure. However, our future interest income may fall short of expectations due to
changes in market interest rates.
Foreign Exchange Risk
All of our net revenues and substantially all of our expenses are denominated in Renminbi. Our exposure to foreign exchange
risk primarily relates to cash and cash equivalent denominated in U.S. dollars. We do not believe that we currently have any significant
direct foreign exchange risk and have not used any derivative financial instruments to hedge exposure to such risk. Although our
exposure to foreign exchange risks should be limited in general, the value of your investment in our ADSs will be affected by the
exchange rate between U.S. dollar and Renminbi because the value of our business is effectively denominated in Renminbi, while our
ADSs will be traded in U.S. dollars.
130
Table of Contents
The value of Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things,
changes in political and economic conditions and the foreign exchange policy adopted by the PRC government. On July 21, 2005, the
PRC government changed its policy of pegging the value of the Renminbi to the U.S. dollar. Following the removal of the U.S. dollar
peg, the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010,
this appreciation halted and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since
June 2010, the PRC government has allowed the Renminbi to appreciate slowly against the U.S. dollar again, and it has appreciated more
than 10% since June 2010. On August 11, 2015, the People’s Bank of China announced plans to improve the central parity rate of the
Renminbi against the U.S. dollar by authorizing market-makers to provide parity to the China Foreign Exchange Trading Center operated
by the People’s Bank of China with reference to the interbank foreign exchange market closing rate of the previous day, the supply and
demand for foreign currencies as well as changes in exchange rates of major international currencies. Effective from October 1, 2016, the
International Monetary Fund added Renminbi to its Special Drawing Rights currency basket. Such change and additional future changes
may increase volatility in the trading value of the Renminbi against foreign currencies. The PRC government may adopt further reforms
of its exchange rate system, including making the Renminbi freely convertible in the future. Accordingly, it is difficult to predict how
market forces or PRC or U.S. government policy may impact the exchange rate between Renminbi and the U.S. dollar in the future.
To the extent that we need to convert U.S. dollars into Renminbi for our operations, appreciation of Renminbi against the U.S.
dollar would reduce the Renminbi amount we receive from the conversion. Conversely, if we decide to convert Renminbi into U.S.
dollars for the purpose of making payments for dividends on our ordinary shares or ADSs, servicing our outstanding debt, or for other
business purposes, appreciation of the U.S. dollar against the Renminbi would reduce the U.S. dollar amounts available to us.
As of December 31, 2020, we had Renminbi-denominated cash and cash equivalents of RMB1,200.3 million
(US$184.0 million). A 10% depreciation of Renminbi against the U.S. dollar based on the foreign exchange rate on December 31, 2020
would result in a decrease of US$18.4 million in cash and cash equivalents. A 10% appreciation of Renminbi against the U.S. dollar
based on the foreign exchange rate on December 31, 2020 would result in an increase of US$18.4 million in cash and cash equivalents.
Item 12. Description of Securities Other Than Equity Securities
A. Debt Securities
Not applicable.
B. Warrants and Rights
Not applicable.
C. Other Securities
Not applicable.
131
Table of Contents
D. American Depositary Shares
Fees and Charges Our ADS Holders May Have to Pay
The Bank of New York Mellon, as depositary, will register and deliver American Depositary shares, also referred to as ADSs.
Each ADS will represent two ordinary shares (or a right to receive two ordinary shares) deposited with The Hong Kong and Shanghai
Banking Corporation Limited, as custodian for the depositary in Hong Kong. Each ADS will also represent any other securities, cash or
other property which may be held by the depositary. The deposited shares together with any other securities, cash or other property held
by the depositary are referred to as the deposited securities. The depositary’s office at which the ADSs will be administered is located at
240 Greenwich Street, New York, New York 10286.
Persons depositing or withdrawing shares or ADS
holders must pay:
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)
$0.05 (or less) per ADS
A fee equivalent to the fee that would be payable if securities
distributed to you had been shares and the shares had been
deposited for issuance of ADSs
$0.05 (or less) per ADS per calendar year
Registration or transfer fees
Expenses of the depositary
Taxes and other governmental charges the depositary or the
custodian has to pay on any ADSs or shares underlying ADSs,
such as stock transfer taxes, stamp duty or withholding taxes
Any charges incurred by the depositary or its agents for servicing
the deposited securities
Fees and Other Payments Made by the Depositary to Us
For:
Issuance of ADSs, including issuances resulting from a
distribution of shares or rights or other property
Cancellation of ADSs for the purpose of withdrawal, including if
the deposit agreement terminates
Any cash distribution to ADS holders
Distribution of securities distributed to holders of deposited
securities (including rights) that are distributed by the depositary
to ADS holders
Depositary services
Transfer and registration of shares on our share register to or
from the name of the depositary or its agent when you deposit or
withdraw shares
Cable and facsimile transmissions (when expressly provided in
the deposit agreement)
Converting foreign currency to U.S. dollars
As necessary
As necessary
The depositary has agreed to reimburse us annually for our expenses incurred in connection with investor relationship programs
and any other program related to our ADS facility and the travel expense of our key personnel in connection with such programs. The
depositary has also agreed to provide additional payments to us based on the applicable performance indicators relating to our ADS
facility. There are limits on the amount of expenses for which the depositary will reimburse us, but the amount of reimbursement
available to us is not necessarily tied to the amount of fees the depositary collects from investors. In 2020, we did not receive any
reimbursement from the depositary for our expenses incurred in connection with investor relationship programs related to the ADS
facility and the travel expense of our key personnel in connection with such programs.
132
Table of Contents
Item 13. Defaults, Dividend Arrearages and Delinquencies
None.
PART II
Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds
Material Modifications to the Rights of Security Holders
See “Item 10. Additional Information—B. Memorandum and Articles of Association—Ordinary Shares” for a description of the
rights of securities holders, which remain unchanged.
Use of Proceeds
The following “Use of Proceeds” information relates to the registration statement on Form F-1, as amended (File Number: 333-
226849) in relation to our initial public offering of 7,175,000 ADSs representing 14,350,000 of our Class A ordinary shares, and the
underwriters’ partial exercise of their option to purchase from us 809,555 additional ADSs representing 1,619,110 Class A ordinary
shares, at an initial offering price of $14.00 per ADS. J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and China International
Capital Corporation Hong Kong Securities Limited are the representatives of the underwriters.
As a result of our initial public offering, we raised an aggregate of approximately US$ 101.2 million in net proceeds, after
deducting underwriting commissions and the offering expenses payable by us. For the period from September 12, 2018, the date that the
F-1 Registration Statement was declared effective by the SEC, to the date of this annual report, we used US$99.8 million of the net
proceeds from our initial public offering for general corporate purposes.
We still intend to use the proceeds from our initial public offering, as disclosed in our registration statements on Form F-1, for
(i) general corporate purposes, including investment in product development, sales and marketing activities, technology infrastructure,
capital expenditures, improvement of corporate facilities and other general and administrative matters, and (ii) acquisition of, or
investment in, technologies, solutions or business that complement our business .
Item 15. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our chief executive officer and our chief
financial officer, we carried out an evaluation of the effectiveness of our disclosure controls and procedures, which is defined in
Rules 13a-15(e) of the Exchange Act, as of December 31, 2020. Based upon that evaluation, our management, with the participation of
our chief executive officer and chief financial officer, has concluded that, as of the end of the period covered by this annual report, our
disclosure controls and procedures were effective in ensuring that the information required to be disclosed by us in this annual report is
recorded, processed, summarized and reported to them for assessment, and required disclosure is made within the time period specified
in the rules and forms of the SEC.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in
Rules 13a-15 (f) under the Exchange Act. Our management, with the participation of our chief executive officer and our chief financial
officer, evaluated the effectiveness of our internal control over financial reporting based on criteria established in the framework in
Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on this evaluation, our management has concluded that our internal control over financial reporting was effective as of
December 31, 2020.
133
Table of Contents
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of
changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.
Attestation Report of the Registered Public Accounting Firm
Deloitte Touche Tohmatsu Certified Public Accountants LLP has audited the effectiveness of our internal control over financial
reporting as of December 31, 2020 as stated in its report, which appears on page F-4 of this annual report on Form 20-F.
Changes in Internal Control over Financial Reporting
In 2018, we identified a material weakness relating to our lack of sufficient competent financial reporting and accounting
personnel with appropriate understanding of U.S. GAAP to design and implement formal period-end financial reporting controls and
procedures, to address complex U.S. GAAP technical accounting and to prepare and review our consolidated financial statements and
related disclosures in accordance with U.S. GAAP and financial reporting requirement set forth by the SEC.
To address this material weakness, we recruited a member of the American Institute of Certified Public Accountants with years
of U.S. GAAP reporting experience and established a more sophisticated accounting team. Other than as described above, there were no
changes in our internal controls over financial reporting that occurred during the period covered by this annual report on Form 20-F that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 16A. Audit Committee Financial Expert
Our board of directors has determined that Mr. Nee Chuan Teo, an independent director (under the standards set forth in Nasdaq
Stock Market Rule 5605(c)(2) and Rule 10A-3 under the Exchange Act) and chairman of our audit committee, is an audit committee
financial expert.
Item 16B. Code of Ethics
Our board of directors adopted a code of business conduct and ethics that applies to our directors, officers, employees and
advisors in August 2018. We have posted a copy of our code of business conduct and ethics on our website at http://ir.111.com.cn.
Item 16C. Principal Accountant Fees and Services
The following table sets forth the aggregate fees by categories specified below in connection with certain professional services
rendered by Deloitte Touche Tohmatsu Certified Public Accountants LLP, our principal external auditors, for the periods indicated.
Audit fees and audit-related fees (1)
2018
For the year ended December 31,
2019
(in thousands)
935
US$
2020
US$ 1,733
US$ 1,671
(1) “Audit fees and audit-related fees” means the aggregate fees billed in each of the fiscal years listed for professional services
rendered by our principal auditors for the audit or review of our annual or quarterly financial statements, audit-related fees include
service relating to the audit of the financial statements of 1 Pharmacy Technology in connection with its proposed initial public
offering on the STAR Market in 2020 and service to support the planned issuance of convertible senior notes in 2020, fees for
assurance services rendered in connection with our initial public offering in 2018.
The policy of our audit committee or our board of directors is to pre-approve all audit and non-audit services provided by
Deloitte Touche Tohmatsu Certified Public Accountants LLP, including audit services, tax services and other services as described above.
134
Table of Contents
Item 16D. Exemptions from the Listing Standards for Audit Committees
Not applicable.
Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers
On August 15, 2019, our board of directors authorized a share repurchase program, under which we may purchase up to US$10
million worth of our shares over the next 12 months from August 15, 2019. The US$10 million share repurchase program was publicly
announced on August 15, 2019. The table below summarizes the repurchases we made in the periods indicated.
Month
August 2019
September 2019
October 2019
November 2019
December 2019
January 2020
February 2020
March 2020
April 1 through August 15, 2020
Total Number of
Ordinary Shares
Purchased
Average Price
Paid Per
Ordinary
Share (US$)
—
1,045,296
69,267
27,399
39,312
126,037
119,842
10,000
—
—
4.15
4.88
5.10
5.15
6.71
6.39
6.38
—
Item 16F. Change in Registrant’s Certifying Accountant
Not applicable.
Item 16G. Corporate Governance
Total Number of
Ordinary Shares
Purchased as Part
of Share
Repurchase Program
—
1,045,296
69,267
27,399
39,312
126,037
119,842
10,000
—
Approximate Dollar
Value of Ordinary
Shares that may yet
be Purchased Under
Share Purchase
Program (US$, in
million)
10.0
5.7
5.3
5.2
5.0
4.1
3.4
3.3
3.3
As a Cayman Islands exempted company listed on NASDAQ, we are subject to the Nasdaq corporate governance listing
standards. However, NASDAQ rules permit a foreign private issuer like us to follow the corporate governance practices of its home
country. Certain corporate governance practices in the Cayman Islands, which is our home country, may differ significantly from the
Nasdaq corporate governance listing standards. See “Item 3. Key Information—D. Risk Factors— Risks Related to the American
Depositary Shares—We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt
from certain provisions applicable to U.S. domestic public companies.”
Maples and Calder (Hong Kong) LLP, our Cayman Islands counsel, has provided letters to the Nasdaq Stock Market certifying
that under Cayman Islands law, i) we are not required to have a majority of our board of directors comprised of independent directors, ii)
we are not required to have a compensation committee of at least two members, each of whom must be an independent director, iii) we
are not required to have a nominations committee comprised solely of independent directors, and iv) we are not required to hold annual
shareholders meetings every year. We followed and intend to continue to follow our home country practice in lieu of the requirements to
i) have our board of directors comprised of a majority of independent directors under Nasdaq Rule 5605(a)(2); (ii) have a compensation
committee of at least two members, each of whom must be an independent director under Nasdaq Rule 5605(d)(2), (iii) have a
nominations committee comprised solely of independent directors under Nasdaq Rule 5605(e)(1), and (iv) hold an annual meeting of
shareholders no later than one year after the end of a fiscal year under Nasdaq Rule 5620(a).
Other than the home country practices described above, we are not aware of any significant differences between our corporate
governance practices and those followed by U.S. domestic companies under Nasdaq Stock Market Rules.
135
Table of Contents
Item 16H. Mine Safety Disclosure
Not applicable.
136
Table of Contents
PART III
Item 17. Financial Statements
We have elected to provide financial statements pursuant to Item 18.
Item 18. Financial Statements
The consolidated financial statements of 111, Inc., its subsidiaries and its consolidated affiliated entities are included at the end
of this annual report.
Item 19. Exhibits
Exhibit
Number
Description of Document
1.1
2.1
2.2
2.3
2.4
4.1
4.2
4.3
4.4
4.5
Twelfth Amended and Restated Memorandum and Articles of Association of the Registrant (incorporated by reference
to Exhibit 3.2 of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the
Securities and Exchange Commission on August 15, 2018)
Registrant’s Specimen American Depositary Receipt (incorporated by reference to Exhibit 4.1 of our registration
statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and Exchange Commission
on August 15, 2018)
Registrant’s Specimen Certificate for Class A Ordinary Shares (incorporated by reference to Exhibit 4.2 of our
registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and Exchange
Commission on August 15, 2018)
Deposit Agreement between the Registrant, the Bank of New York Mellon and all owner and holders from time to time
of ADSs issued thereunder, dated September 12, 2018 (incorporated by reference to Exhibit 4.3 of our registration
statement on Form S-8 (file no. 333-229313), as amended, initially filed with the Securities and Exchange Commission
on January 22, 2019)
Description of Securities (incorporated by reference to Exhibit 2.4 of our Annual Report on Form 20-F (file no. 001-
38639) filed with the Securities and Exchange Commission on April 16, 2020)
English translation of 2013 Share Incentive Policy of the Registrant (incorporated by reference to Exhibit 10.1 of our
Registration Statement on Form F-1 (file no. 333-226849) filed with the Securities and Exchange Commission on
August 15, 2018)
English translation of 2014 Share Incentive Policy of the Registrant (incorporated by reference to Exhibit 10.2 of our
Registration Statement on Form F-1 (file no. 333-226849) filed with the Securities and Exchange Commission on
August 15, 2018)
The 2016 Share Incentive Plan of the Registrant (incorporated by reference to Exhibit 10.3 of our Registration
Statement on Form F-1 (file no. 333-226849) filed with the Securities and Exchange Commission on August 15, 2018)
The 2018 Share Incentive Plan of the Registrant (incorporated by reference to Exhibit 10.4 of our Registration
Statement on Form F-1 (file no. 333-226849) filed with the Securities and Exchange Commission on August 15, 2018)
Form of Employment Agreement between the Registrant and its executive officers (incorporated by reference to
Exhibit 10.5 of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the
Securities and Exchange Commission on August 15, 2018)
137
Table of Contents
Exhibit
Number
Description of Document
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
4.14
4.15
Form of Indemnification Agreement between the Registrant and its directors and executive officers (incorporated by
reference to Exhibit 10.6 of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed
with the Securities and Exchange Commission on August 15, 2018)
English translation of Exclusive Support Services Agreement between Guangdong Yihao Pharmacy Co., Ltd. and Yao
Fang Information Technology (Shanghai) Co., Ltd. dated September 5, 2013 (incorporated by reference to Exhibit 10.7
of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and
Exchange Commission on August 15, 2018)
English translation of Proxy Agreement between Yao Fang Information Technology (Shanghai) Co., Ltd. and
Guangdong Yihao Pharmacy Co., Ltd. dated September 5, 2013 (incorporated by reference to Exhibit 10.8 of our
registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and Exchange
Commission on August 15, 2018)
English translation of Exclusive Option Agreement between Yao Fang Information Technology (Shanghai) Co., Ltd.
and shareholders of Guangdong Yihao Pharmacy Co., Ltd. dated September 5, 2013 (incorporated by reference to
Exhibit 10.9 of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the
Securities and Exchange Commission on August 15, 2018)
English translation of Equity Transfer Agreement between Jing Liu and shareholders of Guangdong Yihao Pharmacy
Co., Ltd. dated July 13, 2017 (incorporated by reference to Exhibit 10.10 of our registration statement on Form F-1 (file
no. 333-226849), as amended, initially filed with the Securities and Exchange Commission on August 15, 2018)
English translation of Rights and Obligations Assignment Agreement among Jing Liu, Shuhong Yuan, Yue Xuan, Yao
Fang Information Technology (Shanghai) Co., Ltd. and Guangdong Yihao Pharmacy Co., Ltd. dated July 13, 2017
(incorporated by reference to Exhibit 10.11 of our Registration Statement on Form F-1 (file no. 333-226849) filed with
the Securities and Exchange Commission on August 15, 2018)
English translation of Equity Pledge Agreement between Yao Fang Information Technology (Shanghai) Co., Ltd. and
shareholders of Guangdong Yihao Pharmacy Co., Ltd. dated July 13, 2017 (incorporated by reference to Exhibit 10.12
of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and
Exchange Commission on August 15, 2018)
English translation of Exclusive Support Services Agreement between Guangdong Yihao Pharmaceutical Chain
Co., Ltd. and Yao Fang Information Technology (Shanghai) Co., Ltd. dated September 5, 2013 (incorporated by
reference to Exhibit 10.13 of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed
with the Securities and Exchange Commission on August 15, 2018)
English translation of Proxy Agreement between Yao Fang Information Technology (Shanghai) Co., Ltd. and
Guangdong Yihao Pharmaceutical Chain Co., Ltd. dated September 5, 2013 (incorporated by reference to Exhibit 10.14
of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and
Exchange Commission on August 15, 2018)
English translation of Equity Pledge Agreement between Yao Fang Information Technology (Shanghai) Co., Ltd. and
Guangdong Yihao Pharmacy Co., Ltd. dated September 5, 2013 (incorporated by reference to Exhibit 10.15 of our
registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and Exchange
Commission on August 15, 2018)
138
Table of Contents
Exhibit
Number
4.16
4.17
4.18
4.19
4.20
4.21
4.22
4.23
4.24
4.25
English translation of Exclusive Option Agreement between Yao Fang Information Technology (Shanghai) Co., Ltd.
and Guangdong Yihao Pharmacy Co., Ltd. dated September 5, 2013 (incorporated by reference to Exhibit 10.16 of our
registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and Exchange
Commission on August 15, 2018)
Description of Document
English translation of Exclusive Support Services Agreement between Shanghai Yaowang E-Commerce Co., Ltd. and
Yao Fang Information Technology (Shanghai) Co., Ltd. dated September 5, 2013 (incorporated by reference to
Exhibit 10.17 of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the
Securities and Exchange Commission on August 15, 2018)
English translation of Exclusive Option Agreement between Yao Fang Information Technology (Shanghai) Co., Ltd.
and Guangdong Yihao Pharmaceutical Chain Co., Ltd. dated September 5, 2013 (incorporated by reference to
Exhibit 10.18 of registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities
and Exchange Commission on August 15, 2018)
English translation of Equity Pledge Agreement between Yao Fang Information Technology (Shanghai) Co., Ltd. and
Guangdong Yihao Pharmaceutical Chain Co., Ltd. dated September 5, 2013 (incorporated by reference to Exhibit 10.19
of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and
Exchange Commission on August 15, 2018)
English translation of Proxy Agreement among Guangdong Yihao Pharmaceutical Chain Co., Ltd., Yao Fang
Information Technology (Shanghai) Co., Ltd. and Shanghai Yaowang E-Commerce Co., Ltd. dated September 5, 2013
(incorporated by reference to Exhibit 10.20 of our registration statement on Form F-1 (file no. 333-226849), as
amended, initially filed with the Securities and Exchange Commission on August 15, 2018)
English translation of Property Lease Contract between Kunshan Fuchan Warehousing Services Co., Ltd. and Yao Fang
Information Technology (Shanghai) Co., Ltd. dated February 5, 2016 (incorporated by reference to Exhibit 10.21 of our
registration statement on Form F-1 (file no. 333-226849), as amended, initially filed with the Securities and Exchange
Commission on August 15, 2018)
English translation of Property Lease/Pre-lease Contract between Shanghai Zhangjiang Hi-tech Park Development
Co., Ltd. and Yao Fang Information Technology (Shanghai) Co., Ltd. dated November 28, 2017 (incorporated by
reference to Exhibit 10.22 of our registration statement on Form F-1 (file no. 333-226849), as amended, initially filed
with the Securities and Exchange Commission on August 15, 2018)
English translation of Amended Exclusive Support Services Agreement between Guangdong Yihao Pharmacy Co., Ltd.
and Yao Fang Information Technology (Shanghai) Co., Ltd. dated July 1, 2019 (incorporated by reference to Exhibit
4.23 of our Annual Report on Form 20-F (file no. 001-38639) filed with the Securities and Exchange Commission on
April 16, 2020)
English translation of Amended Exclusive Support Services Agreement between Guangdong Yihao Pharmaceutical
Chain Co., Ltd. and Yao Fang Information Technology (Shanghai) Co., Ltd. dated July 1, 2019 (incorporated by
reference to Exhibit 4.24 of our Annual Report on Form 20-F (file no. 001-38639) filed with the Securities and
Exchange Commission on April 16, 2020)
English translation of Amended Exclusive Support Services Agreement between Shanghai Yaowang E-Commerce Co.,
Ltd. and Yao Fang Information Technology (Shanghai) Co., Ltd. dated July 1, 2019 (incorporated by reference to
Exhibit 4.25 of our Annual Report on Form 20-F (file no. 001-38639) filed with the Securities and Exchange
Commission on April 16, 2020)
4.26*
English translation of Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.
dated August 10, 2020
139
Table of Contents
Exhibit
Number
4.27*
4.28*
8.1*
11.1
12.1*
12.2*
13.1**
13.2**
15.1*
15.2*
15.3*
Description of Document
English translation of Supplementary Agreement of Capital Increase Agreement in respect of Yao Fang Information
Technology (Shanghai) Co., Ltd. dated August 26, 2020
English translation of Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.
dated December 14, 2020
List of Principal Subsidiaries and Consolidated Affiliated Entities
Code of Business Conduct and Ethics (incorporated by reference to Exhibit 99.1 of our Registration Statement on
Form F-1 (file no. 333-226849) filed with the Securities and Exchange Commission on August 15, 2018)
Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Consent of Commerce & Finance Law Offices
Consent of Maples and Calder (Hong Kong) LLP
Consent of Deloitte Touche Tohmatsu Certified Public Accountants LLP
101.INS*
XBRL Instance Document
101.SCH*
XBRL Taxonomy Extension Schema Document
101.CAL*
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*
XBRL Taxonomy Extension Label Linkbase Document
101.PRE*
XBRL Taxonomy Extension Presentation Linkbase Document
104*
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Filed herewith
** Furnished herewith
140
Table of Contents
The registrant hereby certifies that it meets all of the requirements for filing its annual report on Form 20-F and that it has duly
caused and authorized the undersigned to sign this annual report on its behalf.
SIGNATURES
111, Inc.
/s/ Junling Liu
By:
Name:Junling Liu
Title: Chief Executive Officer and Co-Chairman of the Board
Date: April 30, 2021
141
Table of Contents
111, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Reports of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2019 and 2020
Consolidated Statements of Comprehensive Loss for the years ended December 31, 2018, 2019 and 2020
Consolidated Statements of Changes in Shareholders’ (Deficit) Equity for the years ended December 31, 2018, 2019 and
2020
Consolidated Statements of Cash Flows for the years ended December 31, 2018, 2019 and 2020
Notes to Consolidated Financial Statements
Financial Statements Schedule I — Financial Information for Parent Company
F-2
F-6
F-7
F-8
F-9
F-10
F-43
F-1
Table of Contents
REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
TO SHAREHOLDERS AND THE BOARD OF DIRECTORS OF 111, INC.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of 111, Inc. and its subsidiaries (the "Company"), as of
December 31, 2020 and 2019, the related consolidated statements of comprehensive loss, shareholders' (deficit) equity, and cash flows
for each of the three years in the period ended December 31, 2020 and the related notes and the financial statement schedule (collectively
referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three
years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of
America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (the
"PCAOB"), the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal
Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our
report dated April 29, 2021, expressed an unqualified opinion on the Company’s internal control over financial reporting.
Convenience Translation
Our audits also comprehended the translation of Renminbi amounts into United States dollar amounts and, in our opinion, such
translation has been made in conformity with the basis stated in Note 2(ah). Such United States dollar amounts are presented solely for
the convenience of readers in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on
the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to
be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or
fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that
was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material
to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the
critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by
communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures
to which it relates.
F-2
Table of Contents
Revenue Recognition— Refer to Note 15 to the financial statements
Critical Audit Matter Description
As described in Note 15, the Company generated approximately 99.4% of its revenue from sales of medicines, healthcare
products and other wellness merchandise through its online platforms in year 2020. The Company recognizes revenues from product
sales at the point in time when the delivery was completed and uses automated systems to process and record its revenue transactions.
We identified occurrence of product revenue as a critical audit matter because there is inherent risk around the occurrence of
revenue recorded by the Company's systems given the complexity and the significant volume of data processed by the systems.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to product revenue recognition included the following, among others:
With the assistance of our IT specialists and data specialists:
● We tested the IT environment in which the revenue transactions are processed, including interface controls between
different IT applications.
● We tested key automated controls over product revenue recognition.
● We performed tests on the data to ensure consistency between different operating systems, consistency between operating
systems and third-party information including delivery information from logistic companies and cash flow information
from banks and third party payment service providers, and consistency between operating systems and accounting system,
to evaluate data accuracy and completeness.
● We analyzed product revenue transaction data by comparing data in different periods and identifying transactions with
characteristics of audit interest for further testing to verify the reasonableness of the transaction and other tests of details.
/s/ Deloitte Touche Tohmatsu Certified Public Accountants LLP
Shanghai, China
April 29, 2021
We have served as the Company’s auditor since 2018.
F-3
Table of Contents
REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
TO SHAREHOLDERS AND THE BOARD OF DIRECTORS OF 111, INC.
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of 111, Inc. and its subsidiaries ( the “Company”) as of December
31, 2020 based on criteria established in Internal Control — Integrated Framework (2013 framework) issued by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects,
effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria established in Internal Control —
Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (the
“PCAOB”), the financial statements as of and for the year ended December 31, 2020 of the Company and our report dated April 29,
2021 expressed an unqualified opinion on those financial statements and included an explanatory paragraph regarding the convenience
translation of Renminbi amounts into United States dollar amounts.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report
on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial
reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material
weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and
performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis
for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the
maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in
accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the
financial statements.
F-4
Table of Contents
Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of the effectiveness to future periods are subject to the risk that the controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/Deloitte Touche Tohmatsu Certified Public Accountants LLP
Shanghai, China
April 29, 2021
F-5
Table of Contents
111, INC.
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except for share and per share data)
Notes
2019
RMB
ASSETS
Current assets:
Cash and cash equivalents
Restricted cash
Short-term investments
Accounts receivable, net of allowance of nil and RMB429 as of December 31, 2019 and 2020, respectively
Notes receivable
Inventories
Prepayments and other current assets
Total current assets
Property and equipment
Intangible assets
Long-term investments
Operating lease right-of-use assets
Other non-current asset
Total assets
LIABILITIES AND EQUITY
Current liabilities including amounts of the consolidated VIE without recourse to the Company (Note 2(b)):
Short-term borrowings
Accounts payable
Accrued expenses and other current liabilities
Total current liabilities
Long-term operating lease liabilities
Other non-current liabilities
Total liabilities
Commitments and contingencies (Note 21)
MEZZANINE EQUITY
Redeemable non-controlling interests
SHAREHOLDERS' EQUITY
Ordinary shares Class A ($0.00005 par value per share; 800,000,000 shares authorized; 96,588,106 issued;
92,120,024 and 93,353,402 outstanding as of December 31, 2019 and 2020, respectively)
Ordinary shares Class B ($0.00005 par value per share; 72,000,000 shares authorized, 72,000,000 shares issued
and outstanding as of December 31, 2019 and 2020)
Treasury shares (1,485,862 and 1,997,620 shares as of December 31 2019 and 2020, respectively)
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income
Total shareholders' equity
Non-controlling interest
Total equity
Total liabilities, mezzanine equity and equity
3
4
5
6
7
8
9
10
11
9
12
14
14
13
As of December 31,
2020
2020
US$
(Note 2 (ah))
182,317
19,757
46,003
24,995
1,928
117,476
47,785
440,261
6,657
999
21
15,115
776
463,829
35,134
164,498
50,133
249,765
9,561
573
259,899
RMB
1,189,620
128,914
300,167
163,094
12,583
766,529
311,797
2,872,704
43,439
6,517
140
98,628
5,061
3,026,489
229,250
1,073,352
327,118
1,629,720
62,388
3,736
1,695,844
581,281
116,441
—
65,247
23,587
486,271
208,604
1,481,431
29,836
8,022
140
87,855
3,009
1,610,293
95,081
444,334
234,008
773,423
57,011
5,936
836,370
—
924,245
141,647
30
30
4
25
(22,991)
2,606,486
(1,883,335)
76,441
776,656
(2,733)
773,923
1,610,293
25
(34,972)
2,669,279
(2,339,868)
62,911
357,405
48,995
406,400
3,026,489
4
(5,360)
409,085
(358,600)
9,642
54,775
7,508
62,283
463,829
The accompanying notes are an integral part of these consolidated financial statements.
F-6
Table of Contents
111, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Amounts in thousands, except for share and per share data)
Net revenues
Operating costs and expenses:
Cost of products sold
Fulfillment expenses
Selling and marketing expenses
General and administrative expenses
Technology expenses
Other operating (expenses) income, net
Total operating costs and expenses
Loss from operations
Interest income
Interest expense
Foreign exchange gain (loss)
Other income, net
Loss before income taxes
Income tax expense
Net loss
Net loss attributable to non-controlling interest and redeemable
non-controlling interest
Net loss attributable to ordinary shareholders
Other comprehensive income (loss), net of tax of nil
Unrealized gains of available-for-sale securities
Realized gains of available-for-sale securities
Foreign currency translation adjustments
Comprehensive loss
Loss per share:
Basic and diluted
Notes
2018
RMB
Year Ended December 31,
2019
RMB
2020
RMB
15
1,785,970
3,952,053
8,203,157
(1,681,700)
(73,930)
(260,040)
(98,759)
(71,248)
(668)
(2,186,345)
(400,375)
4,352
—
2,459
11,531
(382,033)
(8)
(382,041)
(3,786,870)
(128,996)
(340,562)
(123,501)
(61,902)
(3,735)
(4,445,566)
(493,513)
4,802
(3,622)
(10,328)
834
(501,827)
—
(501,827)
(7,837,325)
(226,930)
(399,610)
(128,226)
(92,080)
7,703
(8,676,468)
(473,311)
6,312
(8,817)
5,547
3,161
(467,108)
—
(467,108)
18
2020
US$
(Note 2 (ah))
1,257,189
(1,201,123)
(34,779)
(61,243)
(19,651)
(14,112)
1,181
(1,329,727)
(72,538)
967
(1,351)
850
484
(71,588)
—
(71,588)
1,950
(380,091)
2,221
(499,606)
10,575
(456,533)
1,621
(69,967)
8,734
(10,869)
21,658
(360,568)
7,335
(9,635)
11,668
(490,238)
1,137
(970)
(13,697)
(470,063)
174
(149)
(2,099)
(72,041)
17
(3.82)
(3.05)
(2.77)
(0.42)
Weighted average number of shares used in computation of loss
per share:
Basic and diluted
17 99,451,210 163,671,577 164,786,631 164,786,631
The accompanying notes are an integral part of these consolidated financial statements.
F-7
Table of Contents
111, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ (DEFICIT) EQUITY
(Amounts in thousands, except for share data)
Ordinary Shares
Class A
Ordinary Shares
Class B
Outstanding
Shares
Amount
RMB
Outstanding
Shares
Treasury Shares
Amount
Shares
Amount
RMB
RMB
Balance at January 1, 2018
Share surrendered for cancellation (Note14)
Share-based compensation
Re-designation of Class A ordinary shares into Class B
ordinary shares (Note 14)
Issuance of ordinary shares upon initial public offering
(“IPO”), net of issuance costs of RMB19,134
Conversion of preferred shares into Class A ordinary shares
upon IPO
Net loss
Unrealized gains of available-for-sales securities, net of tax
Reclassification of realized gains, net of tax
Foreign currency translation, net of tax
Balance at December 31, 2018
Share-based compensation
Issuance of ordinary shares upon the exercise of stock
options and vesting of restricted share units
Repurchase of shares
Net loss
Unrealized gains of available-for-sale securities, net of tax
Reclassification of realized gains, net of tax
Foreign currency translation, net of tax
Balance at December 31, 2019
Share-based compensation
Issuance of ordinary shares upon the exercise of stock
options and vesting of restricted share units
Repurchase of shares
Capital contribution from non-controlling shareholders
(Note 14)
Net loss
Less: amount attributable to redeemable non-controlling
interest
Unrealized gains of available-for-sale securities, net of tax
Reclassification of realized gains, net of tax
Foreign currency translation, net of tax
Balance at December 31, 2020
72,000,000
—
—
25
—
—
—
—
—
(72,000,000)
(25)
72,000,000
15,969,110
75,118,996
—
—
—
—
91,088,106
—
2,517,780
(1,485,862)
—
—
—
—
92,120,024
—
1,745,136
(511,758)
—
—
—
—
—
—
93,353,402
5
24
—
—
—
—
29
—
1
—
—
—
—
—
30
—
—
—
—
—
—
—
—
—
30
—
—
—
—
—
—
72,000,000
—
—
—
—
—
—
—
72,000,000
—
—
—
—
—
—
—
—
—
72,000,000
—
—
—
25
—
—
—
—
—
—
25
—
—
—
—
—
—
—
25
—
—
—
—
—
—
—
—
—
25
—
—
—
—
—
—
—
—
—
—
—
—
—
1,485,862
—
—
—
—
1,485,862
—
—
511,758
—
—
—
—
—
—
1,997,620
—
—
—
—
—
—
—
—
—
—
—
—
—
(22,991)
—
—
—
—
(22,991)
—
—
(11,981)
—
—
—
—
—
—
(34,972)
Additional
Paid-in
Capital
RMB
12,121
(2,200)
51,359
—
694,873
1,784,725
—
—
—
—
2,540,878
54,281
11,327
—
—
—
—
—
2,606,486
75,695
6,326
—
(19,228)
—
—
—
—
—
2,669,279
Subscription
receivables
RMB
(2,200)
2,200
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Accumulated
deficit
RMB
(1,003,638)
Accumulated
Other
Comprehensive
Income (Loss)
RMB
47,550
—
—
—
—
—
(380,091)
—
—
—
(1,383,729)
—
—
—
(499,606)
—
—
—
(1,883,335)
—
—
—
—
(467,108)
10,575
—
—
—
(2,339,868)
—
—
—
—
—
—
8,734
(10,869)
21,658
67,073
—
—
—
—
7,335
(9,635)
11,668
76,441
—
—
—
—
—
—
1,137
(970)
(13,697)
62,911
Non-
controlling
Interest
RMB
1,438
—
—
—
—
—
(1,950)
—
—
—
(512)
—
—
—
(2,221)
—
—
—
(2,733)
—
—
—
51,728
—
—
—
—
—
48,995
Total
(Deficit)
Equity
RMB
(944,704)
—
51,359
—
694,878
1,784,749
(382,041)
8,734
(10,869)
21,658
1,223,764
54,281
11,328
(22,991)
(501,827)
7,335
(9,635)
11,668
773,923
75,695
6,326
(11,981)
32,500
(467,108)
10,575
1,137
(970)
(13,697)
406,400
The accompanying notes are an integral part of these consolidated financial statements.
F-8
Table of Contents
111, INC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
Operating activities:
Net loss
Adjustments to reconcile net income to net cash used in operating activities:
Share-based compensation
Depreciation and amortization
(Gain) loss on disposal of property and equipment
Inventory write-down
Allowance of credit losses
Impairment loss
Investment Income
Noncash lease expense
Exchange Gain
Changes in operating assets and liabilities:
Accounts receivable
Notes receivable
Inventories
Prepayments and other current assets
Other non-current assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities
Other non-current liabilities
Net cash used in operating activities
Investing activities:
Purchases of property and equipment
Purchases of intangible assets
Purchase of short-term investments
Proceeds from sale or maturity of short-term investments
Proceeds from disposition of property and equipment
Net cash provided by (used in) investing activities
Financing activities:
Net proceeds from issuance of ordinary shares upon exercise of options
Payment for share repurchase
Contribution from redeemable non-controlling interest holders
Contribution from non-controlling interest holders
Proceeds from IPO, net of issuance cost
Proceeds from short-term bank borrowings
Repayment of short-term bank borrowings
Proceeds from other financing activities
Payment for other financing activities
Proceeds from preferred shareholders
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents, and restricted cash
Net increase (decrease) in cash and cash equivalents, and restricted cash
Cash and cash equivalents, and restricted cash at the beginning of the year
Cash and cash equivalents, and restricted cash at the end of the year
Supplemental disclosure of cash flow information:
Interest paid
Income tax paid
Supplemental disclosures of non-cash investing and financing activities:
Change in fair value of available-for-sale investments
Purchases of property and equipment included in payables
2018
RMB
Year Ended December 31,
2020
2019
RMB
RMB
2020
US$
(Note 2 (ah))
(382,041)
(501,827)
(467,108)
(71,588)
51,359
11,266
1,110
—
—
—
(10,869)
—
—
(8,171)
—
(66,780)
(56,329)
(3,376)
84,118
28,560
—
8,135
(343,018)
(14,443)
(376)
(519,187)
578,359
101
44,454
—
—
—
—
694,878
—
—
—
—
277,819
972,697
11,947
686,080
167,660
853,740
—
8
8,734
848
54,281
11,668
(5)
790
—
11,000
(9,635)
25,394
—
(36,678)
(23,587)
(276,225)
(47,457)
367
232,076
74,376
(24,721)
(2,199)
(512,382)
(20,030)
(4,580)
(601,000)
863,106
179
237,675
11,328
(22,991)
—
—
—
150,919
(55,838)
25,569
—
—
108,987
9,702
(156,018)
853,740
697,722
818
—
7,335
1,133
75,695
14,017
162
24,216
(645)
—
(970)
39,303
(5,547)
(98,276)
11,004
(304,474)
(102,119)
(2,052)
629,018
111,284
(38,085)
(2,200)
(116,777)
(25,505)
(289)
(500,000)
200,970
155
(324,669)
6,326
(11,981)
934,820
32,500
—
398,766
(264,597)
—
(25,427)
—
1,070,407
(8,149)
620,812
697,722
1,318,534
10,865
—
1,137
1,771
11,601
2,148
25
3,711
(99)
—
(149)
6,023
(850)
(15,061)
1,686
(46,662)
(15,650)
(314)
96,401
17,055
(5,837)
(337)
(17,897)
(3,909)
(44)
(76,628)
30,800
24
(49,757)
970
(1,836)
143,267
4,981
—
61,114
(40,551)
—
(3,897)
—
164,048
(1,249)
95,145
106,929
202,074
1,665
—
174
271
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of
financial position that sum to the total of the same such amounts shown in the statement of cash flows:
Cash and cash equivalents
Restricted cash
Cash and cash equivalents, and restricted cash
853,740
—
853,740
581,281
116,441
697,722
1,189,620
128,914
1,318,534
182,317
19,757
202,074
The accompanying notes are an integral part of these consolidated financial statements.
F-9
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED December 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
1. ORGANIZATION AND PRINCIPAL ACTIVITIES
111, Inc. (the "Company"), was incorporated under the laws of the Cayman Islands in May 2013. The Company, through its
subsidiaries, variable interest entities ("VIEs") and VIE's subsidiaries (collectively, the "Group"), operates an integrated online and
offline platform in the healthcare ecosystem in China, whereby the Group is principally engaged in the sales of medical and wellness
products through online retail and wholesale pharmacies and offline retail pharmacies, as well as provision of certain value-added
services, such as online consultation services and e-prescription services to consumers in the People's Republic of China (the "PRC").
As of December 31, 2020, the Group operates its business mainly through the following subsidiaries:
Date of
incorporation/
establishment
Place of
incorporation/
establishment
Percentage of
shareholdings
Principal activities
June 4, 2013
Hong Kong
100%
Investment holding
Name of subsidiaries
Yao Wang Corporation Limited ("Yao Wang")
1 Pharmacy Technology (Shanghai) Co., Ltd.
(previously known as Yaofang Information
Technology (Shanghai) Co., Ltd., "1 Pharmacy
Technology")
Guangdong Yihao Pharmacy Co., Ltd. ("Yihao
August 12, 2013
Shanghai
Pharmacy")
March 7, 2003
Guangdong
Guangdong Yihao Pharmaceutical Chain Co.,
Ltd. ("Yihao Pharmaceutical Chain")
Shanghai Yaowang E-commerce Co., Ltd.
November 1, 2001
Guangdong
("Shanghai Yaowang")
January 15, 2013
Shanghai
Wuhan Central China Drug Trading Co., Ltd.
("Wuhan Huazhong")
August 5, 2015
Wuhan
Chongqing Yihao Pharmacy Co., Ltd.
("Chongqing Yihao Pharmacy")
May 18, 2018
Chongqing
Tianjin Yihao Pharmacy Co., Ltd. ("Tianjin
Yihao Pharmacy")
Kunshan Yifang Pharmacy Co., Ltd. ("Kunshan
June 20, 2018
Tianjin
Yifang Pharmacy")
July 30, 2018
Kunshan
Hubei Yihao Pharmacy Co., Ltd
(“Hubei Yihao Pharmacy”)
Fujian Yaofang Pharmacy Co.,Ltd
(“Fujian Yaofang Pharmacy”)
Aug 31, 2019
Wuhuan
Aug 13, 2019
Fuzhou
Shanxi Yaofang Pharmacy Co., Ltd (“Shanxi
Yaofang Pharmacy”)
Oct 15, 2020
Shanxi
Liaoning Yaofang Pharmacy Co., Ltd (“Liaoning
Yaofang Pharmacy”)
Nov 6, 2020
Liaoning
2. SUMMARY OF PRINCIPAL ACCOUNTING POLICIES
(a) Basis of presentation
86%
VIE
VIE
VIE
70%
1 Pharmacy
Technology's
subsidiary
1 Pharmacy
Technology's
subsidiary
VIE's subsidiary
1 Pharmacy
Technology's
subsidiary
1 Pharmacy
Technology's
subsidiary
1 Pharmacy
Technology's
subsidiary
1 Pharmacy
Technology's
subsidiary
Warehousing, logistics, research and
development, and consulting
Warehousing, logistics and procurement
Retail
Electronic Commerce
Software development and information
technology support
Warehousing and logistics
Warehousing and logistics
Warehousing and logistics
Warehousing and logistics
Warehousing and logistics
Warehousing and logistics
Warehousing and logistics
The consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally
accepted in the United States of America ("US GAAP").
(b) Basis of consolidation
The consolidated financial statements include the financial statements of the Company, its subsidiaries, VIEs and VIE’s
subsidiaries for which the Company is the primary beneficiary. All intercompany transactions, balances and unrealized profit and losses
have been eliminated upon consolidation.
F-10
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(b) Basis of consolidation (Continued)
The Group evaluates the need to consolidate certain variable interest entities in which equity investors do not have the
characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without
additional subordinated financial support or the entity is structured with disproportionate voting rights, and substantially all of the
activities are conducted on behalf of an investor with disproportionately few voting rights.
The Group is deemed as the primary beneficiary of and consolidates variable interest entities when the Group has the power to
direct the activities that most significantly impact the economic success of the entities and effectively assumes the obligation to absorb
losses or has the rights to receive benefits that are potentially significant to the entities.
As a foreign-invested company engaged in Internet-based businesses, the Group is subject to significant restrictions under
current PRC laws and regulations, specifically the Company and its PRC subsidiary, 1 Pharmacy Technology, are both restricted from
holding the licenses that are necessary for the online operation in China. To comply with these restrictions, the Company conducts the
online operations principally through Yihao Pharmacy. Yihao Pharmacy holds the licenses necessary to conduct the internet-related
operations of 1 Medicine Marketplace and 1 Pharmacy in China.
Since the Company does not have any equity interests in Yihao Pharmacy, in order to exercise effective control over its
operations, the Company, through its wholly owned subsidiary, 1 Pharmacy Technology, entered into a series of contractual arrangements
with Yihao Pharmacy and its shareholders, pursuant to which the Company is entitled to receive effectively all economic benefits
generated from Yihao Pharmacy shareholders' equity interests in it. Details of the key agreements entered into between 1 Pharmacy
Technology, Yihao Pharmacy and each of its two individual shareholders nominated by the Founders (“Nominees”) in September 2013
are as follows:
The agreements that provide the Company effective control over the VIE include:
Exclusive Option Agreement: Under the exclusive option agreement, the Nominees granted an irrevocable assets and equity
option to 1 Pharmacy Technology, that entitles 1 Pharmacy Technology or its designated entity or individual to acquire all or a portion of
the assets owned by Yihao Pharmacy and its subsidiaries and all the equity interests held by nominees in Yihao Pharmacy and its
subsidiaries at its sole discretion, at zero price or the lowest price permitted under PRC laws then in effect. The option may be exercised
by 1 Pharmacy Technology or its designee. The exclusive option agreement remains effective for the same period as the exclusive
support service agreement.
Proxy Agreement: Under the shareholder voting right proxy agreement, the Nominees irrevocably grant any person designated
by 1 Pharmacy Technology the power to exercise all voting rights. This Agreement may not be terminated without the consent of 1
Pharmacy Technology, which may unilaterally terminate the agreement, by giving a thirty (30) day prior written notice to the Nominees.
The proxy agreement remains in force for the same period as the exclusive support services agreement.
The agreements that transfer economic benefits to the Company include:
Equity Pledge Agreement: Under the equity pledge agreement, all of the equity interest in Yihao Pharmacy were pledged to 1
Pharmacy Technology to guarantee the performance of the obligations of Yihao Pharmacy and Nominees under the exclusive support
services agreement, the proxy agreement, the exclusive option agreement, and repayment of all accounts payable to 1 Pharmacy
Technology from time to time. If the Nominees or Yihao Pharmacy breach their respective contractual obligations, 1 Pharmacy
Technology, as pledgee, will be entitled to certain rights, including the right to dispose the pledged equity interests. Pursuant to the equity
pledge agreement, the Nominees shall not transfer, assign or otherwise create any new encumbrance on their respective equity interest in
Yihao Pharmacy without the prior written consent of 1 Pharmacy Technology. The equity pledge right enjoyed by 1 Pharmacy
Technology will expire when the Nominees and Yihao Pharmacy have fully performed their respective contractual obligations, including
but not limited to pay services fees to the 1 Pharmacy Technology under the exclusive support services agreement, authorize the 1
Pharmacy Technology to act as its attorney-in fact to exercise shareholders' rights of Nominees under the proxy agreements, grant
exclusive option to the 1 Pharmacy Technology or any third party designated by 1 Pharmacy Technology to
F-11
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(b) Basis of consolidation (Continued)
purchase all or part of their respective equity interests at the lowest price permitted by law under the exclusive option
agreements, and repay all accounts payable to 1 Pharmacy Technology.
Exclusive Support Service Agreement: Pursuant to the exclusive support service agreement, 1 Pharmacy Technology provides
Yihao Pharmacy with a series of technical support services and is entitled to receive related fees. This agreement shall be in full force
and effective until Yihao Pharmacy's valid operation term as stated on business license expires. During the term of this agreement, 1
Pharmacy Technology shall be the exclusive provider of the services. Yihao Pharmacy shall not seek or accept similar services from
other providers without the prior written approval of 1 Pharmacy Technology. The agreement will remain effective for ten years and will
be automatically extended for another ten years thereafter, unless 1 Pharmacy Technology terminates the agreement or it is terminated in
advance pursuant to other provisions of the agreement such as bankruptcy of one party or one party's failure to perform its obligation for
more than six consecutive months due to a force majeure event.
In September 2019, exclusive support services agreements with each of the variable interest entities were amended, pursuant to
which, the variable interest entities agree to pay service fees in an amount equivalent to the balance calculated as 3% of quarterly
revenue (exclusive of revenue from related parties) of the variable interest entities on a quarterly basis. 1 Pharmacy Technology has the
right to delay or waive payment of service fees at its discretion and the service fee level is subject to adjustment at any time upon mutual
agreement between 1 Pharmacy Technology and the variable interest entities.
Similar contractual agreements were also entered into by 1 Pharmacy Technology, Yihao Pharmaceutical Chain and Yao Wang,
and their respective shareholders in September 2013 and September 2019.
US GAAP provides guidance on the identification of VIE and financial reporting for entities over which control is achieved
through means other than voting interests. The Group evaluates each of its interests in an entity to determine whether or not the investee
is a VIE and, if so, whether the Group is the primary beneficiary of such VIE. In determining whether the Group is the primary
beneficiary, the Group considers if the Group (1) has power to direct the activities that most significantly affect the economic
performance of the VIE, and (2) receives the economic benefits of the VIE that could be significant to the VIE. If deemed the primary
beneficiary, the Group consolidates the VIE.
The irrevocable power of attorney has conveyed all shareholder rights held by the VIEs' shareholders to 1 Pharmacy
Technology, including the right to appoint board members who nominate the general managers of the VIEs to conduct day-to-day
management of the VIEs' businesses, and to approve significant transactions of the VIEs. In addition, the exclusive option agreements
provide 1 Pharmacy Technology with a substantive kick-out right of the VIEs shareholders through an exclusive option to purchase all or
any part of the shareholders' equity interest in the VIEs at zero price or the lowest price permitted under PRC laws then in effect. In
addition, through the exclusive support services agreements, the Company established the right to receive benefits from the VIEs that
could potentially be significant to the VIEs, and through the equity pledge agreement, the Company has, in substance, an obligation to
absorb losses of the VIEs that could potentially be significant to the VIEs.
F-12
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(b) Basis of consolidation (Continued)
Risks in relation to the VIE structure
The Group believes that the VIE arrangements are in compliance with PRC law and are legally enforceable. However, there are
certain risks related to the VIE arrangements, which include but are not limited to the following:
● If the Group's ownership structure is found to be in violation of any existing or future PRC laws or regulations, the relevant
governmental authorities, including the China Securities Regulatory Commission, would have broad discretion in dealing with
such violation, including levying fines, confiscating its income or the income of 1 Pharmacy Technology, revoking the business
licenses or operating licenses of 1 Pharmacy Technology, shutting down the Group's servers or blocking the Group's websites,
discontinuing or placing restrictions or onerous conditions on the Group's operations, requiring the Group to undergo a costly
and disruptive restructuring, restricting or prohibiting the Group's use of various funding to finance its business and operations
in China, and taking other regulatory or enforcement actions that could be harmful to the Group's business;
● The Group relies on contractual arrangements with the VIEs and their equity holders for a majority of its PRC operations,
which may not be as effective as direct ownership in providing operational control;
● The Group may have to incur significant cost to enforce, or may not be able to effectively enforce, the contractual arrangements
with the VIEs and their equity holders in the event of a breach or non-compliance by the VIEs or their equity holders;
● Under the contractual arrangements with the VIEs and their shareholders, (a) the Company may replace any such individual as
a shareholder of the VIEs at the Company's discretion, and (b) each of two individuals has executed a power of attorney to
appoint 1 Pharmacy Technology or its designated third party to vote on their behalf and exercise shareholder rights of the VIE.
However, the Company cannot assure that these individuals will act in the best interests of the Company should any conflicts of
interest arise, or that any conflicts of interest will be resolved in the Company's favor. These individuals may breach or cause
the VIE to breach the existing contractual arrangements. If the Company cannot resolve any conflicts of interest or disputes
between the Company and any of these individuals, the Company would have to rely on legal proceedings, which may be
expensive, time-consuming and disruptive to its operations. There is also substantial uncertainty as to the outcome of any such
legal proceedings.
F-13
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(b) Basis of consolidation (Continued)
The following amounts and balances of the VIEs were included in the Group’s consolidated financial statements after the
elimination of intercompany balances and transactions:
Current Assets:
Cash and cash equivalents
Restricted cash
Accounts receivable, net
Notes receivable, net
Inventories
Prepayments and other current assets
Total current assets
Property and equipment
Intangible assets, net
Long-term investments
Operating lease right-of-use assets
Other non-current assets
Total assets
Current Liabilities:
Short-term borrowings
Accounts payable
Accrued expenses and other current liabilities
Total current liabilities
Long-term operating lease liabilities
Total liabilities
Net revenues
Total cost and expenses
Net loss
Net cash used in operating activities
Net cash used in investing activities
Net cash provided by (used in) financing activities
As of December 31,
2019
2020
40,964
12,631
60,173
23,274
389,195
171,318
697,555
15,599
774
140
67,103
2,078
783,249
(65,081)
(394,242)
(149,111)
(608,434)
(47,750)
(656,184)
73,838
57,638
143,210
5,496
298,020
246,264
824,466
10,168
920
140
52,439
2,367
890,500
—
(667,032)
(58,975)
(726,007)
(33,843)
(759,850)
Year Ended December 31,
2019
2020
2018
1,785,757
(1,809,656)
(23,899)
3,302,818
(3,383,187)
(80,369)
4,523,586
(4,565,505)
(41,919)
Year Ended December 31,
2019
(263,750)
(4,684)
87,892
2018
(112,425)
(7,308)
—
2020
(194,149)
(4,180)
(64,963)
The VIEs contributed approximately 99%, 84% and 55%of the Group’s consolidated revenues for each of the years ended
December 31, 2018, 2019 and 2020. As of December 31, 2019 and 2020, the VIEs accounted for an aggregate of approximately 49% and
29%, respectively, of the consolidated total assets, and approximately 78% and 45%, respectively, of the consolidated total liabilities.
Since September 2013, 1 Pharmacy Technology started paying advertising fees and marketing fees to external suppliers for the
VIEs and recharges all or portion of these expenses to the VIEs at cost given that VIEs are in a loss position. The advertising fees and
marketing fees charged by 1 Pharmacy Technology were RMB 79,742, RMB 126,831 and RMB 206,083 for the years ended December
31, 2018, 2019 and 2020, respectively.
F-14
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(b) Basis of consolidation (Continued)
There are no terms in any arrangements, considering both explicit arrangements and implicit variable interests that require the
Company or its subsidiaries to provide financial support to the VIEs. However, if the VIEs ever need financial support, the Company or
its subsidiaries may, at its option and subject to statutory limits and restrictions, provide financial support to its VIEs through loans to the
shareholders of the VIEs or entrustment loans to the VIEs.
The Group believes that there are no assets held in the consolidated VIE that can be used only to settle obligations of the VIEs,
except for registered capital and the PRC statutory reserves. As the consolidated VIEs are incorporated as limited liability companies
under the PRC Company Law, creditors of the VIEs do not have recourse to the general credit of the Company for any of the liabilities of
the consolidated VIE.
Relevant PRC laws and regulations restrict the VIEs from transferring a portion of their net assets, equivalent to the balance of
their statutory reserve and their share capital, to the Company in the form of loans and advances or cash dividends.
(c) Use of estimates
The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of
the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment
include estimating inventory write-down, allowance of credit losses, the useful lives of long-lived assets, impairment of long-term
investments and long-lived assets, assumptions used in valuation of share-based compensation, recoverability of deferred tax assets, sales
return and the fair value of the financial instruments. Management bases the estimates on historical experience and various other
assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of
assets and liabilities. Actual results could differ from these estimates.
(d) Cash and cash equivalents
Cash and cash equivalents consist of cash on hand and demand deposits, which are unrestricted as to withdrawal and use, and
which have original maturities of three months or less when purchased.
(e) Restricted cash
Restricted cash mainly represents the Group's deposits to the banks as a form of security with respect to the Group's debt. The
cash held as deposits in the bank are not available to fund the general operating purposes of the Group.
(f) Short-term investments
Available-for-sale financial securities include debt securities and are measured at fair value. Investments classified as available-
for-sale debt securities are reported at fair value with unrealized gains or losses, if any, recorded in accumulated other comprehensive
income (loss) in the consolidated statements of changes in shareholders’ (deficit) equity. Debt securities in this category are wealth
management products with expected return rate. These wealth management products are issued by a commercial bank in China.
F-15
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(f) Short-term investments (Continued)
On January 1, 2020, the Group adopted Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses
(Topic 326): Measurement of Credit Losses on Financial Instruments ("ASC 326") using the modified retrospective transition method.
Available-for-sale debt securities are impaired if their fair value is below their amortized cost basis. Impairment shall be assessed at the
individual security level. The Group does not combine separate contracts for purposes of determining whether an available-for-sale debt
security is impaired or can contractually be prepaid or otherwise settled in such a way that the Group would not recover substantially all
of its cost. The Group analyzes the impairment of its available-for-sale debt securities by considering factors including, but not limited
to, its ability and intent to hold the individual security, and whether a decline in fair value of the Group’s available-for-sale debt securities
is due to any credit related factors. If the Group determines that an impairment of an available-for-sale debt security is due to any credit
related factors, losses related to a credit impairment will be recorded as an allowance for credit losses with an offsetting entry to net
income, and the portion of losses related to a non-credit factors will be recorded in Other Comprehensive Income (“OCI”). If the Group
determines that an impairment of the available-for-sale debt security is not related to any credit related factors, no allowance for credit
loss expense is recorded, and the non-credit impairment loss will be recorded in OCI.
For periods prior to the adoption of ASC 326, the assessment of impairment of short-term investments was based on whether the
decline in fair value is other-than-temporary. The Group assessed its available-for-sale debt securities for other-than-temporary
impairment by considering factors including, but not limited to, its ability and intent to hold the individual security, severity of the
impairment, expected duration of the impairment and forecasted recovery of fair values. If the Group determined a decline in fair value is
other-than-temporary, the cost basis of the individual security was written down to fair value as a new cost basis and the amount of the
write-down was accounted for as a realized loss charged in the consolidated statement of income and comprehensive income. The fair
values of the investments would not be adjusted for subsequent recoveries in fair values.
As of December 31, 2019 and 2020, the fair value of the Group’s available-for-sale debt securities is equal to their amortized
cost amounting to nil and RMB 300,167, respectively. The Group did not identify any factors that are indicative of impairment with
respect to its available-for-sale debt securities.
(g) Accounts receivable, net
Accounts receivable mainly consists of amount due from the Group's customers, which is recorded net of allowance for credit
losses.
On January 1, 2020, the Group adopted Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses
(Topic 326): Measurement of Credit Losses on Financial Instruments using the modified retrospective transition method. ASC 326
replaces the existing incurred loss impairment model with a forward-looking current expected credit loss ("CECL") methodology, which
results in more timely recognition of credit losses. The Group has developed a CECL model based on historical experience, the age of
the accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and supportable forecasts of
future economic conditions, and other factors that may affect its ability to collect from customers. The cumulative effect from the
adoption as of January 1, 2020 was immaterial to the consolidated financial statements.
F-16
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(g) Accounts receivable, net (Continued)
For periods prior to the adoption of ASC 326, the accounts receivable balance reflects invoiced revenue and is presented net of
an allowance for doubtful accounts. The Group established an allowance for doubtful accounts primarily based on the age of the
receivables and factors surrounding the credit risk of specific customers.
Balance at December 31, 2018
Provision for doubtful accounts
Write-Offs
Balance at December 31, 2019
Credit loss expense
Write-Offs
Balance at December 31, 2020
(h) Inventories
Total allowance for
credit losses
—
—
—
—
429
—
429
Inventories, consisting of products available for sale, are accounted for using the weighted average cost method, and are valued
at lower of cost or the net realizable value. Adjustments are recorded to write down the cost of inventory to the estimated market value
due to slow-moving or damaged products, which is dependent upon factors such as historical and forecasted consumer demand, and
promotional environment. Write-downs are recorded in cost of products sold in the consolidated statements of comprehensive loss.
(i) Property and equipment
Property and equipment are stated at cost less accumulated depreciation and impairment. The renovations, betterments and
interest cost incurred during construction are capitalized. Property and equipment are depreciated at their costs less impairment and
residual value, if any, over the estimated useful lives on a straight-line basis. The estimated useful lives are as follows:
Leasehold improvements
Furniture, fixtures and equipment
Electronic equipment
Vehicles
Shorter of the lease term or their estimated useful lives
3-5 years
3-5 years
4-10 years
Construction in progress represents leasehold improvements under construction or being installed and is stated at cost. Cost
comprises original cost of property and equipment, installation, construction and other direct costs. Construction in progress is
transferred to leasehold improvements and depreciation commences when the asset is ready for its intended use.
Expenditures for repairs and maintenance are expensed as incurred. Gain or loss on disposal of property and equipment, if any,
is recognized in the consolidated statements of comprehensive loss as the difference between the net sales proceeds and the carrying
amount of the underlying asset. There was no interest cost capitalized during the years ended December 31, 2018, 2019 and 2020.
(j) Intangible assets
Intangible assets mainly consist of externally purchased software and licenses. Software are amortized over an estimated useful
life of ten years on a straight-line basis. Licenses are amortized over the remaining estimated useful life on a straight-line basis.
F-17
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(k) Impairment of long-lived assets
Long-lived assets are evaluated for impairment whenever events or changes in circumstances (such as a significant adverse
change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be fully
recoverable. When these events occur, the Group evaluates the impairment for the long-lived assets by comparing the carrying value of
the assets to an estimate of future undiscounted cash flows expected to be generated from the use of the assets and their eventual
disposition. If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Group recognizes
an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets. For the years ended December
31, 2018, 2019 and 2020, there was no impairment recognized for the Group's long-lived assets.
(l) Long-term investments
The Group measures its equity securities without a readily determinable fair value at its cost minus impairment, if any, plus or
minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
These investments are measured at fair value on a nonrecurring basis when there are events or changes in circumstances that
may have a significant adverse effect. An impairment loss is recognized in the consolidated statements of comprehensive loss equal to
the amount by which the carrying value exceeds the fair value of the investment.
(m) Revenue recognition
The Group follows five steps for its revenue recognition under ASC 606:
● Step 1: Identify the contract (s) with a customer
● Step 2: Identify the performance obligations in the contract
● Step 3: Determine the transaction price
● Step 4: Allocate the transaction price to the performance obligations in the contract
● Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation
The Group’s revenue is reported net of discount, value added tax and related surcharges. The primary sources of the Group’s
revenues are as follows:
Product Revenues
The Group recognizes revenues from the sale of medicines, healthcare products and other wellness merchandise through its
online platforms, including its internet website 1 Medicine Marketplace, cellular phone application, other online channels and its offline
pharmacies mainly to individual consumers (the "B2C Business"). The Group also generates revenues from the sale of medicines to its
pharmacy customers mainly through the online platform 1 Pharmacy (the "B2B Business"). In 2020, revenue generated from the
corporate customers (mainly E-channel customers) who place orders through 1 Medicine Marketplace platform were reclassified to B2B
business given the nature of the business (see Note 2(ad)) and therefore the classification in prior periods has been revised to conform to
the current year presentation .
F-18
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(m) Revenue recognition (Continued)
Under both B2C Business and B2B Business, revenues from product sales are recognized at the point in time when the delivery
is made and when title and risk of loss transfers to the consumers and pharmacy customers. Revenues are measured as the amount of
consideration the Group expects to receive in exchange for transferring products to consumers and pharmacy customers ("transaction
price"). To the extent that the transaction price includes variable consideration, the Group estimates the amount of variable consideration
that should be included in the transaction price utilizing the most likely amount method. Variable consideration is included in the
transaction price if, in the Group’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will
not occur. The Group provides the right of return in circumstances when there is packing or delivery damage or other quality problems
identified within 30 days which is considered to be a form of variable consideration. The Group estimates sales returns based on
historical experience and based on such, the amount of sales returns accrual was insignificant as of December 31, 2019 and 2020.
The Group voluntarily provides discount coupons through its websites during its marketing activities. These coupons are not
related to prior purchases, and can only be utilized in conjunction with subsequent purchases on the Group’s platforms. The coupons are
recorded as a reduction of revenue at the time of use.
Under both B2B and B2C Businesses the Group utilizes delivery service providers to deliver products to its consumers and
pharmacy customers ("shipping activities") but the delivery service is not considered as a separate obligation as the shipping activities
are performed before the consumers and pharmacy customers obtain control of the products. Therefore, shipping activities are not
considered a separate promised service to the consumers and pharmacy customers, but rather are activities to fulfill the Group’s promise
to transfer the products and are recorded as fulfillment expenses.
Product revenues are recorded net of surcharges and value added tax ("VAT") ranging from 0% to 13% for different kinds of
products based on the sales amount. Surcharges are sales related taxes representing the City Maintenance and Construction Tax and
Education Surtax. The Group records revenues on a gross basis because the Group controls the products before they are transferred to the
consumers and pharmacy customers determined on the basis that: (1) the Group is primarily responsible for fulfilling its promise to
deliver the specified products to consumers and pharmacy customers; (2) the Group has inventory risk before the specified products are
transferred to a consumers and pharmacy customers or after transfer of control to the consumers and pharmacy customers, and (3) the
Group has discretion in establishing the price for the specified products.
Contract Assets and Liabilities
Contract assets include unbilled receivables, which were recorded in accounts receivable and not material as of December 31,
2019 and 2020.
Contract liabilities consist of advanced payments, which were recorded in accrued expenses and other current liabilities and not
material as of December 31, 2019 and 2020.
Service revenues
Service revenues primarily consist of fees charged to third-party marketplace sellers for whom the Group acts as an agent to
facilitate the marketplace sellers' online sales of their products through the online platforms 1 Medicine Marketplace and 1 Pharmacy,
which is referred to as marketplace service ("MP") revenue. The Group has determined it is not the principal in the arrangement as it is
not responsible to fulfill the order for the specified products, it does not bear the inventory risk for the products, nor does it have the
ability to establish prices. The Group charges the marketplace sellers commission fees equal to an agreed percentage of the sales price of
the product when a sale is completed and also charges market place sellers an annual non-refundable up-front fee for platform usage. The
promise to the customer, which is the marketplace seller, is to arrange for the sale which is considered as one performance obligation.
Therefore, the Group recognizes the up-front fee and commission at the point in time when the sale is completed.
F-19
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(n) Cost of products sold
Cost of products sold consists of the purchase price of products and inbound shipping charges. The Group periodically receives
rebates from certain vendors in the form of cash or credits that the Group can apply against trade amounts owed to vendors pursuant to a
binding arrangement only if the Group completes a specified cumulative level of purchases within a specified time period. The rebates do
not represent a payment for assets or services delivered to the vendor or a reimbursement of costs incurred by the Group to sell vendors’
products. The Group accounts for the rebates received from its vendors as a reduction to the price the Group pays for the products
purchased and therefore records such amounts as a reduction of cost of products sold and inventory when recognized in the consolidated
financial statements. Rebates are earned based on reaching minimum purchase thresholds within a specified period, typically on a fiscal
quarterly or annual basis. Cost of products does not include other direct costs related to cost of product sales such as shipping and
handling expense, payroll and benefits of logistics staff, logistics centers rental expenses and depreciation expenses. Therefore, the
Group’s cost of products sold may not be comparable to other companies which include such expenses in their cost of products.
(o) Fulfillment expenses
Fulfillment expenses primarily consist of payroll, bonus and benefits of logistics staff, logistics centers rental expenses, shipping
and handling expenses, and packaging expenses.
(p) Selling and marketing expenses
Selling and marketing expenses primarily consist of payroll, bonus and benefits of sales and marketing staff, advertising costs,
agency fees and costs for promotional materials.
Advertising expenses are charged to the statements of comprehensive loss in the period incurred. The amounts of advertising
expenses incurred were RMB30,221, RMB30,447 and RMB37,577 for the years ended December 31, 2018, 2019 and 2020, respectively.
(q) Technology expenses
Technology expenses primarily consist of technology infrastructure expenses, payroll, bonus and benefits of the employees in
technology and system department as well as costs associated with the computer, storage and telecommunications infrastructure for
internal use and enhancement to the Group's websites and platform applications.
For internal and external use software, the Group expenses all costs incurred for the preliminary project stage and post
implementation-operation stage of development, and costs associated with repair or maintenance of the existing platform. Costs incurred
in the application development stage are capitalized and amortized over the estimated useful life. The amount of the Group’s technology
expenses qualifying for capitalization has been insignificant, and as a result, all development costs incurred for development of internal
used software have been expensed as incurred.
(r) General and administrative expenses
General and administrative expenses primarily consist of payroll, bonus and benefit costs for corporate employees, legal,
finance, rental expenses and other corporate overhead costs.
F-20
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(s) Government grants
Government grants represent rewards provided by the relevant PRC government authorities to the Group for tax refunds and
support for investment in certain local districts, which are typically granted based on the amount of investments the Group made as well
as income generated by the Group in such districts. Such subsidies allow the Group full discretion to utilize the funds and are used by the
Group for general corporate purposes. Normally, the Group does not receive written confirmation from local governments indicating the
approval of the cash subsidy before cash is received, and therefore cash subsidies are recognized when received and when all the
conditions for their receipts have been satisfied. Government grants recognized were RMB2,166, RMB358 and RMB 5,036 for the years
ended December 31, 2018, 2019 and 2020, respectively, which were recorded in other operating income (expenses), net.
(t) Income Taxes
Current income taxes are provided for in accordance with the laws of the relevant taxing authorities. As part of the process of
preparing financial statements, the Group is required to estimate its income taxes in each of the jurisdictions in which it operates. The
Group accounts for income taxes using the liability method. Under this method, deferred income taxes are recognized for tax
consequences in future years of differences between the tax bases of assets and liabilities and their reported amounts in the financial
statements at each year-end and tax loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates
applicable for the differences that are expected to affect taxable income. Deferred tax assets are reduced by a valuation allowance when,
based upon the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be
realized.
(u) Value added taxes
The Group’s PRC subsidiaries are subject to VAT at rates ranged from 0% to 13% on proceeds received from customers, and are
entitled to a deduction for VAT already paid or borne on the products purchased by them. The VAT balance is recorded in other current
assets or other current liabilities on the consolidated balance sheets.
(v) Comprehensive income (loss)
Comprehensive income (loss) is defined to include all changes in equity except those resulting from investments by owners and
distributions to owners. During the periods presented, comprehensive income (loss) is reported in the consolidated statements of
comprehensive loss, and other comprehensive loss includes foreign currency translation adjustments and fair value change of available-
for-sale debt securities.
(w) Foreign currency translation
The reporting currency of the Group is the Renminbi ("RMB"). The functional currency of the Company and Yao Wang is the
United States dollar ("US dollar"). The functional currency of all the other significant subsidiaries and the variable interest entities is
RMB. The determination of the respective functional currency is based on the criteria of Accounting Standard Codification ("ASC") 830,
Foreign Currency Matters.
Monetary assets and liabilities denominated in currencies other than the applicable functional currencies are translated into the
functional currencies at the prevailing rates of exchange at the balance sheet date. Nonmonetary assets and liabilities are remeasured into
the applicable functional currencies at historical exchange rates. Transactions in currencies other than the applicable functional currencies
during the year are converted into the functional currencies at the applicable rates of exchange prevailing at the transaction dates.
Transaction gains and losses are recognized in the consolidated statements of comprehensive loss.
F-21
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(w) Foreign currency translation (Continued)
Assets and liabilities are translated from each entity’s functional currency to the reporting currency at the exchange rate on the
balance sheet date. Equity amounts are translated at historical exchange rates, and revenues, expenses, gains and losses are translated
using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a
separate component of accumulated other comprehensive loss in the consolidated statements of shareholders’ (deficit) equity.
(x) Concentration of credit risk
Financial instruments that potentially expose the Group to concentration of credit risk consist primarily of cash and cash
equivalents, restricted cash, short-term investments, accounts receivable and prepayments. The Group places its cash and cash
equivalents, restricted cash and short-term investments with financial institutions with high-credit ratings and quality. Accounts
receivable mainly consist of amounts receivable from product delivery service providers and payment processing service providers,
which are all with good collection history. There are no significant concentrations of credit risk. With respect to prepayments, the Group
performs on-going credit evaluations of the financial condition of these suppliers.
Concentration of customers
There were no customers individually representing 10% or more of revenues for the years ended December 31, 2018, 2019 and
2020.
The following customer accounted for 10% or more of balances of accounts receivable as of December 31, 2019 and 2020:
Accounts receivable:
A
* Less than 10%.
Concentration of suppliers
As of December 31,
2019
2020
18.8 %
*
The following supplier accounted for 10% or more of purchases for the years ended December 31, 2018, 2019 and 2020:
Product purchases:
A
B
* Less than 10%.
Year Ended December 31,
2019
2018
2020
13.9 %
12.7 %
*
*
*
*
There were no suppliers accounted for 10% or more of balances of accounts payable as of December 31, 2019 and 2020.
F-22
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(y) Foreign currency risk
Renminbi ("RMB") is not a freely convertible currency. The State Administration of Foreign Exchange, under the authority of
the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central
government policies and to international economic and political developments affecting supply and demand in the China Foreign
Exchange Trading System market. The cash and cash equivalents of the Group included aggregated amounts of RMB 336,583 and RMB
1,071,366, which were denominated in RMB, as of December 31, 2019 and 2020, respectively.
(z) Fair value
Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities
required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would
transact and it considers assumptions that market participants would use when pricing the asset or liability.
The established fair value hierarchy requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. The three levels of inputs may be used to measure fair value
include:
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are
observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical
assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in
which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant
to the measurement of the fair value of the assets or liabilities.
When available, the Group uses quoted market prices to determine the fair value of an asset or liability. If quoted market prices
are not available, the Group measures fair value using valuation techniques that use, when possible, current market-based or
independently sourced market parameters, such as interest rates.
The estimated fair value of the Group's financial instruments of which the inputs used to value are classified as Level 2 and are
not reported at fair value, including cash and cash equivalents, restricted cash, short term investments, accounts receivable, other current
assets, accounts payable, other current liabilities, approximates their carrying value due to their short-term nature.
As of December 31, 2020, information about inputs into the fair value measurement of the Group's assets and liabilities that are
measured at fair value on a recurring basis in periods subsequent to their initial recognition is as follows:
Fair Value Measurements at Reporting Date Using
Fair Value
as of
December 31, 2020
Quoted Prices
in Active Markets
for Identical
Assets (Level 1)
Significant Other
Observable
Inputs (Level 2)
Significant
Unobservable
Inputs
(Level 3)
Wealth management products
300,167
—
300,167
—
The fair values of wealth management products are the suggested redemption price provided by the investment bank that sells
such financial products. There are observable and market-based inputs but not quoted prices in active markets for identical assets. The
total gain recognized for change in fair values of wealth management products is RMB 167 for the year ended December 31, 2020.
F-23
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(z) Fair value (Continued)
Since January 1, 2018, the Group adopted the ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10). Under the new
guidance, entities no longer use the cost method of accounting as it was applied before and the new guidance requires equity investments
(except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at
fair value with changes in fair value recognized in net income. However, a company can elect to measure equity investments that do not
have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in
orderly transactions for the identical or a similar investment of the same issuer (the "measurement alternative"). After management's
assessment of each of the equity investments described in Note 8, management concluded that investments do not have readily
determinable fair values, and elects the measurement alternative. Certain non-financial assets are measured at fair value on a
nonrecurring basis, including property, plant, and equipment, right-of-use assets, and intangible assets. They are recorded at fair value
only when impairment is recognized by applying unobservable inputs such as forecasted financial performance, discount rate, and other
significant assumptions to the discounted cash flow valuation methodology. For the years ended December 31, 2018, 2019 and 2020,
there was no impairment recognized for non-financial assets.
(aa) Share-based compensation
Awards Granted to Employees
The Group grants share options and restricted share units of the Company and its subsidiary to eligible employees and accounts
for these share based awards in accordance with ASC 718 Compensation-Stock Compensation.
Employees’ share-based awards are measured at the grant date fair value of the awards and recognized as expenses
a) immediately at grant date if no vesting conditions are required; or b) using straight-line vesting method over the requisite service
period, which is the vesting period. To the extent the required vesting conditions are not met resulting in the forfeiture of the share-based
awards, previously recognized compensation expense relating to those awards are reversed.
Prior to the IPO of the Company on September 12, 2018, the fair value of the stock options granted to employees is determined
with the assistance of an independent third party valuation firm. The Black Scholes option pricing model was applied in determining the
estimated fair value of the options granted to employees.
After the IPO of the Company, in determining the fair value of the share options and Ordinary Share Units, the closing market
price of the underlying shares on the grant date is applied.
The Group estimates the Company's subsidiary's enterprise value for purposes of recording share-based compensation, and the
information considered by the Company mainly include but are not limited to the pricing of recent rounds of financing, future cash flow
forecasts, discount rates, and liquidity factors.
The compensation expense for the awards with performance conditions is based upon the Group's judgement of likely future
performance and may be adjusted in future periods depending on actual performance.
Awards Granted to Non-Employees
Prior to the adoption of Accounting Standard Update 2018-07 Compensation - Stock Compensation (Topic 718), Improvements
to Nonemployee Share-Based Payment Accounting on January 1, 2019, the Group has accounted for equity instruments issued to non-
employees in accordance with the provisions of ASC 505, Equity-based payments to nonemployees. All transactions in which goods or
services are received in exchange for equity instruments are accounted for based on the fair value of the consideration received or the fair
value of the equity instrument issued, whichever is more reliably measurable. As there is no performance commitment associated with
the equity instrument issued to non-employees, the Group remeasures the awards using the then-current
F-24
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(aa) Share-based compensation (Continued)
fair value at each reporting date until the measurement date, generally when the services are completed and awards are vested,
and attributes the changes in those fair values over the service period by straight-line method.
The Group adopted ASU 2018-07 on January 1, 2019 using the modified retrospective method and recognized the cost of
services received from a nonemployee in exchange for an equity instrument based on the award’s grant-date fair value. Unvested equity-
based payments to nonemployees have been remeasured at fair value as of the adoption date. The adoption did not have material effect
on the consolidated financial statements.
(ab) Treasury shares
Treasury shares represent shares repurchased by the Company that are no longer outstanding and are held by the Company.
Treasury shares are accounted for under the cost method. As of December 31, 2020, under the repurchase plan, the Company had
repurchased an aggregate of 1,997,620 ordinary shares on the open market for total cash consideration of RMB 34,972. The repurchased
shares are presented as "treasury shares" in shareholders' equity on the Group's consolidated balance sheets.
(ac) Earnings (loss) per share
Basic earnings (loss) per ordinary share is computed by dividing net income (loss) attributable to ordinary shareholders by
weighted average number of ordinary shares outstanding during the period.
Diluted earnings (loss) per ordinary share reflects the potential dilution that could occur if securities were exercised or converted
into ordinary shares. The Group has stock options and restricted share units, which could potentially dilute basic earnings per share in the
future. To calculate the number of shares for diluted income per share, the effect of the stock options and restricted share units is
computed using the treasury stock method. Ordinary share equivalents are excluded from the computation of the diluted earnings (loss)
per share in years when their effect would be anti-dilutive.
In September 2018, the Company’s shareholders voted in favor of a proposal to adopt a dual-class share structure, pursuant to
which the Company’s authorized share capital were reclassified and redesigned into Class A ordinary shares and Class B ordinary shares
(Note 14). Both Class A ordinary shares and Class B ordinary shares are entitled to the same dividend right, as such, this dual class share
structure has no impacts to the earnings per share calculation. Basic earnings per share and diluted earnings per share are the same for
each Class A ordinary shares and Class B ordinary shares.
F-25
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(ad) Segment reporting
In accordance with ASC 280, Segment Reporting, the Group's chief operating decision maker (the "CODM") has been
identified as the Co-Chairmen and Chief Executive Officer, who review the segment information when making decisions about
allocating resources and assessing performance of the Group. The Group reorganized its operations into two segments: B2C segment and
B2B segment in 2020, consistent with the change of the manner in which the CODM manages the business. As a result, segment
information for all prior periods have been revised to conform to the current year presentation whereby the B2C business represents
revenue generated from individual consumers while B2B business represents revenue generated from corporate customers. There are no
internal revenue transactions between the reportable segments. The Group does not distinguish expenses between segments in its internal
reporting, and reports expenses by nature as a whole. Furthermore, the Group's CODM is not provided with asset information by
segment. As such, no asset information by segment is presented. The following tables summarize the Group's product revenues and
segment profit (loss) generated by its segments.
B2C segment
Product revenues
Service revenues
Cost of products sold*
Segment profit for B2C Business
B2B segment
Product revenues
Service revenues
Cost of products sold*
Segment profit for B2B Business
Total segment profit
Year Ended December 31,
2019
2020
2018
709,585
13,512
(628,590)
94,507
636,430
17,818
(535,577)
118,671
666,223
25,043
(551,998)
139,268
1,061,559
3,293,268
1,314
4,537
(1,053,110)
9,763
(3,251,293)
46,512
7,490,449
21,442
(7,285,327)
226,564
104,270
165,183
365,832
* For segment reporting purpose, purchase rebate is allocated to B2C segment and B2B segment primarily based on the amount
of cost of products sold for each segment. Cost of products sold does not include other direct costs related to cost of product sales such as
shipping and handling expense, payroll and benefits of logistic staff, logistic centers rental expenses and depreciation expenses, which
are recorded in the fulfillment expenses.
As the Group operates in the PRC and all of the Group’s long-lived assets are located in the PRC, no geographical segments are
presented.
F-26
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(ad) Segment reporting (Continued)
The following is a reconciliation of the reportable segments’ measures of profit or loss to the Group’s consolidated loss before
income taxes:
Total profit for reportable segments
Unallocated amounts:
Fulfillment expenses
Selling and marketing expenses
General and administrative expenses
Technology expenses
Other operating income (expenses), net
Interest income
Interest expense
Foreign exchange gain (loss)
Other income, net
Loss before income tax
Year Ended December 31,
2019
2020
2018
104,270
165,183
365,832
(73,930)
(260,040)
(98,759)
(71,248)
(668)
4,352
—
2,459
11,531
(382,033)
(128,996)
(340,562)
(123,501)
(61,902)
(3,735)
4,802
(3,622)
(10,328)
834
(501,827)
(226,930)
(399,610)
(128,226)
(92,080)
7,703
6,312
(8,817)
5,547
3,161
(467,108)
Revenues from different product groups and services are as follows:
2018
Year Ended December 31,
2019
Product Revenues
Drugs
Nutritional supplements
Contact lenses.
Medical supplies and devices
Other products.
Service Revenues
MP Service
Other Services
Total
(ae) Leases
1,771,144
1,490,834
190,425
47,295
26,563
16,027
14,826
12,490
2,336
1,785,970
3,929,698
3,595,419
245,644
18,110
50,178
20,347
22,355
17,239
5,116
3,952,053
2020
8,156,672
7,398,433
559,239
3,420
149,051
46,529
46,485
30,533
15,952
8,203,157
Before January 1, 2019, the Group applied the ASC Topic 840, Leases, under which each lease is classified at the inception date
as either a capital lease or an operating lease. All the Group’s leases were classified as operating lease under ASC Topic 840. The
Group’s reporting for periods prior to January 1, 2019 continued to be reported in accordance with Leases (Topic 840).
After January 1, 2019, the Group adopted the ASC Topic 842, Leases (“ASC 842”). The Group determines if a contract is or
contains a lease at the inception of the contract, and the Group classifies that lease as a finance lease if it meets certain criteria or as an
operating lease when it does not. For a contract, in which the Group is a lessee, that contains fixed payments for both lease and non-lease
components, the Group has elected to account for lease and non-lease components separately.
F-27
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(ae) Leases (Continued)
At the commencement date of a lease, the Group recognizes a lease liability for future fixed lease payments and a right-of-use
("ROU") asset representing the right to use the underlying asset during the lease term. The lease liability is initially measured as the
present value of the future fixed lease payments that will be made over the lease term. The lease term includes lessee options to extend
the lease and periods occurring after a lessee early termination option, only to the extent it is reasonably certain that the Group will
exercise such extension options and not exercise such early termination options, respectively. The future fixed lease payments are
discounted using the rate implicit in the lease, if available, or the incremental borrowing rate ("IBR"). The Group's IBR is estimated to
approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located. Upon
adoption of ASU 2016-02, the Group elected to use the remaining lease term as of January 1, 2019 in the Group's estimation of the
applicable discount rate for leases that were in place at adoption. For the initial measurement of the lease liability for leases commencing
after January 1, 2019, the Group used the discount rate as of the commencement date of the lease, incorporating the entire lease term.
Additionally, the Group elected not to recognize leases with lease terms of 12 months or less at the commencement date in the
consolidated balance sheets. Current maturities and long-term portions of operating lease liabilities are classified as accrued expenses
and other current liabilities and long-term operating lease liabilities, respectively, in the consolidated balance sheets.
The ROU asset is measured at the amount of the lease liability with adjustments, if applicable, for lease prepayments made prior
to or at lease commencement, initial direct costs incurred by the Group and lease incentives. The Group will evaluate the carrying value
of ROU assets if there are indicators of impairment and review the recoverability of the related asset group. If the carrying value of the
asset group is determined to not be recoverable and is in excess of the estimated fair value, the Group will record an impairment loss in
other expenses in the consolidated statements of operations. ROU assets for operating leases are included in operating lease right-of-use
assets in the consolidated balance sheets.
The Group’s leases include offices and warehouses, which are all classified as operating leases with fixed lease payments, or
minimum payments, as contractually stated in the lease agreement. For operating leases, lease expense relating to fixed payments is
recognized on a straight-line basis over the lease term.
(af) Non-controlling interests
For the Company's consolidated subsidiaries and VIEs, non-controlling interests are recognized to reflect the portion of their
equity that is not attributable, directly or indirectly, to the Company as the controlling shareholder. Non-controlling interests are
classified as a separate line item in the equity section of the Group's consolidated balance sheets and have been separately disclosed in
the Group's consolidated statements of operations and comprehensive income/(loss) to distinguish the interests from that of the
Company.
(ag) Recently issued accounting pronouncements
New Accounting Pronouncements Recently Adopted
In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326)”, which has been
subsequently updated by ASU 2019-04, 2019-05, 2019-10, 2019-11 and 2020-03. The amendments change the impairment model for
most financial assets, and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model,
entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized
cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. The Group
adopted this standard effective January 1, 2020 using the modified-retrospective approach, which no cumulative-effect adjustments were
made.
In August 2018, the FASB issued ASU 2018-13 “Fair Value Measurement (Topic 820)—Disclosure Framework—Changes to
the Disclosure Requirements for Fair Value Measurement”. This guidance removes certain disclosure requirements related to the fair
value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements.
The new disclosure requirements include disclosing the changes in unrealized gains and losses for the period included in
F-28
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
2.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (Continued)
(ag) Recently issued accounting pronouncements (Continued)
other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range
and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Certain disclosures required
by this guidance must be applied on a retrospective basis and others on a prospective basis. The guidance will be effective for fiscal years
beginning after December 15, 2019, although early adoption is permitted. The adoption of this standard did not have a material impact on
the disclosures.
New Accounting Pronouncements Not Yet Adopted
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.
This update simplifies the accounting for income taxes as part of the FASB's overall initiative to reduce complexity in accounting
standards. The amendments include removal of certain exceptions to the general principles of ASC 740, Income taxes, and simplification
in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in
fiscal years beginning after December 15, 2020, and interim periods therein, and early adoption is permitted. Certain amendments in this
update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group
does not expect the adoption of this new standard to have any material impact on its consolidated financial statements.
(ah) Convenience translation
Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive loss, and consolidated
statements of cash flows from RMB into US dollar as of and for the year ended December 31, 2020 are solely for the convenience of the
readers and were calculated at the rate of 6.5250, representing the noon buying rate set forth in the H.10 statistical release of the
U.S. Federal Reserve Board on December 31, 2020. No representation is made that the RMB amounts could have been, or could be,
converted, realized or settled into US dollar at that rate on December 31, 2020, or at any other rate.
3. SHORT-TERM INVESTMENTS
Short-term investments as of December 31, 2019 and 2020 were as follows:
Wealth Management Products
As of December 31,
2019
—
2020
300,167
The Group classifies the wealth management products as "available-for-sale" debt securities which are recorded at fair value.
For the years ended December 31, 2018, 2019 and 2020, the Group recorded RMB8,734, RMB 7,335 and RMB 1,137 of changes in fair
value of these available-for-sale debt securities, net of tax, in other comprehensive income (loss), respectively, and RMB10,869, RMB
9,635 and RMB 970 of realized gains transferred from other comprehensive income to other income when the security was sold. The
amortized cost of the available-for-sale debt securities approximate their fair value. No impairment charges were recorded for the years
ended December 31, 2018, 2019, respectively, and no credit loss was recognized for the year ended December 31, 2020.
4. NOTES RECEIVABLE
As of December 31, 2019 and 2020, the total note receivable balance was RMB 23,587 and RMB12,583 and among which
RMB 14,264 and RMB5,969 were pledged as collateral for short-term borrowings and notes payable. No credit loss was recognized for
the year ended December 31, 2019 and 2020.
F-29
Table of Contents
5. INVENTORIES
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
Inventories as of December 31, 2019 and 2020 were as follows:
Products
As of December 31,
2019
486,271
2020
766,529
In 2019 and 2020, inventories were written down by RMB790 and RMB24,216, respectively, to reflect the lower of cost and net
realizable value.
6. PREPAYMENT AND OTHER CURRENT ASSETS
Prepayment and other current assets, as of December 31, 2019 and 2020 were as follows:
Value added tax recoverable
Rebate receivable from suppliers
Deposits (Note)
Advance to suppliers
Prepaid IT & Insurance expense
Others
Total
As of December 31,
2019
112,362
57,749
8,831
14,807
7,249
7,606
208,604
2020
149,343
114,723
25,600
9,891
8,117
4,123
311,797
Note: Deposits consist of amounts paid to certain vendors for purchasing, advertising and rentals to be utilized within one year.
7. PROPERTY AND EQUIPMENT
Property and equipment consists of the following:
Cost:
Leasehold improvements
Electronic equipment
Furniture, fixtures and equipment
Vehicles
Less: Accumulated depreciation
Construction in progress
Property and equipment, net
As of December 31,
2019
2020
42,858
22,373
15,426
898
81,555
(51,719)
29,836
—
29,836
55,941
25,857
21,334
943
104,075
(60,636)
43,439
—
43,439
Depreciation expense was RMB10,643, RMB10,607 and RMB12,223 for the years ended December 31, 2018, 2019 and 2020,
respectively.
F-30
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
8. LONG-TERM INVESTMENTS
Long-term investments as of December 31, 2019 and 2020 were as follows:
Equity securities without a readily determinable fair value:
Xixi
Longyan Huiyuan
Total
As of December 31,
2019
2020
—
140
140
—
140
140
In June 2015, the Group purchased 5.21% equity interest in Shanghai Xixi Maternal and Baby Care Service Co., Ltd. ("Xixi") at
the consideration of RMB11,000 and fully impaired this investment in 2019. In September 2017, the Group purchased 1% equity interest
in Longyan Huiyuan Pharmacy Co., Ltd. ("Longyan Huiyuan") at the consideration of RMB140. The Group elects to measure these
investments at fair value or at cost, less impairment. Nil, RMB 11,000 and nil impairment was recorded for the Group's long-term
investments for the years ended December 31, 2018, 2019 and 2020.
9. LEASES
The Group has operating leases for offices and warehouses. The Group recognized ROU assets of RMB 87,855 and RMB
98,628, and corresponding current liabilities of RMB 31,099 and RMB 37,713 in accrued expense and other current liabilities, and long-
term operating lease liabilities of RMB 57,011 and RMB 62,388, as of December 31, 2019 and 2020.
Lease expenses were RMB 27,089, RMB 29,715 and RMB 41,936 for the year ended December 31, 2018, 2019 and 2020. The
maturities of lease liabilities in accordance with Leases (Topic 842) in each of the next five years and thereafter as of December 31, 2019
and 2020 were as follows:
Year Ending December 31,
2020
2021
2022
2023
2024
2025
Thereafter
Total lease payment
Less: imputed interest
Present value of minimum operating lease payments
As of December 31,
2019
34,948
24,091
15,668
10,807
7,208
3,767
525
97,014
(8,984)
88,030
2020
—
41,893
32,006
15,602
11,507
7,857
616
109,481
(9,380)
100,101
Cash paid for amounts included in the measurement of operating lease liabilities for the year ended 31 December, 2019 and
2020 were RMB 29,042 and RMB 40,792. Right-of-use assets obtained in exchange for the operating lease liabilities in non-cash
transactions for the year ended 31 December, 2019 and 2020 were RMB 50,841 and RMB 50,076.
Weighted-average remaining lease terms and discount rates are as follows:
Weighted-average remaining lease term
Weighted-average discount rate
As of December 31,
2019
2020
3.5years
5.6 %
3.2years
5.0 %
F-31
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
10. SHORT-TERM BORROWINGS
Short-term borrowings were RMB 95,081 and RMB 229,250 as of December 31, 2019 and 2020, respectively, which consisted
of borrowings from financial institutions. All of these borrowings were repayable within one year. As of December 31, 2020, the Group
had an undrawn balance of RMB 700,150 under the credit facilities agreement. All of these borrowings were unsecured and accrue
interest at an average annual interest rate of 5.32%
In December 2018, certain subsidiaries of the Group entered into a revolving credit facility with China Zheshang Bank (CZB)
that allows the Group to borrow up to RMB 500,000 for working capital purpose which will expire in two years. In December 2020, the
Group renewed the credit agreement that allowed the Group to borrow up to RMB 500,000 for working capital purpose which will expire
in two years. Any draw down on the credit facility will mature within 6 months. Cash deposits or notes receivable are required to be
pledged for any draw down. During the year ended December 31, 2019 and 2020, RMB112,334 and nil were drawn down and RMB
47,253 and RMB 65,081 were repaid with the balance of RMB65,081 and nil outstanding as of December 31, 2019 and 2020,
respectively. As of December 31, 2019 and 2020, RMB116,441 and nil restricted cash deposits and RMB14,264 and nil notes receivable
were pledged to the bank. The interest rate for the borrowings in 2019 and 2020 was approximately 4.35 % per annum.
In September 2019, 1 Pharmacy Technology entered into a credit agreement with China Merchant Bank (CMB) which provides
a revolving credit facility that allows 1 Pharmacy Technology to borrow up to RMB 100,000 for working capital purpose in one year. In
September 2020, Yao Fang renewed the credit agreement that allowed Yao Fang to borrow up to RMB 300,000 for working capital
purpose in one year. Any draw down on the credit facility will be charged with interest at six-month loan prime rate published by
People's Bank of China. The borrowings were guaranteed by Yihao Pharmacy. During the year ended December 31, 2019 and 2020,
RMB 38,585 and RMB 229,666 were drawn on this credit facility and RMB8,585 and RMB159,666 were repaid, with the balance of
RMB 30,000 and RMB 100,000 outstanding as of December 31, 2019 and 2020, respectively. The interest rate range for the borrowings
in 2019 and 2020 were from 4.15% to 4.35 % per annum.
In June 2020, 1 Pharmacy Technology entered into a credit agreement with Industrial Bank (IB) which provides a revolving
credit facility that allows 1 Pharmacy Technology to borrow up to RMB 100,000 for working capital purpose in one year. Any draw
down on the credit facility will be charged with interest at one-year loan prime rate published by People's Bank of China minus 0.35%.
The borrowings were guaranteed by Yihao Pharmacy. During the year ended December 31, 2020, RMB 9,850 was drawn on this credit
facility and nil were repaid, with the balance of RMB 9,850 outstanding as of December 31, 2020.
In May 2020, the Group obtained new loan of RMB 40,000 from Shanghai Pudong Technology Financial Service Co., Ltd. with
annual interest rate of 8.5%. The borrowing was guaranteed by Guangdong Yihao Pharmacy Co., Ltd.. No repayment was incurred
during year 2020 and its balance remained RMB 40,000 as of December 31, 2020. The Group also borrowed RMB 10,000 from China
Construction Bank (CCB). The loan agreement includes covenants that Debt to Asset Ratio of 1 Pharmacy Technology should be no
more than 70%, and the Liquidity Ratio should be no less than 1.0. No repayment incurred during year 2020. The Group was in
compliance with the covenants as of December 31, 2020. The interest rate for the borrowings in 2020 was approximately 8.50 % per
annum.
In 2020, the Group also obtained loans from several other financial institutions. During the year ended December 31, 2020,
RMB 109,250 were borrowed and RMB 39,850 were repaid, with the balance of RMB 69,400 outstanding as of December 31, 2020. The
interest rate range for the borrowings in 2020 was from 3.50 % to 4.6% per annum.
F-32
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
11. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities as of December 31, 2019 and 2020 were as follows:
Accrued advertising expense
Salary and welfare payables
Accrued fulfillment expenses
Accrued delivery service fees
Payable to marketplace sellers (note 1)
Deposits from marketplace sellers
Advance from customers
Tax payables
Current portion of operating lease liabilities
Other financing payable (note 2)
Others
Total
As of December 31,
2019
4,551
28,579
14,378
16,255
15,444
11,311
63,456
2,691
31,099
25,569
20,675
234,008
2020
3,244
53,731
13,274
21,108
29,867
13,564
117,451
9,576
37,713
141
27,449
327,118
Note 1: Amounts relate to cash collected on behalf of marketplace sellers for products sold through the Group’s online platform.
Note 2: Starting in 2019, the Group entered into a series of agreements with a third party financing company, pursuant to which
the third party financing company will provide credit to certain B2B customers who chose to participate. Under the terms of the
agreement, the financing company will make an advance payment of a majority of a B2B customer's order amount to the Group. Credit
terms to the customer are typically 30 days. Customers are required to pay the amount owed to the Group when it is due, and the Group
will normally repay the money to the financing company on the same day. The balance represents the advances to Group which are
outstanding as of December 31, 2019 and 2020.
12. REDEEMABLE NON-CONTROLLING INTERESTS
In August and December, 2020, 1 Pharmacy Technology issued its ordinary shares to certain private placement investors at fair
value evaluated by the third party valuer, representing 9.2% of the outstanding shares of 1 Pharmacy Technology for total consideration
of RMB 934,820. Under the agreements, 1 Pharmacy Technology and the new investors agreed to facilitate 1 Pharmacy Technology's
IPO in the Shanghai Sci-Tech Innovation Board ("STAR") prior to June 30, 2023. If the IPO has not been completed and the China
Securities Regulatory Commission has not otherwise approved the registration of the STAR Listing registration application prior to June
30, 2023, the new investors have the rights to require Yao Wang to repurchase all or any portion of their ownership interests in 1
Pharmacy Technology at the cost plus annual interest rate of 6%. The ownership interests held by the new investors were classified as
redeemable non-controlling interests of Yao Wang under ASC 480 Distinguishing Liabilities from Equity as the redemption feature
embedded in the non-controlling interests and not solely within the Group's control.
The redeemable non-controlling interests for the years ended December 31, 2020 are summarized as follows:
Opening balance as of January 1, 2020
Increase in Yao Wang's redeemable non-controlling interests due to issuance of common stock
of 1 Pharmacy Technology
Net loss attributable to the redeemable non-controlling interests shareholders
Ending balance as of December 31, 2020
Number of shares
Amount
—
—
66,318,885
—
66,318,885
934,820
(10,575)
924,245
F-33
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
13. NON-CONTROLLING INTERESTS
In November 2020, the Company’s subsidiary, 1 Pharmacy Technology issued 32,500,000 ordinary shares to 13 limited liability
partnerships (“LLPs”) founded by the employees of 1 Pharmacy Technology with the total consideration of RMB 32,500. With full
shareholders' rights of these ordinary shares issued to the LLPs, these shares are accounted as non-controlling interest of 1 Pharmacy
Technology. The shares issued to the employees in each LLP are not outstanding shares but are restricted with 50% of the shares vesting
within two years from the issuance date and the remaining 50% vesting evenly on an annual basis over the 2 years thereafter , which are
also subject to adjustment based on performance condition. Such arrangement was entered into to provide a share incentive plan to the
employees of 1 Pharmacy Technology. Share-based compensation was recognized over the vesting period based on the excess of the fair
value of these shares over the issuance price (see Note 16).
Non-controlling interest (“NCI”) was recognized at RMB 51,728 based on the proportional net assets of 1 Pharmacy
Technology, with the difference of RMB19,228 recognized as a deduction to additional paid in capital as of December 31, 2020 in
accordance with ASC 810 changes in a parent’s ownership interest without an accompanying change in control.
14. ORDINARY SHARES
As of January 1, 2018, the authorized shares consist of 72,000,000 Class A ordinary shares, 839,209,895 Class B ordinary
shares, and 13,671,109 Class C ordinary shares. In 2015 and 2016, the Group issued total of 1,607,901 Class C Ordinary Shares to Gold
Prized Investment Limited (‘‘Gold Prized’’) to establish a reserve pool for future issuance of equity share incentive to the Group’s
employees. While these ordinary shares were legally issued to Gold Prized, the voting rights and associated economic rights remained
with the Group. As such, none of these ordinary shares were considered to be granted under the incentive plan, and the Company
accounted for these shares as issued but not outstanding. In June 2018, Gold Prized irrevocably surrendered these 1,607,901 Class C
ordinary shares (“Surrendered Shares”) registered under its name to the Group resulting in the cancellation of the related subscription
receivable of RMB2,200, which has no effect on the Group’s total (deficit) equity amount. The Surrendered Shares were cancelled with
effect from June 2018 and the Company reserved those shares in the authorized share capital to be issued pursuant to the Plan.
In September 2018, with the effectiveness of the revised Articles of Association, the Company’s authorized share capital was
changed to US$50 divided into 1,000,000,000 shares comprising (i) 800,000,000 Class A ordinary shares of a par value of US$0.00005
each, (ii) 72,000,000 Class B ordinary shares of a par value of US$0.00005 each and (iii) 128,000,000 shares of a par value of
US$0.00005 each of such class or classes as Company’s board of directors may determine. All 72,000,000 issued and outstanding Class
A ordinary shares beneficially owned by Dr. Gang Yu and Mr. Junling Liu were re-designated as Class B ordinary shares, and all other
issued and outstanding shares were re-designated as Class A ordinary shares. Each Class A ordinary share entitles the holder to one vote,
and each Class B ordinary share entitles the holder to fifteen votes on all matters subject to the vote at general meetings of the Company.
In September 2018, 75,118,996 preferred shares were converted into Class A ordinary shares and the Company issued
15,969,110 Class A ordinary shares with the completion of the IPO.
On January 25, 2019, 5,500,000 Class A ordinary shares were issued to the Company's depositary bank for bulk issuance of
ADSs reserved for future issuances upon the exercise of stock options or vesting of restricted stocks under the 2013 Share Incentive
Policy, 2014 Share Incentive Policy, 2016 Share Incentive Plan and 2018 Share Incentive Plan (together, the "Plans"). As of December
31, 2019 and 2020, 2,517,780 and 4,262,916 Class A ordinary shares are issued and outstanding upon the exercise of stock options and
vesting of restricted stocks, and 2,982,220 and 1,237,084 Class A ordinary shares are deemed issued but not outstanding as they have not
been transferred to grantees.
F-34
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
15. NET REVENUES
Disaggregation of revenues
All of the Group’s revenues for the years ended December 31, 2018, 2019 and 2020 were generated within the PRC. The
following table illustrates the disaggregation of the Group’s revenue streams by type of customers and nature of services the Group
offered:
Product Revenues
B2C Business*
B2B Business*
Service Revenues
MP Service
Other Services
Total
Year Ended December 31,
2019
2018
1,771,144
709,585
1,061,559
14,826
12,490
2,336
1,785,970
3,929,698
636,430
3,293,268
22,355
17,239
5,116
3,952,053
2020
8,156,672
666,223
7,490,449
46,485
30,533
15,952
8,203,157
* Prior to 2019, product revenue was classified as either B2C business or B2B business based on the platform the revenue was
generated, i.e. revenue generated from its platform of 1 Medicine Marketplace and other online channel (individual consumers and
certain corporate customers) was classified as B2C business while revenue generated from 1 Pharmacy (qualified corporate customers)
was classified as B2B business. In 2020, as a result of segment change (see Note 2(ad)), the Group redefined the B2C business as
revenue generated from individual consumers while B2B business as revenue generated from corporate customers. As a result of this
change, revenue for all prior periods have been revised to conform to the current year presentation.
The revenues by different product groups and services has been disclosed in Note 2(ad).
Contract balance
The typical contract term of MP service is no more than one year and the remaining unsatisfied performance obligation as of
December 31, 2019 and 2020 was insignificant.
In some arrangements from which product revenue is generated, the Group receives advance payments from consumers and
pharmacy customers before the product is delivered, which is recorded as advance from customers included in the accrued expenses and
other current liabilities on the consolidated balance sheet. The movements of the Group’s accounts receivable and advances from
customers are as follows:
Opening Balance as of January 1, 2019
Increase/(decrease), net
Ending Balance as of December 31, 2019
Increase/(decrease), net
Ending Balance as of December 31, 2020
Accounts
Receivable
Advances from
Customers
28,569
36,678
65,247
97,847
163,094
15,489
47,967
63,456
53,995
117,451
Revenues with amount of RMB15,489 and RMB 63,456 were recognized in the years ended December 31, 2019 and 2020,
respectively that were included in the balance of advance from customers at the beginning of the each year.
F-35
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
16. SHARE-BASED COMPENSATION
In September 2013, the Board of Directors of the Company approved an Equity Incentive Plan (the “Plan”), under which, the
Board of Directors may grant options to purchase ordinary shares to officers and directors, employees and individual advisors who render
services to the Group to purchase an aggregate of no more than 1,287,500 ordinary shares of the Group (“Option Pool”). From 2014 to
2020, the Board of Directors approved to increase the Option Pool to 16,943,190 ordinary shares.
Employee Share options
During the years ended December 31, 2018, 2019 and 2020, options to purchase 5,296,204, 1,063,293 shares and
965,000 shares respectively, were granted to the Group’s employees. The weighted-average grant-date exercise price of the options
granted to employees in 2018, 2019 and 2020 was US$2.17, US$4.12 and US$2.58 per share, respectively. The options granted have a
contractual term of 10 years and generally vest over a four-year period, with two typical vesting schedules: (1) 40% of the awards vesting
one year after the grant date, with the remaining 60% of the awards vesting evenly on an annual basis over the 3 years thereafter; or
(2) 25% of the awards vesting on the anniversary of the grant date each year.
The Black Scholes model was applied in determining the estimated fair value of the options granted. The model requires the
input of subjective assumptions. The following table presents the assumptions used to estimate the fair values of the share options
granted for the years ended December 31, 2018, 2019 and 2020:
Risk-free rate of return
Contractual life of option
Estimated volatility rate
Dividend yield
Fair value per ordinary share
2018
2019
2020
2.01%~2.63% 1.68%~2.63% 0.10%-1.67%
10 years
27%~38%
Nil
10 years
30%~41%
Nil
10 years
34%-59%
Nil
US$3.00~$9.51 US$2.37~$3.40 US$2.95-$3.74
The weighted-average grant-date fair value of the options granted in 2018, 2019 and 2020 is US$5.69, US$0.49 and US$1.06
per share, respectively.
F-36
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
16. SHARE-BASED COMPENSATION (Continued)
A summary of employee option activity under the Plan during the years ended December 31, 2019 and 2020 is presented below:
Weighted
average
exercise
price
US$
Weighted
average
remaining
contractual
term
Years
8.28
Aggregate
intrinsic
value
US$
36,888
Outstanding at January 1, 2019
Granted
Forfeited
Exercised
Outstanding at December 31, 2019
Granted
Forfeited
Exercised
Outstanding at December 31, 2020
Vested and exercisable as of December 31, 2020
Vested or expected to vest as of December 31, 2020
Number of
Options
8,890,629
1,063,293
(2,086,050)
(1,962,484)
5,905,388
965,000
(247,232)
(325,190)
6,297,966
3,067,157
6,297,966
1.76
4.12
1.99
0.76
2.44
2.58
2.10
1.62
2.52
2.18
2.52
7.96
22,807
7.32
21,389
6.59
7.32
11,500
21,389
The aggregate intrinsic value of options exercised during the year ended December 31, 2019 and 2020 were RMB 22,222 and
RMB 8,680. As of December 31, 2020, there was RMB38,383 of unrecognized compensation expense related to unvested share options,
which is expected to be recognized over a weighted average period of 1.7 years.
Non-Employee Share options
At January 1, 2018, options to purchase 1,071,587 shares were outstanding with weighted average exercise price of US$1.00
and 1,008,462 options have been vested. During the years ended December 31, 2018, options to purchase 35,000 shares, were issued to
individual advisors who are non-employees of the Group, all with an exercise price of US$1.99. No option was issued to individual
advisors during the year ended December 31, 2019 and 2020. Options totaling 254,068 and 781,894 were exercised in year 2019 and
2020. The options were issued in payment for their consultation services which was expected to be performed over 4 years from the date
of issuance. As services are performed, 25% of the awards vest on the anniversary of the grant date each year. The estimated fair value of
the awards were determined using the Black Scholes model with the same assumptions used in employee share options. As of December
31, 2020, 70,625 options were outstanding of which, 29,063 are vested and exercisable and the remainder are expected to vest. As of
December 31, 2020, there was RMB 116 of unrecognized compensation expense related to unvested share options, which is expected to
be recognized over a weighted average period of 1.1 years.
Restricted share units
The fair value of restricted share units with service conditions or performance conditions is based on the fair market value of the
underlying ordinary shares on the date of grant.
In 2019 and 2020, the Group granted 3,050,427 and 1,716,950 restricted share units and vest over a four-year period that 25% of
the awards vesting on the anniversary of the grant date each year.
F-37
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
16. SHARE-BASED COMPENSATION (Continued)
The following table summarized the Group's restricted share unit activities in 2019 and 2020.
Restricted share units outstanding at January 1, 2019
Granted
Forfeited
Vested
Restricted share units outstanding at December 31, 2019
Granted
Forfeited
Vested
Restricted share units outstanding at December 31, 2020
Number of
Restricted Weighted Average Grant Date
Share Units
Fair Value
US$
—
3,050,427
(195,200)
(301,228)
2,553,999
1,716,950
(565,116)
(638,052)
3,067,781
—
3.90
3.10
4.60
3.88
3.28
2.83
4.12
3.69
The total fair value of restricted share units vested during the year ended December 31, 2019 and 2020 was RMB 9,050 and
RMB 17,017, respectively. The fair value of restricted share units was computed based on the fair value of the Group’s ordinary shares
on the grant date. As of December 31, 2020, there was RMB 66,179 in total unrecognized compensation expense related to such non-
vested restricted shares, which is expected to be recognized over a weighted-average period of 2.8 years.
Employee ownership plan of 1 Pharmacy Technology
As disclosed in Note 13, the excess of the fair value of the restricted shares of LLPs issued to the employees of 1 Pharmacy
Technology over the issuance price of RMB 32,500 is recognized as share based compensation over the vesting period.
The Group determined the fair value of the restricted shares using income approach with the assistance from third party
valuation specialist. The fair value of the restricted shares was estimated at RMB 14.2 per share compared with the issuance price of
RMB 1.0 per share.
The number of restricted shares of LLPs unvested and expected to be vested was 32,500,000 as of December 31, 2020.
Total share-based compensation expense recognized in 2020 was RMB 17 million.
As of December 31, 2020, there was RMB 408,188 of unrecognized compensation expense related to the unvested restricted
shares of LLPs, which is expected to be recognized over a weighted average period of 3.8 years.
F-38
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
16. SHARE-BASED COMPENSATION (Continued)
Share-based compensation for all share options, restricted share units and employee ownership plan of 1 Pharmacy Technology
The Group recorded share based compensation expense of RMB 51,359, RMB 54,281 and RMB 75,695 for the years ended
December 31, 2018, 2019 and 2020, respectively, which were classified in the accompanying consolidated statements of operations as
follows:
General and administrative expenses
Selling and marketing expenses
Technology and content expenses
Total
2018
RMB
Year Ended December 31,
2019
RMB
22,477
23,561
5,321
51,359
25,412
24,772
4,097
54,281
2020
RMB
22,727
40,562
12,406
75,695
As of December 31, 2020, there was RMB 512,866 of total unrecognized compensation expense related to unvested share
options and restricted share units. That cost is expected to be recognized over a weighted-average period of 3.5 years.
17. LOSS PER SHARE
The following table sets forth the computation of basic and diluted loss per share for the years indicated:
Net loss attributable to Class A and Class B ordinary shareholders
Weighted average number of Class A and Class B ordinary shares-basic and
diluted
Net loss per Class A and Class B ordinary share-basic and diluted
2018
Year Ended December 31,
2019
Class A and Class B Class A and Class B Class A and Class B
(456,533)
(499,606)
(380,091)
2020
99,451,210
(3.82)
163,671,577
(3.05)
164,786,631
(2.77)
As a result of the Group’s net loss for the three years ended December 31, 2018, 2019 and 2020, share options and restricted
share units outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would
have been anti-dilutive.
Share options and restricted share units
18. INCOME TAX EXPENSE
Cayman Islands
Year Ended December 31,
2019
2018
9,997,216
9,311,906
2020
9,436,372
Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gain.
Hong Kong
Yao Wang is subject to Hong Kong profit tax at a rate of 16.5%. No Hong Kong profit tax has been provided as the Group has
not had assessable profit that was earned in or derived from Hong Kong during the years presented.
F-39
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
18.
INCOME TAX EXPENSE (Continued)
PRC
Under the Law of the People’s Republic of China on Enterprise Income Tax ("EIT Law"), domestically-owned enterprises and
foreign-invested enterprises are subject to a uniform tax rate of 25%. High-technology enterprises may obtain a preferential tax rate of
15% provided they meet the related criteria. In December 2019, 1 Pharmacy Technology received approval from relevant government
authorities to be classified as a "High and New Technology Enterprise" ("HNTE") and 1 Pharmacy Technology is still on the position of
loss. The HNTE qualification is valid for three years through 2021.
There is no provision for income taxes because the Company and all of its owned subsidiaries are in cumulative loss positions
for all the periods presented.
A reconciliation between the effective income tax rate and the PRC statutory income tax rate is as follows:
PRC statutory tax rate
Tax effect of other expenses that are not deductible in determining taxable profit
Effect of changing tax rate due to high-tech enterprise qualification
Taxable income derived from the inter group loan waiver
Effect of enacted tax rate change
Effect of change in valuation allowance
Effective tax rate
Year Ended December 31,
2020
2019
25 %
(3)%
(11)%
—
5 %
(16)%
0 %
25 %
(3)%
—
(35)%
6 %
7 %
0 %
The principal components of the Group’s deferred income tax assets and liabilities as of December 31, 2019 and 2020 are as
follows:
Deferred tax assets:
Net loss carryforward
Advertising expense carried forward for future deduction
Accrued expenses and payroll payable
Provision for impairment of assets
Others
Valuation allowance
Total deferred tax assets
Deferred tax liabilities:
Total deferred tax liabilities
As of December 31,
2019
2020
337,214
19,613
10,805
—
890
(368,522)
—
286,356
30,827
12,594
7,072
781
(337,630)
—
—
—
As of December 31, 2019 and 2020, valuation allowance of RMB368,522 and RMB 337,630 was provided, respectively. The
Group considers positive and negative evidence to determine whether some portion or all of the deferred tax assets will more likely than
not be realized. This assessment considers, among other matters, the nature, frequency and severity of recent losses, forecasts of future
profitability, the duration of statutory carryforward periods, the Group’s experience with tax attributes expiring unused and tax planning
alternatives. Valuation allowances have been established for deferred tax assets based on a more likely than not threshold. The Group’s
ability to realize deferred tax assets depends on its ability to generate sufficient taxable income within the carryforward periods provided
for in the tax law.
As of December 31, 2020, the Group had tax loss carryforwards of RMB 1,145,424 which will expire between 2020 and 2030 if
not used.
F-40
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
18.
INCOME TAX EXPENSE (Continued)
The Group determines whether or not a tax position is "more-likely-than-not" of being sustained upon audit based solely on the
technical merits of the position. The Group does not anticipate any significant changes to its liability for unrecognized tax benefits within
the next 12 months.
According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of
income taxes is due to computational errors made by the taxpayer. The statute of limitations will be extended to five years under special
circumstances, which are not clearly defined, but an underpayment of income tax liability exceeding RMB100 is specifically listed as a
special circumstance. In the case of a transfer pricing related adjustment, the statute of limitations is ten years. There is no statute of
limitations in the case of tax evasion. The Group’s PRC subsidiaries are therefore subject to examination by the PRC tax authorities from
2014 through 2020 on non-transfer pricing matters, and from 2010 through 2020 on transfer pricing matters.
19. RELATED PARTY TRANSACTIONS
The table below sets forth the related party and its relationship with the Group
Zhejiang Youzhan Information Technology Co., Ltd.
Entity controlled by Chief Operating Officers of the Group
Name of related party
Relationship with the Group
In September 2018, the Group purchased electronic equipment RMB157 from Zhejiang Youzhan Information Technology Co.,
Ltd., and there were no similar purchases occurred in 2019 and 2020.
The following table presents amounts owed from related parties as of December 31, 2018, 2019 and 2020:
Accrued expenses and other current liabilities
20. MAINLAND CHINA CONTRIBUTION PLAN
2018
157
As of December 31,
2019
—
2020
—
Full time employees of the Group in the PRC participate in a government-mandated defined contribution plan pursuant to which
certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to
employees. PRC labor regulations require the Group to accrue for these benefits based on a certain percentage of the employees’ salaries.
The total contribution for such employee benefits were RMB44,598, RMB50,046 and RMB 28,044 for the years ended December 31,
2018, 2019 and 2020, respectively. The Group has no ongoing obligation to its employees subsequent to its contributions to the PRC
plan.
21. RESTRICTED NET ASSETS
Pursuant to laws applicable to entities incorporated in the PRC, the subsidiaries of the Group in the PRC must make
appropriations from after-tax profit to non-distributable reserve funds. These reserve funds include one or more of the following: (i) a
general reserve, (ii) an enterprise expansion fund and (iii) a staff bonus and welfare fund. Subject to certain cumulative limits, the general
reserve fund requires annual appropriation of 10% of after tax profit (as determined under accounting principles generally accepted in the
PRC at each year-end) until the accumulative amount of such reserve fund reaches 50% of their registered capital; the other fund
appropriations are at the subsidiaries’ discretion. These reserve funds can only be used for the specific purposes of offsetting future
losses, enterprise expansion and staff bonus and welfare and are not distributable as cash dividends. During the years ended
December 31, 2018, 2019 and 2020, no appropriation to statutory reserves was made because the PRC subsidiaries had substantial losses
during such periods. In addition, due to restrictions on the distribution of share capital from the Company’s PRC subsidiaries and VIEs,
the PRC subsidiaries and VIEs' share capital of RMB 1,667,461 and RMB 984,959 at December 31, 2019 and 2020 is considered
restricted, which are not available for distribution to the Company by its PRC subsidiaries in the form of dividends, loans or advances.
F-41
Table of Contents
111, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2018, 2019 and 2020
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
22. COMMITMENTS AND CONTINGENCIES
The Group is subject to periodic legal or administrative proceedings in the ordinary course of its business. The Group does not
believe that any currently pending legal or administrative proceeding to which the Group is a party will have a material adverse effect on
the financial statements.
F-42
Table of Contents
ADDITIONAL FINANCIAL INFORMATION - FINANCIAL STATEMENTS SCHEDULE I
111, INC.
FINANCIAL INFORMATION FOR PARENT COMPANY
BALANCE SHEETS
(Amounts in thousands, except for share data and per share data, unless otherwise stated)
ASSETS
Current assets:
Cash and cash equivalents
Prepayments and other current assets
Total current assets
Investment in subsidiaries and VIEs
Total assets
LIABILITIES AND EQUITY
Other current liabilities
Other non-current liabilities
Total liabilities
SHAREHOLDERS' (DEFICIT) EQUITY
Ordinary shares Class A ($0.00005 par value per share; 800,000,000 shares authorized, 96,588,106 shares issued
and 92,120,024 and 93,353,402 outstanding as of December 31, 2019 and 2020, respectively)
Ordinary shares Class B ($0.00005 par value per share; 72,000,000 shares authorized, 72,000,000 shares issued and
outstanding as of December 31, 2019 and 2020)
Treasury shares (1,485,862 and 1,997,620 shares as of December 31 2019 and 2020)
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income
Total shareholders' equity
Total liabilities and shareholders' equity
F-43
2019
RMB
2020
RMB
2020
US$
(Note 2 (ag))
176,001
608,918
784,919
—
784,919
2,327
5,936
8,263
14,696
355,942
370,638
—
370,638
9,497
3,736
13,233
2,252
54,552
56,804
—
56,804
1,456
573
2,029
30
30
4
25
(22,991)
2,606,486
(1,883,335)
76,441
776,656
784,919
25
(34,972)
2,669,279
(2,339,868)
62,911
357,405
370,638
4
(5,360)
409,085
(358,600)
9,642
54,775
56,804
Table of Contents
ADDITIONAL FINANCIAL INFORMATION - FINANCIAL STATEMENTS SCHEDULE I
111, INC.
FINANCIAL INFORMATION FOR PARENT COMPANY
STATEMENTS OF COMPREHENSIVE LOSS
(Amounts in thousands, unless otherwise stated)
Operating expenses:
General and administrative expenses
Interest income (expense), net
Other operating income (expense), net
Other income, net
Income (loss) before tax and loss from investment in subsidiaries and VIEs
Share of loss of subsidiaries and VIEs
Net loss attributable to ordinary shareholders
Other comprehensive income (loss) (net of tax of nil)
Unrealized securities holding (loss) gains
Realized securities holding gains
Foreign currency translation adjustments
Unrealized securities holding gains of subsidiaries and VIEs
Realized securities holding gains of subsidiaries and VIEs
Comprehensive loss
F-44
Years Ended December 31,
2018
RMB
2019
RMB
2020
RMB
2020
US$
(Note 2 (ag))
(2,145)
371
31
3,253
1,510
(8,523)
593
—
7,161
(769)
(14,202)
166
—
2,199
(11,837)
(2,176)
25
337
(1,814)
(381,601)
(380,091)
(498,837)
(499,606)
(444,696)
(456,533)
(68,153)
(69,967)
(286)
(399)
21,658
9,020
(10,470)
(360,568)
3,356
(4,962)
11,668
3,979
(4,673)
(490,238)
—
—
(13,697)
1,137
(970)
(470,063)
—
—
(2,099)
174
(149)
(72,041)
Table of Contents
ADDITIONAL FINANCIAL INFORMATION - FINANCIAL STATEMENTS SCHEDULE I
111, INC.
FINANCIAL INFORMATION FOR PARENT COMPANY
STATEMENTS OF CASH FLOWS
(Amounts in thousands, unless otherwise stated)
Operating activities:
Net loss
Adjustments to reconcile net income to net cash (used in) provided by operating
(380,091)
(499,606)
(456,533)
(69,967)
Years Ended December 31,
2018
RMB
2019
RMB
2020
RMB
2020
US$
(Note 2 (ag))
activities:
Share of loss of subsidiaries and VIEs
Other current liabilities
Other non-current liabilities
Investment income
Net cash provided by (used in) operating activities
Investing activities:
Purchase of investment in subsidiaries and VIEs
Payment for shareholder loan to subsidiaries
Proceeds from sale or maturity of short-term investments
Net cash used in investing activities
Financing activities:
Proceeds from ordinary shareholders
Payment of share repurchase
Proceeds from IPO, net of issuance cost
Proceeds of preferred shareholders
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents, and restricted cash
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
381,601
2,284
8,135
(2,591)
9,338
498,837
43
(2,199)
(4,962)
(7,887)
444,696
7,170
(2,200)
—
(6,867)
(821,962)
—
25,160
(796,802)
—
(203,388)
117,214
(86,174)
—
(135,254)
—
(135,254)
—
—
694,878
277,819
972,697
75,672
260,905
1,954
262,859
11,328
(22,991)
—
—
(11,663)
18,866
(86,858)
262,859
176,001
6,327
(11,981)
—
—
(5,654)
(13,530)
(161,305)
176,001
14,696
68,153
1,099
(337)
—
(1,052)
—
(20,729)
—
(20,729)
970
(1,836)
—
—
(866)
(2,074)
(24,721)
26,973
2,252
F-45
Table of Contents
ADDITIONAL FINANCIAL INFORMATION - FINANCIAL STATEMENTS SCHEDULE I
111, INC.
FINANCIAL INFORMATION FOR PARENT COMPANY
Note to Schedule I
Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04-(c) of Regulation S-X, which require
condensed financial information as to the financial position, change in financial position and results of operations of a parent company as
of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted
net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed
fiscal year.
The condensed financial information has been prepared using the same accounting policies as set out in the accompanying
consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries and VIEs.
Such investments in subsidiaries and VIEs are presented on the balance sheets as investment in subsidiaries and VIEs and the loss of the
subsidiaries and VIEs is presented as share of loss of subsidiaries and VIEs.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting
principles generally accepted in the United States of America have been condensed or omitted. The footnote disclosures contain
supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the
notes to the accompanying consolidated financial statements.
As of December 31, 2020, there are no material contingencies, mandatory dividend and significant provisions for long-term
obligations or guarantees of the Company, except for those which have separately disclosed in the consolidated financial statements.
F-46
Exhibit 4.26
Capital Increase Agreement
in respect of
Yao Fang Information Technology (Shanghai) Co., Ltd.
Dated August 10, 2020
Section
Table of Contents
1. Definitions and Interpretation
2. Capital Increase
3. Payment
4. Warranties and Covenants
5. Completion of the Capital Increase
6. Rights and Obligations of the Shareholders
7. Employee Incentive Plan
8. Corporate Conversion
9. Admission of New Investors
10. Debt Forgiveness
11. Confidentiality
12. Indemnification
13. Rescission and Termination
14. Notices
15. Force Majeure
16. Governing Law and Dispute Resolution
17. Miscellaneous
Exhibit 1 List of Investors
Exhibit 2 Shareholding Structure of the Company Immediately after the Completion of the Capital Increase
Exhibit 3 List of Competitors
Page
2
4
4
5
6
6
12
12
13
13
14
14
15
15
17
17
17
30
31
32
This Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd. (this “Agreement”) is made
in Shanghai as of August 10, 2020 (the “Signing Date”) by and among:
A.
B.
C.
D.
E.
F.
G.
H.
I.
Yao Fang Information Technology (Shanghai) Co., Ltd., a limited liability company duly incorporated and validly existing
under the PRC Laws, whose unified social credit code is 913101150747824207 and registered address is at Room 805, Tower B,
Building 1#, No. 977 Shangfeng Road, Tangzhen, Pudong New Area, Shanghai (the “Company” or “Yao Fang Shanghai”);
Yao Wang Corporation Limited (company number: 1918271), a limited company duly incorporated and validly existing under
the laws of Hong Kong, China, whose registered address is at Unit 402, 4th Floor, Fairmont House, No. 8 Cotton Tree Drive,
Admiralty, Hong Kong (the “Existing Shareholder” or “Yao Wang”);
Ningbo Youkai Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91330225MA283KBGX3 and registered address is at 3/F, northeast of Zhaohui
Road and Changming Road, Xizhou Town, Xiangshan County, Zhejiang (“Youkai”);
Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP), a limited partnership duly incorporated
and validly existing under the PRC Laws, whose unified social credit code is 91310000MA1FL5U017 and registered address is at
2A, Building 1#, No. 9 Zhenning Road, Changning District, Shanghai (the “SOE Reform Fund”);
Ningbo Liangji Industrial Co., Ltd., a limited liability company duly incorporated and validly existing under the PRC Laws,
whose unified social credit code is 913302825839883985 and registered address is at 30 & 32, Sanhai Road, East Zone,
Guanhaiwei Town Industrial Park, Cixi, Zhejiang (“Liangji”);
Zhenjiang Huixin Equity Investment Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91321102MA21QR306J and registered address is at Room 301, Building 2#,
Cloud Times Square, No. 259 Miaojiawan Road, Zhengdonglu Street, Jingkou District, Zhenjiang (“Huixin”);
Hezhou Hongshi Equity Investment Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91451100MA5NH9YN91 and registered address is at No. 1 Tianhe Avenue,
Hezhou Eco-Industrial Park, Guangxi (“Hongshi”);
Shanghai Yaoxing Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91310115MA1HBBND7J and registered address is at 1/F, Building 1#, No. 977
Shangfeng Road, Pudong New Area, Shanghai (“Yaoxing”);
Shanghai Yaoshu Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91310115MA1HBBGY4Q and registered address is at 1/F, Building 1#, No.
977 Shangfeng Road, Pudong New Area, Shanghai (“Yaoshu”); and
1
J.
Xinjiang Junying Hongyin Investment Management Partnership (LP), a limited partnership duly incorporated and validly
existing under the PRC Laws, whose unified social credit code is 91650100MA77W62Q2L and registered address is at Room
702, 7/F, Weixing Plaza, No. 473 Weixing Road, Urumqi Economic & Technological Development Zone, Xinjiang (“Junying”).
Each of Youkai, the SOE Reform Fund, Liangji, Huixin, Hongshi, Yaoxing, Yaoshu and Junying is referred to herein individually as an
“Investor” and collectively as the “Investors”, and each of Yao Fang Shanghai, Yao Wang and the Investors is referred to herein
individually as a “Party” and collectively as the “Parties”.
WHEREAS:
1. As at the Signing Date, Yao Fang Shanghai has a registered capital of USD250,000,000, equivalent to RMB1,637,461,056.16
according to the USD to RMB exchange rate prevailing at the time of the relevant capital contribution. Yao Wang holds 100% of
the shares of Yao Fang Shanghai;
2. The pre-money valuation of Yao Fang Shanghai prior to the Capital Increase is USD1,200,000,000, equivalent to
RMB8,328,960,000, by reference to the RMB/USD central parity rate published by the People’s Bank of China on August 7, 2020
(USD 1 = RMB6.9408). With the addition of the Total Investment Amount of RMB419,820,000, the post-money valuation of Yao
Fang Shanghai will become RMB8,748,780,000 after the Completion of the Capital increase.
3. Subject to and on the terms and conditions set forth herein, Yao Fang Shanghai intends to increase its share capital and change the
currency of its registered capital from USD into RMB. The newly increased registered capital of Yao Fang Shanghai shall be
RMB82,479,371.31 (the Newly Increased Registered Capital”), which shall be jointly subscribed for by the Investors according
to the amount and percentage of the Newly Increased Registered Capital to be subscribed for by them respectively as set out in
Exhibit 1 (the “Capital Increase”).
4. After the Completion of the Capital increase, the registered capital of Yao Fang Shanghai shall change from USD250,000,000 into
RMB1,719,940,427.47, and its shareholding structure is set out in Exhibit 2, of which, Yao Wang shall hold 95.2046% of the
shares of the Company, and the Investors shall hold 4.7954% of the shares of the Company in aggregate.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, and intending to be legally bound hereby, the Parties
hereby agree as follows:
1. Definitions and Interpretation
1.1 Definitions
For purpose of this Agreement, unless otherwise specified herein, the following terms shall have the meanings set forth
below:
“Amended Articles” means the articles of association of the Company as amended and jointly executed by the Existing
Shareholder and the Investors;
2
“Business Day” means any day (other than a Saturday, Sunday or public holiday) on which the banks in China are open
for business;
“PRC” means the People’s Republic of China, but solely for the purpose of this Agreement, excluding the Hong Kong
Special Administrative Region, the Macau Special Administrative Region and Taiwan;
“Capital Increase” shall have the meaning set out in the preamble;
“Investment Amount” shall have the meaning set out in Section 3.1;
“Total Investment Amount” shall have the meaning set out in Section 3.1;
“Completion” means the completion of the Capital Increase pursuant to Section 5.2;
“Completion Date” means the date on which the Capital Increase is completed pursuant to Section 5.2;
“Encumbrance” means any mortgage, security, pledge, lien, option, restriction, right of first refusal, preemptive right,
third-party right, or any other encumbrance or security interest of any kind, or any other kind of preferential arrangement
with similar effect, including without limitation transfer or retention of title;
“PRC Laws” means the laws, regulations, codes and judicial interpretations officially promulgated and published by the
legislative, administrative and judicial authorities of the PRC at all levels, but solely for the purpose of this Agreement,
excluding the laws, regulations, codes, judicial interpretations and legal precedents of the Hong Kong Special
Administrative Region, the Macau Special Administrative Region and Taiwan;
“RMB” means the lawful currency of the PRC;
“Registration Authority” means the State Administration for Market Regulation or its authorized local counterparts; and
“Event of Force Majeure” means any event or circumstance unforeseeable by and beyond the control of a Party, including
without limitation natural disaster, war, terrorism, riot, sabotage, civil disturbance, blockade, fire, explosion, flood,
accident, government and strike.
1.2 Interpretation
(1) Section headings used herein are for convenience only and shall not affect the interpretation of this Agreement.
(2) Unless the context otherwise requires, if the day on which any right or obligation hereunder must be exercised or
performed is not a Business Day, such right or obligation shall be exercised or performed on the next Business Day.
(3) References to time are to Beijing time of the PRC.
3
(4) The word “hereof” or other words of similar import refer to this Agreement as a whole and not to any particular
Section. Unless otherwise expressly provided herein, the term “including” shall be construed to be “including
without limitation”, regardless of whether it is actually followed by “without limitation”.
(5) References to this Agreement include this Agreement and its amendments, modifications, supplements,
replacements and/or restatements in whatever form made from time to time. Unless the context otherwise requires,
references to sections, paragraphs, subparagraphs and exhibits are to sections, paragraphs and subparagraphs of and
exhibits to this Agreement.
2. Capital Increase
2.1 The Investors shall subscribe for the Newly Increased Registered Capital of RMB82,479,371.31 in aggregate at the price
of RMB5.09 for each RMB1 of the registered capital, representing 4.7954% of the shares of the Company after the
Completion of the Capital increase. The respective amount of registered capital subscribed for by each Investor and the
corresponding shareholding percentage represented thereby are set out in Exhibit 2.
2.2 The Parties agree that the Company’s pre-money valuation is USD1,200,000,000, equivalent to RMB8,328,960,000, by
reference to the RMB/USD central parity rate published by the People’s Bank of China on August 7, 2020 (USD 1 =
RMB6.9408) (the “Initial Valuation”). The Parties acknowledge that the Total Investment Amount is RMB419,820,000,
so the Company’s post-money valuation will become RMB8,748,780,000 after the Completion of the Capital increase (the
“Post-money Valuation”).
3. Payment
3.1 Investment Amount
With respect to the proposed subscription by the Investors for RMB82,479,371.31 of the Company’s Newly Increased
Registered Capital, the total price payable by the Investors shall be RMB419,820,000 (the “Total Investment Amount”),
of which, RMB82,479,371.31 shall be recorded in the registered capital of the Company, and the balance shall be recorded
in the capital reserve of the Company. The respective amount of the registered capital subscribed for and the price payable
by each Investor (the “Investment Amount” of such Investor) and the portion of the Investment Amount paid by each
Investor that will be recorded in the capital reserve of the Company are set out in Exhibit 1.
3.2 Use of the Investment Amount
Unless otherwise provided herein or agreed by the Parties, the Company shall use the Investment Amount solely for the
conduct of the Company’s main business, including investment in technologies, expansion of the current business and
investment in innovative business, among others, and not for any other purpose.
4
3.3 Payment
(1) The Investors shall, severally but not jointly, pay their respective Investment Amount in full to the following bank
account designated by the Company for collecting the Investment Amount hereunder, within five (5) Business Days
from the Signing Date:
Account name: Yao Fang Information Technology (Shanghai) Co., Ltd.
Account number: 121911552610808
Bank: China Merchants Bank Dongfang Sub-Branch of Shanghai
(2) If any Investor fails to pay its Investment Amount in full within the period prescribed in Section 3.3(1), the Company
shall have the right to impose a penalty on such Investor in an amount equal to 25% of the Investment Amount
payable by such Investor, and if such Investor still fails to pay its Investment Amount in full within five (5) Business
Days after the Company delivers a written notice to it requesting it to do so, to rescind this Agreement with such
Investor by giving written notice to it.
(3) Within five (5) Business Days after the Investors have paid their respective Investment Amount in full, the Company
shall deliver to each Investor a certificate of capital contribution and a copy of its updated register of shareholders.
4. Warranties and Covenants
4.1 The Company hereby warrants and covenants to the Investors that:
(1) it is duly incorporated and validly existing under the PRC Laws;
(2) it has full power, right and authority to execute, deliver and perform this Agreement;
(3) the execution, delivery and performance of this Agreement will not result in any violation by the Company of any
applicable laws, rules or regulations or the provisions of any material contract document binding on the Company;
and
(4) the shares acquired by the Investors through the Capital Increase are free and clear of any Encumbrance.
4.2 Each Investor hereby warrants and covenants to the Company that:
(1) it is duly incorporated and validly existing under the PRC Laws, neither it nor any of its shareholders is a contract-
based private fund, asset management plan or trust plan, and it is qualified as a shareholder under the PRC Laws;
(2) it has full power, right and authority to execute, deliver and perform this Agreement;
(3) the execution, delivery and performance of this Agreement will not result in any violation by it of any applicable
laws, rules or regulations or the provisions of any material contract document binding on it; and
(4) it has sufficient funds available for the Capital Increase, which come from legal sources.
5
5. Completion of the Capital Increase
5.1 The Company shall endeavor to complete all registration, filing and reporting procedures with the competent market
supervision administration and commerce authority in connection with the changes in its registered capital, shareholding
structure, articles of association and currency of the registered capital and other matters relating to the Capital Increase (the
“Government Procedures”) prior to August 31, 2020.
If the Company fails to complete the Government Procedures in connection with the Capital Increase prior to August 31,
2020, the Investors agree to grant to the Company a grace period of two (2) months, in which case, the Company shall
complete the Government Procedures in connection with the Capital Increase no later than October 31, 2020. If the
Company still fails to complete the Government Procedures in connection with the Capital Increase within such grace
period, except for any reason attributable to the Investors, either Investor may rescind this Agreement by giving written
notice to the Company.
For the purpose stated above, the Investors shall use their best endeavors to provide the Company with all necessary
assistance required in connection with the Government Procedures, including without limitation execution of the relevant
documents and performance of the necessary procedures.
5.2 The Completion of the Capital Increase shall be contingent on the payment of the Investment Amount by the Investors to
the Company in full.
5.3 Limit on the shareholding percentage of the Investors
The Investors agree and acknowledge that, without the prior written consent of the Company, the total equities or shares
directly or indirectly held by the Investors and their respective affiliates and/or concert parties, if any, in the Company in
any manner shall in no event exceed 5% of the registered capital or total shares of the Company at any time after the
Completion of the Capital Increase and till the date of Qualified IPO (as defined below) of the Company.
5.4 After the Completion of the Capital Increase, for purpose of achieving a Qualified IPO, the Parties agree to cooperate with
the Company to take or do, or cause to be taken or done, all necessary or appropriate actions or things in accordance with
the relevant examination requirements of the Shanghai Stock Exchange (the “Exchange”), the China Securities Regulatory
Commission and other competent regulatory authorities, including without limitation amendment, modification or
termination of the relevant provisions hereof.
6. Rights and Obligations of the Shareholders
Each Investor shall, from the date it has paid its Investment Amount to the Company in full, enjoy the rights and assume the
obligations as a shareholder of the Company to the extent of its subscribed registered capital of the Company, pursuant to the
provisions of the PRC Laws, listing-related regulatory rules, this Agreement and the Amended Articles.
6
6.1 Preemptive right
(1) If, during the period from the Completion of the Capital Increase and till the date the Company formally submits an
application for Qualified IPO to the Exchange, the Company intends to increase its registered capital by offering
any warrants, convertible bonds, or other securities convertible into the shares of the Company or other equity
interests or otherwise, each shareholder of the Company shall have the preemptive right to subscribe for such newly
increased registered capital in proportion to its actual capital contribution to the Company then (“Preemptive
Right”).
Subject to Section 6.1(2), the Company shall first deliver to each shareholder a notice (the “Capital Increase
Notice”), setting forth the propose amount, subscription price, terms of payment, closing conditions and other
information in respect of the newly increased registered capital. Within ten (10) Business Days following receipt of
the Capital Increase Notice from the Company, any shareholder electing to exercise its Preemptive Right (each a
“Subscribing Shareholder”) shall notify the Company in writing of its intention to exercise the Preemptive Right
and the amount it intends to subscribe for. If the total amount that the Subscribing Shareholders intend to subscribe
for exceeds the amount of the newly increased registered capital, they shall subscribe for the newly increased
registered capital in proportion to their respective shareholder percentages then at the same subscription price and
on the same conditions.
(2) The Subscribing Shareholders’ Preemptive Right shall not apply to any newly increased registered capital:
(a) issued for purpose of implementing the Employee Incentive Plan contemplated by Section 7; or
(b) issued to all shareholders of the Company (including the Investors) as a result of capitalization of the
unappropriated profits or capital reserves or otherwise.
(3) After all shareholders have fully exercised their respective Preemptive Right, the Company may sell or issue the
remaining newly increased registered capital (if any), that has not been subscribed by the shareholders, to any third
party.
6.2 Anti-dilution protection
(1) Subject to the provisions hereof, if, after the Completion of the Capital Increase, the Company issues any additional
shares at a price lower than the price per share paid by the Investors to the Company in the Capital Increase, the
shares held by the Investors shall be adjusted using the broad-based weighted average calculation, so that the price
per share of all shares held by the Investors in the Company will not be higher than the price per share offered by
the Company to the subsequent investors subscribing for the newly increased registered capital (“Anti-dilution
Adjustment”), taking into account any share split, distribution of dividends, consolidation of shares or restructuring
of the Company (if any).
7
(2) After the Anti-dilution Adjustment, each Investor shall have the right to adjust its shareholding percentage in the
Company to such percentage of the shares of the Company that its Investment Amount can purchase at the price per
share as adjusted.
(3) Where it is necessary to make an Anti-dilution Adjustment, to the extent permitted by law, the Investors shall have
the right to: (i) subscribe for the newly increased registered capital of the Company at the nominal price of RMB1
or the lowest price permitted by law; (ii) request Yao Wang to transfer such number of shares as required to effect
the Anti-dilution Adjustment at the nominal price of RMB1 or the lowest price permitted by law; or (iii) receive
other compensation available under the law. If an Investor elects to acquire compensatory shares at the nominal
price of RMB1, but is unable to effect the same due to the restrictions of the applicable laws, when the Investor
enters into the relevant agreement for transfer of compensatory shares with Yao Wang or subscription agreement
with the Company (as the case may be) pursuant to which the Investor has the obligation to pay certain
consideration, Yao Wang or the Company shall issue a written waiver to the satisfaction of the Investor, releasing
the Investor from the obligation to pay the consideration for such compensatory shares.
(4) Notwithstanding the foregoing, the Investors shall not enjoy the anti-dilution protection stated above when the
Company issues any newly increase registered capital for purpose of implementing the Employee Incentive Plan
contemplated by Section 7.
6.3 Restrictions on share transfer
(1) Without the written consent of the Investors, prior to the achievement and consummation of a Qualified IPO by the
Company, Yao Wang shall not, directly or indirectly, transfer (for the avoidance of doubt, including without
limitation transfer by agreement that is not required to the registered with the Company’s Registration Authority),
assign, donate, substitute, exchange, place into trust, appoint a nominee to hold, contribute, surrender, pledge,
encumber or otherwise dispose of any shares held by it in the Company or any interests therein, which will result in
a change of control over the Company.
(2) Without the prior written consent of the Company, neither Investor may directly or indirectly transfer any share of
the Company to any entity competing with the Company as listed in Exhibit 3 (each a “Competitor”) or any of its
affiliates.
(3) Within one (1) year after the Qualified IPO of the Company or such longer period as required by the applicable laws
and regulations, Investor may neither transfer or appoint another person to manage the shares held by it in the
Company in any manner, nor request the Company to repurchase such shares. After the expiration of such period,
the shares held by the Investors in the Company, except for those subject to any mandatory prohibition on sale
pursuant to the applicable laws, will become tradable on the relevant market, provided that the Investors shall
strictly comply with the applicable laws, administrative regulations, department rules, normative documents and the
relevant provisions of the Exchange and other competent regulatory authorities, and perform the relevant obligation
of information disclosure.
8
6.4 Right of first refusal
(1) Subject to Section 6.3, if any shareholder (the “Transferring Shareholder”) intends to transfer all or part of the
shares held by it in the Company directly or indirectly (“Offered Shares”) to any third party who is not a
shareholder of the Company (“Proposed Transfer”), the shareholders other than the Transferring Shareholder (the
“Other Shareholders”) shall have the right to purchase the Offered Shares at the same price and on the same terms
and conditions as are offered to such third party (the “Right of First Refusal”). The Transferring Shareholder
intending to make the Proposed Transfer shall deliver to the Other Shareholders a written notice (the “Transfer
Notice”), which shall specify: (i) details of the Offered Shares, including without limitation percentage of the
registered capital that the Offered Shares represent, transfer price and terms of payment of the transfer price; (ii)
identity of the person to acquire the Offered Shares, including without limitation his name, actual controller and
scope of business (if applicable); and (iii) main terms and conditions of the Proposed Transfer. The Transfer Notice
shall constitute an offer by the Transferring Shareholder to the Other Shareholders in respect of the Offered Shares.
(2) Notwithstanding the foregoing, the Right of First Refusal shall not apply to:
(a) any share transfer made for purpose of implementing the Employee Incentive Plan contemplated by Section
7; or
(b) any transfer of shares by the Transferring Shareholder to any of its affiliates, provided that: (i) such affiliate
shall enjoy the rights and assume the obligations in respect of the shares acquired by it from the Transferring
Shareholder, and be bound by this Agreement, the articles of association of the Company and other
applicable documents; (ii) such affiliate is not a Competitor of the Company; (iii) the Transferring
Shareholder shall notify the Company and the other Shareholders at least ten (10) Business Days prior to
such transfer; (iv) the Transferring Shareholder shall provide the Other Shareholders with proofs in writing
showing that such transferee is an affiliate of the Transferring Shareholder meeting the conditions set forth
above; and (v) the Transferring Shareholder shall procure that such transferee remains an affiliate of the
Transferring Shareholder at any time after the completion of such transfer.
(3) Within twenty (20) days after receiving the Transfer Notice (the “Offer Period”), each Other Shareholder may give
a written notice (the “Acceptance Notice”) to the Transferring Shareholder to accept such offer, and purchase all or
part of the Offered Shares in preference to such third party. If the aggregate number of shares that the Other
Shareholders intend to purchase exceed the number of the Offered Shares, the Company shall limit the proportion of
the Offered Shares that each Other Shareholder has the right to purchase to the lower of: (i) the proportion of the
Offered Shares that such Other Shareholder intends to purchase as specified in its Acceptance Notice; and (ii) the
ratio of the paid-in registered capital held by such Other Shareholder to the registered capital of the Company at the
date of the Transfer Notice. During the Offer Period, the Transferring Period shall promptly provide the Other
Shareholders with the information about the business and financial conditions of the transferee that may be
reasonably requested by any Other Shareholder for the purpose of determining whether or not to exercise the Right
of First Refusal.
9
6.5 Right of co-sale
(1) If Yao Wang, as the Transferring Shareholder, intends to transfer any shares held by it in the Company (except for
any transfer for purpose of implementing the Employee Incentive Plan) to any third party other than any of its
affiliates or the Other Shareholders (the “Transferee”), and the Other Shareholders elect not to exercise their Right
of First Refusal, each Investor shall have the right to deliver a written notice (the “Co-sale Notice”) after receiving
the Transfer Notice, but in any event within the Offer Period set forth in Section 6.4, requesting the Transferee to
purchase the shares held by such Investor in the Company corresponding to the paid-in registered capital held by
such Investor then (the “Right of Co-sale”), to the extent of the relative ratio of the paid-in registered capital held
by such Investor then to that held by Yao Wang then (the “Co-sale Percentage”), and specifying the proportion of
the shares proposed to be transferred to the registered capital in the Co-sale Notice.
(2) The number salable by an Investor through the exercise of the Right of Co-sale is equal to the number of shares that
Yao Wang proposes to sell multiplied by the Investor’s Co-sale Percentage, which is equal to the paid-in registered
capital held by such Investor divided by the sum of the total paid-in registered capital held by the Investors electing
to exercise their Right of Co-sale and the paid-in registered capital held by Yao Wang.
(3) The failure of an Investor to deliver a Co-sale Notice within the Offer Period or exercise its Right of First Refusal
pursuant to Section 6.4 shall be deemed to be a waiver of its Right of Co-sale.
(4) Notwithstanding the foregoing, if such proposed sale of share by Yao Wang is sufficient to result in a change of
actual control over the Company, including without limitation acquisition of all shares of the Company by a third
party, each Investor shall have the right to transfer the shares held by it in the Company in preference to Yao Wang,
in which case the consummation of the share transfer between Yao Wang and the Transferee shall be contingent on
the transfer of all of the shares held by the Investors in the Company to such Transferee.
10
(5) If any Investor elects to exercise its Right of Co-sale, but the other shareholders waive their Right of First Refusal
in respect of the shares proposed to be sold by Yao Wang and such Investor, Yao Wang shall ensure the exercise of
such Right of Co-sale by reducing the amount of shares sold by it or otherwise. If any Investor elects to exercise its
Right of Co-sale pursuant to this Agreement, but the Transferee refuses to purchase the shares from such Investor,
or fails to obtain any necessary consent, approval or waiver from any third party, including any government
authority, as a result of which such Right of Co-sale fails to be exercised, Yao Wang shall not sell any shares held by
it in the Company to the Transferee. Any transfer of shares by Yao Wang in violation of this Section 6.5 shall be
null and void.
6.6 Equal treatment
If, after the Completion of the Capital Increase, the Company admits any new shareholder at a price not higher than the
valuation of the Company in the Capital Increase, as a result of which any shareholder of the Company, whether existing
presently or admitted after the date of this Agreement, enjoys any rights more favorable than those granted to the Investors
under this Agreement and other transaction documents or any additional rights which the investors do not have (“More
Favorable Terms”), the Investors shall be automatically entitled to such More Favorable Terms. In such case, the Parties
shall enter into a separate agreement or amend or supplement this Agreement, to ensure such More Favorable Terms apply
to the Investors. If, after the Completion of the Capital Increase, the Company admits any new shareholder at a price higher
than the valuation of the Company in the Capital Increase, and such new shareholder gets More Favorable Terms which are
apparently unfair commercially, the Investors shall also be entitled to such More Favorable Terms. In such case, the Parties
shall enter into a separate agreement or amend or supplement this Agreement, to ensure such More Favorable Terms apply
to the Investors.
6.7 Qualified IPO of the Company
The Parties agree to use their best endeavors to procure the completion of the initial public offering of the Company and
listing of its shares on the Shanghai Stock Exchange’s Sci-Tech innovAtion boaRd (“Qualified IPO”, which shall be
deemed to have been achieved when the shares of the Company are officially listed and traded on the Exchange) no later
than June 30, 2023 or such other date as agreed by the Company, Yao Wang and the Investors in writing (the “Expected
Date of IPO”).
The Company wishes to formally submit an IPO application to the Exchange within eighteen (18) months following the
Completion of the Capital Increase with the cooperation of the relevant securities company, law firm, accounting firm and
other intermediaries.
11
6.8 Right of redemption
(1) If the Company fails to achieve a Qualified IPO prior to the Expected Date of IPO, from the date immediately
following the Expected Date of IPO or such later date as agreed pursuant to Section 6.7, each Investor shall have
the right to request the Company or Yao Wang (to the extent permitted by the PRC Laws) to redeem all or part of
the shares held by it in the Company then (“Sale Shares”) at such price and in such manner as set forth in Section
6.8(2), provided that such Investor shall deliver a written notice of redemption to the Company at least ninety (90)
days in advance, so that the Company will have sufficient time to arrange such redemption.
(2) The price to be paid by the Company for the Sale Shares pursuant to Section 6.8(1) shall be equal to the price paid
by such Investor in the Capital Increase, i.e. RMB5.09 for each RMB1 of the registered capital, plus interest at the
rate of 6% per annum (simple interest). If the redemption occurs at any date that is not an anniversary of the
Completion Date, the interest shall be calculated on the basis of the actual period in which such Investor holds the
shares of the Company.
6.9 Information rights
After the Completion of the Capital Increase, subject to compliance with the applicable domestic and foreign laws, rules
and regulatory policies, at the request of any Investor, the Company shall provide to such Investor:
(1) prior to May 31 of each accounting year, the annual consolidated auditor’s report issued by a PRC certified public
accounting firm engaged by the Company for such accounting year in accordance with the accounting standards of
the PRC; and
(2) within sixty (60) Business Days after the end of each quarter, the unaudited quarterly consolidated financial
statements of the Company for such quarter prepared in accordance with the accounting standards of the PRC.
7. Employee Incentive Plan
In order to motivate the employees of the Company, the Investors agree and acknowledge that the Company will reserve 7% of
the total share capital of the Company prior to the IPO of the Company for providing share/option incentives to its directors and
employees (“Employee Incentive Plan”). For such purpose, the Investors further agree to take all necessary and reasonable
actions, including without limitation voting in favor of the relevant resolutions (if necessary) in the relevant decision-making
process of the Company, executing necessary documents and giving cooperation in completing the necessary registration
procedures, to facilitate the adoption and implementation of the Employee Incentive Plan.
8. Corporate Conversion
For purpose of achieving a Qualified IPO, after the Completion of the Capital Increase, the Company shall be converted into a
company limited by shares at such time as the Company deems appropriate (“Corporate Conversion”).
12
According to the adjustment of the Company’s business and shareholding structure, the Company may reduce its registered
capital according to law prior to or during the process of the Corporate Conversion. The Investors agree to cooperate with the
Company to take all necessary and reasonable actions, including without limitation voting in favor of the relevant resolutions (if
necessary) in the relevant decision-making process of the Company, executing necessary documents and giving cooperation in
completing the necessary registration procedures, to effect the reduction of the Company’s registered capital.
9. Admission of New Investors
9.1 The Company shall have the right to admit new investors after the Completion of the Capital Increase. Subject to Sections
6.1 and 6.2, the Investors agree to cooperate with the Company to take all necessary and reasonable actions for such
purpose, including without limitation voting in favor of the relevant resolutions (if necessary) in the relevant decision-
making process of the Company, executing necessary documents and giving cooperation in completing the necessary
registration procedures.
9.2 If the Company admits any new investor after the Completion of the Capital Increase, the agreement entered into between
the Company and such new investor shall not amend any right enjoyed by the Investors hereunder, including without
limitation the Preemptive Right under Section 6.1, the anti-dilution protection under Section 6.2, the Right of First Refusal
under Section 6.4, the Right of Co-sale under Section 6.5, the equal treatment under Section 6.6 and the Right of
Redemption under Section 6.8, except for any amendment or supplement made pursuant to Section 6.6.
10. Debt Forgiveness
10.1 Yao Wang has provided the Company with a loan of USD69,000,000.00, as of August 3, 2020, the interest accrued on
which is USD653,833.33. The board of directors of Yao Wang approved a resolution on August 3, 2020, forgiving such
debt owed by the Company. In addition, Yao Wang has entered into an External Debt Forgiveness Agreement with the
Company, pursuant to which Yao Wang has forgiven the principal of such debt and the interest accrued thereon, and agreed
that the Company does not need to repay such debt. The Company is responsible for going through the necessary approval
procedures with the competent foreign exchange authority and other competent authorities with respect to the forgiveness
of such external debt, and has completed the relevant filing procedures on August 4, 2020.
10.2 Yao Wang has provided the Company with a loan of RMB159,918,291.99 via its cash pool through China Merchants Bank
Co., Ltd. Hualing Sub-Branch of Shanghai. The board of directors of Yao Wang approved a resolution on August 3, 2020,
forgiving such debt owed by the Company. The Parties acknowledge and agree that, according to the regulatory policies of
the People’s Bank of China and the requirements of China Merchants Bank regarding cash pool, the debts under the cash
pool shall be repaid to the creditor through China Merchants Bank Co., Ltd. Hualing Sub-Branch of Shanghai to complete
the relevant procedures of the Bank. Therefore, Yao Wang and the Company shall take further actions to complete the debt
forgiveness procedures pursuant to the applicable laws, including without limitation, that the Company shall repay the loan
of RMB159,918,291.99 first, and then Yao Wang shall grant a USD loan of an equivalent amount to the Company. Yao
Wang and the Company shall go through the necessary approval procedures with the competent foreign exchange authority
and other competent authorities with respect to the forgiveness of such external debt. The Company is expected to
complete the filing procedures in respect of the forgiveness of such external debt prior to September 30, 2020.
13
11. Confidentiality
11.1 Each Party shall keep in strict confidence and shall not disclose or use any information contained herein or obtained or
accessed by it as a result of negotiating and/or executing this Agreement, including without limitation:
(1) the existence and terms of this Agreement;
(2) negotiations relating to this Agreement; or
(3) any Party hereto, or business activities conducted by any Party or any of its affiliates.
11.2 Nothing contained in this Section 11 shall prevent the disclosure or use of any information:
(1) as required by the applicable laws, rules of the stock exchange on which the shares of any Party are listed or any
competent government authority;
(2) for purpose of any legal proceedings arising out of this Agreement or any other agreement executed under or
pursuant to this Agreement, or to any tax authority in connection with the taxation affairs of the disclosing Party;
(3) to the officers, directors, employees, attorneys, accountants, financial advisors or other agents or representatives
(“Representatives”) of a Party who need to know such information for purpose of consummating the transactions
contemplated by this Agreement or any other agreement executed pursuant to this Agreement, provided that such
Representatives have undertaken to comply with the provisions of Section 11.1, as if they were a Party hereto;
(4) that is publicly available, other than as a result of any violation of the non-disclosure agreement (if any) or this
Agreement; or
(5) with the prior written consent of the other Parties.
12. Indemnification
12.1 If any Party violates any provision, warranty or covenant contained herein, the defaulting Party shall indemnify the other
Parties for the losses arising therefrom, without prejudice to the other rights available to the non-defaulting Parties
hereunder.
12.2 Yao Wang shall be ultimately responsible for all expenses incurred, whether prior to or after the Completion Date, in
connection with any liabilities or contingent liabilities (except for those already disclosed by the Company) not reflected
on the financial statements of the Company that may be incurred by the Company prior to the Completion Date or due to
any reason arising prior to the Completion Date, which shall not be the responsibility of the Investors.
14
13. Rescission and Termination
13.1 Special termination provisions
(1) The provisions of Section 6 shall automatically cease to be effective from the date the Company formally submits
an IPO application to the Exchange.
(2) The provisions of Section 6 shall automatically become effective again from the date the IPO application of the
Company has been withdrawn by the Company or refused by the Exchange, the China Securities Regulatory
Commission or other competent regulatory authorities.
(3) This Agreement may be terminated with mutual consent of the Parties in writing.
(4) If a Party ceases to hold any shares in the Company directly or indirectly, such Party shall no longer be bound by
this Agreement.
13.2 Prior to the Completion of the Capital Increase, this Agreement may be rescinded and the transactions contemplated
hereby may be terminated or cancelled if:
(1) any Party materially breaches this Agreement and the non-defaulting Parties elect to rescind this Agreement by
giving written notice to the defaulting Party;
(2) the Company rescinds this Agreement with any defaulting Investor by giving written notice to such defaulting
Investor pursuant to Section 3.3(2); of
(3) the Parties unanimously agree to terminate this Agreement in writing.
13.3 Consequences of termination
Subject to Section 13.4, if this Agreement is terminated pursuant to Section 13.2 or the applicable laws, this Agreement
shall cease to be effective, provided that such termination shall in no event release any Party from any liability incurred as
a result of or in connection with any default or misrepresentation by such Party hereunder, or be deemed to be a waiver of
any available remedy (including specific performance, if available) against such default or misrepresentation.
13.4 Survival
The provisions of Sections 11, 12, 13, 16 and 17 shall survive the termination of this Agreement.
14. Notices
14.1 Any notice given by a Party under or in connection with this Agreement shall be made in writing and delivered to the
respective Parties at the addresses or email addresses set forth below, or such other address or email address for a Party as
designated by such Party by a similar notice:
15
Yao Fang Information Technology (Shanghai) Co., Ltd.
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
Yao Wang Corporation Limited
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
Ningbo Youkai Business Management Partnership (LP)
Address: No. 58 Xinfa Road, Suzhou Industrial Park
Email: [ ]
Attention: ZHENG Wenyong
Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP)
Address: Building 8#, Changning Financial Park, No. 1320 Yuyuan Road, Changning District, Shanghai
Email: [ ]
Attention: CHEN Dawei
Ningbo Liangji Industrial Co., Ltd.
Address: 2406A, Jin Mao Tower, No. 88 Century Avenue, Pudong New Area, Shanghai
Email: [ ]
Attention: RUAN Shuhong
Zhenjiang Huixin Equity Investment Partnership (LP)
Address: 212-214, Building 7#, No. 2789 West Guangfu Road, Putuo District, Shanghai
Email: [ ]
Attention: ZHANG Wei
Hezhou Hongshi Equity Investment Partnership (LP)
Address: Room 1617, Guangming Plaza, Chaoyang District, Beijing
Email: [ ]
Attention: FENG Yuanwei
Shanghai Yaoxing Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
Shanghai Yaoshu Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
16
Xinjiang Junying Hongyin Investment Management Partnership (LP)
Address: Room 2805, Tower E, Xinhua Tianxi International Finance Center, Shifu Avenue, Shenhe District, Shenyang,
Liaoning
Email: [ ]
Attention: LI Nan
14.2 Any notice shall be deemed effectively given upon personal delivery to the recipient, or three (3) Business Days after
deposit with an internationally recognized courier, or upon delivery to the recipient’s server if sent by facsimile or email,
provided that the hard copy of the same notice shall be immediately delivered to the recipient by an international overnight
courier.
15. Force Majeure
15.1 If any Party is prevented from performing any of its duties and obligations hereunder by an Event of Force Majeure, such
Party shall notify the other Parties in writing within thirty (30) days after the occurrence of such Event of Force Majeure,
provide the other Parties with detailed information and proofs regarding such Event of Force Majeure, including written
certificates issued by government or other competent authorities, explaining the reason for its inability to perform this
Agreement, and take measures to reduce the losses arising therefrom to the maximum extent practicable.
15.2 If an Event of Force Majeure occurs, neither Party shall not be liable for any damage, increased cost or loss that the other
Parties may sustain by reason of failure or delay on the part of such Party to perform any of its obligations hereunder due
to such event, and such failure or delay shall not be deemed a breach of this Agreement, provided that the Party claiming
the occurrence of an Event of Force Majeure shall take appropriate measures to minimize or remove the effect of such
Event of Force Majeure, and within the shortest possible time, use its best endeavors to resume performance of the
obligations affected by such Event of Force Majeure.
16. Governing Law and Dispute Resolution
16.1 The formation, validity, execution, interpretation and dispute resolution in respect of this Agreement shall be governed by
the PRC Laws.
16.2 Any dispute arising out of or in connection with this Agreement, or any breach, termination or invalidity of this Agreement,
shall be submitted to the Shanghai International Arbitration Center (“SHIAC”), for settlement by arbitration in Shanghai in
accordance with the arbitration rules of the SHIAC in force when the arbitration notice is submitted. The language of
arbitration shall be Chinese. The arbitration award made by the tribunal shall be final and binding upon the Parties.
17. Miscellaneous
17.1 Effectiveness
This Agreement shall take effect on the date it is executed by the Parties.
17.2 Expenses
Unless otherwise provided herein, each Party shall bear its own legal and other expenses incurred in connection with the
preparation, negotiation and execution of this Agreement and other transaction documents.
17
17.3 Amendment
Unless otherwise provided herein, any amendment, modification, waiver, rescission or termination in respect of this
Agreement shall be made by a written agreement signed by the Parties.
17.4 Assignment
With the prior written consent of the Company and Yao Wang, an Investor may assign its rights and obligations hereunder
to an affiliate designated by it, by giving ten (10) Business Days’ written notice to the other Parties. Subject to the
foregoing, neither Party may assign any of its rights or obligations hereunder without the prior written consent of the other
Parties.
17.5 Severability
If any provision hereof is held illegal, invalid of unenforceable in whole or in part under the applicable laws, such illegal,
invalid of unenforceable provision or part shall not be deemed as part of this Agreement, but the legality, validity and
enforceability of the remaining provisions of this Agreement shall not be affected. The Parties shall negotiate to replace
such provision that is deemed to be deleted from this Agreement with a legal, valid and acceptable provision that comes
closest to expressing the original intent of the Parties herein.
17.6 Waiver
Failure or delay on the part of any Party to exercise any right, power or privilege hereunder shall not operate as a waiver of
such right, power or privilege, nor shall any single or partial exercise of any right, power or privilege preclude the exercise
of any other right, power or privilege.
17.7 Independence
The rights and obligations of each Investor hereunder shall constitute independent, several and not joint rights and
obligations.
17.8 Version for purpose of registration with the administration for commerce and industry
For purpose of registering the relevant changes with the administration for commerce and industry, the Parties agree to
cooperate with each other to execute a simple capital increase agreement separately with respect of the Capital Increase in
such form as required by the administration for commerce and industry (“Standard Version”). In case of any conflict or
discrepancy between such Standard Version and this Agreement, the provisions of this Agreement shall prevail.
18
17.9 Language and counterparts
This Agreement shall be made in Chinese and executed in twelve (12) counterparts. Each Party shall hold one (1)
counterpart, and the remaining counterparts shall be kept by the Company, for use in the relevant approval, filing and
registration procedures.
(End of text)
19
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Yao Fang Information Technology (Shanghai) Co., Ltd. (seal)
/s/ Seal of Yao Fang Information Technology (Shanghai) Co., Ltd.
By: /s/ Qing Mou
Name: Qing Mou
Title: Legal representative
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Yao Wang Corporation Limited (seal)
/s/ Seal of Yao Wang Corporation Limited
By: /s/ Gang Yu
Name: Gang Yu
Title: Authorized representative
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Ningbo Youkai Business Management Partnership (LP) (seal)
/s/ Seal of Ningbo Youkai Business Management Partnership (LP)
By: /s/ Wenyong Zheng
Name: Wenyong Zheng
Title: Managing Partner
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP) (seal)
/s/ Seal of Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP)
By: /s/ Weiguang Shou
Name: Weiguang Shou
Title: Authorized representative
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Ningbo Liangji Industrial Co., Ltd. (seal)
/s/ Seal of Ningbo Liangji Industrial Co., Ltd.
By: /s/ Liping Ruan
Name: Liping Ruan
Title: Legal representative or authorized representative
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Zhenjiang Huixin Equity Investment Partnership (LP) (seal)
/s/ Seal of Zhenjiang Huixin Equity Investment Partnership (LP)
By: /s/ Bo Wu
Name: Bo Wu
Title: Authorized representative
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Hezhou Hongshi Equity Investment Partnership (LP) (seal)
/s/ Seal of Hezhou Hongshi Equity Investment Partnership (LP)
By: /s/ Zhengdong Ding
Name: Zhengdong Ding
Title: Managing Partner
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Yaoxing Business Management Partnership (LP) (seal)
/s/ Seal of Shanghai Yaoxing Business Management Partnership
By: /s/ Ding Liu
Name: Ding Liu
Title: Managing Partner
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Yaoshu Business Management Partnership (LP) (seal)
/s/ Seal of Shanghai Yaoshu Business Management Partnership
By: /s/ Yang Chen
Name: Yang Chen
Title: Managing Partner
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Xinjiang Junying Hongyin Investment Management Partnership (LP) (seal)
/s/ Seal of Xinjiang Junying Hongyin Investment Management Partnership (LP)
By: /s/ Yang Yang
Name: Yang Yang
Title: Authorized representative
Exhibit 1 List of Investors
Investment
amount (RMB)
Subscribed
registered
capital (RMB)
Amount
recorded in
capital reserve
(RMB)
Shareholding
percentage
(%)
100,000,000.00
19,646,365.42
80,353,634.58
1.1423
5,000,000.00
982,318.27
4,017,681.73
0.0571
55,380,000.00
10,880,157.17
44,499,842.83
0.6326
150,000,000.00
29,469,548.13
120,530,451.87
1.7134
70,000,000.00
13,752,455.80
56,247,544.20
0.7996
15,000,000.00
2,946,954.81
12,053,045.19
0.1713
14,640,000.00
2,876,227.90
11,763,772.10
0.1672
No.
Investor
Shanghai SOE Reform &
Development Equity
Investment Fund Partnership
(LP)
Xinjiang Junying Hongyin
Investment Management
Partnership (LP)
Zhenjiang Huixin Equity
Investment Partnership (LP)
Ningbo Youkai Business
Management Partnership (LP)
Ningbo Liangji Industrial Co.,
Ltd.
Hezhou Hongshi Equity
Investment Partnership (LP)
Shanghai Yaoxing Business
Management Partnership (LP)
Shanghai Yaoshu Business
Management Partnership (LP)
1
2
3
4
5
6
7
8
9,800,000.00
1,925,343.81
7,874,656.19
Total
419,820,000.00
82,479,371.31
337,340,628.69
0.1119
4.7954
Exhibit 2 Shareholding Structure of the Company Immediately after the Completion of the Capital Increase
No.
Shareholder
Registered
capital (RMB)
Shareholding
percentage (%)
1
2
3
4
5
6
7
8
9
Yao Wang Corporation Limited
1,637,461,056.16
Ningbo Youkai Business Management Partnership (LP)
29,469,548.13
Shanghai SOE Reform & Development Equity Investment
Fund Partnership (LP)
Ningbo Liangji Industrial Co., Ltd.
Zhenjiang Huixin Equity Investment Partnership (LP)
Hezhou Hongshi Equity Investment Partnership (LP)
Shanghai Yaoxing Business Management Partnership (LP)
Shanghai Yaoshu Business Management Partnership (LP)
Xinjiang Junying Hongyin Investment Management
Partnership (LP)
19,646,365.42
13,752,455.80
10,880,157.17
2,946,954.81
2,876,227.90
1,925,343.81
982,318.27
95.2046
1.7134
1.1423
0.7996
0.6326
0.1713
0.1672
0.1119
0.0571
Total
1,719,940,427.47
100.0000
Exhibit 3 List of Competitors
Supplementary Agreement of Capital Increase Agreement
in respect of
Yao Fang Information Technology (Shanghai) Co., Ltd.
Exhibit 4.27
Dated August 26, 2020
1
This Supplementary Agreement of Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd. (this
“Supplementary Agreement”) is made in Shanghai as of August 26, 2020 by and among:
A. Yao Fang Information Technology (Shanghai) Co., Ltd., a limited liability company duly incorporated and validly existing
under the PRC Laws, whose unified social credit code is 913101150747824207 and registered address is at Room 805, Tower B,
Building 1#, No. 977 Shangfeng Road, Tangzhen, Pudong New Area, Shanghai (the “Company” or “Yao Fang Shanghai”);
B. Yao Wang Corporation Limited (company number: 1918271), a limited company duly incorporated and validly existing under
the laws of Hong Kong, China, whose registered address is at Unit 402, 4th Floor, Fairmont House, No. 8 Cotton Tree Drive,
Admiralty, Hong Kong (the “Existing Shareholder” or “Yao Wang”);
C. Ningbo Youkai Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91330225MA283KBGX3 and registered address is at 3/F, northeast of Zhaohui
Road and Changming Road, Xizhou Town, Xiangshan County, Zhejiang (“Youkai”);
D. Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP), a limited partnership duly incorporated
and validly existing under the PRC Laws, whose unified social credit code is 91310000MA1FL5U017 and registered address is at
2A, Building 1#, No. 9 Zhenning Road, Changning District, Shanghai (the “SOE Reform Fund”);
E. Ningbo Liangji Industrial Co., Ltd., a limited liability company duly incorporated and validly existing under the PRC Laws,
whose unified social credit code is 913302825839883985 and registered address is at 30 & 32, Sanhai Road, East Zone,
Guanhaiwei Town Industrial Park, Cixi, Zhejiang (“Liangji”);
F. Zhenjiang Huixin Equity Investment Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91321102MA21QR306J and registered address is at Room 301, Building 2#,
Cloud Times Square, No. 259 Miaojiawan Road, Zhengdonglu Street, Jingkou District, Zhenjiang (“Huixin”);
G. Hezhou Hongshi Equity Investment Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91451100MA5NH9YN91 and registered address is at No. 1 Tianhe Avenue,
Hezhou Eco-Industrial Park, Guangxi (“Hongshi”);
H. Shanghai Yaoxing Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91310115MA1HBBND7J and registered address is at 1/F, Building 1#, No.
977 Shangfeng Road, Pudong New Area, Shanghai (“Yaoxing”);
I. Shanghai Yaoshu Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91310115MA1HBBGY4Q and registered address is at 1/F, Building 1#, No.
977 Shangfeng Road, Pudong New Area, Shanghai (“Yaoshu”); and
2
J. Xinjiang Junying Hongyin Investment Management Partnership (LP), a limited partnership duly incorporated and validly
existing under the PRC Laws, whose unified social credit code is 91650100MA77W62Q2L and registered address is at Room
702, 7/F, Weixing Plaza, No. 473 Weixing Road, Urumqi Economic & Technological Development Zone, Xinjiang (“Junying”).
Each of Youkai, the SOE Reform Fund, Liangji, Huixin, Hongshi, Yaoxing, Yaoshu and Junying is referred to herein individually as an
“Investor” and collectively as the “Investors”, and each of Yao Fang Shanghai, Yao Wang and the Investors is referred to herein
individually as a “Party” and collectively as the “Parties”.
WHEREAS:
1. The Parties of this Supplementary Agreement have signed the Capital Increase Agreement on August 10, 2020 (“Capital
Increase Agreement”), according to the terms and conditions of which the Investors have subscribed RMB82,479,371.31 of the
Company’s Newly Increased Registered Capital at the total price of RMB419,820,000.
2. After the Completion of the Capital increase, the registered capital of Yao Fang Shanghai shall change from USD250,000,000
into RMB1,719,940,427.47, of which, Yao Wang shall hold 95.2046% of the shares of the Company, and the Investors shall hold
4.7954% of the shares of the Company in aggregate.
The Parties hereby agree to sign this Supplementary Agreement and further agree as follows:
1. The Article 6.8 (Right of redemption) of Capital Increase Agreement shall be amended as below:
(1) If the Company fails to achieve a Qualified IPO prior to the Expected Date of IPO, from the date immediately
following the Expected Date of IPO or such later date as agreed pursuant to Section 6.7, each Investor shall have
the right to request the Yao Wang (to the extent permitted by the PRC Laws) to redeem all or part of the shares held
by it in the Company then (“Sale Shares”) at such price and in such manner as set forth in Section 6.8(2), provided
that such Investor shall deliver a written notice of redemption to the Company at least ninety (90) days in advance,
so that the Company will have sufficient time to arrange such redemption. The Company shall assume the liability
for guaranteeing the performance of such obligation of redemption by Yao Wang.
(2) The price to be paid by the Company for the Sale Shares pursuant to Section 6.8(1) shall be equal to the price paid
by such Investor in the Capital Increase, i.e. RMB5.09 for each RMB1 of the registered capital, plus interest at the
rate of 6% per annum (simple interest). If the redemption occurs at any date that is not an anniversary of the
Completion Date, the interest shall be calculated on the basis of the actual period in which such Investor holds the
shares of the Company.
2. Confidentiality
Without the prior written consent of the other parties to this Supplementary Agreement, neither party in this Supplementary
Agreement shall and shall require its respective affiliates, consultants and their respective representatives not to disclose this
Supplementary Agreement and any of its terms to any third party, unless (i) as required by the applicable laws, rules of the stock
exchange on which the shares of any Party are listed or any competent government authority; or (ii) to the representatives or
consultant of a Party who need to know such information provided that such representatives or consultant have undertaken to comply
with the provisions.
3
3. Governing Law and Dispute Resolution
3.1 The formation, validity, execution, interpretation and dispute resolution in respect of this Supplementary Agreement shall be
governed by the PRC Laws.
3.2 Any dispute arising out of or in connection with this Supplementary Agreement, or any breach, termination or invalidity of this
Supplementary Agreement, shall be submitted to the Shanghai International Arbitration Center (“SHIAC”), for settlement by
arbitration in Shanghai in accordance with the arbitration rules of the SHIAC in force when the arbitration notice is submitted.
The language of arbitration shall be Chinese. The arbitration award made by the tribunal shall be final and binding upon the
Parties.
4. Miscellaneous
4.1 This Supplementary Agreement shall take effect on the date it is executed by the Parties and constitute an integral part of the
Capital Increase Agreement. In case this Supplementary Agreement is inconsistent with the Capital Increase Agreement, this
Supplementary Agreement shall prevail. Any other matters not stipulated in this Supplementary Agreement shall be governed by
the relevant stipulations of the Capital Increase Agreement.
4.2 Any amendment, modification, waiver, rescission or termination in respect of this Supplementary Agreement shall be made by a
written agreement signed by the Parties.
4.3 Unless otherwise provided herein, the relevant interpretation or abbreviation of the Capital Increase Agreement also applies to
this Supplementary Agreement.
4.4 If any provision hereof is held illegal, invalid of unenforceable in whole or in part under the applicable laws, such illegal, invalid
of unenforceable provision or part shall not be deemed as part of this Supplementary Agreement, but the legality, validity and
enforceability of the remaining provisions of this Supplementary Agreement shall not be affected. The Parties shall negotiate to
replace such provision that is deemed to be deleted from this Supplementary Agreement with a legal, valid and acceptable
provision that comes closest to expressing the original intent of the Parties herein.
4.5 This Supplementary Agreement shall be made in Chinese and executed in twelve (12) counterparts. Each Party shall hold one
(1) counterpart, and the remaining counterparts shall be kept by the Company, for use in the relevant approval, filing and
registration procedures.
(End of text)
4
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Yao Fang Information Technology (Shanghai) Co., Ltd. (seal)
/s/ Seal of Yao Fang Information Technology (Shanghai) Co., Ltd.
By:
/s/ Qing Mou
Name: Qing Mou
Title: Legal representative
5
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Yao Wang Corporation Limited (seal)
/s/ Seal of Yao Wang Corporation Limited
By:
/s/ Gang Yu
Name: Gang Yu
Title: Authorized representative
6
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Ningbo Youkai Business Management Partnership (LP) (seal)
/s/ Seal of Ningbo Youkai Business Management Partnership (LP)
By:
/s/ Wenyong Zheng
Name: Wenyong Zheng
Title: Managing Partner
7
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP) (seal)
/s/ Seal of Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP)
By:
/s/ Weiguang Shou
Name: Weiguang Shou
Title: Authorized representative
8
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Ningbo Liangji Industrial Co., Ltd. (seal)
/s/ Seal of Ningbo Liangji Industrial Co., Ltd.
By:
/s/ Liping Ruan
Name: Liping Ruan
Title: Legal representative or authorized representative
9
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Zhenjiang Huixin Equity Investment Partnership (LP) (seal)
/s/ Seal of Zhenjiang Huixin Equity Investment Partnership (LP)
By:
/s/ Bo Wu
Name: Bo Wu
Title: Authorized representative
10
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Hezhou Hongshi Equity Investment Partnership (LP) (seal)
/s/ Seal of Hezhou Hongshi Equity Investment Partnership (LP)
By:
/s/ Zhengdong Ding
Name: Zhengdong Ding
Title: Managing Partner
11
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Yaoxing Business Management Partnership (LP) (seal)
/s/ Seal of Shanghai Yaoxing Business Management Partnership
By:
/s/ Ding Liu
Name: Ding Liu
Title: Managing Partner
12
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Yaoshu Business Management Partnership (LP) (seal)
/s/ Seal of Shanghai Yaoshu Business Management Partnership
By:
/s/ Yang Chen
Name: Yang Chen
Title: Managing Partner
13
[Signature Page to Capital Increase Agreement in respect of Yao Fang Information Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Xinjiang Junying Hongyin Investment Management Partnership (LP) (seal)
/s/ Seal of Xinjiang Junying Hongyin Investment Management Partnership (LP)
By:
/s/ Yang Yang
Name: Yang Yang
Title: Authorized representative
14
Exhibit 4.28
Capital Increase Agreement
in respect of
1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.
Dated December 14, 2020
Table of Contents
Section
Definitions and Interpretation
1.
Capital Increase
2.
Payment
3.
Warranties and Covenants
4.
Completion of the Capital Increase
5.
Rights and Obligations of the Shareholders
6.
Employee Incentive Plan
7.
Admission of New Investors
8.
Confidentiality
9.
Indemnification
10.
Rescission and Termination
11.
Notices
12.
Force Majeure
13.
Governing Law and Dispute Resolution
14.
Miscellaneous
15.
List of Investors
Exhibit 1
Shareholding Structure of the Company Immediately after the Completion of the Capital Increase
Exhibit 2
List of Competitors
Exhibit 3
Exhibit 4 Mailing and Service Information
Page
5
7
7
9
10
11
18
18
19
19
20
21
21
21
22
60
61
63
65
This Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd. (this “Agreement”) is made
in Shanghai as of December 14, 2020 (the “Signing Date”) by and among:
A. 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd., formerly known as Yao Fang Information Technology (Shanghai)
Co., Ltd., a company limited by shares duly incorporated and validly existing under the PRC Laws, whose unified social credit
code is 913101150747824207 and registered address is at Room 805, Tower B, Building 1#, No. 977 Shangfeng Road, Tangzhen,
Pudong New Area, Shanghai (the “Company” or “1 Pharmacy”);
B. Yao Wang Corporation Limited (company number: 1918271), a limited company duly incorporated and validly existing under
the laws of Hong Kong, China, whose registered address is at Unit 402, 4th Floor, Fairmont House, No. 8 Cotton Tree Drive,
Admiralty, Hong Kong (the “Controlling Shareholder” or “Yao Wang”);
C. Ningbo Youkai Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91330225MA283KBGX3 and registered address is at 3/F, northeast of Zhaohui
Road and Changming Road, Xizhou Town, Xiangshan County, Zhejiang (“Youkai”);
D. Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP), a limited partnership duly incorporated
and validly existing under the PRC Laws, whose unified social credit code is 91310000MA1FL5U017 and registered address is at
2A, Building 1#, No. 9 Zhenning Road, Changning District, Shanghai (the “SOE Reform Fund”);
E. Ningbo Liangji Industrial Co., Ltd., a limited liability company duly incorporated and validly existing under the PRC Laws,
whose unified social credit code is 913302825839883985 and registered address is at 30 & 32, Sanhai Road, East Zone,
Guanhaiwei Town Industrial Park, Cixi, Zhejiang (“Liangji”);
F. Zhenjiang Huixin Equity Investment Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91321102MA21QR306J and registered address is at Room 301, Building 2#,
Cloud Times Square, No. 259 Miaojiawan Road, Zhengdonglu Street, Jingkou District, Zhenjiang (“Huixin”);
G. Hezhou Hongshi Equity Investment Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91451100MA5NH9YN91 and registered address is at No. 1 Tianhe Avenue,
Hezhou Eco-Industrial Park, Guangxi (“Hongshi”);
H. Shanghai Yaoxing Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91310115MA1HBBND7J and registered address is at 1/F, Building 1#, No.
977 Shangfeng Road, Pudong New Area, Shanghai (“Yaoxing”);
I. Shanghai Yaoshu Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91310115MA1HBBGY4Q and registered address is at 1/F, Building 1#, No.
977 Shangfeng Road, Pudong New Area, Shanghai (“Yaoshu”);
1
J. Xinjiang Junying Hongyin Investment Management Partnership (LP), a limited partnership duly incorporated and validly
existing under the PRC Laws, whose unified social credit code is 91650100MA77W62Q2L and registered address is at Room
702, 7/F, Weixing Plaza, No. 473 Weixing Road, Urumqi Economic & Technological Development Zone, Xinjiang (“Junying”);
K. Tianjin Gangling Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91120118MA07624C5F and registered address is at Room 211, 2/F, No. 1
Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-
038 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Gangling”);
L. Tianjin Yaocheng Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91120118MA07637J4T and registered address is at Room 211, 2/F, No. 1
Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-
042 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaocheng”);
M. Tianjin Yaosheng Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91120118MA07638EXR and registered address is at Room 211, 2/F, No. 1
Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-
043 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaosheng”);
N. Tianjin Yaopeng Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91120118MA0763TJ4N and registered address is at Room 211, 2/F, No. 1
Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-
044 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaopeng”);
O. Tianjin Yaohua Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91120118MA0764GB9D and registered address is at Room 211, 2/F, No. 1
Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-
045 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaohua”);
P. Tianjin Yaoming Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91120118MA0764LB08 and registered address is at Room 211, 2/F, No. 1
Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-
046 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaoming”);
Q. Tianjin Yaotian Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91120118MA07643T3G and registered address is at Room 211, 2/F, No. 1
Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-
047 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaotian”);
2
R. Tianjin Yaoding Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91120118MA0763TU40 and registered address is at Room 211, 2/F, No. 1
Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-
048 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaoding”);
S. Tianjin Yao Cheng Business Management Partnership (LP), a limited partnership duly incorporated and validly existing
under the PRC Laws, whose unified social credit code is 91120118MA0763TN74 and registered address is at Room 211, 2/F, No.
1 Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No.
WK-049 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yao Cheng”);
T. Tianjin Yaojun Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91120118MA0763UL7P and registered address is at Room 211, 2/F, No. 1 Second
Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-050 by
Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaojun”);
U. Tianjin Yaowei Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91120118MA0763FR03 and registered address is at Room 211, 2/F, No. 1 Second
Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-051 by
Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaowei”);
V. Tianjin Yaoan Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91120118MA0767T69N and registered address is at Room 211, 2/F, No. 1 Second
Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-052 by
Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaoan”);
W. Tianjin Yaogong Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91120118MA07637T69 and registered address is at Room 211, 2/F, No. 1
Second Avenue, International Logistics Park, Tianjin Pilot Free Trade Zone (Tianjin Airport Economic Area) (Custody No. WK-
053 by Sunwukong (Tianjin) Business Secretary Co., Ltd.) (“Yaogong”);
X. SAIF Partners (Nanjing) Equity Investment Fund (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91320191MA200CDW8L and registered address is at C28, Weike Space, Building
1#, Yangtze River New Finance Creative Block, No. 396 Binjiang Avenue, China (Jiangsu) Pilot Free Trade Zone Nanjing Area
(“SAIF Nanjing”);
Y. SAIF Partners (Huangshan) Tourist Culture Industrial Development Fund (LP), a limited partnership duly incorporated and
validly existing under the PRC Laws, whose unified social credit code is 91341000MA2RF5U44N and registered address is at
No. 54 Yingbin Avenue, Tunxi District, Huangshan (“SAIF Huangshan”);
3
Z. SAIF Partners (Nanjing) Hengzhun Venture Capital Fund (LP), a limited partnership duly incorporated and validly existing
under the PRC Laws, whose unified social credit code is 91320113MA1Q0PQN4Q and registered address is at 2-3 Zidong Road,
Maqun Street, Xixia District, Nanjing (“SAIF Hengzhun”);
AA. Jiaxing Tengyuan Investment Partnership (LP), a limited partnership duly incorporated and validly existing under the PRC
Laws, whose unified social credit code is 91330402MA28AJ2T4U and registered address is at Room 102-46, Building 2#, Fund
Town, No. 1856 Nanjiang Road, Nanhu District, Jiaxing, Zhejiang (“Tengyuan”);
BB. Shanghai Shenli Business Management Partnership (LP), a limited partnership duly incorporated and validly existing under
the PRC Laws, whose unified social credit code is 91310230MA1HGX4E1F and registered address is at Room 527, Zone J, No. 2
Alley 921, Xinshen Road, Xinhe Town, Chongming District, Shanghai (Shanghai Fusheng Economic Development Zone)
(“Shenli”);
CC. Huasai Zhikang (Shanghai) Equity Investment Fund Partnership (LP), a limited partnership duly incorporated and validly
existing under the PRC Laws, whose unified social credit code is 91310000MA1FL7A34H and registered address is at Room
406A, 4/F, Building 13#, No. 269 Humin Road, Minhang District, Shanghai (“Huasai”);
DD. Shanghai Zhangjiang Torch Venture Capital Co., Ltd., a limited liability company duly incorporated and validly existing
under the PRC Laws, whose unified social credit code is 9131011505592143XK and registered address is at Room 107, Building
10#, No. 399 Keyuan Road, China (Shanghai) Pilot Free Trade Zone (“Torch”);
EE. Shanghai Zhilin Yiqu Venture Capital Partnership (LP), a limited partnership duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91310109MA1G5QB1X3 and registered address is at 4/F, 391-393 East Daming
Road, Hongkou District, Shanghai (place of centralized registration) (“Zhilin”);
FF. Shanghai Technology Venture Capital Co., Ltd., a limited liability company duly incorporated and validly existing under the
PRC Laws, whose unified social credit code is 91310000132215222E and registered address is at Unit 6, 39/F (actually located on
Floor 34), No. 669 Xinzha Road, Jing’an District, Shanghai (“STVC”);
GG. Shanghai Pudong Renmin Zhaoyin Cultural Industry Equity Investment Fund Partnership (LP), a limited partnership duly
incorporated and validly existing under the PRC Laws, whose unified social credit code is 91310000MA1FL5EN8R and
registered address is at Room 3301, No. 88 South Shendi Road, Pudong New Area, Shanghai (“Renmin Zhaoyin”);
HH. Gongqingcheng Ideate Investment Management Partnership (LP), a limited partnership duly incorporated and validly
existing under the PRC Laws, whose unified social credit code is 91360405MA36351Q72 and registered address is at Private
Fund Innovation Park, Gongqingcheng, Jiujiang, Jiangxi (“Ideate Investment”);
II. Shanghai Zhangjiang Technology Venture Capital Co., Ltd., a limited liability company duly incorporated and validly existing
under the PRC Laws, whose unified social credit code is 913100007679066259 and registered address is at Room 209, Podium
Building, Block 1, No. 3000 Longdong Avenue, China (Shanghai) Pilot Free Trade Zone (“ZTVC”); and
4
JJ. Hangzhou Hengqin Investment Management Partnership (LP), a limited partnership duly incorporated and validly existing
under the PRC Laws, whose unified social credit code is 91330102MA28NNR165 and registered address is at Room 190-18, No.
88-1 Yuanshuaimiao, Shangcheng District, Hangzhou, Zhejiang (“Hengqin”).
Each of SAIF Nanjing, SAIF Huangshan, SAIF Hengzhun, Tengyuan, Shenli, Huasai, Torch, Zhilin, STVC, Renmin Zhaoyin, Ideate
Investment, ZTVC and Hengqin is referred to herein individually as an “Investor” and collectively as the “Investors”; Youkai, the SOE
Reform Fund, Liangji, Huixin, Hongshi, Yaoxing, Yaoshu and Junying are referred to herein collectively as the “Prior Investors”; Yao
Wang, the Prior Investors, Gangling, Yaocheng, Yaosheng, Yaopeng, Yaohua, Yaoming, Yaotian, Yaoding, Yao Cheng, Yaojun, Yaowei,
Yaoan and Yaogong are referred to herein collectively as the “Existing Shareholders”; and each of 1 Pharmacy, the Existing
Shareholders and the Investors is referred to herein individually as a “Party” and collectively as the “Parties”.
WHEREAS:
1. As of the Signing Date, 1 Pharmacy has a registered capital of RMB682‚500‚000, and Yao Wang, as the Controlling Shareholder
of 1 Pharmacy, holds 90.6711% of the shares of 1 Pharmacy;
2. Subject to and on the terms and conditions set forth herein, 1 Pharmacy intends to increase its share capital by issuing 35‚148‚785
shares to the Investors, representing RMB35‚148‚785 of its newly increased registered capital (the “New Shares”), which shall be
jointly subscribed for by the Investors in such number and at such percentage of the New Shares as set opposite the relevant
Investor’s name on Exhibit 1 (the “Capital Increase”);
3. After the Completion of the Capital increase, the total share capital of 1 Pharmacy will increase from 682‚500‚000 shares to
717‚648‚785 shares, and its registered capital will increase from RMB682‚500‚000 to RMB717‚648‚785. The shareholding
structure of 1 Pharmacy immediately after the Completion of the Capital increase is set out in Exhibit 2, of which, Yao Wang
holds 86.2302% of the shares of the Company, and the Investors hold 4.8977% of the shares of the Company in aggregate;
4. Prior to the Completion of the Capital increase, 1 Pharmacy has a pre-money valuation of RMB10 billion. With the addition of
the Total Investment Amount of RMB515‚000,000, the post-money valuation of 1 Pharmacy will become RMB10‚515‚000,000
after the Completion of the Capital increase.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, and intending to be legally bound hereby, the Parties
hereby agree as follows:
1. Definitions and Interpretation
1.1 Definitions
For purpose of this Agreement, unless otherwise specified herein, the following terms shall have the meanings set forth
below:
5
“Amended Articles” means the articles of association of the Company as amended and jointly executed by the Existing
Shareholder and the Investors;
“Business Day” means any day (other than a Saturday, Sunday or public holiday) on which the banks in China are
generally open for business;
“PRC” means the People’s Republic of China, but solely for the purpose of this Agreement, excluding the Hong Kong
Special Administrative Region, the Macau Special Administrative Region and Taiwan;
“Investor” means each of the investors participating in the Capital Increase as set out in Exhibit 1, and “Investors” refer to
such investors collectively;
“New Shares” shall have the meaning set out in the preamble;
“Capital Increase” shall have the meaning set out in the preamble;
“Investment Amount” shall have the meaning set out in Section 3.1;
“Total Investment Amount” shall have the meaning set out in Section 3.1;
“Closing Date” means the date on which the Investors have paid their respective Investment Amounts in full pursuant to
Section 3.3;
“Completion” means the completion of the Capital Increase pursuant to Section 5.2;
“Completion Date” means the date on which the Capital Increase is completed pursuant to Section 5.2;
“Encumbrance” means any mortgage, security, pledge, lien, option, restriction, right of first refusal, preemptive right,
third-party right, or any other encumbrance or security interest of any kind, or any other kind of preferential arrangement
with similar effect, including without limitation transfer or retention of title;
“PRC Laws” means the laws, regulations, codes and judicial interpretations officially promulgated and published by the
legislative, administrative and judicial authorities of the PRC at all levels, but solely for the purpose of this Agreement,
excluding the laws, regulations, codes, judicial interpretations and legal precedents of the Hong Kong Special
Administrative Region, the Macau Special Administrative Region and Taiwan;
“RMB” means the lawful currency of the PRC;
“Registration Authority” means the State Administration for Market Regulation or its authorized local counterparts; and
“Event of Force Majeure” means any event or circumstance unforeseeable by and beyond the control of a Party, including
without limitation natural disaster, war, terrorism, riot, sabotage, civil disturbance, blockade, fire, explosion, flood,
accident, government act and strike.
6
1.2 Interpretation
(1) Section headings used herein are for convenience only and shall not affect the interpretation of this Agreement.
(2) Unless the context otherwise requires, if the day on which any right or obligation hereunder must be exercised or
performed is not a Business Day, such right or obligation shall be exercised or performed on the next Business Day.
(3) References to time are to Beijing time of the PRC.
(4) The word “hereof” or other words of similar import refer to this Agreement as a whole and not to any particular
Section. Unless otherwise expressly provided herein, the term “including” shall be construed to be “including
without limitation”, regardless of whether it is actually followed by “without limitation”.
(5) References to this Agreement include this Agreement and its amendments, modifications, supplements,
replacements and/or restatements in whatever form made from time to time. Unless the context otherwise requires,
references to sections, paragraphs, subparagraphs and exhibits are to sections, paragraphs and subparagraphs of and
exhibits to this Agreement.
2. Capital Increase
2.1 The Investors shall subscribe for 35‚148‚785 New Shares in aggregate at the price of RMB14.652 per share in cash,
representing RMB35‚148‚785 of the newly increased registered capital of the Company, or 4.8977% of the shares of the
Company after the Completion of the Capital Increase. The respective number of the New Shares subscribed for by each
Investor and the amount of registered capital and shareholding percentage represented by such New Shares are set out in
Exhibit 1.
2.2 The Parties agree that the Company’s pre-money valuation is RMB10 billion, and acknowledge that the Total Investment
Amount is RMB515‚000,000, so the Company’s post-money valuation will become RMB10‚515‚000,000 after the
Completion of the Capital increase.
3. Payment
3.1 Investment Amount
With respect to 35‚148‚785 New Shares, representing RMB35‚148‚785 of the newly increased registered capital of the
Company, to be subscribed for by the Investors, the total price payable by the Investors shall be RMB515‚000,000 (the
“Total Investment Amount”), of which, RMB35‚148‚785 shall be recorded in the registered capital of the Company, and
the balance shall be recorded in the capital reserve of the Company. The respective number of the New Shares subscribed
for by each Investor, and the amount of registered capital represented by such New Shares, the amount payable for such
New Shares (the “Investment Amount” of such Investor) and the portion of the Investment Amount paid by each Investor
that will be recorded in the capital reserve of the Company are set out in Exhibit 1.
7
3.2 Use of the Investment Amount
Unless otherwise provided herein or agreed by the Parties, the Company shall use the Investment Amount solely for the
conduct of its main business, including investment in technologies, expansion of the current business and investment in
innovative business, among others, and not for any other purpose without the prior written consent of the Investors.
3.3 Payment
(1) The Investors shall, severally but not jointly, pay their respective Investment Amounts in full to the bank account
designated by the Company within five (5) Business Days after the satisfaction of each of the following conditions:
i. after this Agreement takes effect, the Company shall have delivered to the Investors copies of the resolutions
of its board of directors and shareholders’ meeting approving the Capital Increase, and the Amended Articles
or the relevant amendment to the articles of association of the Company (as applicable), in each case, stamped
with the seal of the Company; and
ii. as of the Closing Date, all representations and warranties made by the Company and the Existing Shareholders
herein shall remain true, accurate and complete, and the Company and the Existing Shareholders shall have
performed their respective covenants that are required to be performed on or prior to the Closing Date, and
have not engaged in any act in violation of the provisions hereof that may hinder the Qualified IPO.
The bank account designated by the Company for collecting the Investment Amounts hereunder is as follows:
Account name: 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.
Account number: 121911552610808
Bank: China Merchants Bank Dongfang Sub-Branch of Shanghai
(2) If any Investor fails to pay its Investment Amount in full within the time limit set forth in Section 3.3(1), the
Company shall have the right to impose a penalty on such Investor in an amount equal to 25% of the Investment
Amount payable by such Investor, and if such Investor still fails to pay its Investment Amount in full within five (5)
Business Days after the date of receipt of written notice from the Company requesting it to do so, to rescind this
Agreement with such Investor by giving written notice to it.
(3) Within five (5) Business Days after the Investors have paid their respective Investment Amounts in full, the
Company shall deliver to each Investor a copy of its updated register of shareholders. Within five (5) Business Days
after the Investors have paid their respective Investment Amounts in full and provided all information required for
the alteration registration in connection with the Capital Increase, the Company shall go through the applicable
alteration registration procedures with the competent administration for industry and commerce. If the Company
fails to go through the alteration registration procedures or provide the Investors with its updated register of
shareholders pursuant to this Section 3.3(3), the Investors shall have the right to request the Company to pay them a
penalty in an amount equal to 25% of the Investment Amount paid by the Investors, and if the Company still fails to
perform such obligations within five (5) Business Days after the date of receipt of written notice from the Investors
requesting it to do so, to rescind this Agreement by giving written notice to the Company, and request the Company
to return all Investment Amounts paid by the Investors and pay the Investors a penalty as stated above within five
(5) Business Days after the date of receipt of such written notice.
8
4. Warranties and Covenants
4.1 The Company and the Controlling Shareholder hereby warrant and covenant to the Investors that:
(1) the Company is duly incorporated and validly existing under the PRC Laws;
(2) the Controlling Shareholder is duly incorporated and validly existing under the laws of the jurisdiction of its
incorporation, without major violations of laws and regulations;
(3) each of the Company and its consolidated subsidiaries and other entities controlled by the Company by contract has
obtained all qualifications, permits and licenses required for its production and operation, which are not subject to
any revocation or withdrawal, and will not become non-renewable upon expiration thereof, except for any
qualification, permit or license the grant of which is not supported by the applicable local policies;
(4) unless otherwise disclosed to the Investors prior to the Signing Date, none of the Company and its consolidated
subsidiaries and other entities controlled by the Company by contract or any director, supervisor or executive of the
Company is involved in any administrative penalty, pending litigation or potential dispute or controversy that may
hinder the Qualified IPO;
(5) the Company and the Existing Shareholders have full power, right and authority to execute, deliver and perform this
Agreement;
(6) the execution, delivery and performance of this Agreement will not result in any violation by the Company of any
applicable laws, rules or regulations or the provisions of any material contract document binding on the Company;
(7) the shares acquired by the Investors through the Capital Increase are free and clear of all Encumbrances; and
(8) all documents, data and information provided by the Company and the Existing Shareholders to the Investors prior
to and after the Signing Date at the reasonable request of the Investors are true, accurate and free from any material
omission or misleading statement.
9
4.2 Each Investor hereby warrants and covenants to the Company that:
(1) it is duly incorporated and validly existing under the PRC Laws, neither it nor any of its shareholders is a contract-
based private fund, asset management plan or trust plan, and it is qualified as a shareholder under the PRC Laws;
(2) it has full power, right and authority to execute, deliver and perform this Agreement;
(3) the execution, delivery and performance of this Agreement will not result in any violation by it of any applicable
laws, rules or regulations or the provisions of any material contract document binding on it; and
(4) it has sufficient funds available for the Capital Increase, which come from legal sources.
5. Completion of the Capital Increase
5.1 The Company shall go through the applicable alteration registration procedures in connection with the Capital Increase
with the competent administration for industry and commerce within five (5) Business Days after the Investors have paid
their respective Investment Amounts in full and provided all information required for the alteration registration, and
endeavor to complete all alteration registration, filing and reporting procedures with the competent market supervision
administration and commerce authority in connection with the changes in its registered capital, shareholding structure,
articles of association and other matters relating to the Capital Increase (the “Government Procedures”) prior to
December 31, 2020.
For the purpose stated above, the Investors shall use their best endeavors to provide the Company with all necessary
assistance required in connection with the Government Procedures, including without limitation execution of the relevant
documents and performance of the necessary procedures.
5.2 The Completion of the Capital Increase shall be contingent on the payment of the receptive Investment Amounts by the
Investors to the Company in full.
5.3 Limit on the shareholding percentage of the Investors
The Investors agree and acknowledge that, without the prior written consent of the Company, the total equities or shares
directly or indirectly held by the Investors and their respective affiliates and/or concert parties, if any, in the Company in
any manner shall in no event exceed 5% of the registered capital or total shares of the Company at any time after the
Completion of the Capital Increase and till the completion of the Qualified IPO (as defined below) of the Company.
Notwithstanding the foregoing, the Investors may hold more than 5% of the registered capital or total shares of the
Company to the extent resulting from any exercise of their rights under Sections 6.1 and 6.2.
5.4 After the Completion of the Capital Increase, for purpose of consummating the Qualified IPO, the Parties agree to
cooperate with the Company to take or do, or cause to be taken or done, all necessary or appropriate actions or things in
accordance with the relevant examination requirements of the Shanghai Stock Exchange (the “Exchange”), the China
Securities Regulatory Commission and other competent regulatory authorities, including without limitation amendment,
modification or termination of the relevant provisions hereof. The Parties agree that the provisions of Section 6 shall
automatically become effective again upon occurrence of any event described in Section 11.1(2).
10
6. Rights and Obligations of the Shareholders
Each Investor shall, from the date it has paid its Investment Amount to the Company in full, enjoy the rights and assume the
obligations as a shareholder of the Company to the extent of its subscribed shares of the Company, pursuant to the provisions of
the PRC Laws, listing-related regulatory rules, this Agreement and the Amended Articles.
For the avoidance of doubt, the rights and obligations of the Prior Investors under the Capital Increase Agreement entered into by
and among Yao Fang Information Technology (Shanghai) Co., Ltd., Yao Wang and the Prior Investors on August 10, 2020 shall
remain in full force and effect.
6.1 Preemptive right
(1) If, during the period from the Completion of the Capital Increase and till the date the Company formally submits an
application for Qualified IPO to the Exchange, the Company intends to increase its registered capital by offering
any warrants, convertible bonds, or other securities convertible into the shares of the Company or other equity
interests or otherwise, each shareholder of the Company shall have the preemptive right to subscribe for such newly
increased registered capital in proportion to its actual capital contribution to the Company then (the “Preemptive
Right”).
Subject to Section 6.1(2), the Company shall first deliver to each shareholder a notice (the “Capital Increase
Notice”), setting forth the proposed amount, subscription price, terms of payment, closing conditions and other
information in respect of the newly increased registered capital. Within ten (10) Business Days following receipt of
the Capital Increase Notice from the Company, any shareholder electing to exercise its Preemptive Right (each a
“Subscribing Shareholder”) shall notify the Company in writing of its intention to exercise the Preemptive Right
and the amount it intends to subscribe for. If the total amount that the Subscribing Shareholders intend to subscribe
for exceeds the amount of the newly increased registered capital, they shall subscribe for the newly increased
registered capital in proportion to their respective shareholder percentages then at the same subscription price and
on the same conditions.
(2) The Subscribing Shareholders’ Preemptive Right shall not apply to any newly increased registered capital:
(a) issued for purpose of implementing the Employee Incentive Plan contemplated by Section 7; or
(b) issued to all shareholders of the Company (including the Investors) as a result of capitalization of the
unappropriated profits or capital reserve or otherwise.
11
(3) After all shareholders have fully exercised their respective Preemptive Right, the Company may sell or issue the
remaining newly increased registered capital (if any), that has not been subscribed for by the shareholders, to any
third party.
(4) Each of the Existing Shareholders agrees to waive its Preemptive Right in respect of the Capital Increase.
6.2 Anti-dilution protection
(1) Subject to the provisions hereof, if, after the Completion of the Capital Increase, the Company issues any additional
shares at a price lower than the price per share paid by the Investors to the Company in the Capital Increase, the
shares held by the Investors shall be adjusted using the broad-based weighted average calculation, so that the price
per share of all shares held by the Investors in the Company will not be higher than the price per share offered by
the Company to the subsequent investors subscribing for the newly increased registered capital (the “Anti-dilution
Adjustment”), taking into account any share split, distribution of dividends, consolidation of shares or restructuring
of the Company (if any).
(2) After the Anti-dilution Adjustment, each Investor shall have the right to adjust its shareholding percentage in the
Company to such percentage of the shares of the Company that its Investment Amount can purchase at the price per
share as adjusted.
(3) Where it is necessary to make an Anti-dilution Adjustment, to the extent permitted by law, the Investors shall have
the right to: (i) subscribe for the newly increased registered capital of the Company at the nominal price of RMB1
or the lowest price permitted by law; (ii) request Yao Wang to transfer such number of shares as required to effect
the Anti-dilution Adjustment at the nominal price of RMB1 or the lowest price permitted by law; or (iii) receive
other compensation available under the law. If an Investor elects to acquire compensatory shares at the nominal
price of RMB1, but is unable to effect the same due to the restrictions of the applicable laws, when the Investor
enters into the relevant agreement for transfer of compensatory shares with Yao Wang or subscription agreement
with the Company (as the case may be) pursuant to which the Investor has the obligation to pay certain
consideration, Yao Wang or the Company shall issue a written waiver to the satisfaction of the Investor, releasing
the Investor from the obligation to pay the consideration for such compensatory shares.
(4) Notwithstanding the foregoing, the Investors shall not enjoy the anti-dilution protection stated above when the
Company issues any newly increase registered capital for purpose of implementing the Employee Incentive Plan
contemplated by Section 7.
12
6.3 Restrictions on share transfer
(1) Without the written consent of the Investors, prior to the consummation of a Qualified IPO by the Company, Yao
Wang shall not, directly or indirectly, transfer (for the avoidance of doubt, including without limitation transfer by
agreement that is not required to be registered with the Company’s Registration Authority), assign, donate,
substitute, exchange, place into trust, appoint a nominee to hold, contribute, surrender, pledge, encumber or
otherwise dispose of any shares held by it in the Company or any interests therein, which will result in a change of
control over the Company.
(2) Without the prior written consent of the Company, neither Investor may directly or indirectly transfer any share of
the Company to any entity competing with the Company as listed in Exhibit 3 (each a “Competitor”) or any of its
affiliates.
(3) To the extent that the Company submits an application for listing on the Shanghai Stock Exchange’s Sci-Tech
innovAtion boaRd (the “STAR Market”) to the Exchange prior to April 30, 2021, each Investor acknowledges and
agrees that pursuant to the Q&A on the Review of Applications for Listing of Stocks on the Sci-tech Innovation
Board of the Shanghai Stock Exchange (II), it shall covenant in the application for listing on the STAR Market
submitted by the Company that within 36 months after the completion of the alteration registration procedures in
connection with the Capital Increase with the competent administration for industry and commerce or such other
period as required by the applicable laws and regulations, it will not transfer or appoint another person to manage
the shares held by it in the Company in any manner, or request the Company to redeem such shares. After the
expiration of such period, the shares held by the Investors in the Company, except for those subject to any
mandatory prohibition on sale pursuant to the applicable laws, will become tradable on the relevant market,
provided that the Investors shall strictly comply with the applicable laws, administrative regulations, department
rules, codes and the relevant provisions of the Exchange and other competent regulatory authorities, and perform
the relevant obligation of information disclosure. If the Company fails to submit its application for listing on the
STAR Market within such time limit, the lock-up period for the shares held by the Investors shall be subject to the
applicable laws, regulations and codes then in effect.
6.4 Right of first refusal
(1) Subject to Section 6.3, if any shareholder (the “Transferring Shareholder”) intends to transfer all or part of the
shares held by it in the Company directly or indirectly (the “Offered Shares”) to any third party who is not a
shareholder of the Company (the “Proposed Transfer”), the shareholders other than the Transferring Shareholder
(the “Other Shareholders”) shall have the right to purchase the Offered Shares at the same price and on the same
terms and conditions as are offered to such third party (the “Right of First Refusal”). The Transferring Shareholder
intending to make the Proposed Transfer shall deliver to the Other Shareholders a written notice (the “Transfer
Notice”), which shall specify: (i) details of the Offered Shares, including without limitation percentage of the
registered capital that the Offered Shares represent, transfer price and terms of payment of the transfer price; (ii)
identity of the person to acquire the Offered Shares, including without limitation his name, actual controller and
scope of business (if applicable); and (iii) main terms and conditions of the Proposed Transfer. The Transfer Notice
shall constitute an offer by the Transferring Shareholder to the Other Shareholders in respect of the Offered Shares.
13
(2) Notwithstanding the foregoing, the Right of First Refusal shall not apply to:
(a) any share transfer made for purpose of implementing the Employee Incentive Plan contemplated by Section
7; or
(b) any transfer of shares by the Transferring Shareholder to any of its affiliates, provided that: (i) such affiliate
shall enjoy the rights and assume the obligations in respect of the shares acquired by it from the Transferring
Shareholder, and be bound by this Agreement, the articles of association of the Company and other
applicable documents; (ii) such affiliate is not a Competitor of the Company; (iii) the Transferring
Shareholder shall notify the Company and the other Shareholders at least ten (10) Business Days prior to
such transfer; (iv) the Transferring Shareholder shall provide the Other Shareholders with proofs in writing
showing that such transferee is an affiliate of the Transferring Shareholder meeting the conditions set forth
above; and (v) the Transferring Shareholder shall cause such transferee to remain an affiliate of the
Transferring Shareholder at any time after the completion of such transfer.
(3) Within twenty (20) days after receiving the Transfer Notice (the “Offer Period”), each Other Shareholder may give
a written notice (the “Acceptance Notice”) to the Transferring Shareholder to accept such offer, and purchase all or
part of the Offered Shares in preference to such third party. If the aggregate number of shares that the Other
Shareholders intend to purchase exceed the number of the Offered Shares, the Company shall limit the proportion of
the Offered Shares that each Other Shareholder has the right to purchase to the lower of: (i) the proportion of the
Offered Shares that such Other Shareholder intends to purchase as specified in its Acceptance Notice; and (ii) the
ratio of the paid-in registered capital held by such Other Shareholder to the registered capital of the Company at the
date of the Transfer Notice. During the Offer Period, the Transferring Period shall promptly provide the Other
Shareholders with the information about the business and financial conditions of the transferee that may be
reasonably requested by any Other Shareholder for the purpose of determining whether or not to exercise the Right
of First Refusal.
6.5 Right of co-sale
(1) If Yao Wang, as the Transferring Shareholder, intends to transfer any shares held by it in the Company (except for
any transfer for purpose of implementing the Employee Incentive Plan) to any third party other than any of its
affiliates or the Other Shareholders (the “Transferee”), and the Other Shareholders elect not to exercise their Right
of First Refusal, each Investor shall have the right to deliver a written notice (the “Co-sale Notice”) after receiving
the Transfer Notice, but in any event within the Offer Period set forth in Section 6.4, requesting the Transferee to
purchase the shares held by such Investor in the Company corresponding to the paid-in registered capital held by
such Investor then (the “Right of Co-sale”), to the extent of the relative ratio of the paid-in registered capital held
by such Investor then to that held by Yao Wang then (the “Co-sale Percentage”), and specifying the proportion of
the shares proposed to be transferred to the registered capital in the Co-sale Notice.
14
(2) The number salable by an Investor through the exercise of the Right of Co-sale is equal to the number of shares that
Yao Wang proposes to sell multiplied by such Investor’s Co-sale Percentage, which is equal to the paid-in registered
capital held by such Investor divided by the sum of the total paid-in registered capital held by the Investors electing
to exercise their Right of Co-sale and the paid-in registered capital held by Yao Wang.
(3) The failure of an Investor to deliver a Co-sale Notice within the Offer Period or exercise its Right of First Refusal
pursuant to Section 6.4 shall be deemed to be a waiver of its Right of Co-sale.
(4) Notwithstanding the foregoing, if such proposed sale of share by Yao Wang is sufficient to result in a change of
actual control over the Company, including without limitation acquisition of all shares of the Company by a third
party, each Investor shall have the right to transfer the shares held by it in the Company in preference to Yao Wang,
in which case the consummation of the share transfer between Yao Wang and the Transferee shall be contingent on
the transfer of all of the shares held by the Investors in the Company to such Transferee.
(5) If any Investor elects to exercise its Right of Co-sale, but the other shareholders waive their Right of First Refusal
in respect of the shares proposed to be sold by Yao Wang and such Investor, Yao Wang shall ensure the exercise of
such Right of Co-sale by reducing the amount of shares sold by it or otherwise. If any Investor elects to exercise its
Right of Co-sale pursuant to this Agreement, but the Transferee refuses to purchase the shares from such Investor,
or fails to obtain any necessary consent, approval or waiver from any third party, including any government
authority, as a result of which such Right of Co-sale fails to be exercised, Yao Wang shall not sell any shares held by
it in the Company to the Transferee. Any transfer of shares by Yao Wang in violation of this Section 6.5 shall be
null and void.
6.6 Right of exchange
If the Company proposes to adjust the listed entity and arrange for any of its affiliates to apply for the initial public offering
and listing of its shares, each Investor shall have the right to request the Company to allow such Investor to exchange the
shares held by it in the Company into such number of the shares of such proposed listed entity that will cause such Investor
to hold the same percentage of shares in such proposed listed entity as it holds in the Company, without any additional cost
to such Investor or at such price as requested by such Investor, subject to the applicable laws and regulations. If the
proposed listed entity is an offshore company, and any Investor waives its right of exchange as stated above, to the extent
permitted by the PRC Laws, such Investor shall have the right to request Yao Wang to redeem all or part of the shares then
held by it in the Company (the “Redeemed Shares”) at such price and in such manner as set forth in Section 6.9, provided
that such Investor shall give at least ninety (90) days’ notice of redemption to Yao Wang in writing, so that Yao Wang will
have sufficient time to arrange such redemption. The Company shall assume the liability for guaranteeing the performance
of such obligation of redemption by Yao Wang.
15
6.7 Equal treatment
If, after the Completion of the Capital Increase, the Company admits any new shareholder at a price not higher than the
post-money valuation of the Company immediately after the Completion of the Capital Increase (the “Post-money
Valuation”), as a result of which any shareholder of the Company, whether existing presently or admitted after the date of
this Agreement, enjoys any rights more favorable than those granted to the Investors under this Agreement and other
transaction documents or any additional right which the Investors do not have (the “More Favorable Terms”), the
Investors shall be automatically entitled to such More Favorable Terms. In such case, the Parties shall enter into a separate
agreement or amend or supplement this Agreement, to ensure such More Favorable Terms apply to the Investors. If, after
the Completion of the Capital Increase, the Company admits any new shareholder at a price higher than the Post-money
Valuation, and such new shareholder gets More Favorable Terms which are apparently unfair commercially, the Investors
shall also be entitled to such More Favorable Terms. In such case, the Parties shall enter into a separate agreement or
amend or supplement this Agreement, to ensure such More Favorable Terms apply to the Investors.
6.8 Qualified IPO of the Company
The Parties agree to use their best endeavors to procure the completion of the initial public offering and listing of the
shares of the Company on the STAR Market of the Shanghai Stock Exchange (the “Qualified IPO”, which shall be
deemed to have occurred when the shares of the Company are officially listed and traded on the Exchange) no later than
June 30, 2023 or such other date as agreed by the Parties in writing (the “Expected Date of Listing”).
The Company wishes to formally submit an IPO application to the Exchange within fifteen (15) months following the
Completion of the Capital Increase with the cooperation of the relevant securities company, law firm, accounting firm and
other intermediaries.
16
6.9 Right of Redemption
(1) If the Company fails to complete the Qualified IPO as of the Expected Date of Listing, the covenant on the lock-up
of shares made by the Investors pursuant to Section 6.3(3) shall automatically cease to be effective, and from the
date immediately following the Expected Date of Listing or such later date as agreed pursuant to Section 6.8, to the
extent permitted by the PRC Laws, each Investor shall have the right to request Yao Wang to redeem all or part of
the shares held by it in the Company then (“Redeemed Shares”) at such price and in such manner as set forth in
Section 6.9(2), provided that such Investor shall give at least ninety (90) days’ notice of redemption to Yao Wang in
writing, so that Yao Wang will have sufficient time to arrange such redemption. The Company shall assume the
liability for guaranteeing the performance of such obligation of redemption by Yao Wang. After receiving such
notice of redemption from any Investor, Yao Wang shall have the obligation to immediately notify the other
Investors, to ensure all Investors can exercise their right of redemption. The Parties acknowledge that the Investors
and the Prior Investors shall have equal right of redemption, and no Investor may exercise its right of redemption in
preference to the other Investors even if it delivers the notice of redemption earlier than the other Investors.
The price to be paid by Yao Wang for the Redeemed Shares of any Investor pursuant to Section 6.9(1) shall be
equal to the price paid by such Investor in the Capital Increase, i.e. RMB14.652 for each RMB1 of the registered
capital, plus interest at a simple annual rate of 6%. If the redemption occurs at any date that is not an anniversary of
the Completion Date, the interest shall be calculated on the basis of the actual period in which such Investor holds
the shares of the Company. Yao Wang shall pay the Investors the redemption price as stated above within ninety
(90) days after the date of receipt of the notice of redemption. The Parties further acknowledge and agree that
before Yao Wang pays the redemption price to the Investors, Yao Wang shall, or cause the consolidated subsidiaries
of the Company and other entities controlled by the Company by contract to, take actions to the extent permitted by
the applicable laws, to raise sufficient funds to enable Yao Wang to perform its obligation of redemption under this
Section 6.9. Each Party hereby agrees and undertakes to unconditionally take all measures and actions that may be
required in connection with the exercise of the right of redemption by the Prior Investors and the Investors,
including without limitation execution of the relevant power of attorney and share transfer agreement, and approval
of the relevant resolutions.
(2) The Investors further agree that if any Investor refuses to make a covenant on the lock-up of shares pursuant to
Section 6.3(3) or cooperate with the Company to take all necessary and appropriate actions required for the
completion of the Qualified IPO, or the Qualified IPO fails to be consummated as of the Expected Date of Listing
solely due to any reason attributable to such Investor, Yao Wang shall have the right, by giving a written notice to
such Investor within the notice period set forth in Section 6.9(1), to redeem all or part of the shares held by such
Investor in the Company then, at a price equal to the price paid by such Investor in the Capital Increase, i.e.
RMB14.652 for each RMB1 of the registered capital, in which case, such Investor shall take all necessary actions,
including execution of all necessary documents, that may be required by the Company to complete the relevant
procedures.
17
6.10 Information rights
After the Completion of the Capital Increase, subject to the applicable domestic and foreign laws, rules and regulatory
policies, at the request of any Investor, the Company shall provide to such Investor:
(1) prior to May 31 of each accounting year, the annual consolidated auditor’s report issued by a PRC certified public
accounting firm engaged by the Company for the preceding accounting year in accordance with the accounting
standards of the PRC; and
(2) within sixty (60) Business Days after the end of each quarter, the unaudited quarterly consolidated financial
statements of the Company for such quarter prepared in accordance with the accounting standards of the PRC.
7. Employee Incentive Plan
7.1 The Parties acknowledge and agree that the Company has adopted and implemented an employee incentive plan prior to
the Capital Increase. As of the Signing Date, the Company does not have any other employment incentive arrangement.
The Parties understand that if the Expected Date of Listing is later than June 30, 2023, the Company may launch a new
employee incentive plan, which will be submitted to the Company’s shareholders’ meeting for consideration pursuant to
the Company Law and other applicable laws and regulations and the articles of association of the Company (together with
the existing employee incentive plan, the “Employee Incentive Plan”). After the Employee Incentive Plan has been
approved by the Company’s shareholders’ meeting, the Parties agree to take all necessary and reasonable actions, including
without limitation voting in favor of the relevant resolutions (if necessary) in the relevant decision-making process of the
Company, executing necessary documents and giving cooperation in completing the necessary registration procedures, to
facilitate the adoption and implementation of the Employee Incentive Plan.
8. Admission of New Investors
8.1 The Company shall have the right to admit new investors after the Completion of the Capital Increase. Subject to Sections
6.1 and 6.2, the Investors agree to cooperate with the Company to take all necessary and reasonable actions for such
purpose, including without limitation voting in favor of the relevant resolutions (if necessary) in the relevant decision-
making process of the Company, executing necessary documents and giving cooperation in completing the necessary
registration procedures.
18
8.2 If the Company admits any new investor after the Completion of the Capital Increase, the agreement entered into between
the Company and such new investor shall not alter any right enjoyed by the Investors hereunder, including without
limitation the Preemptive Right under Section 6.1, the anti-dilution protection under Section 6.2, the Right of First Refusal
under Section 6.4, the Right of Co-sale under Section 6.5, the right of exchange under Section 6.6, the equal treatment
under Section 6.7 and the right of redemption under Section 6.9, subject to any amendment or supplement made pursuant
to Section 6.7.
9. Confidentiality
9.1 Each Party shall keep in strict confidence and shall not disclose or use any information contained herein or obtained or
accessed by it as a result of negotiating and/or executing this Agreement, including without limitation:
(1) the existence and terms of this Agreement;
(2) negotiations relating to this Agreement; or
(3) any Party hereto, or business activities conducted by any Party or any of its affiliates.
9.2 Nothing contained in this Section 9 shall prevent the disclosure or use of any information:
(1) as required by the applicable laws, rules of the stock exchange on which the shares of any Party are listed or any
competent government authority;
(2) for purpose of any legal proceedings arising out of this Agreement or any other agreement executed under or
pursuant to this Agreement, or to any tax authority in connection with the taxation affairs of the disclosing Party;
(3) to the officers, directors, employees, attorneys, accountants, financial advisors or other agents or representatives
(“Representatives”) of a Party who need to know such information for purpose of consummating the transactions
contemplated by this Agreement or any other agreement executed pursuant to this Agreement, provided that such
Representatives have undertaken to comply with the provisions of Section 9.1, as if they were a Party hereto;
(4) that is publicly available, other than as a result of any violation of the non-disclosure agreement (if any) or this
Agreement; or
(5) with the prior written consent of the other Parties.
10. Indemnification
10.1 If any Party violates any provision, warranty or covenant contained herein, the defaulting Party shall indemnify the other
Parties for any and all liabilities, losses, expenses, costs, interest and penalties (including without limitation legal expenses)
arising therefrom (the “Losses”), without prejudice to the other rights available to the non-defaulting Parties hereunder.
19
The Company and Yao Wang shall, jointly and severally, indemnify and hold harmless the Investors from and against the
Losses arising out of:
(1) any breach of the representations, warranties and covenants made by the Company and Yao Wang herein; or
(2) any breach of the obligations of the Company and Yao Wang hereunder,
without prejudice to the other remedies available to the Investors hereunder (and the Investors shall have the right to
choose the indemnifying Party).
10.2 Yao Wang, as the Controlling Shareholder, shall be ultimately responsible for all expenses incurred, whether prior to or
after the Completion Date, in connection with any liabilities or contingent liabilities (except for those already disclosed by
the Company) not reflected on the financial statements of the Company that may be incurred by the Company prior to the
Completion Date or due to any reason arising prior to the Completion Date, which shall not be the responsibility of the
Investors.
11. Rescission and Termination
11.1 Special termination provisions
(1) The provisions of Section 6 shall cease to be effective from the date the Company formally submits an IPO
application to the Exchange.
(2) The provisions of Section 6 shall automatically become effective again from the date the IPO application of the
Company has been withdrawn by the Company or refused by the Exchange, the China Securities Regulatory
Commission or other competent regulatory authorities.
(3) This Agreement may be terminated with mutual consent of the Parties in writing.
(4) If a Party ceases to hold any shares in the Company directly or indirectly, such Party shall no longer be bound by
this Agreement.
11.2 Prior to the Completion of the Capital Increase, this Agreement may be rescinded and the transactions contemplated
hereby may be terminated or cancelled if:
(1) any Party materially breaches this Agreement and the non-defaulting Parties elect to rescind this Agreement by
giving written notice to the defaulting Party;
(2) the non-defaulting Parties delivers written notice of rescission to the defaulting Party pursuant to Section 3.3; or
(3) the Parties unanimously agree to terminate this Agreement in writing.
11.3 Consequences of termination
Subject to Section 11.4, if this Agreement is terminated pursuant to Section 11.2 or the applicable laws, this Agreement
shall cease to be effective, provided that such termination shall in no event release any Party from any liability incurred as
a result of or in connection with any default or misrepresentation by such Party hereunder, or be deemed to be a waiver of
any available remedy (including specific performance, if available) against such default or misrepresentation.
20
11.4 Survival
The provisions of Sections 9, 10, 11, 14 and 15 shall survive the termination of this Agreement.
12. Notices
12.1 Any notice given by a Party under or in connection with this Agreement shall be made in writing and delivered to the
respective Parties at the addresses or email addresses set forth in Exhibit 4, or such other address or email address for a
Party as designated by such Party by a similar notice.
12.2 Any notice shall be deemed effectively given upon personal delivery to the recipient, or three (3) Business Days after
deposit with an internationally recognized courier, or upon delivery to the recipient’s server if sent by facsimile or email,
provided that a hard copy of the same notice shall be immediately delivered to the recipient by an international overnight
courier.
13. Force Majeure
13.1 If any Party is prevented from performing any of its duties and obligations hereunder by an Event of Force Majeure, such
Party shall notify the other Parties in writing within thirty (30) days after the occurrence of such Event of Force Majeure,
provide the other Parties with detailed information and proofs regarding such Event of Force Majeure, including written
certificates issued by government or other competent authorities, explaining the reason for its inability to perform this
Agreement, and take measures to reduce the losses arising therefrom to the maximum extent practicable.
13.2 If an Event of Force Majeure occurs, neither Party shall be liable for any damage, increased cost or loss that the other
Parties may sustain by reason of failure or delay on the part of such Party to perform any of its obligations hereunder due
to such event, and such failure or delay shall not be deemed to be a breach of this Agreement, provided that the Party
claiming the occurrence of an Event of Force Majeure shall take appropriate measures to minimize or remove the effect of
such Event of Force Majeure, and within the shortest possible time, use its best endeavors to resume performance of the
obligations affected by such Event of Force Majeure.
14. Governing Law and Dispute Resolution
14.1 The formation, validity, execution, interpretation and dispute resolution in respect of this Agreement shall be governed by
the PRC Laws.
14.2 Any dispute arising out of or in connection with this Agreement, or any breach, termination or invalidity of this Agreement,
shall be submitted to the Shanghai International Arbitration Center (“SHIAC”), for settlement by arbitration in Shanghai in
accordance with the arbitration rules of the SHIAC in force when the arbitration notice is submitted. The language of
arbitration shall be Chinese. The arbitration award made by the tribunal shall be final and binding upon the Parties.
21
15. Miscellaneous
15.1 Effectiveness
This Agreement shall take effect on the date it is executed by the Parties.
15.2 Expenses
Unless otherwise provided herein, each Party shall bear its own legal and other expenses incurred in connection with the
preparation, negotiation and execution of this Agreement and other transaction documents.
15.3 Amendment
Unless otherwise provided herein, any amendment, modification, waiver, rescission or termination in respect of this
Agreement shall be made by a written agreement signed by the Parties.
15.4 Assignment
With the prior written consent of the Company and Yao Wang, an Investor may assign its rights and obligations hereunder
to an affiliate designated by it, by giving ten (10) Business Days’ written notice to the other Parties. Subject to the
foregoing, neither Party may assign any of its rights or obligations hereunder without the prior written consent of the other
Parties.
15.5 Severability
If any provision hereof is held illegal, invalid of unenforceable in whole or in part under the applicable laws, such illegal,
invalid of unenforceable provision or part shall not be deemed as part of this Agreement, but the legality, validity and
enforceability of the remaining provisions of this Agreement shall not be affected. The Parties shall negotiate to replace
such provision that is deemed to be deleted from this Agreement with a legal, valid and acceptable provision that comes
closest to expressing the original intent of the Parties herein.
15.6 Waiver
Failure or delay on the part of any Party to exercise any right, power or privilege hereunder shall not operate as a waiver of
such right, power or privilege, nor shall any single or partial exercise of any right, power or privilege preclude the exercise
of any other right, power or privilege.
15.7 Independence
The rights and obligations of each Investor hereunder shall constitute independent, several and not joint rights and
obligations.
15.8 Version for purpose of registration with the administration for commerce and industry
For purpose of registering the relevant changes with the administration for commerce and industry, the Parties agree to
cooperate with each other to execute a simple capital increase agreement separately with respect of the Capital Increase in
such form as required by the administration for commerce and industry (“Standard Version”). In case of any conflict or
discrepancy between such Standard Version and this Agreement, the provisions of this Agreement shall prevail.
22
15.9 Language and counterparts
This Agreement shall be made in Chinese and executed in thirty two (32) counterparts. Each Party shall hold one (1)
counterpart, and the remaining counterparts shall be kept by the Company, for use in the relevant approval, filing and
registration procedures.
(End of text)
23
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd. (seal)
/s/ Seal of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.
By:
/s/ Gang Yu
Name: Gang YU
Title: Legal representative
24
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Yao Wang Corporation Limited (seal)
/s/ Seal of Yao Wang Corporation Limited
By:
/s/ Gang Yu
Name: Gang Yu
Title: Authorized representative
25
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Ningbo Youkai Business Management Partnership (LP) (seal)
/s/ Seal of Ningbo Youkai Business Management Partnership (LP)
By:
/s/ Wenyong Zheng
Name: Wenyong Zheng
Title: Legal or authorized representative
26
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP) (seal)
/s/ Seal of Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP)
By:
/s/ Weiguang Shou
Name: Weiguang Shou
Title: Legal or authorized representative
27
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Ningbo Liangji Industrial Co., Ltd. (seal)
/s/ Seal of Ningbo Liangji Industrial Co., Ltd.
By:
/s/ Liping Ruan
Name: Liping Ruan
Title: Legal or authorized representative
28
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Zhenjiang Huixin Equity Investment Partnership (LP) (seal)
/s/ Seal of Zhenjiang Huixin Equity Investment Partnership (LP)
By:
/s/ Bo Wu
Name: Bo Wu
Title: Legal or authorized representative
29
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Hezhou Hongshi Equity Investment Partnership (LP) (seal)
/s/ Seal of Hezhou Hongshi Equity Investment Partnership (LP)
By:
/s/ Zhengdong Ding
Name: Zhengdong Ding
Title: Legal or authorized representative
30
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Yaoxing Business Management Partnership (LP) (seal)
/s/ Seal of Shanghai Yaoxing Business Management Partnership (LP)
By:
/s/ Ding Liu
Name: Ding Liu
Title: Legal or authorized representative
31
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Yaoshu Business Management Partnership (LP) (seal)
/s/ Seal of Shanghai Yaoshu Business Management Partnership (LP)
By:
/s/ Yang Chen
Name: Yang Chen
Title: Legal or authorized representative
32
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Xinjiang Junying Hongyin Investment Management Partnership (LP) (seal)
/s/ Seal of Xinjiang Junying Hongyin Investment Management Partnership (LP)
By:
/s/ Yang Yang
Name: Yang Yang
Title: Legal or authorized representative
33
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Gangling Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Gangling Business Management Partnership (LP)
By:
/s/ Yang Zhang
Name: Yang Zhang
Title: Legal or authorized representative
34
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaocheng Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaocheng Business Management Partnership (LP)
By:
/s/ Yang Chen
Name: Yang Chen
Title: Legal or authorized representative
35
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaosheng Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaosheng Business Management Partnership (LP)
By:
/s/ Yang Zhang
Name: Yang Zhang
Title: Legal or authorized representative
36
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaopeng Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaopeng Business Management Partnership (LP)
By:
/s/ Yang Chen
Name: Yang Chen
Title: Legal or authorized representative
37
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaohua Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaohua Business Management Partnership (LP)
By:
/s/ Yang Zhang
Name: Yang Zhang
Title: Legal or authorized representative
38
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaoming Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaoming Business Management Partnership (LP)
By:
/s/ Yang Chen
Name: Yang Chen
Title: Legal or authorized representative
39
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaotian Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaotian Business Management Partnership (LP)
By:
/s/ Yang Chen
Name: Yang Chen
Title: Legal or authorized representative
40
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaoding Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaoding Business Management Partnership (LP)
By:
/s/ Yang Zhang
Name: Yang Zhang
Title: Legal or authorized representative
41
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yao Cheng Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yao Cheng Business Management Partnership (LP)
By:
/s/ Yang Chen
Name: Yang Chen
Title: Legal or authorized representative
42
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaojun Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaojun Business Management Partnership (LP)
By:
/s/ Yang Zhang
Name: Yang Zhang
Title: Legal or authorized representative
43
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaowei Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaowei Business Management Partnership (LP)
By:
/s/ Yang Zhang
Name: Yang Zhang
Title: Legal or authorized representative
44
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaoan Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaoan Business Management Partnership (LP)
By:
/s/ Yang Zhang
Name: Yang Zhang
Title: Legal or authorized representative
45
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Tianjin Yaogong Business Management Partnership (LP) (seal)
/s/ Seal of Tianjin Yaogong Business Management Partnership (LP)
By:
/s/ Yang Zhang
Name: Yang Zhang
Title: Legal or authorized representative
46
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
SAIF Partners (Nanjing) Equity Investment Fund (LP) (seal)
/s/ Seal of SAIF Partners (Nanjing) Equity Investment Fund (LP)
By:
/s/ Yanchao Zhao
Name: Yanchao Zhao
Title: Legal or authorized representative
47
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
SAIF Partners (Huangshan) Tourist Culture Industrial Development Fund (LP) (seal)
/s/ Seal of SAIF Partners (Huangshan) Tourist Culture Industrial Development Fund (LP)
By:
/s/ Yan Yan
Name: Yan Yan
Title: Legal or authorized representative
48
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
SAIF Partners (Nanjing) Hengzhun Venture Capital Fund (LP) (seal)
/s/ Seal of SAIF Partners (Nanjing) Hengzhun Venture Capital Fund (LP)
By:
/s/ Yan Yan
Name: Yan Yan
Title: Legal or authorized representative
49
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Jiaxing Tengyuan Investment Partnership (LP) (seal)
/s/ Seal of Jiaxing Tengyuan Investment Partnership (LP)
By:
/s/ Hongli Yu
Name: Hongli Yu
Title: Legal or authorized representative
50
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Shenli Business Management Partnership (LP) (seal)
/s/ Seal of Shanghai Shenli Business Management Partnership (LP)
/s/ Seal of Shanghai Quanjie Culture Communication Co., Ltd.
By:
/s/ Jian Wang
Name: Jian Wang
Title: Legal or authorized representative
51
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Huasai Zhikang (Shanghai) Equity Investment Fund Partnership (LP) (seal)
/s/ Seal of Huasai Zhikang (Shanghai) Equity Investment Fund Partnership (LP)
By:
/s/ Ting Cheng
Name: Ting Cheng
Title: Legal or authorized representative
52
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Zhangjiang Torch Venture Capital Co., Ltd. (seal)
/s/ Seal of Shanghai Zhangjiang Torch Venture Capital Co., Ltd.
By:
/s/ Shaoqiong Ding
Name: Shaoqiong Ding
Title: Legal or authorized representative
53
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Zhilin Yiqu Venture Capital Partnership (LP) (seal)
/s/ Seal of Shanghai Zhilin Yiqu Venture Capital Partnership (LP)
/s/ Seal of Shanghai Linrong Business Management Partnership (LP)
By:
/s/ Haotian Jiang
Name: Haotian Jiang
Title: Legal or authorized representative
54
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Technology Venture Capital Co., Ltd. (seal)
/s/ Seal of Shanghai Technology Venture Capital Co., Ltd.
By:
/s/ Weiguo Shen
Name: Weiguo Shen
Title: Legal or authorized representative
55
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Pudong Renmin Zhaoyin Cultural Industry Equity Investment Fund Partnership (LP) (seal)
/s/ Seal of Shanghai Pudong Renmin Zhaoyin Cultural Industry Equity Investment Fund Partnership (LP)
/s/ Shenzhen People's Houpu Private Equity Investment Co., Ltd.
By:
/s/ Yuxing Liu
Name: Yuxing Liu
Title: Legal or authorized representative
56
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Gongqingcheng Ideate Investment Management Partnership (LP) (seal)
/s/ Seal of Gongqingcheng Ideate Investment Management Partnership (LP)
/s/ Seal of Gongqingcheng Ideate Investment Management Co., Ltd.
By:
/s/ Jun Gao
Name: Jun Gao
Title: Legal or authorized representative
57
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Shanghai Zhangjiang Technology Venture Capital Co., Ltd. (seal)
/s/ Seal of Shanghai Zhangjiang Technology Venture Capital Co., Ltd.
By:
/s/ Hongliang Yu
Name: Hongliang Yu
Title: Legal or authorized representative
58
[Signature Page to Capital Increase Agreement in respect of 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as
of the date first above written.
Hangzhou Hengqin Investment Management Partnership (LP) (seal)
/s/ Seal of Hangzhou Hengqin Investment Management Partnership (LP)
/s/ Seal of Hangzhou Huazhi Rongke Investment Management Co., Ltd.
By:
/s/ Chunping Li
Name: Chunping Li
Title: Legal or authorized representative
59
No.
Investor
Exhibit 1 List of Investors
Investment
amount
(RMB)
Number of
New Shares
subscribed
Subscribed
registered
capital
(RMB)
1 SAIF Partners (Nanjing) Equity Investment Fund (LP)
100,000,000
6,825,007
6,825,007
Amount
recorded in
capital
reserve
(RMB)
93,174,993
Shareholding
percentage
(%)
0.9510%
2
3
SAIF Partners (Huangshan) Tourist Culture Industrial
Development Fund (LP)
SAIF Partners (Nanjing) Hengzhun Venture Capital Fund
(LP)
30,000,000
2,047,502
2,047,502
27,952,498
0.2853%
20,000,000
1,365,001
1,365,001
18,634,999
0.1902%
4 Jiaxing Tengyuan Investment Partnership (LP)
5 Shanghai Shenli Business Management Partnership (LP)
30,000,000
80,000,000
2,047,502
5,460,006
2,047,502
5,460,006
27,952,498
74,539,994
0.2853%
0.7608%
6
Huasai Zhikang (Shanghai) Equity Investment Fund
Partnership (LP)
50,000,000
3,412,503
3,412,503
46,587,497
0.4755%
7 Shanghai Zhangjiang Torch Venture Capital Co., Ltd.
8 Shanghai Zhilin Yiqu Venture Capital Partnership (LP)
9 Shanghai Technology Venture Capital Co., Ltd.
45,000,000
40,000,000
30,000,000
3,071,253
2,730,003
2,047,502
3,071,253
2,730,003
2,047,502
41,928,747
37,269,997
27,952,498
0.4280%
0.3804%
0.2853%
10
11
12
13
Ideate
Shanghai Pudong Renmin Zhaoyin Cultural Industry
Equity Investment Fund Partnership (LP)
Gongqingcheng
Partnership (LP)
Shanghai Zhangjiang Technology Venture Capital Co.,
Ltd.
Hangzhou Hengqin Investment Management Partnership
(LP)
Investment Management
30,000,000
2,047,502
2,047,502
27,952,498
0.2853%
30,000,000
2,047,502
2,047,502
27,952,498
0.2853%
20,000,000
1,365,001
1,365,001
18,634,999
0.1902%
10,000,000
682,501
682,501
9,317,499
0.0951%
Total
515,000,000 35,148,785
35,148,785
479,851,215
4.8977%
60
Exhibit 2 Shareholding Structure of the Company Immediately after the Completion of the Capital Increase
No.
Shareholder
1
2
3
4
5
6
7
8
9
10
11
12
13
Yao Wang Corporation Limited
Ningbo Youkai Business Management Partnership (LP)
Shanghai SOE Reform & Development Equity
Investment Fund Partnership (LP)
Ningbo Liangji Industrial Co., Ltd.
Zhenjiang Huixin Equity Investment Partnership (LP)
Hezhou Hongshi Equity Investment Partnership (LP)
Shanghai Yaoxing Business Management Partnership
(LP)
Shanghai Yaoshu Business Management Partnership
(LP)
Xinjiang Junying Hongyin Investment Management
Partnership (LP)
Tianjin Gangling Business Management Partnership
(LP)
Tianjin Yaocheng Business Management Partnership
(LP)
Tianjin Yaosheng Business Management Partnership
(LP)
Tianjin Yaopeng Business Management Partnership
(LP)
14 Tianjin Yaohua Business Management Partnership (LP)
Tianjin Yaoming Business Management Partnership
(LP)
15
17
16 Tianjin Yaotian Business Management Partnership (LP)
Tianjin Yaoding Business Management Partnership
(LP)
Tianjin Yao Cheng Business Management Partnership
(LP)
18
19 Tianjin Yaojun Business Management Partnership (LP)
20 Tianjin Yaowei Business Management Partnership (LP)
61
Number of shares
held
618,829,900
11,137,100
Registered capital
(RMB)
Shareholding
percentage (%)
618,829,900
11,137,100
86.2302
1.5519
7,424,950
5,197,400
4,111,900
1,113,450
1,086,800
727,350
371,150
7,424,950
5,197,400
4,111,900
1,113,450
1,086,800
727,350
371,150
13,010,000
13,010,000
7,978,111
7,978,111
923,584
858,628
994,715
923,584
858,628
994,715
1,042,567
1,042,567
828,029
904,595
807,581
960,645
550,461
828,029
904,595
807,581
960,645
550,461
1.0346
0.7242
0.5730
0.1552
0.1514
0.1014
0.0517
1.8129
1.1117
0.1287
0.1196
0.1386
0.1453
0.1154
0.1261
0.1125
0.1339
0.0767
22
24
26
27
25
23
21 Tianjin Yaoan Business Management Partnership (LP)
Tianjin Yaogong Business Management Partnership
(LP)
SAIF Partners (Nanjing) Equity Investment Fund (LP)
SAIF Partners (Huangshan) Tourist Culture Industrial
Development Fund (LP)
SAIF Partners (Nanjing) Hengzhun Venture Capital
Fund (LP)
Jiaxing Tengyuan Investment Partnership (LP)
Shanghai Shenli Business Management Partnership
(LP)
Huasai Zhikang (Shanghai) Equity Investment Fund
Partnership (LP)
Shanghai Zhangjiang Torch Venture Capital Co., Ltd.
Shanghai Zhilin Yiqu Venture Capital Partnership (LP)
Shanghai Technology Venture Capital Co., Ltd.
Shanghai Pudong Renmin Zhaoyin Cultural Industry
Equity Investment Fund Partnership (LP)
Gongqingcheng
Partnership (LP)
Shanghai Zhangjiang Technology Venture Capital Co.,
Ltd.
Hangzhou Hengqin
Partnership (LP)
Investment Management
Investment Management
29
30
31
Ideate
35
33
34
32
28
974,096
2,666,988
6,825,007
2,047,502
1,365,001
2,047,502
5,460,006
3,412,503
3,071,253
2,730,003
2,047,502
2,047,502
2,047,502
1,365,001
682,501
974,096
2,666,988
6,825,007
2,047,502
1,365,001
2,047,502
5,460,006
3,412,503
3,071,253
2,730,003
2,047,502
2,047,502
2,047,502
1,365,001
682,501
0.1357
0.3716
0.9510
0.2853
0.1902
0.2853
0.7608
0.4755
0.4280
0.3804
0.2853
0.2853
0.2853
0.1902
0.0951
Total
717,648,785
717,648,785
100.0000
62
Exhibit 3 List of Competitors
Exhibit 4 Mailing and Service Information
1. 1 Pharmacy Yao Fang Technology (Shanghai) Co., Ltd.
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
2. Yao Wang Corporation Limited
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
3. Ningbo Youkai Business Management Partnership (LP)
Address: No. 58 Xinfa Road, Suzhou Industrial Park
Email: [ ]
Attention: ZHENG Wenyong
4. Shanghai SOE Reform & Development Equity Investment Fund Partnership (LP)
Address: Building 8#, Changning Financial Park, No. 1320 Yuyuan Road, Changning District, Shanghai
Email: [ ]
Attention: CHEN Dawei
5. Ningbo Liangji Industrial Co., Ltd.
Address: 2406A, Jin Mao Tower, No. 88 Century Avenue, Pudong New Area, Shanghai
Email: [ ]
Attention: RUAN Shuhong
6. Zhenjiang Huixin Equity Investment Partnership (LP)
Address: 212-214, Building 7#, No. 2789 West Guangfu Road, Putuo District, Shanghai
Email: [ ]
Attention: ZHANG Wei
7. Hezhou Hongshi Equity Investment Partnership (LP)
Address: Room 1617, Guangming Plaza, Chaoyang District, Beijing
Email: [ ]
Attention: FENG Yuanwei
63
8. Shanghai Yaoxing Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
9. Shanghai Yaoshu Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
10. Xinjiang Junying Hongyin Investment Management Partnership (LP)
Address: Room 2805, Tower E, Xinhua Tianxi International Finance Center, Shifu Avenue, Shenhe
District, Shenyang, Liaoning
Email: [ ]
Attention: LI Nan
11. Tianjin Gangling Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
12. Tianjin Yaocheng Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
13. Tianjin Yaosheng Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
14. Tianjin Yaopeng Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
64
15. Tianjin Yaohua Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
16. Tianjin Yaoming Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
17. Tianjin Yaotian Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
18. Tianjin Yaoding Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
19. Tianjin Yao Cheng Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
20. Tianjin Yaojun Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
21. Tianjin Yaowei Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
65
22. Tianjin Yaoan Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
23. Tianjin Yaogong Business Management Partnership (LP)
Address: 4/F, No. 295 Zuchongzhi Road, Pudong New Area, Shanghai
Email: [ ]
Attention: SUN Baohua
24. SAIF Partners (Nanjing) Equity Investment Fund (LP)
Address: 18/F, Tower C, Central International Trade Center, A-6, Jianguomenwai Street, Chaoyang
District, Beijing
Email: [ ]
Attention: MA Xiaoning
25. SAIF Partners (Huangshan) Tourist Culture Industrial Development Fund (LP)
Address: 18/F, Tower C, Central International Trade Center, A-6, Jianguomenwai Street, Chaoyang
District, Beijing
Email: [ ]
Attention: ZHANG Xin
26. SAIF Partners (Nanjing) Hengzhun Venture Capital Fund (LP)
Address: Apartment 16, Zone C, Hongqiao State Guest House, No. 1591 Hongqiao Road, Shanghai
Email: [ ]
Attention: ZHU Zhen
27. Jiaxing Tengyuan Investment Partnership (LP)
Address: 18/F, Tower C, Central International Trade Center, A-6, Jianguomenwai Street, Chaoyang
District, Beijing
Email: [ ]
Attention: ZHAO Yi
66
28. Shanghai Shenli Business Management Partnership (LP)
Address: 2/F, No. 399 East Huanlin Road, Pudong New Area, Shanghai
Email: [ ]
Attention: WANG Jian
29. Huasai Zhikang (Shanghai) Equity Investment Fund Partnership (LP)
Address: 36/F, CITIC Plaza, No. 859 North Sichuan Road, Hongkou District, Shanghai
Email: [ ]
Attention: MO Hongjun
30. Shanghai Zhangjiang Torch Venture Capital Co., Ltd.
Address: 17/F, No. 118 Rongke Road, Pudong New Area, Shanghai
Email: [ ]
Attention: LIU Zhen
31. Shanghai Zhilin Yiqu Venture Capital Partnership (LP)
Address: 3205, Huaihai Plaza, No. 1045 Middle Huaihai Road, Xuhui District, Shanghai
Email: [ ]
Attention: XU Jiawen
32. Shanghai Technology Venture Capital Co., Ltd.
Attention: 39/F, No. 669 Xinzha Road, Jing’an District
Attention: [ ]
Attention: XING Xiu
33. Shanghai Pudong Renmin Zhaoyin Cultural Industry Equity Investment Fund Partnership (LP)
Address: People’s Daily New Media Building, No. 2 West Jintai Road, Chaoyang District, Beijing
Email: [ ]
Attention: LIU Yuxing
34. Gongqingcheng Ideate Investment Management Partnership (LP)
Address: 23C, Shentong Information Plaza, No. 55 West Huaihai Road, Xuhui District, Shanghai
Email: [ ]
Attention: LI Jialin
67
35. Shanghai Zhangjiang Technology Venture Capital Co., Ltd.
Attention: Block D, Building 16#, No. 1387 Zhangdong Road, Pudong New Area, Shanghai
Email: [ ]
Attention: ZHAO Yuming
36. Hangzhou Hengqin Investment Management Partnership (LP)
Address: 11/F, Tonghua Technology Plaza, No. 55 Jinhu Road, Pudong New Area, Shanghai
Email: [ ]
Attention: ZHENG Wenjie
68
Principal Subsidiaries, Consolidated Affiliated Entities and Subsidiaries of Consolidated Affiliated Entities of the Registrant
Exhibit 8.1
Subsidiaries:
Yao Wang Corporation Limited, a Hong Kong company
1 Pharmacy Technology (Shanghai) Co., Ltd., a PRC company
Chongqing Yihao Pharmacy Co., Ltd., a PRC company
Wuhan Central China Drug Trading Co., Ltd., a PRC company
Fujian Yaofang Pharmacy Co., Ltd., a PRC company
Hubei Yihao Pharmacy Co., Ltd., a PRC company
Liaoning Yihao Pharmacy Co., Ltd., a PRC Company
Shanghai Hanhong Medical Technology Co., Ltd., a PRC Company
Shanxi Yihao Yaofang Pharmacy Co., Ltd., a PRC Company
Tianjin Yihao Pharmacy Co., Ltd., a PRC Company
Consolidated Affiliated Entities:
Guangdong Yihao Pharmacy Co., Ltd., a PRC company
Guangdong Yihao Pharmaceutical Chain Co., Ltd., a PRC company
Shanghai Yaowang E-Commerce Co., Ltd., a PRC company
Subsidiaries of Consolidated Affiliated Entities:
Anshun Southwest Internet Hospital Co., Ltd., a PRC company
Chengdu Yizhen Internet Hospital Co., Ltd., a PRC company
Kunshan Yihua Hospital Co., Ltd., a PRC company
Kunshan Yifang Pharmacy Co., Ltd., a PRC company
Certification by the Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 12.1
I, Junling Liu, certify that:
1.
I have reviewed this annual report on Form 20-F of 111, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mate rial
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly pres ent
in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in
this report;
4.
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in
Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the company, including its consolidated subsid iaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial re porting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and
(d)
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the
period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the com pany’s internal
control over financial reporting; and
5.
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal con trol
over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing
the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial re ‐
porting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial
information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the
company’s internal control over financial reporting.
Date: April 30, 2021
By:
/s/ Junling Liu
Name: Junling Liu
Title: Chief Executive Officer
Certification by the Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 12.2
I, Junling Liu, certify that:
1.
I have reviewed this annual report on Form 20-F of 111, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mate rial
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly pres ent
in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in
this report;
4.
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in
Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the company, including its consolidated subsid iaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial re porting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and
(d)
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the
period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the com pany’s internal
control over financial reporting; and
5.
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal con trol
over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing
the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial re ‐
porting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial
information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the
company’s internal control over financial reporting.
Date: April 30, 2021
By:
/s/ Junling Liu
Name:Junling Liu
Title: Chief Executive Officer, acting in the capacity of Chief
Financial Officer
Certification by the Principal Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 13.1
In connection with the Annual Report of 111, Inc. (the “Company”) on Form 20-F for the year ended December 31, 2020 as
filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Junling Liu, Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my
knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
Date: April 30, 2021
By:
/s/ Junling Liu
Name:
Title:
Junling Liu
Chief Executive Officer
Certification by the Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 13.2
In connection with the Annual Report of 111, Inc. (the “Company”) on Form 20-F for the year ended December 31, 2020 as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), I, Junling Liu, acting in the capacity of Chief Financial
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
Date: April 30, 2021
By:
/s/ Junling Liu
Name:Junling Liu
Title: Chief Executive Officer, acting in the capacity of
Chief Financial Officer
中国北京市建国门外大街甲12号新华保险大厦6层100022
6/F, NCI Tower, A12 Jianguomenwai Avenue, Beijing 100022, China
电话 Tel: +86 10 6569 3399 传真 Fax: +86 10 6569 3838
电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com
Exhibit 15.1
April 30, 2021
111, Inc.
3-4/F, No. 295 ZuChongZhi Road,
Pudong New Area
Shanghai, 201203
The People’s Republic of China
Dear Sirs,
We consent to the reference to our firm under the headings “Item 3. Key Information — D. Risk Factors,” and
“Item 4. Information on the Company — C. Organizational Structure,” in 111, Inc.’s Annual Report on Form 20-F
for the year ended December 31, 2020, which will be filed with the Securities and Exchange Commission in the
month of April 2020, and further consent to the incorporation by reference of the summaries of our opinions under
these captions into 111, Inc.’s Registration Statements on Form S-8 (No. 333-229313) that were filed on January
22, 2019.
Yours faithfully,
/s/ Commerce & Finance Law Offices
Commerce & Finance Law Offices
Exhibit 15.2
Our ref KKZ/742474-000001/19339623v1
111, Inc.
3-5/F, No.295 ZuChongZhi Road,
Pudong New Area
Shanghai, 201203
The People’s Republic of China
30 April 2021
Dear Sir and/or Madam
111, Inc.
We have acted as legal advisers as to the laws of the Cayman Islands to 111, Inc., an exempted limited liability company incorporated in
the Cayman Islands (the “Company”), in connection with the filing by the Company with the United States Securities and Exchange
Commission (the “SEC”) of an annual report on Form 20-F for the year ended 31 December 2020 (the “Annual Report”).
We hereby consent to the reference to our firm under the headings “Item 10. Additional Information—B. Memorandum and Articles of
Association” and “Item 10. Additional Information—E. Taxation—Cayman Islands Taxation” in the Annual Report, and we further
consent to the incorporation by reference of the summary of our opinions under these headings into the Company’s registration statement
on Form S-8 (File No. 333-229313) that was filed on 22 January 2019, pertaining to the Company’s 2013 Share Incentive Policy, 2014
Share Incentive Policy, 2016 Share Incentive Plan and 2018 Share Incentive Plan.
We consent to the filing with the SEC of this consent letter as an exhibit to the Annual Report. In giving such consent, we do not thereby
admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, or under the
Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.
Yours faithfully
/s/ Maples and Calder (Hong Kong) LLP
Maples and Calder (Hong Kong) LLP
Exhibit 15.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-229313 on Form S-8 of our
reports dated April 29, 2021, relating to the financial statements of 111, Inc. and the effectiveness of 111, Inc.’s
internal control over financial reporting, appearing in this Annual Report on Form 20-F for the year ended
December 31, 2020.
/s/ Deloitte Touche Tohmatsu Certified Public Accountants LLP
Shanghai, China
April 29, 2021